CN113186203A - Vaccine agent for treating or preventing coronavirus diseases - Google Patents
Vaccine agent for treating or preventing coronavirus diseases Download PDFInfo
- Publication number
- CN113186203A CN113186203A CN202110109503.2A CN202110109503A CN113186203A CN 113186203 A CN113186203 A CN 113186203A CN 202110109503 A CN202110109503 A CN 202110109503A CN 113186203 A CN113186203 A CN 113186203A
- Authority
- CN
- China
- Prior art keywords
- sequence
- seq
- mrna
- nucleotides
- utr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 126
- 241000711573 Coronaviridae Species 0.000 title claims abstract description 80
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract description 20
- 201000010099 disease Diseases 0.000 title abstract description 16
- 108020004999 messenger RNA Proteins 0.000 claims abstract description 210
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 55
- 125000003729 nucleotide group Chemical group 0.000 claims description 401
- 239000002773 nucleotide Substances 0.000 claims description 201
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 85
- -1 C-5 propynyl-uridine Chemical compound 0.000 claims description 44
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 43
- 229940126582 mRNA vaccine Drugs 0.000 claims description 43
- 230000000295 complement effect Effects 0.000 claims description 41
- 108700021021 mRNA Vaccine Proteins 0.000 claims description 35
- 150000002632 lipids Chemical class 0.000 claims description 33
- 239000002105 nanoparticle Substances 0.000 claims description 32
- 229920000642 polymer Polymers 0.000 claims description 27
- 230000004048 modification Effects 0.000 claims description 25
- 238000012986 modification Methods 0.000 claims description 25
- 108020005345 3' Untranslated Regions Proteins 0.000 claims description 21
- 239000002502 liposome Substances 0.000 claims description 21
- 229920001223 polyethylene glycol Polymers 0.000 claims description 18
- 229920002873 Polyethylenimine Polymers 0.000 claims description 11
- 229930182558 Sterol Natural products 0.000 claims description 10
- 150000003432 sterols Chemical class 0.000 claims description 10
- 235000003702 sterols Nutrition 0.000 claims description 10
- ZDTFMPXQUSBYRL-UUOKFMHZSA-N 2-Aminoadenosine Chemical compound C12=NC(N)=NC(N)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O ZDTFMPXQUSBYRL-UUOKFMHZSA-N 0.000 claims description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol Substances OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- 125000002091 cationic group Chemical group 0.000 claims description 8
- 229940106189 ceramide Drugs 0.000 claims description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 6
- WALUVDCNGPQPOD-UHFFFAOYSA-M 2,3-di(tetradecoxy)propyl-(2-hydroxyethyl)-dimethylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCOCC(C[N+](C)(C)CCO)OCCCCCCCCCCCCCC WALUVDCNGPQPOD-UHFFFAOYSA-M 0.000 claims description 6
- JQKOHRZNEOQNJE-ZZEZOPTASA-N 2-azaniumylethyl [3-octadecanoyloxy-2-[(z)-octadec-9-enoyl]oxypropyl] phosphate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCC\C=C/CCCCCCCC JQKOHRZNEOQNJE-ZZEZOPTASA-N 0.000 claims description 6
- ZAYHVCMSTBRABG-JXOAFFINSA-N 5-methylcytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZAYHVCMSTBRABG-JXOAFFINSA-N 0.000 claims description 6
- 108010088751 Albumins Proteins 0.000 claims description 6
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 6
- 229930183167 cerebroside Natural products 0.000 claims description 6
- SRLOHQKOADWDBV-NRONOFSHSA-M sodium;[(2r)-2,3-di(octadecanoyloxy)propyl] 2-(2-methoxyethoxycarbonylamino)ethyl phosphate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCCNC(=O)OCCOC)OC(=O)CCCCCCCCCCCCCCCCC SRLOHQKOADWDBV-NRONOFSHSA-M 0.000 claims description 6
- UVBYMVOUBXYSFV-XUTVFYLZSA-N 1-methylpseudouridine Chemical compound O=C1NC(=O)N(C)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UVBYMVOUBXYSFV-XUTVFYLZSA-N 0.000 claims description 5
- 102000009027 Albumins Human genes 0.000 claims description 5
- 241000282472 Canis lupus familiaris Species 0.000 claims description 5
- 108010010803 Gelatin Proteins 0.000 claims description 5
- 235000010443 alginic acid Nutrition 0.000 claims description 5
- 229920000615 alginic acid Polymers 0.000 claims description 5
- 229920000159 gelatin Polymers 0.000 claims description 5
- 235000019322 gelatine Nutrition 0.000 claims description 5
- 235000011852 gelatine desserts Nutrition 0.000 claims description 5
- 230000000670 limiting effect Effects 0.000 claims description 5
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims description 4
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims description 4
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims description 4
- 102000007327 Protamines Human genes 0.000 claims description 4
- 108010007568 Protamines Proteins 0.000 claims description 4
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims description 4
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 4
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 4
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims description 4
- 239000008273 gelatin Substances 0.000 claims description 4
- 238000003780 insertion Methods 0.000 claims description 4
- 230000037431 insertion Effects 0.000 claims description 4
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims description 4
- NEZDNQCXEZDCBI-WJOKGBTCSA-N (2-aminoethoxy)[(2r)-2,3-bis(tetradecanoyloxy)propoxy]phosphinic acid Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCC NEZDNQCXEZDCBI-WJOKGBTCSA-N 0.000 claims description 3
- JSPNNZKWADNWHI-PNANGNLXSA-N (2r)-2-hydroxy-n-[(2s,3r,4e,8e)-3-hydroxy-9-methyl-1-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]heptadecanamide Chemical compound CCCCCCCCCCCCCCC[C@@H](O)C(=O)N[C@H]([C@H](O)\C=C\CC\C=C(/C)CCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JSPNNZKWADNWHI-PNANGNLXSA-N 0.000 claims description 3
- RIFDKYBNWNPCQK-IOSLPCCCSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-(6-imino-3-methylpurin-9-yl)oxolane-3,4-diol Chemical compound C1=2N(C)C=NC(=N)C=2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O RIFDKYBNWNPCQK-IOSLPCCCSA-N 0.000 claims description 3
- LVNGJLRDBYCPGB-LDLOPFEMSA-N (R)-1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-LDLOPFEMSA-N 0.000 claims description 3
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims description 3
- SLKDGVPOSSLUAI-PGUFJCEWSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCCCC SLKDGVPOSSLUAI-PGUFJCEWSA-N 0.000 claims description 3
- RKSLVDIXBGWPIS-UAKXSSHOSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 RKSLVDIXBGWPIS-UAKXSSHOSA-N 0.000 claims description 3
- QLOCVMVCRJOTTM-TURQNECASA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-prop-1-ynylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C#CC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 QLOCVMVCRJOTTM-TURQNECASA-N 0.000 claims description 3
- PISWNSOQFZRVJK-XLPZGREQSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-2-sulfanylidenepyrimidin-4-one Chemical compound S=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 PISWNSOQFZRVJK-XLPZGREQSA-N 0.000 claims description 3
- WTJKGGKOPKCXLL-VYOBOKEXSA-N 1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC WTJKGGKOPKCXLL-VYOBOKEXSA-N 0.000 claims description 3
- FHQVHHIBKUMWTI-ZCXUNETKSA-N 1-palmitoyl-2-oleoyl phosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC FHQVHHIBKUMWTI-ZCXUNETKSA-N 0.000 claims description 3
- PGYFLJKHWJVRMC-ZXRZDOCRSA-N 2-[4-[[(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]butoxy]-n,n-dimethyl-3-[(9z,12z)-octadeca-9,12-dienoxy]propan-1-amine Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OCCCCOC(CN(C)C)COCCCCCCCC\C=C/C\C=C/CCCCC)C1 PGYFLJKHWJVRMC-ZXRZDOCRSA-N 0.000 claims description 3
- JRYMOPZHXMVHTA-DAGMQNCNSA-N 2-amino-7-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound C1=CC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O JRYMOPZHXMVHTA-DAGMQNCNSA-N 0.000 claims description 3
- SHCCKWGIFIPGNJ-NSUCVBPYSA-N 2-aminoethyl [(2r)-2,3-bis[(z)-octadec-9-enoxy]propyl] hydrogen phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCCOC[C@H](COP(O)(=O)OCCN)OCCCCCCCC\C=C/CCCCCCCC SHCCKWGIFIPGNJ-NSUCVBPYSA-N 0.000 claims description 3
- RHFUOMFWUGWKKO-XVFCMESISA-N 2-thiocytidine Chemical compound S=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 RHFUOMFWUGWKKO-XVFCMESISA-N 0.000 claims description 3
- GJTBSTBJLVYKAU-XVFCMESISA-N 2-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=S)NC(=O)C=C1 GJTBSTBJLVYKAU-XVFCMESISA-N 0.000 claims description 3
- ZISVTYVLWSZJAL-UHFFFAOYSA-N 3,6-bis[4-[bis(2-hydroxydodecyl)amino]butyl]piperazine-2,5-dione Chemical compound CCCCCCCCCCC(O)CN(CC(O)CCCCCCCCCC)CCCCC1NC(=O)C(CCCCN(CC(O)CCCCCCCCCC)CC(O)CCCCCCCCCC)NC1=O ZISVTYVLWSZJAL-UHFFFAOYSA-N 0.000 claims description 3
- LMMLLWZHCKCFQA-UGKPPGOTSA-N 4-amino-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-prop-1-ynyloxolan-2-yl]pyrimidin-2-one Chemical compound C1=CC(N)=NC(=O)N1[C@]1(C#CC)O[C@H](CO)[C@@H](O)[C@H]1O LMMLLWZHCKCFQA-UGKPPGOTSA-N 0.000 claims description 3
- XXSIICQLPUAUDF-TURQNECASA-N 4-amino-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-prop-1-ynylpyrimidin-2-one Chemical compound O=C1N=C(N)C(C#CC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 XXSIICQLPUAUDF-TURQNECASA-N 0.000 claims description 3
- ZAYHVCMSTBRABG-UHFFFAOYSA-N 5-Methylcytidine Natural products O=C1N=C(N)C(C)=CN1C1C(O)C(O)C(CO)O1 ZAYHVCMSTBRABG-UHFFFAOYSA-N 0.000 claims description 3
- AGFIRQJZCNVMCW-UAKXSSHOSA-N 5-bromouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 AGFIRQJZCNVMCW-UAKXSSHOSA-N 0.000 claims description 3
- FHIDNBAQOFJWCA-UAKXSSHOSA-N 5-fluorouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 FHIDNBAQOFJWCA-UAKXSSHOSA-N 0.000 claims description 3
- KDOPAZIWBAHVJB-UHFFFAOYSA-N 5h-pyrrolo[3,2-d]pyrimidine Chemical compound C1=NC=C2NC=CC2=N1 KDOPAZIWBAHVJB-UHFFFAOYSA-N 0.000 claims description 3
- BXJHWYVXLGLDMZ-UHFFFAOYSA-N 6-O-methylguanine Chemical compound COC1=NC(N)=NC2=C1NC=N2 BXJHWYVXLGLDMZ-UHFFFAOYSA-N 0.000 claims description 3
- UEHOMUNTZPIBIL-UUOKFMHZSA-N 6-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-7h-purin-8-one Chemical compound O=C1NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O UEHOMUNTZPIBIL-UUOKFMHZSA-N 0.000 claims description 3
- HCAJQHYUCKICQH-VPENINKCSA-N 8-Oxo-7,8-dihydro-2'-deoxyguanosine Chemical compound C1=2NC(N)=NC(=O)C=2NC(=O)N1[C@H]1C[C@H](O)[C@@H](CO)O1 HCAJQHYUCKICQH-VPENINKCSA-N 0.000 claims description 3
- 229920001661 Chitosan Polymers 0.000 claims description 3
- 102000008186 Collagen Human genes 0.000 claims description 3
- 108010035532 Collagen Proteins 0.000 claims description 3
- 229920000858 Cyclodextrin Polymers 0.000 claims description 3
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims description 3
- XULFJDKZVHTRLG-JDVCJPALSA-N DOSPA trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)CCNC(=O)C(CCCNCCCN)NCCCN)OCCCCCCCC\C=C/CCCCCCCC XULFJDKZVHTRLG-JDVCJPALSA-N 0.000 claims description 3
- 229920002307 Dextran Polymers 0.000 claims description 3
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 3
- 229930010555 Inosine Natural products 0.000 claims description 3
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims description 3
- 229920000954 Polyglycolide Polymers 0.000 claims description 3
- 229930185560 Pseudouridine Natural products 0.000 claims description 3
- PTJWIQPHWPFNBW-UHFFFAOYSA-N Pseudouridine C Natural products OC1C(O)C(CO)OC1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-UHFFFAOYSA-N 0.000 claims description 3
- RBPWQIKZHBYIEY-PXCYNBOKSA-N [(2r)-2,3-bis[(z)-octadec-9-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCCOC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC RBPWQIKZHBYIEY-PXCYNBOKSA-N 0.000 claims description 3
- NYDLOCKCVISJKK-WRBBJXAJSA-N [3-(dimethylamino)-2-[(z)-octadec-9-enoyl]oxypropyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(CN(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC NYDLOCKCVISJKK-WRBBJXAJSA-N 0.000 claims description 3
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims description 3
- WGDUUQDYDIIBKT-UHFFFAOYSA-N beta-Pseudouridine Natural products OC1OC(CN2C=CC(=O)NC2=O)C(O)C1O WGDUUQDYDIIBKT-UHFFFAOYSA-N 0.000 claims description 3
- RIZIAUKTHDLMQX-UHFFFAOYSA-N cerebroside D Natural products CCCCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O RIZIAUKTHDLMQX-UHFFFAOYSA-N 0.000 claims description 3
- 229920001436 collagen Polymers 0.000 claims description 3
- 150000001982 diacylglycerols Chemical class 0.000 claims description 3
- UMGXUWVIJIQANV-UHFFFAOYSA-M didecyl(dimethyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCC[N+](C)(C)CCCCCCCCCC UMGXUWVIJIQANV-UHFFFAOYSA-M 0.000 claims description 3
- 150000002270 gangliosides Chemical class 0.000 claims description 3
- 150000002402 hexoses Chemical class 0.000 claims description 3
- 125000002883 imidazolyl group Chemical group 0.000 claims description 3
- 229960003786 inosine Drugs 0.000 claims description 3
- NFQBIAXADRDUGK-KWXKLSQISA-N n,n-dimethyl-2,3-bis[(9z,12z)-octadeca-9,12-dienoxy]propan-1-amine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCOCC(CN(C)C)OCCCCCCCC\C=C/C\C=C/CCCCC NFQBIAXADRDUGK-KWXKLSQISA-N 0.000 claims description 3
- GLGLUQVVDHRLQK-WRBBJXAJSA-N n,n-dimethyl-2,3-bis[(z)-octadec-9-enoxy]propan-1-amine Chemical compound CCCCCCCC\C=C/CCCCCCCCOCC(CN(C)C)OCCCCCCCC\C=C/CCCCCCCC GLGLUQVVDHRLQK-WRBBJXAJSA-N 0.000 claims description 3
- GJVFBWCTGUSGDD-UHFFFAOYSA-L pentamethonium bromide Chemical compound [Br-].[Br-].C[N+](C)(C)CCCCC[N+](C)(C)C GJVFBWCTGUSGDD-UHFFFAOYSA-L 0.000 claims description 3
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 3
- 229920000771 poly (alkylcyanoacrylate) Polymers 0.000 claims description 3
- 229920000058 polyacrylate Polymers 0.000 claims description 3
- 229920001610 polycaprolactone Polymers 0.000 claims description 3
- 229950008679 protamine sulfate Drugs 0.000 claims description 3
- PTJWIQPHWPFNBW-GBNDHIKLSA-N pseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 claims description 3
- RHFUOMFWUGWKKO-UHFFFAOYSA-N s2C Natural products S=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 RHFUOMFWUGWKKO-UHFFFAOYSA-N 0.000 claims description 3
- 150000003408 sphingolipids Chemical class 0.000 claims description 3
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 2
- FGRBYDKOBBBPOI-UHFFFAOYSA-N 10,10-dioxo-2-[4-(N-phenylanilino)phenyl]thioxanthen-9-one Chemical compound O=C1c2ccccc2S(=O)(=O)c2ccc(cc12)-c1ccc(cc1)N(c1ccccc1)c1ccccc1 FGRBYDKOBBBPOI-UHFFFAOYSA-N 0.000 claims description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 2
- 108010041986 DNA Vaccines Proteins 0.000 claims description 2
- 229940021995 DNA vaccine Drugs 0.000 claims description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 claims description 2
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims description 2
- HCAJCMUKLZSPFT-KWXKLSQISA-N [3-(dimethylamino)-2-[(9z,12z)-octadeca-9,12-dienoyl]oxypropyl] (9z,12z)-octadeca-9,12-dienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OCC(CN(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC HCAJCMUKLZSPFT-KWXKLSQISA-N 0.000 claims description 2
- 229940072056 alginate Drugs 0.000 claims description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 2
- 239000004632 polycaprolactone Substances 0.000 claims description 2
- 230000002441 reversible effect Effects 0.000 claims description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 2
- CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 claims 1
- AMCPECLBZPXAPB-UHFFFAOYSA-N propane-1,2,3-triol;sodium Chemical compound [Na].OCC(O)CO AMCPECLBZPXAPB-UHFFFAOYSA-N 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 abstract description 154
- 108091007433 antigens Proteins 0.000 abstract description 68
- 102000036639 antigens Human genes 0.000 abstract description 68
- 239000000427 antigen Substances 0.000 abstract description 67
- 238000002360 preparation method Methods 0.000 abstract description 27
- 238000011282 treatment Methods 0.000 abstract description 16
- 239000012634 fragment Substances 0.000 abstract description 10
- 230000001976 improved effect Effects 0.000 abstract description 5
- 230000002265 prevention Effects 0.000 abstract description 4
- 108090000623 proteins and genes Proteins 0.000 description 138
- 102000039446 nucleic acids Human genes 0.000 description 125
- 108020004707 nucleic acids Proteins 0.000 description 125
- 241000699670 Mus sp. Species 0.000 description 111
- 102000004169 proteins and genes Human genes 0.000 description 105
- 108020004459 Small interfering RNA Proteins 0.000 description 100
- 210000004072 lung Anatomy 0.000 description 99
- 210000004027 cell Anatomy 0.000 description 97
- 235000018102 proteins Nutrition 0.000 description 94
- 230000003053 immunization Effects 0.000 description 82
- 238000002649 immunization Methods 0.000 description 78
- 108091036066 Three prime untranslated region Proteins 0.000 description 76
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 73
- 238000000034 method Methods 0.000 description 72
- 108020004414 DNA Proteins 0.000 description 70
- 241001465754 Metazoa Species 0.000 description 67
- 210000002966 serum Anatomy 0.000 description 67
- 239000000243 solution Substances 0.000 description 65
- 230000003472 neutralizing effect Effects 0.000 description 62
- 238000001514 detection method Methods 0.000 description 60
- 241000700605 Viruses Species 0.000 description 58
- 210000001519 tissue Anatomy 0.000 description 55
- 238000012360 testing method Methods 0.000 description 54
- 241000699666 Mus <mouse, genus> Species 0.000 description 47
- 108700026244 Open Reading Frames Proteins 0.000 description 47
- 230000014509 gene expression Effects 0.000 description 45
- 238000002474 experimental method Methods 0.000 description 44
- 108090000765 processed proteins & peptides Proteins 0.000 description 44
- 239000012895 dilution Substances 0.000 description 40
- 238000010790 dilution Methods 0.000 description 40
- 239000000523 sample Substances 0.000 description 40
- 208000025721 COVID-19 Diseases 0.000 description 39
- 239000000203 mixture Substances 0.000 description 39
- 102000004196 processed proteins & peptides Human genes 0.000 description 39
- 108091023045 Untranslated Region Proteins 0.000 description 36
- 229920001184 polypeptide Polymers 0.000 description 35
- 230000003612 virological effect Effects 0.000 description 35
- 238000011740 C57BL/6 mouse Methods 0.000 description 32
- 241001678559 COVID-19 virus Species 0.000 description 32
- 241001112090 Pseudovirus Species 0.000 description 28
- 238000013518 transcription Methods 0.000 description 28
- 230000035897 transcription Effects 0.000 description 27
- 102000040430 polynucleotide Human genes 0.000 description 26
- 108091033319 polynucleotide Proteins 0.000 description 26
- 239000002157 polynucleotide Substances 0.000 description 26
- 230000014616 translation Effects 0.000 description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- 241000282693 Cercopithecidae Species 0.000 description 23
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 22
- 239000007788 liquid Substances 0.000 description 22
- 239000008194 pharmaceutical composition Substances 0.000 description 22
- 108091027974 Mature messenger RNA Proteins 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 21
- 239000003153 chemical reaction reagent Substances 0.000 description 21
- 238000000338 in vitro Methods 0.000 description 21
- 230000001965 increasing effect Effects 0.000 description 21
- 238000003556 assay Methods 0.000 description 20
- 150000001875 compounds Chemical class 0.000 description 20
- 230000000694 effects Effects 0.000 description 20
- 239000002609 medium Substances 0.000 description 20
- 108010061238 threonyl-glycine Proteins 0.000 description 20
- 230000037396 body weight Effects 0.000 description 19
- 238000013519 translation Methods 0.000 description 19
- 239000003814 drug Substances 0.000 description 18
- 230000028993 immune response Effects 0.000 description 18
- 208000015181 infectious disease Diseases 0.000 description 17
- 239000013598 vector Substances 0.000 description 17
- 235000001014 amino acid Nutrition 0.000 description 16
- 229940024606 amino acid Drugs 0.000 description 16
- 150000001413 amino acids Chemical class 0.000 description 16
- 108010050848 glycylleucine Proteins 0.000 description 16
- 239000012528 membrane Substances 0.000 description 16
- 235000002639 sodium chloride Nutrition 0.000 description 16
- 239000000872 buffer Substances 0.000 description 15
- 239000000126 substance Substances 0.000 description 15
- 229910001868 water Inorganic materials 0.000 description 15
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 14
- 241000282414 Homo sapiens Species 0.000 description 14
- 230000006870 function Effects 0.000 description 14
- 239000000463 material Substances 0.000 description 14
- 238000000746 purification Methods 0.000 description 14
- 230000002829 reductive effect Effects 0.000 description 14
- 239000006228 supernatant Substances 0.000 description 14
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 13
- 210000001744 T-lymphocyte Anatomy 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 13
- 238000011161 development Methods 0.000 description 13
- 230000018109 developmental process Effects 0.000 description 13
- 230000001575 pathological effect Effects 0.000 description 13
- 239000013612 plasmid Substances 0.000 description 13
- 230000008569 process Effects 0.000 description 13
- 238000005406 washing Methods 0.000 description 13
- 238000011725 BALB/c mouse Methods 0.000 description 12
- 241000282560 Macaca mulatta Species 0.000 description 12
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 12
- 239000011162 core material Substances 0.000 description 12
- 238000011156 evaluation Methods 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 108010073472 leucyl-prolyl-proline Proteins 0.000 description 12
- 239000000725 suspension Substances 0.000 description 12
- 230000008719 thickening Effects 0.000 description 12
- 238000012546 transfer Methods 0.000 description 12
- 102100031673 Corneodesmosin Human genes 0.000 description 11
- 101710139375 Corneodesmosin Proteins 0.000 description 11
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- 108010047495 alanylglycine Proteins 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 229940088598 enzyme Drugs 0.000 description 11
- 230000005847 immunogenicity Effects 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 238000006386 neutralization reaction Methods 0.000 description 11
- 238000005457 optimization Methods 0.000 description 11
- 230000002028 premature Effects 0.000 description 11
- SMCGQGDVTPFXKB-XPUUQOCRSA-N Ala-Gly-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N SMCGQGDVTPFXKB-XPUUQOCRSA-N 0.000 description 10
- 108020005004 Guide RNA Proteins 0.000 description 10
- PURRNJBBXDDWLX-ZDLURKLDSA-N Ser-Thr-Gly Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CO)N)O PURRNJBBXDDWLX-ZDLURKLDSA-N 0.000 description 10
- CAJFZCICSVBOJK-SHGPDSBTSA-N Thr-Ala-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CAJFZCICSVBOJK-SHGPDSBTSA-N 0.000 description 10
- 230000008859 change Effects 0.000 description 10
- 238000000576 coating method Methods 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 238000011534 incubation Methods 0.000 description 10
- 230000035800 maturation Effects 0.000 description 10
- 230000008488 polyadenylation Effects 0.000 description 10
- 230000009467 reduction Effects 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- 241000283707 Capra Species 0.000 description 9
- 108020004705 Codon Proteins 0.000 description 9
- 108060001084 Luciferase Proteins 0.000 description 9
- 239000005089 Luciferase Substances 0.000 description 9
- 210000003719 b-lymphocyte Anatomy 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- 241000894007 species Species 0.000 description 9
- 239000003981 vehicle Substances 0.000 description 9
- 229920001212 Poly(beta amino esters) Polymers 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 8
- 108010087924 alanylproline Proteins 0.000 description 8
- 230000000890 antigenic effect Effects 0.000 description 8
- 230000000740 bleeding effect Effects 0.000 description 8
- 229910002092 carbon dioxide Inorganic materials 0.000 description 8
- 238000004113 cell culture Methods 0.000 description 8
- 239000011248 coating agent Substances 0.000 description 8
- 235000014304 histidine Nutrition 0.000 description 8
- 108010057821 leucylproline Proteins 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 230000036961 partial effect Effects 0.000 description 8
- 108010090894 prolylleucine Proteins 0.000 description 8
- 230000001681 protective effect Effects 0.000 description 8
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 8
- SWQALSGKVLYKDT-UHFFFAOYSA-N Gly-Ile-Ala Natural products NCC(=O)NC(C(C)CC)C(=O)NC(C)C(O)=O SWQALSGKVLYKDT-UHFFFAOYSA-N 0.000 description 7
- JQFILXICXLDTRR-FBCQKBJTSA-N Gly-Thr-Gly Chemical compound NCC(=O)N[C@@H]([C@H](O)C)C(=O)NCC(O)=O JQFILXICXLDTRR-FBCQKBJTSA-N 0.000 description 7
- XVZCXCTYGHPNEM-UHFFFAOYSA-N Leu-Leu-Pro Natural products CC(C)CC(N)C(=O)NC(CC(C)C)C(=O)N1CCCC1C(O)=O XVZCXCTYGHPNEM-UHFFFAOYSA-N 0.000 description 7
- DPURXCQCHSQPAN-AVGNSLFASA-N Leu-Pro-Pro Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 DPURXCQCHSQPAN-AVGNSLFASA-N 0.000 description 7
- 239000000232 Lipid Bilayer Substances 0.000 description 7
- 108091081024 Start codon Proteins 0.000 description 7
- DWYAUVCQDTZIJI-VZFHVOOUSA-N Thr-Ala-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O DWYAUVCQDTZIJI-VZFHVOOUSA-N 0.000 description 7
- 210000000612 antigen-presenting cell Anatomy 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- 239000003085 diluting agent Substances 0.000 description 7
- 238000001962 electrophoresis Methods 0.000 description 7
- 230000002163 immunogen Effects 0.000 description 7
- 210000004969 inflammatory cell Anatomy 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 230000010076 replication Effects 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 229940124597 therapeutic agent Drugs 0.000 description 7
- 208000016261 weight loss Diseases 0.000 description 7
- DCVYRWFAMZFSDA-ZLUOBGJFSA-N Ala-Ser-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O DCVYRWFAMZFSDA-ZLUOBGJFSA-N 0.000 description 6
- NZGRHTKZFSVPAN-BIIVOSGPSA-N Ala-Ser-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N NZGRHTKZFSVPAN-BIIVOSGPSA-N 0.000 description 6
- 108091026890 Coding region Proteins 0.000 description 6
- 208000001528 Coronaviridae Infections Diseases 0.000 description 6
- 102000053602 DNA Human genes 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- PYTZFYUXZZHOAD-WHFBIAKZSA-N Gly-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)CN PYTZFYUXZZHOAD-WHFBIAKZSA-N 0.000 description 6
- 208000029523 Interstitial Lung disease Diseases 0.000 description 6
- UGTHTQWIQKEDEH-BQBZGAKWSA-N L-alanyl-L-prolylglycine zwitterion Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O UGTHTQWIQKEDEH-BQBZGAKWSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 229930040373 Paraformaldehyde Natural products 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 6
- LEIKGVHQTKHOLM-IUCAKERBSA-N Pro-Pro-Gly Chemical compound OC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 LEIKGVHQTKHOLM-IUCAKERBSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 108010000605 Ribosomal Proteins Proteins 0.000 description 6
- 102000002278 Ribosomal Proteins Human genes 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 6
- 108010076324 alanyl-glycyl-glycine Proteins 0.000 description 6
- 125000000539 amino acid group Chemical group 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 239000013592 cell lysate Substances 0.000 description 6
- 239000006285 cell suspension Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000007865 diluting Methods 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 6
- 238000009396 hybridization Methods 0.000 description 6
- 230000008595 infiltration Effects 0.000 description 6
- 238000001764 infiltration Methods 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 238000010255 intramuscular injection Methods 0.000 description 6
- 239000007927 intramuscular injection Substances 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 108091070501 miRNA Proteins 0.000 description 6
- 229920002866 paraformaldehyde Polymers 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 6
- 108010014614 prolyl-glycyl-proline Proteins 0.000 description 6
- 239000012898 sample dilution Substances 0.000 description 6
- 108010026333 seryl-proline Proteins 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 210000004989 spleen cell Anatomy 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 230000009385 viral infection Effects 0.000 description 6
- 230000004580 weight loss Effects 0.000 description 6
- JBVSSSZFNTXJDX-YTLHQDLWSA-N Ala-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)N JBVSSSZFNTXJDX-YTLHQDLWSA-N 0.000 description 5
- NOGFDULFCFXBHB-CIUDSAMLSA-N Ala-Leu-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)O)N NOGFDULFCFXBHB-CIUDSAMLSA-N 0.000 description 5
- IPZQNYYAYVRKKK-FXQIFTODSA-N Ala-Pro-Ala Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O IPZQNYYAYVRKKK-FXQIFTODSA-N 0.000 description 5
- NLYYHIKRBRMAJV-AEJSXWLSSA-N Ala-Val-Pro Chemical compound C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N NLYYHIKRBRMAJV-AEJSXWLSSA-N 0.000 description 5
- OMSKGWFGWCQFBD-KZVJFYERSA-N Ala-Val-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OMSKGWFGWCQFBD-KZVJFYERSA-N 0.000 description 5
- 206010002091 Anaesthesia Diseases 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 5
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 5
- NSVOVKWEKGEOQB-LURJTMIESA-N Gly-Pro-Gly Chemical compound NCC(=O)N1CCC[C@H]1C(=O)NCC(O)=O NSVOVKWEKGEOQB-LURJTMIESA-N 0.000 description 5
- TVTZEOHWHUVYCG-KYNKHSRBSA-N Gly-Thr-Thr Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O TVTZEOHWHUVYCG-KYNKHSRBSA-N 0.000 description 5
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 5
- 241000880493 Leptailurus serval Species 0.000 description 5
- WNGVUZWBXZKQES-YUMQZZPRSA-N Leu-Ala-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O WNGVUZWBXZKQES-YUMQZZPRSA-N 0.000 description 5
- WMIOEVKKYIMVKI-DCAQKATOSA-N Leu-Pro-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O WMIOEVKKYIMVKI-DCAQKATOSA-N 0.000 description 5
- 229920001213 Polysorbate 20 Polymers 0.000 description 5
- HAAQQNHQZBOWFO-LURJTMIESA-N Pro-Gly-Gly Chemical compound OC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1 HAAQQNHQZBOWFO-LURJTMIESA-N 0.000 description 5
- 208000037847 SARS-CoV-2-infection Diseases 0.000 description 5
- HHJFMHQYEAAOBM-ZLUOBGJFSA-N Ser-Ser-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O HHJFMHQYEAAOBM-ZLUOBGJFSA-N 0.000 description 5
- 230000005867 T cell response Effects 0.000 description 5
- BSNZTJXVDOINSR-JXUBOQSCSA-N Thr-Ala-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O BSNZTJXVDOINSR-JXUBOQSCSA-N 0.000 description 5
- MEJHFIOYJHTWMK-VOAKCMCISA-N Thr-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)[C@@H](C)O MEJHFIOYJHTWMK-VOAKCMCISA-N 0.000 description 5
- CPGJELLYDQEDRK-NAKRPEOUSA-N Val-Ile-Ala Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](N)C(C)C)C(=O)N[C@@H](C)C(O)=O CPGJELLYDQEDRK-NAKRPEOUSA-N 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 230000037005 anaesthesia Effects 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 239000011258 core-shell material Substances 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 108010060199 cysteinylproline Proteins 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 231100000517 death Toxicity 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 238000001502 gel electrophoresis Methods 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 210000001102 germinal center b cell Anatomy 0.000 description 5
- 108010077515 glycylproline Proteins 0.000 description 5
- 239000006166 lysate Substances 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 231100000915 pathological change Toxicity 0.000 description 5
- 230000036285 pathological change Effects 0.000 description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 108010020755 prolyl-glycyl-glycine Proteins 0.000 description 5
- 108010053725 prolylvaline Proteins 0.000 description 5
- 230000002685 pulmonary effect Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- XVZCXCTYGHPNEM-IHRRRGAJSA-N (2s)-1-[(2s)-2-[[(2s)-2-amino-4-methylpentanoyl]amino]-4-methylpentanoyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(O)=O XVZCXCTYGHPNEM-IHRRRGAJSA-N 0.000 description 4
- BRPMXFSTKXXNHF-IUCAKERBSA-N (2s)-1-[2-[[(2s)-pyrrolidine-2-carbonyl]amino]acetyl]pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H]1NCCC1 BRPMXFSTKXXNHF-IUCAKERBSA-N 0.000 description 4
- 108010036211 5-HT-moduline Proteins 0.000 description 4
- CXRCVCURMBFFOL-FXQIFTODSA-N Ala-Ala-Pro Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O CXRCVCURMBFFOL-FXQIFTODSA-N 0.000 description 4
- VGPWRRFOPXVGOH-BYPYZUCNSA-N Ala-Gly-Gly Chemical compound C[C@H](N)C(=O)NCC(=O)NCC(O)=O VGPWRRFOPXVGOH-BYPYZUCNSA-N 0.000 description 4
- LMFXXZPPZDCPTA-ZKWXMUAHSA-N Ala-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N LMFXXZPPZDCPTA-ZKWXMUAHSA-N 0.000 description 4
- VNYMOTCMNHJGTG-JBDRJPRFSA-N Ala-Ile-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O VNYMOTCMNHJGTG-JBDRJPRFSA-N 0.000 description 4
- SOBIAADAMRHGKH-CIUDSAMLSA-N Ala-Leu-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O SOBIAADAMRHGKH-CIUDSAMLSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 238000012935 Averaging Methods 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 102000053642 Catalytic RNA Human genes 0.000 description 4
- 108090000994 Catalytic RNA Proteins 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 108060002716 Exonuclease Proteins 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- QSDKBRMVXSWAQE-BFHQHQDPSA-N Gly-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)CN QSDKBRMVXSWAQE-BFHQHQDPSA-N 0.000 description 4
- GLACUWHUYFBSPJ-FJXKBIBVSA-N Gly-Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)CN GLACUWHUYFBSPJ-FJXKBIBVSA-N 0.000 description 4
- 102100027685 Hemoglobin subunit alpha Human genes 0.000 description 4
- 108091005902 Hemoglobin subunit alpha Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- AQCUAZTZSPQJFF-ZKWXMUAHSA-N Ile-Ala-Gly Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O AQCUAZTZSPQJFF-ZKWXMUAHSA-N 0.000 description 4
- 108091092195 Intron Proteins 0.000 description 4
- BQSLGJHIAGOZCD-CIUDSAMLSA-N Leu-Ala-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O BQSLGJHIAGOZCD-CIUDSAMLSA-N 0.000 description 4
- XBBKIIGCUMBKCO-JXUBOQSCSA-N Leu-Ala-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XBBKIIGCUMBKCO-JXUBOQSCSA-N 0.000 description 4
- DBSLVQBXKVKDKJ-BJDJZHNGSA-N Leu-Ile-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O DBSLVQBXKVKDKJ-BJDJZHNGSA-N 0.000 description 4
- SBANPBVRHYIMRR-UHFFFAOYSA-N Leu-Ser-Pro Natural products CC(C)CC(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O SBANPBVRHYIMRR-UHFFFAOYSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 239000002033 PVDF binder Substances 0.000 description 4
- 206010035664 Pneumonia Diseases 0.000 description 4
- KIZQGKLMXKGDIV-BQBZGAKWSA-N Pro-Ala-Gly Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 KIZQGKLMXKGDIV-BQBZGAKWSA-N 0.000 description 4
- IFMDQWDAJUMMJC-DCAQKATOSA-N Pro-Ala-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O IFMDQWDAJUMMJC-DCAQKATOSA-N 0.000 description 4
- CLNJSLSHKJECME-BQBZGAKWSA-N Pro-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H]1CCCN1 CLNJSLSHKJECME-BQBZGAKWSA-N 0.000 description 4
- CGSOWZUPLOKYOR-AVGNSLFASA-N Pro-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 CGSOWZUPLOKYOR-AVGNSLFASA-N 0.000 description 4
- KIDXAAQVMNLJFQ-KZVJFYERSA-N Pro-Thr-Ala Chemical compound C[C@@H](O)[C@H](NC(=O)[C@@H]1CCCN1)C(=O)N[C@@H](C)C(O)=O KIDXAAQVMNLJFQ-KZVJFYERSA-N 0.000 description 4
- BTKUIVBNGBFTTP-WHFBIAKZSA-N Ser-Ala-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)NCC(O)=O BTKUIVBNGBFTTP-WHFBIAKZSA-N 0.000 description 4
- GXUWHVZYDAHFSV-FLBSBUHZSA-N Thr-Ile-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GXUWHVZYDAHFSV-FLBSBUHZSA-N 0.000 description 4
- MXDOAJQRJBMGMO-FJXKBIBVSA-N Thr-Pro-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O MXDOAJQRJBMGMO-FJXKBIBVSA-N 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 4
- 108091023040 Transcription factor Proteins 0.000 description 4
- 102000040945 Transcription factor Human genes 0.000 description 4
- XBJKAZATRJBDCU-GUBZILKMSA-N Val-Pro-Ala Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O XBJKAZATRJBDCU-GUBZILKMSA-N 0.000 description 4
- GBIUHAYJGWVNLN-UHFFFAOYSA-N Val-Ser-Pro Natural products CC(C)C(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O GBIUHAYJGWVNLN-UHFFFAOYSA-N 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 230000005856 abnormality Effects 0.000 description 4
- 108010024078 alanyl-glycyl-serine Proteins 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 230000036760 body temperature Effects 0.000 description 4
- 238000004422 calculation algorithm Methods 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 239000007771 core particle Substances 0.000 description 4
- 230000002354 daily effect Effects 0.000 description 4
- 210000004443 dendritic cell Anatomy 0.000 description 4
- 239000008121 dextrose Substances 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 238000002224 dissection Methods 0.000 description 4
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 4
- 102000013165 exonuclease Human genes 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 210000001508 eye Anatomy 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 210000002683 foot Anatomy 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 108010051307 glycyl-glycyl-proline Proteins 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- 230000028996 humoral immune response Effects 0.000 description 4
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 description 4
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 108010044311 leucyl-glycyl-glycine Proteins 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 125000003835 nucleoside group Chemical group 0.000 description 4
- 238000002515 oligonucleotide synthesis Methods 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 4
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 4
- 108010029020 prolylglycine Proteins 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 108091092562 ribozyme Proteins 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 238000007789 sealing Methods 0.000 description 4
- 239000011257 shell material Substances 0.000 description 4
- 108091029842 small nuclear ribonucleic acid Proteins 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 4
- 238000004448 titration Methods 0.000 description 4
- 210000003437 trachea Anatomy 0.000 description 4
- 238000010023 transfer printing Methods 0.000 description 4
- 210000000689 upper leg Anatomy 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- GSHCNPAEDNETGJ-HKOLQMFGSA-N 2-[2,3-bis[[(z)-octadec-9-enoyl]oxy]propoxy-ethoxyphosphoryl]oxyethyl-trimethylazanium Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(=O)(OCC)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC GSHCNPAEDNETGJ-HKOLQMFGSA-N 0.000 description 3
- DQVAZKGVGKHQDS-UHFFFAOYSA-N 2-[[1-[2-[(2-amino-4-methylpentanoyl)amino]-4-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-4-methylpentanoic acid Chemical compound CC(C)CC(N)C(=O)NC(CC(C)C)C(=O)N1CCCC1C(=O)NC(CC(C)C)C(O)=O DQVAZKGVGKHQDS-UHFFFAOYSA-N 0.000 description 3
- 108020003589 5' Untranslated Regions Proteins 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 3
- UQJUGHFKNKGHFQ-VZFHVOOUSA-N Ala-Cys-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(O)=O UQJUGHFKNKGHFQ-VZFHVOOUSA-N 0.000 description 3
- ZVFVBBGVOILKPO-WHFBIAKZSA-N Ala-Gly-Ala Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O ZVFVBBGVOILKPO-WHFBIAKZSA-N 0.000 description 3
- PCIFXPRIFWKWLK-YUMQZZPRSA-N Ala-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N PCIFXPRIFWKWLK-YUMQZZPRSA-N 0.000 description 3
- MQIGTEQXYCRLGK-BQBZGAKWSA-N Ala-Gly-Pro Chemical compound C[C@H](N)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O MQIGTEQXYCRLGK-BQBZGAKWSA-N 0.000 description 3
- OBVSBEYOMDWLRJ-BFHQHQDPSA-N Ala-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N OBVSBEYOMDWLRJ-BFHQHQDPSA-N 0.000 description 3
- OYJCVIGKMXUVKB-GARJFASQSA-N Ala-Leu-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N OYJCVIGKMXUVKB-GARJFASQSA-N 0.000 description 3
- MEFILNJXAVSUTO-JXUBOQSCSA-N Ala-Leu-Thr Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MEFILNJXAVSUTO-JXUBOQSCSA-N 0.000 description 3
- FFZJHQODAYHGPO-KZVJFYERSA-N Ala-Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)N FFZJHQODAYHGPO-KZVJFYERSA-N 0.000 description 3
- WQKAQKZRDIZYNV-VZFHVOOUSA-N Ala-Ser-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O WQKAQKZRDIZYNV-VZFHVOOUSA-N 0.000 description 3
- ARHJJAAWNWOACN-FXQIFTODSA-N Ala-Ser-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O ARHJJAAWNWOACN-FXQIFTODSA-N 0.000 description 3
- HIIJOGIBQXHFKE-HHKYUTTNSA-N Ala-Thr-Ala-Pro Chemical compound C[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O HIIJOGIBQXHFKE-HHKYUTTNSA-N 0.000 description 3
- IOFVWPYSRSCWHI-JXUBOQSCSA-N Ala-Thr-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)N IOFVWPYSRSCWHI-JXUBOQSCSA-N 0.000 description 3
- 239000001856 Ethyl cellulose Substances 0.000 description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 3
- UGVQELHRNUDMAA-BYPYZUCNSA-N Gly-Ala-Gly Chemical compound [NH3+]CC(=O)N[C@@H](C)C(=O)NCC([O-])=O UGVQELHRNUDMAA-BYPYZUCNSA-N 0.000 description 3
- PEZZSFLFXXFUQD-XPUUQOCRSA-N Gly-Cys-Val Chemical compound [H]NCC(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(O)=O PEZZSFLFXXFUQD-XPUUQOCRSA-N 0.000 description 3
- UQJNXZSSGQIPIQ-FBCQKBJTSA-N Gly-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)CN UQJNXZSSGQIPIQ-FBCQKBJTSA-N 0.000 description 3
- OLPPXYMMIARYAL-QMMMGPOBSA-N Gly-Gly-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)CNC(=O)CN OLPPXYMMIARYAL-QMMMGPOBSA-N 0.000 description 3
- SWQALSGKVLYKDT-ZKWXMUAHSA-N Gly-Ile-Ala Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O SWQALSGKVLYKDT-ZKWXMUAHSA-N 0.000 description 3
- SCWYHUQOOFRVHP-MBLNEYKQSA-N Gly-Ile-Thr Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SCWYHUQOOFRVHP-MBLNEYKQSA-N 0.000 description 3
- LHYJCVCQPWRMKZ-WEDXCCLWSA-N Gly-Leu-Thr Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LHYJCVCQPWRMKZ-WEDXCCLWSA-N 0.000 description 3
- GGLIDLCEPDHEJO-BQBZGAKWSA-N Gly-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)CN GGLIDLCEPDHEJO-BQBZGAKWSA-N 0.000 description 3
- FFJQHWKSGAWSTJ-BFHQHQDPSA-N Gly-Thr-Ala Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O FFJQHWKSGAWSTJ-BFHQHQDPSA-N 0.000 description 3
- ZZWUYQXMIFTIIY-WEDXCCLWSA-N Gly-Thr-Leu Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O ZZWUYQXMIFTIIY-WEDXCCLWSA-N 0.000 description 3
- AFMOTCMSEBITOE-YEPSODPASA-N Gly-Val-Thr Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O AFMOTCMSEBITOE-YEPSODPASA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 229920002907 Guar gum Polymers 0.000 description 3
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 3
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 3
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 3
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- NKVZTQVGUNLLQW-JBDRJPRFSA-N Ile-Ala-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)O)N NKVZTQVGUNLLQW-JBDRJPRFSA-N 0.000 description 3
- 102000004388 Interleukin-4 Human genes 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- VDIARPPNADFEAV-WEDXCCLWSA-N Leu-Thr-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O VDIARPPNADFEAV-WEDXCCLWSA-N 0.000 description 3
- AAKRWBIIGKPOKQ-ONGXEEELSA-N Leu-Val-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O AAKRWBIIGKPOKQ-ONGXEEELSA-N 0.000 description 3
- 108010079364 N-glycylalanine Proteins 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 108091093037 Peptide nucleic acid Proteins 0.000 description 3
- DZZCICYRSZASNF-FXQIFTODSA-N Pro-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 DZZCICYRSZASNF-FXQIFTODSA-N 0.000 description 3
- AFXCXDQNRXTSBD-FJXKBIBVSA-N Pro-Gly-Thr Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O AFXCXDQNRXTSBD-FJXKBIBVSA-N 0.000 description 3
- FXGIMYRVJJEIIM-UWVGGRQHSA-N Pro-Leu-Gly Chemical compound OC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1 FXGIMYRVJJEIIM-UWVGGRQHSA-N 0.000 description 3
- KDBHVPXBQADZKY-GUBZILKMSA-N Pro-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 KDBHVPXBQADZKY-GUBZILKMSA-N 0.000 description 3
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 3
- 108700008625 Reporter Genes Proteins 0.000 description 3
- KDGARKCAKHBEDB-NKWVEPMBSA-N Ser-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CO)N)C(=O)O KDGARKCAKHBEDB-NKWVEPMBSA-N 0.000 description 3
- SFTZWNJFZYOLBD-ZDLURKLDSA-N Ser-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CO SFTZWNJFZYOLBD-ZDLURKLDSA-N 0.000 description 3
- AZWNCEBQZXELEZ-FXQIFTODSA-N Ser-Pro-Ser Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O AZWNCEBQZXELEZ-FXQIFTODSA-N 0.000 description 3
- XQJCEKXQUJQNNK-ZLUOBGJFSA-N Ser-Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O XQJCEKXQUJQNNK-ZLUOBGJFSA-N 0.000 description 3
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 3
- 102000039471 Small Nuclear RNA Human genes 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- TYVAWPFQYFPSBR-BFHQHQDPSA-N Thr-Ala-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)NCC(O)=O TYVAWPFQYFPSBR-BFHQHQDPSA-N 0.000 description 3
- SLUWOCTZVGMURC-BFHQHQDPSA-N Thr-Gly-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O SLUWOCTZVGMURC-BFHQHQDPSA-N 0.000 description 3
- WYKJENSCCRJLRC-ZDLURKLDSA-N Thr-Gly-Cys Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](CS)C(=O)O)N)O WYKJENSCCRJLRC-ZDLURKLDSA-N 0.000 description 3
- AYCQVUUPIJHJTA-IXOXFDKPSA-N Thr-His-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(O)=O AYCQVUUPIJHJTA-IXOXFDKPSA-N 0.000 description 3
- VRUFCJZQDACGLH-UVOCVTCTSA-N Thr-Leu-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VRUFCJZQDACGLH-UVOCVTCTSA-N 0.000 description 3
- DEGCBBCMYWNJNA-RHYQMDGZSA-N Thr-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)[C@@H](C)O DEGCBBCMYWNJNA-RHYQMDGZSA-N 0.000 description 3
- DEGUERSKQBRZMZ-FXQIFTODSA-N Val-Ser-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O DEGUERSKQBRZMZ-FXQIFTODSA-N 0.000 description 3
- CEKSLIVSNNGOKH-KZVJFYERSA-N Val-Thr-Ala Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C)C(=O)O)NC(=O)[C@H](C(C)C)N)O CEKSLIVSNNGOKH-KZVJFYERSA-N 0.000 description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
- 230000010530 Virus Neutralization Effects 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 150000003838 adenosines Chemical class 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 230000003542 behavioural effect Effects 0.000 description 3
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 210000000621 bronchi Anatomy 0.000 description 3
- 238000005251 capillar electrophoresis Methods 0.000 description 3
- 229960001631 carbomer Drugs 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 150000001783 ceramides Chemical class 0.000 description 3
- 150000001784 cerebrosides Chemical class 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 238000009295 crossflow filtration Methods 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 108010016616 cysteinylglycine Proteins 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 description 3
- 108010054813 diprotin B Proteins 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000012154 double-distilled water Substances 0.000 description 3
- 210000005069 ears Anatomy 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 235000019325 ethyl cellulose Nutrition 0.000 description 3
- 229920001249 ethyl cellulose Polymers 0.000 description 3
- 229960004667 ethyl cellulose Drugs 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 230000003325 follicular Effects 0.000 description 3
- 229940014259 gelatin Drugs 0.000 description 3
- 108010026364 glycyl-glycyl-leucine Proteins 0.000 description 3
- 108010089804 glycyl-threonine Proteins 0.000 description 3
- 229940015043 glyoxal Drugs 0.000 description 3
- 238000000227 grinding Methods 0.000 description 3
- 235000010417 guar gum Nutrition 0.000 description 3
- 239000000665 guar gum Substances 0.000 description 3
- 229960002154 guar gum Drugs 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 210000002443 helper t lymphocyte Anatomy 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000016784 immunoglobulin production Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 229940028885 interleukin-4 Drugs 0.000 description 3
- 238000001361 intraarterial administration Methods 0.000 description 3
- 239000012669 liquid formulation Substances 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 239000002679 microRNA Substances 0.000 description 3
- 239000011859 microparticle Substances 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 239000007923 nasal drop Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 238000010827 pathological analysis Methods 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 108010093296 prolyl-prolyl-alanine Proteins 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 235000020183 skimmed milk Nutrition 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 230000014621 translational initiation Effects 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 3
- 229940045145 uridine Drugs 0.000 description 3
- 239000012224 working solution Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- OTEWWRBKGONZBW-UHFFFAOYSA-N 2-[[2-[[2-[(2-azaniumylacetyl)amino]-4-methylpentanoyl]amino]acetyl]amino]acetate Chemical compound NCC(=O)NC(CC(C)C)C(=O)NCC(=O)NCC(O)=O OTEWWRBKGONZBW-UHFFFAOYSA-N 0.000 description 2
- HDZZVAMISRMYHH-UHFFFAOYSA-N 9beta-Ribofuranosyl-7-deazaadenin Natural products C1=CC=2C(N)=NC=NC=2N1C1OC(CO)C(O)C1O HDZZVAMISRMYHH-UHFFFAOYSA-N 0.000 description 2
- RLMISHABBKUNFO-WHFBIAKZSA-N Ala-Ala-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O RLMISHABBKUNFO-WHFBIAKZSA-N 0.000 description 2
- MIPWEZAIMPYQST-FXQIFTODSA-N Ala-Cys-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(O)=O MIPWEZAIMPYQST-FXQIFTODSA-N 0.000 description 2
- VWEWCZSUWOEEFM-WDSKDSINSA-N Ala-Gly-Ala-Gly Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(O)=O VWEWCZSUWOEEFM-WDSKDSINSA-N 0.000 description 2
- NBTGEURICRTMGL-WHFBIAKZSA-N Ala-Gly-Ser Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O NBTGEURICRTMGL-WHFBIAKZSA-N 0.000 description 2
- LXAARTARZJJCMB-CIQUZCHMSA-N Ala-Ile-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LXAARTARZJJCMB-CIQUZCHMSA-N 0.000 description 2
- MNZHHDPWDWQJCQ-YUMQZZPRSA-N Ala-Leu-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O MNZHHDPWDWQJCQ-YUMQZZPRSA-N 0.000 description 2
- DPNZTBKGAUAZQU-DLOVCJGASA-N Ala-Leu-His Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N DPNZTBKGAUAZQU-DLOVCJGASA-N 0.000 description 2
- XWFWAXPOLRTDFZ-FXQIFTODSA-N Ala-Pro-Ser Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O XWFWAXPOLRTDFZ-FXQIFTODSA-N 0.000 description 2
- RTZCUEHYUQZIDE-WHFBIAKZSA-N Ala-Ser-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O RTZCUEHYUQZIDE-WHFBIAKZSA-N 0.000 description 2
- NCQMBSJGJMYKCK-ZLUOBGJFSA-N Ala-Ser-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O NCQMBSJGJMYKCK-ZLUOBGJFSA-N 0.000 description 2
- QOIGKCBMXUCDQU-KDXUFGMBSA-N Ala-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C)N)O QOIGKCBMXUCDQU-KDXUFGMBSA-N 0.000 description 2
- KUFVXLQLDHJVOG-SHGPDSBTSA-N Ala-Thr-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](C)N)O KUFVXLQLDHJVOG-SHGPDSBTSA-N 0.000 description 2
- 108020005544 Antisense RNA Proteins 0.000 description 2
- 108091023037 Aptamer Proteins 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 208000031636 Body Temperature Changes Diseases 0.000 description 2
- 208000031648 Body Weight Changes Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 206010006100 Bradykinesia Diseases 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- ALNKNYKSZPSLBD-ZDLURKLDSA-N Cys-Thr-Gly Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O ALNKNYKSZPSLBD-ZDLURKLDSA-N 0.000 description 2
- IQXSTXKVEMRMMB-XAVMHZPKSA-N Cys-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CS)N)O IQXSTXKVEMRMMB-XAVMHZPKSA-N 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 102000004533 Endonucleases Human genes 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108700039887 Essential Genes Proteins 0.000 description 2
- 206010015548 Euthanasia Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- VSVZIEVNUYDAFR-YUMQZZPRSA-N Gly-Ala-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)CN VSVZIEVNUYDAFR-YUMQZZPRSA-N 0.000 description 2
- LJPIRKICOISLKN-WHFBIAKZSA-N Gly-Ala-Ser Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O LJPIRKICOISLKN-WHFBIAKZSA-N 0.000 description 2
- CCQOOWAONKGYKQ-BYPYZUCNSA-N Gly-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)CN CCQOOWAONKGYKQ-BYPYZUCNSA-N 0.000 description 2
- XPJBQTCXPJNIFE-ZETCQYMHSA-N Gly-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)CN XPJBQTCXPJNIFE-ZETCQYMHSA-N 0.000 description 2
- BUEFQXUHTUZXHR-LURJTMIESA-N Gly-Gly-Pro zwitterion Chemical compound NCC(=O)NCC(=O)N1CCC[C@H]1C(O)=O BUEFQXUHTUZXHR-LURJTMIESA-N 0.000 description 2
- UESJMAMHDLEHGM-NHCYSSNCSA-N Gly-Ile-Leu Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O UESJMAMHDLEHGM-NHCYSSNCSA-N 0.000 description 2
- PAWIVEIWWYGBAM-YUMQZZPRSA-N Gly-Leu-Ala Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O PAWIVEIWWYGBAM-YUMQZZPRSA-N 0.000 description 2
- LCRDMSSAKLTKBU-ZDLURKLDSA-N Gly-Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CN LCRDMSSAKLTKBU-ZDLURKLDSA-N 0.000 description 2
- YGHSQRJSHKYUJY-SCZZXKLOSA-N Gly-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN YGHSQRJSHKYUJY-SCZZXKLOSA-N 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000006083 Hypokinesia Diseases 0.000 description 2
- CYHYBSGMHMHKOA-CIQUZCHMSA-N Ile-Ala-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N CYHYBSGMHMHKOA-CIQUZCHMSA-N 0.000 description 2
- WIZPFZKOFZXDQG-HTFCKZLJSA-N Ile-Ile-Ala Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O WIZPFZKOFZXDQG-HTFCKZLJSA-N 0.000 description 2
- KLBVGHCGHUNHEA-BJDJZHNGSA-N Ile-Leu-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)O)N KLBVGHCGHUNHEA-BJDJZHNGSA-N 0.000 description 2
- CNMOKANDJMLAIF-CIQUZCHMSA-N Ile-Thr-Ala Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O CNMOKANDJMLAIF-CIQUZCHMSA-N 0.000 description 2
- YBKKLDBBPFIXBQ-MBLNEYKQSA-N Ile-Thr-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)O)N YBKKLDBBPFIXBQ-MBLNEYKQSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- RCFDOSNHHZGBOY-UHFFFAOYSA-N L-isoleucyl-L-alanine Natural products CCC(C)C(N)C(=O)NC(C)C(O)=O RCFDOSNHHZGBOY-UHFFFAOYSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- WSGXUIQTEZDVHJ-GARJFASQSA-N Leu-Ala-Pro Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@@H]1C(O)=O WSGXUIQTEZDVHJ-GARJFASQSA-N 0.000 description 2
- VWHGTYCRDRBSFI-ZETCQYMHSA-N Leu-Gly-Gly Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)NCC(O)=O VWHGTYCRDRBSFI-ZETCQYMHSA-N 0.000 description 2
- VGPCJSXPPOQPBK-YUMQZZPRSA-N Leu-Gly-Ser Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O VGPCJSXPPOQPBK-YUMQZZPRSA-N 0.000 description 2
- LIINDKYIGYTDLG-PPCPHDFISA-N Leu-Ile-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LIINDKYIGYTDLG-PPCPHDFISA-N 0.000 description 2
- IEWBEPKLKUXQBU-VOAKCMCISA-N Leu-Leu-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O IEWBEPKLKUXQBU-VOAKCMCISA-N 0.000 description 2
- KWLWZYMNUZJKMZ-IHRRRGAJSA-N Leu-Pro-Leu Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O KWLWZYMNUZJKMZ-IHRRRGAJSA-N 0.000 description 2
- IRMLZWSRWSGTOP-CIUDSAMLSA-N Leu-Ser-Ala Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O IRMLZWSRWSGTOP-CIUDSAMLSA-N 0.000 description 2
- ZJZNLRVCZWUONM-JXUBOQSCSA-N Leu-Thr-Ala Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O ZJZNLRVCZWUONM-JXUBOQSCSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- QEVRUYFHWJJUHZ-DCAQKATOSA-N Met-Ala-Leu Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC(C)C QEVRUYFHWJJUHZ-DCAQKATOSA-N 0.000 description 2
- CIDICGYKRUTYLE-FXQIFTODSA-N Met-Ser-Ala Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O CIDICGYKRUTYLE-FXQIFTODSA-N 0.000 description 2
- GWADARYJIJDYRC-XGEHTFHBSA-N Met-Thr-Ser Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O GWADARYJIJDYRC-XGEHTFHBSA-N 0.000 description 2
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 2
- 206010028347 Muscle twitching Diseases 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 2
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 2
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- FZHBZMDRDASUHN-NAKRPEOUSA-N Pro-Ala-Ile Chemical compound CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1)C(O)=O FZHBZMDRDASUHN-NAKRPEOUSA-N 0.000 description 2
- HFZNNDWPHBRNPV-KZVJFYERSA-N Pro-Ala-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O HFZNNDWPHBRNPV-KZVJFYERSA-N 0.000 description 2
- FKKHDBFNOLCYQM-FXQIFTODSA-N Pro-Cys-Ala Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CS)C(=O)N[C@@H](C)C(O)=O FKKHDBFNOLCYQM-FXQIFTODSA-N 0.000 description 2
- DXTOOBDIIAJZBJ-BQBZGAKWSA-N Pro-Gly-Ser Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CO)C(O)=O DXTOOBDIIAJZBJ-BQBZGAKWSA-N 0.000 description 2
- PEYNRYREGPAOAK-LSJOCFKGSA-N Pro-His-Ala Chemical compound C([C@@H](C(=O)N[C@@H](C)C([O-])=O)NC(=O)[C@H]1[NH2+]CCC1)C1=CN=CN1 PEYNRYREGPAOAK-LSJOCFKGSA-N 0.000 description 2
- IBGCFJDLCYTKPW-NAKRPEOUSA-N Pro-Ile-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]1CCCN1 IBGCFJDLCYTKPW-NAKRPEOUSA-N 0.000 description 2
- FMLRRBDLBJLJIK-DCAQKATOSA-N Pro-Leu-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1 FMLRRBDLBJLJIK-DCAQKATOSA-N 0.000 description 2
- MCWHYUWXVNRXFV-RWMBFGLXSA-N Pro-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@@H]2CCCN2 MCWHYUWXVNRXFV-RWMBFGLXSA-N 0.000 description 2
- SUENWIFTSTWUKD-AVGNSLFASA-N Pro-Leu-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O SUENWIFTSTWUKD-AVGNSLFASA-N 0.000 description 2
- POQFNPILEQEODH-FXQIFTODSA-N Pro-Ser-Ala Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O POQFNPILEQEODH-FXQIFTODSA-N 0.000 description 2
- DCHQYSOGURGJST-FJXKBIBVSA-N Pro-Thr-Gly Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O DCHQYSOGURGJST-FJXKBIBVSA-N 0.000 description 2
- GZNYIXWOIUFLGO-ZJDVBMNYSA-N Pro-Thr-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GZNYIXWOIUFLGO-ZJDVBMNYSA-N 0.000 description 2
- FIODMZKLZFLYQP-GUBZILKMSA-N Pro-Val-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O FIODMZKLZFLYQP-GUBZILKMSA-N 0.000 description 2
- 229940096437 Protein S Drugs 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- 108091030071 RNAI Proteins 0.000 description 2
- 108091028733 RNTP Proteins 0.000 description 2
- 108091028664 Ribonucleotide Proteins 0.000 description 2
- SNNSYBWPPVAXQW-ZLUOBGJFSA-N Ser-Cys-Cys Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)O)N)O SNNSYBWPPVAXQW-ZLUOBGJFSA-N 0.000 description 2
- UQFYNFTYDHUIMI-WHFBIAKZSA-N Ser-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](N)CO UQFYNFTYDHUIMI-WHFBIAKZSA-N 0.000 description 2
- ZOPISOXXPQNOCO-SVSWQMSJSA-N Ser-Ile-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](CO)N ZOPISOXXPQNOCO-SVSWQMSJSA-N 0.000 description 2
- XNCUYZKGQOCOQH-YUMQZZPRSA-N Ser-Leu-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O XNCUYZKGQOCOQH-YUMQZZPRSA-N 0.000 description 2
- FLONGDPORFIVQW-XGEHTFHBSA-N Ser-Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO FLONGDPORFIVQW-XGEHTFHBSA-N 0.000 description 2
- ZSDXEKUKQAKZFE-XAVMHZPKSA-N Ser-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CO)N)O ZSDXEKUKQAKZFE-XAVMHZPKSA-N 0.000 description 2
- YEDSOSIKVUMIJE-DCAQKATOSA-N Ser-Val-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O YEDSOSIKVUMIJE-DCAQKATOSA-N 0.000 description 2
- SIEBDTCABMZCLF-XGEHTFHBSA-N Ser-Val-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SIEBDTCABMZCLF-XGEHTFHBSA-N 0.000 description 2
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 description 2
- 102000042773 Small Nucleolar RNA Human genes 0.000 description 2
- 108020003224 Small Nucleolar RNA Proteins 0.000 description 2
- 101710198474 Spike protein Proteins 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 235000019486 Sunflower oil Nutrition 0.000 description 2
- 101710137500 T7 RNA polymerase Proteins 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- 108020005038 Terminator Codon Proteins 0.000 description 2
- IGROJMCBGRFRGI-YTLHQDLWSA-N Thr-Ala-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O IGROJMCBGRFRGI-YTLHQDLWSA-N 0.000 description 2
- PXQUBKWZENPDGE-CIQUZCHMSA-N Thr-Ala-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)N PXQUBKWZENPDGE-CIQUZCHMSA-N 0.000 description 2
- IMULJHHGAUZZFE-MBLNEYKQSA-N Thr-Gly-Ile Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(O)=O IMULJHHGAUZZFE-MBLNEYKQSA-N 0.000 description 2
- MSIYNSBKKVMGFO-BHNWBGBOSA-N Thr-Gly-Pro Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)N1CCC[C@@H]1C(=O)O)N)O MSIYNSBKKVMGFO-BHNWBGBOSA-N 0.000 description 2
- JKGGPMOUIAAJAA-YEPSODPASA-N Thr-Gly-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O JKGGPMOUIAAJAA-YEPSODPASA-N 0.000 description 2
- BVOVIGCHYNFJBZ-JXUBOQSCSA-N Thr-Leu-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O BVOVIGCHYNFJBZ-JXUBOQSCSA-N 0.000 description 2
- QHUWWSQZTFLXPQ-FJXKBIBVSA-N Thr-Met-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCSC)C(=O)NCC(O)=O QHUWWSQZTFLXPQ-FJXKBIBVSA-N 0.000 description 2
- DNCUODYZAMHLCV-XGEHTFHBSA-N Thr-Pro-Cys Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(=O)O)N)O DNCUODYZAMHLCV-XGEHTFHBSA-N 0.000 description 2
- MROIJTGJGIDEEJ-RCWTZXSCSA-N Thr-Pro-Pro Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 MROIJTGJGIDEEJ-RCWTZXSCSA-N 0.000 description 2
- GVMXJJAJLIEASL-ZJDVBMNYSA-N Thr-Pro-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O GVMXJJAJLIEASL-ZJDVBMNYSA-N 0.000 description 2
- FWTFAZKJORVTIR-VZFHVOOUSA-N Thr-Ser-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O FWTFAZKJORVTIR-VZFHVOOUSA-N 0.000 description 2
- VUXIQSUQQYNLJP-XAVMHZPKSA-N Thr-Ser-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N)O VUXIQSUQQYNLJP-XAVMHZPKSA-N 0.000 description 2
- 108700009124 Transcription Initiation Site Proteins 0.000 description 2
- 108700029229 Transcriptional Regulatory Elements Proteins 0.000 description 2
- 108020004566 Transfer RNA Proteins 0.000 description 2
- 101150044878 US18 gene Proteins 0.000 description 2
- ZLFHAAGHGQBQQN-GUBZILKMSA-N Val-Ala-Pro Natural products CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O ZLFHAAGHGQBQQN-GUBZILKMSA-N 0.000 description 2
- SLLKXDSRVAOREO-KZVJFYERSA-N Val-Ala-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)N)O SLLKXDSRVAOREO-KZVJFYERSA-N 0.000 description 2
- PIFJAFRUVWZRKR-QMMMGPOBSA-N Val-Gly-Gly Chemical compound CC(C)[C@H]([NH3+])C(=O)NCC(=O)NCC([O-])=O PIFJAFRUVWZRKR-QMMMGPOBSA-N 0.000 description 2
- KZKMBGXCNLPYKD-YEPSODPASA-N Val-Gly-Thr Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O KZKMBGXCNLPYKD-YEPSODPASA-N 0.000 description 2
- BTWMICVCQLKKNR-DCAQKATOSA-N Val-Leu-Ser Chemical compound CC(C)[C@H]([NH3+])C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C([O-])=O BTWMICVCQLKKNR-DCAQKATOSA-N 0.000 description 2
- SYSWVVCYSXBVJG-RHYQMDGZSA-N Val-Leu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)N)O SYSWVVCYSXBVJG-RHYQMDGZSA-N 0.000 description 2
- GBIUHAYJGWVNLN-AEJSXWLSSA-N Val-Ser-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N GBIUHAYJGWVNLN-AEJSXWLSSA-N 0.000 description 2
- DVLWZWNAQUBZBC-ZNSHCXBVSA-N Val-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C(C)C)N)O DVLWZWNAQUBZBC-ZNSHCXBVSA-N 0.000 description 2
- JAIZPWVHPQRYOU-ZJDVBMNYSA-N Val-Thr-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](C(C)C)N)O JAIZPWVHPQRYOU-ZJDVBMNYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 210000001132 alveolar macrophage Anatomy 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000004579 body weight change Effects 0.000 description 2
- 239000012888 bovine serum Substances 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000003026 cod liver oil Substances 0.000 description 2
- 235000012716 cod liver oil Nutrition 0.000 description 2
- 239000003184 complementary RNA Substances 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229940099112 cornstarch Drugs 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 108010004073 cysteinylcysteine Proteins 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 210000003162 effector t lymphocyte Anatomy 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 208000026500 emaciation Diseases 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000009368 gene silencing by RNA Effects 0.000 description 2
- 108010000434 glycyl-alanyl-leucine Proteins 0.000 description 2
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 2
- 108010078326 glycyl-glycyl-valine Proteins 0.000 description 2
- 108010054666 glycyl-leucyl-glycyl-glycine Proteins 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 150000002411 histidines Chemical class 0.000 description 2
- 108010040030 histidinoalanine Proteins 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 108010027338 isoleucylcysteine Proteins 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 239000012160 loading buffer Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000001806 memory b lymphocyte Anatomy 0.000 description 2
- 210000003071 memory t lymphocyte Anatomy 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 210000001331 nose Anatomy 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 239000000575 pesticide Substances 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 150000004713 phosphodiesters Chemical class 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 108700042769 prolyl-leucyl-glycine Proteins 0.000 description 2
- 108010077112 prolyl-proline Proteins 0.000 description 2
- 108010087846 prolyl-prolyl-glycine Proteins 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 230000000384 rearing effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000012772 sequence design Methods 0.000 description 2
- 108010071207 serylmethionine Proteins 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 229960001866 silicon dioxide Drugs 0.000 description 2
- 239000004055 small Interfering RNA Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 210000001562 sternum Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000012089 stop solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000002600 sunflower oil Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- HDZZVAMISRMYHH-KCGFPETGSA-N tubercidin Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O HDZZVAMISRMYHH-KCGFPETGSA-N 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 108010027510 vaccinia virus capping enzyme Proteins 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 210000003501 vero cell Anatomy 0.000 description 2
- 210000002268 wool Anatomy 0.000 description 2
- KPDTZVSUQCBOAE-HTFCKZLJSA-N (2s)-2-[[(2s)-1-[(2s)-2-[[(2s)-2-[[(2s)-2-aminopropanoyl]amino]propanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]propanoic acid Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O KPDTZVSUQCBOAE-HTFCKZLJSA-N 0.000 description 1
- YPBKTZBXSBLTDK-PKNBQFBNSA-N (3e)-3-[(3-bromo-4-fluoroanilino)-nitrosomethylidene]-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole Chemical compound NS(=O)(=O)NCCNC1=NON\C1=C(N=O)/NC1=CC=C(F)C(Br)=C1 YPBKTZBXSBLTDK-PKNBQFBNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- LNETULKMXZVUST-UHFFFAOYSA-N 1-naphthoic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=CC2=C1 LNETULKMXZVUST-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QMOQBVOBWVNSNO-UHFFFAOYSA-N 2-[[2-[[2-[(2-azaniumylacetyl)amino]acetyl]amino]acetyl]amino]acetate Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(O)=O QMOQBVOBWVNSNO-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 102100040768 60S ribosomal protein L32 Human genes 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 208000035657 Abasia Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- SBGXWWCLHIOABR-UHFFFAOYSA-N Ala Ala Gly Ala Chemical compound CC(N)C(=O)NC(C)C(=O)NCC(=O)NC(C)C(O)=O SBGXWWCLHIOABR-UHFFFAOYSA-N 0.000 description 1
- UWQJHXKARZWDIJ-ZLUOBGJFSA-N Ala-Ala-Cys Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CS)C(O)=O UWQJHXKARZWDIJ-ZLUOBGJFSA-N 0.000 description 1
- LGQPPBQRUBVTIF-JBDRJPRFSA-N Ala-Ala-Ile Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O LGQPPBQRUBVTIF-JBDRJPRFSA-N 0.000 description 1
- CXZFXHGJJPVUJE-CIUDSAMLSA-N Ala-Cys-Leu Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)O)N CXZFXHGJJPVUJE-CIUDSAMLSA-N 0.000 description 1
- LJFNNUBZSZCZFN-WHFBIAKZSA-N Ala-Gly-Cys Chemical compound N[C@@H](C)C(=O)NCC(=O)N[C@@H](CS)C(=O)O LJFNNUBZSZCZFN-WHFBIAKZSA-N 0.000 description 1
- BTBUEVAGZCKULD-XPUUQOCRSA-N Ala-Gly-His Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BTBUEVAGZCKULD-XPUUQOCRSA-N 0.000 description 1
- PNALXAODQKTNLV-JBDRJPRFSA-N Ala-Ile-Ala Chemical compound C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O PNALXAODQKTNLV-JBDRJPRFSA-N 0.000 description 1
- OKIKVSXTXVVFDV-MMWGEVLESA-N Ala-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C)N OKIKVSXTXVVFDV-MMWGEVLESA-N 0.000 description 1
- RUQBGIMJQUWXPP-CYDGBPFRSA-N Ala-Leu-Ala-Pro Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O RUQBGIMJQUWXPP-CYDGBPFRSA-N 0.000 description 1
- FCXAUASCMJOFEY-NDKCEZKHSA-N Ala-Leu-Thr-Pro Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(O)=O FCXAUASCMJOFEY-NDKCEZKHSA-N 0.000 description 1
- DYJJJCHDHLEFDW-FXQIFTODSA-N Ala-Pro-Cys Chemical compound C[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(=O)O)N DYJJJCHDHLEFDW-FXQIFTODSA-N 0.000 description 1
- ADSGHMXEAZJJNF-DCAQKATOSA-N Ala-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)N ADSGHMXEAZJJNF-DCAQKATOSA-N 0.000 description 1
- YHBDGLZYNIARKJ-GUBZILKMSA-N Ala-Pro-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)N YHBDGLZYNIARKJ-GUBZILKMSA-N 0.000 description 1
- HOVPGJUNRLMIOZ-CIUDSAMLSA-N Ala-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)N HOVPGJUNRLMIOZ-CIUDSAMLSA-N 0.000 description 1
- OEVCHROQUIVQFZ-YTLHQDLWSA-N Ala-Thr-Ala Chemical compound C[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](C)C(O)=O OEVCHROQUIVQFZ-YTLHQDLWSA-N 0.000 description 1
- WNHNMKOFKCHKKD-BFHQHQDPSA-N Ala-Thr-Gly Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O WNHNMKOFKCHKKD-BFHQHQDPSA-N 0.000 description 1
- KTXKIYXZQFWJKB-VZFHVOOUSA-N Ala-Thr-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O KTXKIYXZQFWJKB-VZFHVOOUSA-N 0.000 description 1
- IETUUAHKCHOQHP-KZVJFYERSA-N Ala-Thr-Val Chemical compound CC(C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](C)N)[C@@H](C)O)C(O)=O IETUUAHKCHOQHP-KZVJFYERSA-N 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 description 1
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 238000003737 Bright-Glo Luciferase Assay System Methods 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282421 Canidae Species 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241001137251 Corvidae Species 0.000 description 1
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- TVYMKYUSZSVOAG-ZLUOBGJFSA-N Cys-Ala-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O TVYMKYUSZSVOAG-ZLUOBGJFSA-N 0.000 description 1
- CVLIHKBUPSFRQP-WHFBIAKZSA-N Cys-Gly-Ala Chemical compound [H]N[C@@H](CS)C(=O)NCC(=O)N[C@@H](C)C(O)=O CVLIHKBUPSFRQP-WHFBIAKZSA-N 0.000 description 1
- SKSJPIBFNFPTJB-NKWVEPMBSA-N Cys-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CS)N)C(=O)O SKSJPIBFNFPTJB-NKWVEPMBSA-N 0.000 description 1
- XVLMKWWVBNESPX-XVYDVKMFSA-N Cys-His-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CS)N XVLMKWWVBNESPX-XVYDVKMFSA-N 0.000 description 1
- SNHRIJBANHPWMO-XGEHTFHBSA-N Cys-Met-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)N)O SNHRIJBANHPWMO-XGEHTFHBSA-N 0.000 description 1
- CMYVIUWVYHOLRD-ZLUOBGJFSA-N Cys-Ser-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O CMYVIUWVYHOLRD-ZLUOBGJFSA-N 0.000 description 1
- FCXJJTRGVAZDER-FXQIFTODSA-N Cys-Val-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O FCXJJTRGVAZDER-FXQIFTODSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 108091027757 Deoxyribozyme Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 238000011510 Elispot assay Methods 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108091092584 GDNA Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- GQGAFTPXAPKSCF-WHFBIAKZSA-N Gly-Ala-Cys Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@@H](CS)C(=O)O GQGAFTPXAPKSCF-WHFBIAKZSA-N 0.000 description 1
- YMUFWNJHVPQNQD-ZKWXMUAHSA-N Gly-Ala-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)CN YMUFWNJHVPQNQD-ZKWXMUAHSA-N 0.000 description 1
- JRDYDYXZKFNNRQ-XPUUQOCRSA-N Gly-Ala-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)CN JRDYDYXZKFNNRQ-XPUUQOCRSA-N 0.000 description 1
- YWAQATDNEKZFFK-BYPYZUCNSA-N Gly-Gly-Ser Chemical compound NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O YWAQATDNEKZFFK-BYPYZUCNSA-N 0.000 description 1
- ADZGCWWDPFDHCY-ZETCQYMHSA-N Gly-His-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 ADZGCWWDPFDHCY-ZETCQYMHSA-N 0.000 description 1
- LUJVWKKYHSLULQ-ZKWXMUAHSA-N Gly-Ile-Cys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)CN LUJVWKKYHSLULQ-ZKWXMUAHSA-N 0.000 description 1
- AAHSHTLISQUZJL-QSFUFRPTSA-N Gly-Ile-Ile Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O AAHSHTLISQUZJL-QSFUFRPTSA-N 0.000 description 1
- CCBIBMKQNXHNIN-ZETCQYMHSA-N Gly-Leu-Gly Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O CCBIBMKQNXHNIN-ZETCQYMHSA-N 0.000 description 1
- LRQXRHGQEVWGPV-NHCYSSNCSA-N Gly-Leu-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)CN LRQXRHGQEVWGPV-NHCYSSNCSA-N 0.000 description 1
- UHPAZODVFFYEEL-QWRGUYRKSA-N Gly-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)CN UHPAZODVFFYEEL-QWRGUYRKSA-N 0.000 description 1
- UUYBFNKHOCJCHT-VHSXEESVSA-N Gly-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN UUYBFNKHOCJCHT-VHSXEESVSA-N 0.000 description 1
- HHRODZSXDXMUHS-LURJTMIESA-N Gly-Met-Gly Chemical compound CSCC[C@H](NC(=O)C[NH3+])C(=O)NCC([O-])=O HHRODZSXDXMUHS-LURJTMIESA-N 0.000 description 1
- LPHQAFLNEHWKFF-QXEWZRGKSA-N Gly-Met-Ile Chemical compound [H]NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O LPHQAFLNEHWKFF-QXEWZRGKSA-N 0.000 description 1
- HFPVRZWORNJRRC-UWVGGRQHSA-N Gly-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)CN HFPVRZWORNJRRC-UWVGGRQHSA-N 0.000 description 1
- OOCFXNOVSLSHAB-IUCAKERBSA-N Gly-Pro-Pro Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 OOCFXNOVSLSHAB-IUCAKERBSA-N 0.000 description 1
- IRJWAYCXIYUHQE-WHFBIAKZSA-N Gly-Ser-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)CN IRJWAYCXIYUHQE-WHFBIAKZSA-N 0.000 description 1
- VNNRLUNBJSWZPF-ZKWXMUAHSA-N Gly-Ser-Ile Chemical compound [H]NCC(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VNNRLUNBJSWZPF-ZKWXMUAHSA-N 0.000 description 1
- WNGHUXFWEWTKAO-YUMQZZPRSA-N Gly-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CN WNGHUXFWEWTKAO-YUMQZZPRSA-N 0.000 description 1
- HUFUVTYGPOUCBN-MBLNEYKQSA-N Gly-Thr-Ile Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O HUFUVTYGPOUCBN-MBLNEYKQSA-N 0.000 description 1
- MYXNLWDWWOTERK-BHNWBGBOSA-N Gly-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN)O MYXNLWDWWOTERK-BHNWBGBOSA-N 0.000 description 1
- FFALDIDGPLUDKV-ZDLURKLDSA-N Gly-Thr-Ser Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O FFALDIDGPLUDKV-ZDLURKLDSA-N 0.000 description 1
- RYAOJUMWLWUGNW-QMMMGPOBSA-N Gly-Val-Gly Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O RYAOJUMWLWUGNW-QMMMGPOBSA-N 0.000 description 1
- SBVMXEZQJVUARN-XPUUQOCRSA-N Gly-Val-Ser Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O SBVMXEZQJVUARN-XPUUQOCRSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- BIAKMWKJMQLZOJ-ZKWXMUAHSA-N His-Ala-Ala Chemical compound C[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(O)=O BIAKMWKJMQLZOJ-ZKWXMUAHSA-N 0.000 description 1
- HTZKFIYQMHJWSQ-INTQDDNPSA-N His-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CN=CN2)N HTZKFIYQMHJWSQ-INTQDDNPSA-N 0.000 description 1
- DZMVESFTHXSSPZ-XVYDVKMFSA-N His-Ala-Ser Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O DZMVESFTHXSSPZ-XVYDVKMFSA-N 0.000 description 1
- PMWSGVRIMIFXQH-KKUMJFAQSA-N His-His-Leu Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](N)CC=1NC=NC=1)C1=CN=CN1 PMWSGVRIMIFXQH-KKUMJFAQSA-N 0.000 description 1
- VYUXYMRNGALHEA-DLOVCJGASA-N His-Leu-Ala Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O VYUXYMRNGALHEA-DLOVCJGASA-N 0.000 description 1
- ILUVWFTXAUYOBW-CUJWVEQBSA-N His-Ser-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CN=CN1)N)O ILUVWFTXAUYOBW-CUJWVEQBSA-N 0.000 description 1
- UPJODPVSKKWGDQ-KLHWPWHYSA-N His-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CN=CN2)N)O UPJODPVSKKWGDQ-KLHWPWHYSA-N 0.000 description 1
- XGBVLRJLHUVCNK-DCAQKATOSA-N His-Val-Ser Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O XGBVLRJLHUVCNK-DCAQKATOSA-N 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 241000711467 Human coronavirus 229E Species 0.000 description 1
- 241000482741 Human coronavirus NL63 Species 0.000 description 1
- 241001428935 Human coronavirus OC43 Species 0.000 description 1
- HDOYNXLPTRQLAD-JBDRJPRFSA-N Ile-Ala-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)O)N HDOYNXLPTRQLAD-JBDRJPRFSA-N 0.000 description 1
- NZOCIWKZUVUNDW-ZKWXMUAHSA-N Ile-Gly-Ala Chemical compound CC[C@H](C)[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O NZOCIWKZUVUNDW-ZKWXMUAHSA-N 0.000 description 1
- MQFGXJNSUJTXDT-QSFUFRPTSA-N Ile-Gly-Ile Chemical compound N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)O MQFGXJNSUJTXDT-QSFUFRPTSA-N 0.000 description 1
- APDIECQNNDGFPD-PYJNHQTQSA-N Ile-His-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](C(C)C)C(=O)O)N APDIECQNNDGFPD-PYJNHQTQSA-N 0.000 description 1
- AXNGDPAKKCEKGY-QPHKQPEJSA-N Ile-Ile-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N AXNGDPAKKCEKGY-QPHKQPEJSA-N 0.000 description 1
- HPCFRQWLTRDGHT-AJNGGQMLSA-N Ile-Leu-Leu Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O HPCFRQWLTRDGHT-AJNGGQMLSA-N 0.000 description 1
- PHRWFSFCNJPWRO-PPCPHDFISA-N Ile-Leu-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N PHRWFSFCNJPWRO-PPCPHDFISA-N 0.000 description 1
- IVXJIMGDOYRLQU-XUXIUFHCSA-N Ile-Pro-Leu Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O IVXJIMGDOYRLQU-XUXIUFHCSA-N 0.000 description 1
- KTNGVMMGIQWIDV-OSUNSFLBSA-N Ile-Pro-Thr Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O KTNGVMMGIQWIDV-OSUNSFLBSA-N 0.000 description 1
- PXKACEXYLPBMAD-JBDRJPRFSA-N Ile-Ser-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PXKACEXYLPBMAD-JBDRJPRFSA-N 0.000 description 1
- RQJUKVXWAKJDBW-SVSWQMSJSA-N Ile-Ser-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N RQJUKVXWAKJDBW-SVSWQMSJSA-N 0.000 description 1
- KBDIBHQICWDGDL-PPCPHDFISA-N Ile-Thr-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)O)N KBDIBHQICWDGDL-PPCPHDFISA-N 0.000 description 1
- WCNWGAUZWWSYDG-SVSWQMSJSA-N Ile-Thr-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)O)N WCNWGAUZWWSYDG-SVSWQMSJSA-N 0.000 description 1
- YJRSIJZUIUANHO-NAKRPEOUSA-N Ile-Val-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)O)N YJRSIJZUIUANHO-NAKRPEOUSA-N 0.000 description 1
- 241001100935 Ilex purpurea Species 0.000 description 1
- 235000003366 Ilex purpurea Nutrition 0.000 description 1
- 102000010787 Interleukin-4 Receptors Human genes 0.000 description 1
- 108010038486 Interleukin-4 Receptors Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241000283986 Lepus Species 0.000 description 1
- PBCHMHROGNUXMK-DLOVCJGASA-N Leu-Ala-His Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 PBCHMHROGNUXMK-DLOVCJGASA-N 0.000 description 1
- HUEBCHPSXSQUGN-GARJFASQSA-N Leu-Cys-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)N1CCC[C@@H]1C(=O)O)N HUEBCHPSXSQUGN-GARJFASQSA-N 0.000 description 1
- FOEHRHOBWFQSNW-KATARQTJSA-N Leu-Cys-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)N)O FOEHRHOBWFQSNW-KATARQTJSA-N 0.000 description 1
- WCTCIIAGNMFYAO-DCAQKATOSA-N Leu-Cys-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(O)=O WCTCIIAGNMFYAO-DCAQKATOSA-N 0.000 description 1
- OXRLYTYUXAQTHP-YUMQZZPRSA-N Leu-Gly-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(O)=O OXRLYTYUXAQTHP-YUMQZZPRSA-N 0.000 description 1
- QJUWBDPGGYVRHY-YUMQZZPRSA-N Leu-Gly-Cys Chemical compound CC(C)C[C@@H](C(=O)NCC(=O)N[C@@H](CS)C(=O)O)N QJUWBDPGGYVRHY-YUMQZZPRSA-N 0.000 description 1
- HYIFFZAQXPUEAU-QWRGUYRKSA-N Leu-Gly-Leu Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC(C)C HYIFFZAQXPUEAU-QWRGUYRKSA-N 0.000 description 1
- YFBBUHJJUXXZOF-UWVGGRQHSA-N Leu-Gly-Pro Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O YFBBUHJJUXXZOF-UWVGGRQHSA-N 0.000 description 1
- HYMLKESRWLZDBR-WEDXCCLWSA-N Leu-Gly-Thr Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O HYMLKESRWLZDBR-WEDXCCLWSA-N 0.000 description 1
- CFZZDVMBRYFFNU-QWRGUYRKSA-N Leu-His-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)NCC(O)=O CFZZDVMBRYFFNU-QWRGUYRKSA-N 0.000 description 1
- OHZIZVWQXJPBJS-IXOXFDKPSA-N Leu-His-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OHZIZVWQXJPBJS-IXOXFDKPSA-N 0.000 description 1
- SGIIOQQGLUUMDQ-IHRRRGAJSA-N Leu-His-Val Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](C(C)C)C(=O)O)N SGIIOQQGLUUMDQ-IHRRRGAJSA-N 0.000 description 1
- ORWTWZXGDBYVCP-BJDJZHNGSA-N Leu-Ile-Cys Chemical compound SC[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CC(C)C ORWTWZXGDBYVCP-BJDJZHNGSA-N 0.000 description 1
- QJXHMYMRGDOHRU-NHCYSSNCSA-N Leu-Ile-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(O)=O QJXHMYMRGDOHRU-NHCYSSNCSA-N 0.000 description 1
- YOKVEHGYYQEQOP-QWRGUYRKSA-N Leu-Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O YOKVEHGYYQEQOP-QWRGUYRKSA-N 0.000 description 1
- KYIIALJHAOIAHF-KKUMJFAQSA-N Leu-Leu-His Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 KYIIALJHAOIAHF-KKUMJFAQSA-N 0.000 description 1
- RXGLHDWAZQECBI-SRVKXCTJSA-N Leu-Leu-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O RXGLHDWAZQECBI-SRVKXCTJSA-N 0.000 description 1
- DDVHDMSBLRAKNV-IHRRRGAJSA-N Leu-Met-Leu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(O)=O DDVHDMSBLRAKNV-IHRRRGAJSA-N 0.000 description 1
- HDHQQEDVWQGBEE-DCAQKATOSA-N Leu-Met-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(O)=O HDHQQEDVWQGBEE-DCAQKATOSA-N 0.000 description 1
- UCBPDSYUVAAHCD-UWVGGRQHSA-N Leu-Pro-Gly Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O UCBPDSYUVAAHCD-UWVGGRQHSA-N 0.000 description 1
- YUTNOGOMBNYPFH-XUXIUFHCSA-N Leu-Pro-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(O)=O YUTNOGOMBNYPFH-XUXIUFHCSA-N 0.000 description 1
- JDBQSGMJBMPNFT-AVGNSLFASA-N Leu-Pro-Val Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O JDBQSGMJBMPNFT-AVGNSLFASA-N 0.000 description 1
- RGUXWMDNCPMQFB-YUMQZZPRSA-N Leu-Ser-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O RGUXWMDNCPMQFB-YUMQZZPRSA-N 0.000 description 1
- SBANPBVRHYIMRR-GARJFASQSA-N Leu-Ser-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N SBANPBVRHYIMRR-GARJFASQSA-N 0.000 description 1
- BRTVHXHCUSXYRI-CIUDSAMLSA-N Leu-Ser-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O BRTVHXHCUSXYRI-CIUDSAMLSA-N 0.000 description 1
- KLSUAWUZBMAZCL-RHYQMDGZSA-N Leu-Thr-Pro Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(O)=O KLSUAWUZBMAZCL-RHYQMDGZSA-N 0.000 description 1
- ILDSIMPXNFWKLH-KATARQTJSA-N Leu-Thr-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O ILDSIMPXNFWKLH-KATARQTJSA-N 0.000 description 1
- GZRABTMNWJXFMH-UVOCVTCTSA-N Leu-Thr-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GZRABTMNWJXFMH-UVOCVTCTSA-N 0.000 description 1
- AIQWYVFNBNNOLU-RHYQMDGZSA-N Leu-Thr-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O AIQWYVFNBNNOLU-RHYQMDGZSA-N 0.000 description 1
- TUIOUEWKFFVNLH-DCAQKATOSA-N Leu-Val-Cys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(O)=O TUIOUEWKFFVNLH-DCAQKATOSA-N 0.000 description 1
- FDBTVENULFNTAL-XQQFMLRXSA-N Leu-Val-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N FDBTVENULFNTAL-XQQFMLRXSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000219745 Lupinus Species 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- YRAWWKUTNBILNT-FXQIFTODSA-N Met-Ala-Ala Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O YRAWWKUTNBILNT-FXQIFTODSA-N 0.000 description 1
- UZVKFARGHHMQGX-IUCAKERBSA-N Met-Gly-Met Chemical compound CSCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCSC UZVKFARGHHMQGX-IUCAKERBSA-N 0.000 description 1
- RBGLBUDVQVPTEG-DCAQKATOSA-N Met-Leu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCSC)N RBGLBUDVQVPTEG-DCAQKATOSA-N 0.000 description 1
- VQILILSLEFDECU-GUBZILKMSA-N Met-Pro-Ala Chemical compound [H]N[C@@H](CCSC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O VQILILSLEFDECU-GUBZILKMSA-N 0.000 description 1
- BJPQKNHZHUCQNQ-SRVKXCTJSA-N Met-Pro-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCSC)N BJPQKNHZHUCQNQ-SRVKXCTJSA-N 0.000 description 1
- PHURAEXVWLDIGT-LPEHRKFASA-N Met-Ser-Pro Chemical compound CSCC[C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N PHURAEXVWLDIGT-LPEHRKFASA-N 0.000 description 1
- MIXPUVSPPOWTCR-FXQIFTODSA-N Met-Ser-Ser Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O MIXPUVSPPOWTCR-FXQIFTODSA-N 0.000 description 1
- WXJLBSXNUHIGSS-OSUNSFLBSA-N Met-Thr-Ile Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WXJLBSXNUHIGSS-OSUNSFLBSA-N 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 102000016397 Methyltransferase Human genes 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 102000013967 Monokines Human genes 0.000 description 1
- 108010050619 Monokines Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 229930182474 N-glycoside Natural products 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- YGACXVRLDHEXKY-WXRXAMBDSA-N O[C@H](C[C@H]1c2c(cccc2F)-c2cncn12)[C@H]1CC[C@H](O)CC1 Chemical group O[C@H](C[C@H]1c2c(cccc2F)-c2cncn12)[C@H]1CC[C@H](O)CC1 YGACXVRLDHEXKY-WXRXAMBDSA-N 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 108010038988 Peptide Hormones Proteins 0.000 description 1
- 102000015731 Peptide Hormones Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- CGBYDGAJHSOGFQ-LPEHRKFASA-N Pro-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@@H]2CCCN2 CGBYDGAJHSOGFQ-LPEHRKFASA-N 0.000 description 1
- HQVPQXMCQKXARZ-FXQIFTODSA-N Pro-Cys-Ser Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)O HQVPQXMCQKXARZ-FXQIFTODSA-N 0.000 description 1
- FKLSMYYLJHYPHH-UWVGGRQHSA-N Pro-Gly-Leu Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O FKLSMYYLJHYPHH-UWVGGRQHSA-N 0.000 description 1
- VWXGFAIZUQBBBG-UWVGGRQHSA-N Pro-His-Gly Chemical compound C([C@@H](C(=O)NCC(=O)[O-])NC(=O)[C@H]1[NH2+]CCC1)C1=CN=CN1 VWXGFAIZUQBBBG-UWVGGRQHSA-N 0.000 description 1
- VZKBJNBZMZHKRC-XUXIUFHCSA-N Pro-Ile-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O VZKBJNBZMZHKRC-XUXIUFHCSA-N 0.000 description 1
- NFLNBHLMLYALOO-DCAQKATOSA-N Pro-Leu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@@H]1CCCN1 NFLNBHLMLYALOO-DCAQKATOSA-N 0.000 description 1
- SBVPYBFMIGDIDX-SRVKXCTJSA-N Pro-Pro-Pro Chemical compound OC(=O)[C@@H]1CCCN1C(=O)[C@H]1N(C(=O)[C@H]2NCCC2)CCC1 SBVPYBFMIGDIDX-SRVKXCTJSA-N 0.000 description 1
- FDMKYQQYJKYCLV-GUBZILKMSA-N Pro-Pro-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 FDMKYQQYJKYCLV-GUBZILKMSA-N 0.000 description 1
- ZMLRZBWCXPQADC-TUAOUCFPSA-N Pro-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@@H]2CCCN2 ZMLRZBWCXPQADC-TUAOUCFPSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 108090000878 Ribosomal protein S9 Proteins 0.000 description 1
- 102000004282 Ribosomal protein S9 Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 101150010882 S gene Proteins 0.000 description 1
- ZUGXSSFMTXKHJS-ZLUOBGJFSA-N Ser-Ala-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O ZUGXSSFMTXKHJS-ZLUOBGJFSA-N 0.000 description 1
- WTWGOQRNRFHFQD-JBDRJPRFSA-N Ser-Ala-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WTWGOQRNRFHFQD-JBDRJPRFSA-N 0.000 description 1
- HRNQLKCLPVKZNE-CIUDSAMLSA-N Ser-Ala-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O HRNQLKCLPVKZNE-CIUDSAMLSA-N 0.000 description 1
- JPIDMRXXNMIVKY-VZFHVOOUSA-N Ser-Ala-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O JPIDMRXXNMIVKY-VZFHVOOUSA-N 0.000 description 1
- RNFKSBPHLTZHLU-WHFBIAKZSA-N Ser-Cys-Gly Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)NCC(=O)O)N)O RNFKSBPHLTZHLU-WHFBIAKZSA-N 0.000 description 1
- DSSOYPJWSWFOLK-CIUDSAMLSA-N Ser-Cys-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(O)=O DSSOYPJWSWFOLK-CIUDSAMLSA-N 0.000 description 1
- UIGMAMGZOJVTDN-WHFBIAKZSA-N Ser-Gly-Ser Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O UIGMAMGZOJVTDN-WHFBIAKZSA-N 0.000 description 1
- SFTZTYBXIXLRGQ-JBDRJPRFSA-N Ser-Ile-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O SFTZTYBXIXLRGQ-JBDRJPRFSA-N 0.000 description 1
- FUMGHWDRRFCKEP-CIUDSAMLSA-N Ser-Leu-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O FUMGHWDRRFCKEP-CIUDSAMLSA-N 0.000 description 1
- IUXGJEIKJBYKOO-SRVKXCTJSA-N Ser-Leu-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CO)N IUXGJEIKJBYKOO-SRVKXCTJSA-N 0.000 description 1
- KCGIREHVWRXNDH-GARJFASQSA-N Ser-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CO)N KCGIREHVWRXNDH-GARJFASQSA-N 0.000 description 1
- RXSWQCATLWVDLI-XGEHTFHBSA-N Ser-Met-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O RXSWQCATLWVDLI-XGEHTFHBSA-N 0.000 description 1
- VGQVAVQWKJLIRM-FXQIFTODSA-N Ser-Ser-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O VGQVAVQWKJLIRM-FXQIFTODSA-N 0.000 description 1
- VLMIUSLQONKLDV-HEIBUPTGSA-N Ser-Thr-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VLMIUSLQONKLDV-HEIBUPTGSA-N 0.000 description 1
- MFQMZDPAZRZAPV-NAKRPEOUSA-N Ser-Val-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CO)N MFQMZDPAZRZAPV-NAKRPEOUSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- 108091060271 Small temporal RNA Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- LVHHEVGYAZGXDE-KDXUFGMBSA-N Thr-Ala-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C)C(=O)N1CCC[C@@H]1C(=O)O)N)O LVHHEVGYAZGXDE-KDXUFGMBSA-N 0.000 description 1
- XPNSAQMEAVSQRD-FBCQKBJTSA-N Thr-Gly-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)NCC(=O)NCC(O)=O XPNSAQMEAVSQRD-FBCQKBJTSA-N 0.000 description 1
- QQWNRERCGGZOKG-WEDXCCLWSA-N Thr-Gly-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O QQWNRERCGGZOKG-WEDXCCLWSA-N 0.000 description 1
- DJDSEDOKJTZBAR-ZDLURKLDSA-N Thr-Gly-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O DJDSEDOKJTZBAR-ZDLURKLDSA-N 0.000 description 1
- KBBRNEDOYWMIJP-KYNKHSRBSA-N Thr-Gly-Thr Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)O)N)O KBBRNEDOYWMIJP-KYNKHSRBSA-N 0.000 description 1
- YJCVECXVYHZOBK-KNZXXDILSA-N Thr-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H]([C@@H](C)O)N YJCVECXVYHZOBK-KNZXXDILSA-N 0.000 description 1
- ODXKUIGEPAGKKV-KATARQTJSA-N Thr-Leu-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)O)N)O ODXKUIGEPAGKKV-KATARQTJSA-N 0.000 description 1
- RFKVQLIXNVEOMB-WEDXCCLWSA-N Thr-Leu-Gly Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)O)N)O RFKVQLIXNVEOMB-WEDXCCLWSA-N 0.000 description 1
- XIULAFZYEKSGAJ-IXOXFDKPSA-N Thr-Leu-His Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CNC=N1 XIULAFZYEKSGAJ-IXOXFDKPSA-N 0.000 description 1
- KZSYAEWQMJEGRZ-RHYQMDGZSA-N Thr-Leu-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O KZSYAEWQMJEGRZ-RHYQMDGZSA-N 0.000 description 1
- WTMPKZWHRCMMMT-KZVJFYERSA-N Thr-Pro-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O WTMPKZWHRCMMMT-KZVJFYERSA-N 0.000 description 1
- YGCDFAJJCRVQKU-RCWTZXSCSA-N Thr-Pro-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)[C@@H](C)O YGCDFAJJCRVQKU-RCWTZXSCSA-N 0.000 description 1
- NDZYTIMDOZMECO-SHGPDSBTSA-N Thr-Thr-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O NDZYTIMDOZMECO-SHGPDSBTSA-N 0.000 description 1
- UQCNIMDPYICBTR-KYNKHSRBSA-N Thr-Thr-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O UQCNIMDPYICBTR-KYNKHSRBSA-N 0.000 description 1
- PJCYRZVSACOYSN-ZJDVBMNYSA-N Thr-Thr-Met Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCSC)C(O)=O PJCYRZVSACOYSN-ZJDVBMNYSA-N 0.000 description 1
- ZESGVALRVJIVLZ-VFCFLDTKSA-N Thr-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@@H]1C(=O)O)N)O ZESGVALRVJIVLZ-VFCFLDTKSA-N 0.000 description 1
- LECUEEHKUFYOOV-ZJDVBMNYSA-N Thr-Thr-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](N)[C@@H](C)O LECUEEHKUFYOOV-ZJDVBMNYSA-N 0.000 description 1
- OGOYMQWIWHGTGH-KZVJFYERSA-N Thr-Val-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O OGOYMQWIWHGTGH-KZVJFYERSA-N 0.000 description 1
- AXEJRUGTOJPZKG-XGEHTFHBSA-N Thr-Val-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)O)N)O AXEJRUGTOJPZKG-XGEHTFHBSA-N 0.000 description 1
- AKHDFZHUPGVFEJ-YEPSODPASA-N Thr-Val-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O AKHDFZHUPGVFEJ-YEPSODPASA-N 0.000 description 1
- MNYNCKZAEIAONY-XGEHTFHBSA-N Thr-Val-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O MNYNCKZAEIAONY-XGEHTFHBSA-N 0.000 description 1
- KZTLZZQTJMCGIP-ZJDVBMNYSA-N Thr-Val-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KZTLZZQTJMCGIP-ZJDVBMNYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- WOCYUGQDXPTQPY-FXQIFTODSA-N Val-Ala-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](C(C)C)N WOCYUGQDXPTQPY-FXQIFTODSA-N 0.000 description 1
- ASQFIHTXXMFENG-XPUUQOCRSA-N Val-Ala-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O ASQFIHTXXMFENG-XPUUQOCRSA-N 0.000 description 1
- ZLFHAAGHGQBQQN-AEJSXWLSSA-N Val-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C(C)C)N ZLFHAAGHGQBQQN-AEJSXWLSSA-N 0.000 description 1
- URIRWLJVWHYLET-ONGXEEELSA-N Val-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)C(C)C URIRWLJVWHYLET-ONGXEEELSA-N 0.000 description 1
- UKEVLVBHRKWECS-LSJOCFKGSA-N Val-Ile-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](C(C)C)N UKEVLVBHRKWECS-LSJOCFKGSA-N 0.000 description 1
- UMPVMAYCLYMYGA-ONGXEEELSA-N Val-Leu-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O UMPVMAYCLYMYGA-ONGXEEELSA-N 0.000 description 1
- XTDDIVQWDXMRJL-IHRRRGAJSA-N Val-Leu-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](C(C)C)N XTDDIVQWDXMRJL-IHRRRGAJSA-N 0.000 description 1
- NHXZRXLFOBFMDM-AVGNSLFASA-N Val-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)C(C)C NHXZRXLFOBFMDM-AVGNSLFASA-N 0.000 description 1
- UGFMVXRXULGLNO-XPUUQOCRSA-N Val-Ser-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O UGFMVXRXULGLNO-XPUUQOCRSA-N 0.000 description 1
- PZTZYZUTCPZWJH-FXQIFTODSA-N Val-Ser-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PZTZYZUTCPZWJH-FXQIFTODSA-N 0.000 description 1
- JSOXWWFKRJKTMT-WOPDTQHZSA-N Val-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N JSOXWWFKRJKTMT-WOPDTQHZSA-N 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010049040 Weight fluctuation Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 1
- NRLNQCOGCKAESA-KWXKLSQISA-N [(6z,9z,28z,31z)-heptatriaconta-6,9,28,31-tetraen-19-yl] 4-(dimethylamino)butanoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC\C=C/C\C=C/CCCCC NRLNQCOGCKAESA-KWXKLSQISA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000004847 absorption spectroscopy Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000009798 acute exacerbation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 108010087049 alanyl-alanyl-prolyl-valine Proteins 0.000 description 1
- 108010070944 alanylhistidine Proteins 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- AWYJLEYTTIDFHY-UHFFFAOYSA-N calcium;dihydroxy(dioxido)silane;phosphoric acid Chemical compound [Ca+2].O[Si](O)([O-])[O-].OP(O)(O)=O AWYJLEYTTIDFHY-UHFFFAOYSA-N 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000005549 deoxyribonucleoside Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 108010054812 diprotin A Proteins 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000006334 disulfide bridging Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 229950006370 epacadostat Drugs 0.000 description 1
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000000695 excitation spectrum Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000001808 exosome Anatomy 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 108700014844 flt3 ligand Proteins 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000003269 fluorescent indicator Substances 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 210000001280 germinal center Anatomy 0.000 description 1
- 238000012826 global research Methods 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 108010027668 glycyl-alanyl-valine Proteins 0.000 description 1
- 108010001064 glycyl-glycyl-glycyl-glycine Proteins 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 108010064833 guanylyltransferase Proteins 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- MAHXCOMHJBHBGO-RTKIROINSA-N hematoxin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H](OC)C11C=CC(=O)C(O)=C1OC2 MAHXCOMHJBHBGO-RTKIROINSA-N 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 108010018006 histidylserine Proteins 0.000 description 1
- 210000003701 histiocyte Anatomy 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 108010078274 isoleucylvaline Proteins 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 229940090046 jet injector Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000006655 lysosomal degradation pathway Effects 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 230000012976 mRNA stabilization Effects 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000037230 mobility Effects 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 238000007837 multiplex assay Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 230000001293 nucleolytic effect Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002892 organic cations Chemical class 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 229960005030 other vaccine in atc Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 150000002921 oxetanes Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 238000009304 pastoral farming Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000001095 phosphatidyl group Chemical group 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 229940067605 phosphatidylethanolamines Drugs 0.000 description 1
- 150000008106 phosphatidylserines Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229920001987 poloxamine Polymers 0.000 description 1
- 102000028499 poly(A) binding Human genes 0.000 description 1
- 108091023021 poly(A) binding Proteins 0.000 description 1
- 229920000723 poly(D-arginine) polymer Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 210000004896 polypeptide structure Anatomy 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000011165 process development Methods 0.000 description 1
- 108010020432 prolyl-prolylisoleucine Proteins 0.000 description 1
- 108010031719 prolyl-serine Proteins 0.000 description 1
- 108010015796 prolylisoleucine Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 230000007319 proteasomal degradation pathway Effects 0.000 description 1
- 108010030416 proteoliposomes Proteins 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 210000003456 pulmonary alveoli Anatomy 0.000 description 1
- IGFXRKMLLMBKSA-UHFFFAOYSA-N purine Chemical compound N1=C[N]C2=NC=NC2=C1 IGFXRKMLLMBKSA-UHFFFAOYSA-N 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002342 ribonucleoside Substances 0.000 description 1
- 108010025325 ribosomal protein L32 Proteins 0.000 description 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 239000002924 silencing RNA Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000005100 tissue tropism Effects 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 239000006217 urethral suppository Substances 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000009723 vascular congestion Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 239000005723 virus inoculator Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052726 zirconium Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3235—Chemical structure of the sugar modified ring structure having the O of the ribose replaced by another atom
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/333—Modified A
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/335—Modified T or U
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/336—Modified G
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides a vaccine agent for the treatment or prevention of a coronavirus disease, which agent comprises an mRNA fragment of a coronavirus antigen, or relates to an improved nucleic acid fragment for use in the preparation of a coronavirus vaccine agent.
Description
Related document
The present application claims priority, application number, of the following prior applications: 202010090564.4, respectively; application date 2020, 2 month 13; application No.: 202010418211.2, filing date 2020, 5/18; application No.: 202010767364.8, filing date 2020, 8/03; the disclosure of these documents is made as part of the present invention.
Technical Field
The invention belongs to the technical field of biology, and particularly relates to a vaccine or a vaccine reagent for treating and preventing coronavirus infection.
Background
The description of the background art is intended to be merely a general description of the invention in order to facilitate an understanding of the invention and is not intended to limit the invention in any way.
Coronavirus infection is distributed in many areas throughout the world, and infection by the virus occurs mainly in winter and early spring. Human diseases caused by coronaviruses are mainly respiratory infections, which are very temperature sensitive and grow well at 33 ℃ but are inhibited at 35 ℃. Due to this property, winter and early spring are the epidemic seasons of the viral disease. Coronavirus is one of the main pathogens of common cold of adults and is also an important pathogen for acute exacerbation of adult chronic tracheitis patients.
There is a need to develop a prophylactic as well as a therapeutic vaccine agent that can produce antibodies in humans or mammals against coronavirus infection or to treat humans or mammals infected with coronavirus.
Disclosure of Invention
The present invention provides a coronavirus vaccine agent having preventive and therapeutic effects, which can exert both the preventive and therapeutic effects on a coronavirus disease and the therapeutic effects on the disease.
In one aspect, the present invention provides a vaccine agent comprising an mRNA fragment of a coronavirus antigen, wherein the mRNA fragment comprises one or a combination of S, S1, RBD, N, E, M, etc. antigen sequences. In some embodiments, the fragment portions are manually optimized or modified.
Herein, the coronavirus is a human or mammalian coronavirus. In some embodiments, the coronavirus is one of Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS), and new coronary pneumonia (COVID-19). In some embodiments, the coronavirus virus is one or more of HCoV-229E, HCoV-OC43, HCoV-NL63, and HCoV-HKU 1.
In some embodiments, the mRNA sequence is selected from SEQ NOs: 1.1-1.9. In some embodiments, the sequence is SEQ NO: 1.1. in some embodiments, the mRNA sequence is modified by nucleic acid, the ratio of modification being 20-100%. In some embodiments, the modification is modification of uridine with 1-methylpseudouracil. The structure of 1-methyl-pseudouracil is as follows:
in some embodiments, the modification is a modification of uridine with 1-methylpseudouracil at a ratio of 50%.
In some embodiments, the nucleic acid further comprises a cap structure. In some aspects, the cap structure is as follows:
the additional cap is at the 5' end. In some embodiments, capping may also be performed at the 3' end.
In some embodiments, the nucleic acid is encapsulated, and the encapsulated structure comprises a core structure formed by mixing the nucleic acid with a polymer or protein. In some embodiments, the core structure further comprises a shell structure, such as a shell structure formed by a phospholipid.
In another aspect, the invention provides a DNA sequence as set forth in SEQ NO: 1. the amino acid sequence of SEQ NO: 2. the amino acid sequence of SEQ NO: 3. the amino acid sequence of SEQ NO: 4. the amino acid sequence of SEQ NO: 5. the amino acid sequence of SEQ NO: 6. the amino acid sequence of SEQ NO: 7. The amino acid sequence of SEQ NO: 8 or SEQ NO: 9, or a sequence having 60% to 100% homology to one of said arbitrary sequences, or a sequence functionally identical thereto. Or the sequences may be complementary.
In some embodiments, the sequence is SEQ NO:1, SEQ NO: 2. the amino acid sequence of SEQ NO: 4. the amino acid sequence of SEQ NO: 5. The amino acid sequence of SEQ NO: 8 or SEQ NO: 9; or a sequence functionally equivalent thereto.
In some embodiments, the sequence is SEQ NO:1, or a fragment thereof.
In some embodiments, the sequence further comprises at the 5' end the sequence as set forth in SEQ NO:11, and (c) the sequence shown in fig. 11.
In some embodiments, the sequence further comprises at the 5' end the sequence as set forth in SEQ NO:12, or a sequence shown in figure 12.
In some embodiments, the sequence further comprises at the 3' end the sequence as set forth in SEQ NO: 13, or a sequence shown in figure 13.
In some embodiments, the sequence further comprises at the 3' end the sequence as set forth in SEQ NO: 14, or a sequence shown in fig. 14.
In some approaches, a tail sequence is also included. In some preferred forms, the tail sequence is SEQ NO: 15, or a pharmaceutically acceptable salt thereof.
In some embodiments, the homology is 65-100%. In some embodiments, the homology is 70-100%. In some embodiments, the homology is 71-100%. In some embodiments, the homology is 73-100%. In some embodiments, the homology is 74-100%. In some embodiments, the homology is 100%.
In some forms, the polypeptide has a sequence identical to SEQ NO:1, the homology of the sequence shown in 1 is 70-100 percent; and SEQ NO:3, the homology of the sequence shown in the sequence is 74-100 percent; and SEQ NO: 5, sequences with 70-100% homology; and SEQ NO: 6 has 65-100% homology; and SEQ NO: 7, and 65-100% of the sequence shown in the sequence table; and SEQ NO: 8, the sequence with 70-100% of homology; or with SEQ NO: 9 said sequence homology is 70-100% sequence.
In another aspect, the present invention provides an RNA sequence as set forth in SEQ NO: 1.1, SEQ NO: 2.2, SEQ NO: 3.3, SEQ NO: 4.4, SEQ NO: 5.5, SEQ NO: 6.6, SEQ NO: 7.7, SEQ NO: 8.8 or SEQ NO: 9.9, or 60% to 100% homologous to one of said sequences; or a sequence functionally equivalent thereto, or a sequence complementary thereto. In some preferred forms, the sequence is SEQ NO: 1.1, SEQ NO: 2.2, SEQ NO: 4.4, SEQ NO: 5.5, SEQ NO: 8.8 or SEQ NO: 9.9 one or more of the sequences shown; or 60% to 100% homology to one of said sequences.
In some preferred forms, the sequence is SEQ NO:1 or a sequence having 60% to 100% homology to said sequence. In some preferred forms, the homology is between 65 and 100%. In some preferred forms, the homology is between 75 and 100%. In some preferred forms, the homology is between 85 and 100%. In some preferred forms, the homology is 95 to 100%. In some preferred forms, the homology is between 98 and 100%. In some preferred forms, wherein the homology is 99-100%. In some preferred forms, the homology is 100%.
In some preferred embodiments, the sequence further comprises a sequence such as UTR at the 5 'end of the sequence and/or a sequence such as UTR at the 3' end of the sequence. In some embodiments, the 5-terminal further comprises an initiator region. In some embodiments, the 3-end further comprises a tail structure. In some preferred forms, the sequence further comprises at the 5' end the sequence as set forth in SEQ NO: 36-1 to SEQ NO: 36-12. In some preferred forms, the sequence further comprises at the 5' end thereof a sequence as set forth in SEQ NO: 36-11 or SEQ NO: 36-12. In some preferred forms, the sequence further comprises at the 3' end the sequence as set forth in SEQ NO: 37-1 to SEQ NO: 37-12. In some preferred forms, the sequence further comprises at the 3' end the sequence as set forth in SEQ NO: 37-11 or SEQ NO: 37-12. In some embodiments, the sequence may also be at the 5' end as set forth in SEQ NO:11, and (c) the sequence shown in fig. 11. In some embodiments, the sequence may also be at the 5' end as set forth in SEQ NO:12, the sequence shown in figure. In some embodiments, the sequence may also be, at the 3' end of the sequence, as set forth in SEQ NO: 13, or a sequence shown in figure 13.
In some embodiments, the sequence further comprises at the 3' end the sequence as set forth in SEQ NO: 14, or a sequence shown in fig. 14.
In some embodiments, the 3-terminal further comprises a tail sequence of SEQ NO: 15, or a pharmaceutically acceptable salt thereof.
In some modes, the 5-end also comprises a promoter, and in some modes, the sequence of the promoter is the sequence shown in SEQ ID NO. 12.
In some embodiments, the sequence further includes the additional sequence shown in SEQ ID NO 38 or SEQ ID NO 39. In some forms, the sequences are inserted after the AUG nucleotide. In some embodiments, the additional sequence is at the 5-terminus.
In some embodiments, the RNA sequence comprises an ORF sequence, a promoter sequence, a5 'UTR sequence and/or a 3' UTR sequence. In some embodiments, the ORF sequence comprises the additional sequence. In some modes, the following modes are sequentially adopted according to the sequencing mode from the 5 end to the 3' end: promoter sequence-5 'end UTR sequence-ORF sequence-3' end UTR sequence-tail sequence.
In another aspect, the invention provides a coronavirus mRNA vaccine agent, said vaccine agent comprising an mRNA sequence according to any of the claims, or an mRNA sequence obtained from the in vitro inversion rate of a DNA sequence according to any of the preceding claims.
In some embodiments, the mRNA includes modified nucleotides, wherein the modified nucleotides are selected from one or more of the following nucleotides: 2-aminoadenosine, 2-thiothymidine, inosine, pyrrolopyrimidine, 3-methyladenosine, 5-methylcytidine, C-5 propynyl-cytidine, C-5 propynyl-uridine, 2-aminoadenosine, C5-bromouridine, C5-fluorouridine, C5-iodouridine, C5-propynyl-uridine, C5-propynyl-cytidine, C5-methylcytidine, 2-aminoadenosine, 7-deazaadenosine, 7-deazaguanosine, 8-oxoadenosine, 8-oxoguanosine, O (6) -methylguanine, pseudouridine, N-1-methyl-pseudouridine, 2-thiouridine, and 2-thiocytidine; a methylated base; an insertion base; 2 '-fluororibose, ribose, 2' -deoxyribose, arabinose, and hexose; a phosphorothioate group and a 5' -N-phosphoramidite bond. And modified nucleotides described in PCT/CN2020/074825, PCT/CN 2020/106696. In some forms, the mRNA includes a modified nucleotide, the modified nucleotide being N-1-methyl-pseudouridine.
In some embodiments, the modification ratio is 0.1% to 100%. In some embodiments, the modification ratio is 2% to 90%. In some embodiments, the modification ratio is 5% to 80%. In some embodiments, the modification ratio is 20% to 80%. In some embodiments, the modification ratio is 40% to 70%. In some embodiments, the modification ratio is 50%.
In some embodiments, the reagent further comprises a polymer, the polymer and the nucleotide form a nanoparticle, and the polymer is selected from one or more of the following polymers: polyacrylate, polyalkylcyanoacrylate, polylactide-polyglycolide copolymer, polycaprolactone, dextran, albumin, gelatin, alginate, collagen, chitosan, cyclodextrin, Polyethyleneimine (PEI), or branched PEI. In some embodiments, the agent further comprises a liposome, and the core structure comprising the nucleotide polymer is encapsulated in the liposome to form a nanoparticle.
In some embodiments, the agent further comprises a liposome, and the nucleotide is encapsulated by the liposome to form a nanoparticle. In some embodiments, the liposome is selected from one or more of the following liposomes: cationic lipids, non-cationic lipids, sterol-based lipids, and/or PEG-modified lipids. In some embodiments, the cationic lipid comprises: c12-200, MC3, DLinDMA, DLinkC2DMA, cKK-E12, ICE (imidazolyl), HGT5000, HGT5001, OF-02, DODAC, DDAB, DMRIE, DOSPA, DOGS, DODAP, DODMA and DMDMA, DODAC, DLenDMA, DMRIE, CLinDMA, CpLinDMA, DMOBA, DOcarDAP, DLinDAP, DLincarDAP, DLinCDAP, KLin-K-DMA, DLin-K-XTC2-DMA and HGT4003, or a combination thereof. In some ways, non-limiting examples of the non-cationic lipid may include ceramides, cephalins, cerebrosides, diacylglycerols, 1, 2-dipalmitoyl-sn-glycero-3-phosphorylglycero sodium salt (DPPG), 1, 2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE), 1, 2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1, 2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1, 2-dioleyl-sn-glycero-3-phosphoethanolamine (DOPE), 1, 2-dioleyl-sn-glycero-3-phosphocholine (DOPC), 1, 2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (DPPE), 1, 2-dimyristoyl-sn-glycero-3-phosphoethanolamine (DMPE), and 1, 2-dioleoyl-sn-glycero-3-phospho- (1' -rac-glycerol) (DOPG), 1-palmitoyl-2-oleoyl-phosphatidylethanolamine (POPE), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1-stearoyl-2-oleoyl-phosphatidylethanolamine (SOPE), sphingomyelin, or a combination thereof. In some forms, the sterol-based cationic lipid can comprise no more than 70% of the total lipid in the lipid nanoparticle. In some embodiments, the sterol-based cationic lipid comprises a phosphatidyl compound, a phosphatidyl glycerol, a phosphatidyl choline, a phosphatidyl serine, a phosphatidyl ethanolamine, a sphingolipid, a cerebroside, and a ganglioside, or a combination thereof. In some embodiments, PEG-modified lipids, such as DMG-PEG, DMG-PEG2K, C8-PEG, DOGPEG, ceramide PEG, and DSPE-PEG, or combinations thereof, are also included.
In some embodiments, the vaccine agent further comprises protamine sulfate, DOPE, DSPE-mPEG2000, and M5, the structure of M5 is as follows:
in some embodiments, the M5: DOPE: DSPE-mPEG 2000: 49:2 (mass ratio).
The present invention provides a DNA vaccine agent comprising the NDA sequence of any of the preceding claims. In some embodiments, the sequence is selected from SEQ id NO: one or more of 1-9 sequences.
In one aspect, the invention provides a UTR sequence comprising a sequence as set forth in SEQ NO: 36-1 to 36-12, or' SEQ NO: 37-1 to 37-12. In some forms, the 5' sequence is SEQ NO: 36-11, 3 is SEQ NO: 37-11; or the 5' sequence is SEQ NO: 36-12, 3 is SEQ NO: 37-12.
In another aspect, the invention provides a 3' UTR sequence, said sequence comprising; the amino acid sequence of SEQ NO: 37-11 or SEQ NO: 37-12.
In another aspect of the invention, there is provided an additional sequence of RNA for the ORF, said additional sequence being as set forth in SEQ NO:38 or SEQ NO:39, or a sequence shown in seq id no. In some embodiments, the additional sequence is at the 5-terminus. In some embodiments, the additional sequence is inserted from an AUG sequence. In some embodiments, the ORF sequence of the RNA is one of any of the sequences in any of the preceding embodiments.
Drawings
FIG. 1 is a schematic diagram of the structure of a DNA template in a plasmid, showing that the DNA sequence includes a T1 promoter, a UTR sequence and a joining schematic diagram of an ORF sequence of DNA.
FIG. 2 is a diagram of the structure of an RNA sequence transcribed from a DNA template, and this diagram also contains a T7, UTR sequence and PolyA sequence transcribed from a DNA sequence.
FIG. 3 is a graph of the results of antigen expression at the level of liposome-infected cells using the 9 RNA sequences.
FIG. 4 is a comparison of the immunogenicity of 9 mRNA vaccines in mice, where PBS is a blank control, and other nucleocapsid-structured nanoparticles containing different RNA Sequences (ORFs) can be compared in mice, and some are found to be higher than the blank control, some are lower than the blank control, and some are not immunogenic, i.e., they do not cause the production of antibodies or the amount or titer of antibodies by the mammal is low.
FIG. 5 is a graph showing the effect of the vaccine agents screened on the change in body weight of mice (different concentrations of COVID-19-LPP-mRNA immunization C57BL/6 mouse assay).
FIG. 6 is a BALB/c mouse antibody assay dilution curve (for different doses of vaccine reagents)
FIG. 7 is a dilution curve of the C57BL/6 mouse antibody assay (for different doses of vaccine agent).
Figure 8 comparison of specific IgG titers (for different doses of vaccine agent).
Figure 9 is a BALB/c mouse neutralizing antibody titer curve (for different doses of vaccine agents)).
FIG. 10 is a curve of neutralizing antibody titers (for various doses of vaccine agent) for C57BL/6 mice.
Figure 11 is a summary of pseudovirus neutralizing antibody titers (for different doses of vaccine agent) in two mice.
FIG. 12 is a graph of BALB/c mouse neutralizing antibody titers (for different doses of vaccine agents).
FIG. 13 is a graph of neutralizing antibody titers (for various doses of vaccine agent) for C57BL/6 mice
Figure 14 is a summary plot of antibody titers (for different doses of vaccine agent).
Figure 15 is a graph of antibody titer results for different antibody subtypes (different concentrations or different doses of vaccine agent). Wherein FIG. 15A is IgM, FIG. 15B is IgG, and FIG. 15C is IgM.
FIG. 16A is a graph showing the results of the evaluation of the level of antigen-specific T cell responses in mice following immunization with different doses of COVID-LPP-mRNA. FIG. 16B is a graph showing the results of an evaluation of the level of neutralizing antibodies in the mouse serum after immunization with different doses of COVID-LPP-mRNA (dot plot).
FIG. 17 is a graph showing the results of the evaluation of the level of neutralizing antibodies in the mouse serum after immunization with different doses of COVID-LPP-mRNA.
FIG. 18 evaluation of the protective effect of the mice against SARS-CoV-2 infection after immunization with COVID-19-LPP-mRNA (Balb/C mouse weight Change)
FIG. 19 is an evaluation of the protective effect of COVID-19-LPP-mRNA immunized on mice against SARS-CoV-2 infection (C57 mouse body weight change).
FIG. 20 is the lung tissue viral load of Balb/C mice on day 4 post challenge, where FIG. 20A shows RNA copy number and FIG. 20B is a graph comparing TCID50 titer data.
FIG. 21 is a graph of lung tissue viral load of C57BL/6 mice at day 4 post challenge, where FIG. 21A shows RNA copy number and FIG. 21B is a comparison of TCID50 titer data.
Figure 22 is a pathological section of Balb/C mice lung tissue at day 4 post challenge (different experimental treatments, HD for high dose (top), LD for low dose (middle), and coronavirus comparison (bottom)).
FIG. 23 is a pathological section of C57BL/6 mice lung tissue at day 4 post challenge (different experimental treatments, HD for high dose (double needle DD-up), HD for high dose (single needle SD-up); LD for low dose double needle (DD) and single needle (SD), and coronavirus comparison (down)).
FIG. 24 shows the results of gRNA detection in lung tissue, trachea and bronchi after experimental monkeys were infected with SARS-CoV-2.
FIG. 25 is a graph showing the results of gRNA detection in lung lavage fluid of experimental monkey infected with SARS-CoV-2.
FIG. 26 is a graph showing the results of gRNA detection in nasal swabs after experimental monkeys were infected with SARS-CoV-2.
FIG. 27 is a graph showing the results of gRNA detection in pharyngeal swabs after experimental monkeys were infected with SARS-CoV-2.
FIG. 28 is a photograph of a lung histological section of control PBS numbered 16139 showing local thickening of the lung septum, mild bleeding, lymphocyte nodules, local thickening of the vessel wall, intraluminal thrombosis, and tracheal intraluminal blood cell-like exudation.
FIG. 29 is a photograph of a histological section of lung tissue from control PBS numbered 16113 showing mild bleeding of the lung space, inflammatory cell infiltration, pigmentation, local vessel wall thickening and intraluminal thrombosis.
FIG. 30 is a photograph of a lung tissue section of control PBS numbered 16217 showing a large thickening of the lung septum, mild to moderate bleeding, lymphocyte nodules, local thickening of the vessel wall, thrombosis in the vessel lumen, histiocyte sloughing in the tracheal lumen, and local carbon deposits.
FIG. 31 is a photograph of a histological section of lung from the vaccine group numbered 16145 showing relatively intact alveolar structures, mild to moderate bleeding of the pulmonary septum, and inflammatory cell infiltration.
Fig. 32 is a photograph of a tissue section of the lungs of vaccine group number 16045, showing relatively intact alveolar structure, mild thickening of lung spaces and small inflammatory infiltration of fine lines.
FIG. 33 is a photograph of a histological section of lung from the vaccine group numbered 16175 showing relatively intact alveolar structures, mild thickening of the pulmonary septum, bleeding, and lymphocyte nodules.
Fig. 34 is a photograph of a tissue section of the lungs of vaccine group No. 16249 showing mild thickening of lung spaces, mild bleeding, focal dust cell distribution, vascular congestion, inflammatory cell infiltration.
Fig. 35 is the natural sequence numbering SEQ NO: 1-1-1 and the optimized sequence SEQ NO: 1.1 results of RNA homology comparison.
Figure 36 is the native sequence numbering of SEQ NO: 2-2-2 and the optimized sequence SEQ NO: 2.2 comparison of RNA homology.
Figure 37 is the native sequence numbering of SEQ NO: 3-3-3 and the optimized sequence SEQ NO: 3.3 results of RNA homology comparison. Figure 38 is the native sequence numbering of SEQ NO: 4-4-4 and the optimized sequence SEQ NO: 4.4 comparison of RNA homology.
FIG. 39 is a natural sequence numbering SEQ NO: 5-5-5 and the optimized sequence SEQ NO: 5.5 results of RNA homology comparison.
Figure 40 is the native sequence numbering SEQ NO: 6-6-6 and the optimized sequence SEQ NO: 7.7 RNA homology comparison results.
Figure 41 is the native sequence numbering of SEQ NO: 7-7-7 and the optimized sequence SEQ NO: 7.7 results of RNA homology comparison.
Figure 42 is the native sequence numbering SEQ NO: 8-8-8 and the optimized sequence SEQ NO: 8.8 comparison of RNA homology.
Figure 43 is the native sequence numbering of SEQ NO: 9-9-9 and the optimized sequence SEQ NO: 9.1 results of RNA homology comparison.
Detailed Description
Definition of
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The following references provide those skilled in the art with a general definition of many of the terms used in the present invention: dictionary of Biochemistry and Molecular Biology (Dictionary of Biochemistry and Molecular Biology), (2 nd edition) j.stenesh (eds.), Wiley-Interscience (1989); the Dictionary of Microbiology and Molecular Biology (Dictionary of Microbiology and Molecular Biology) (3 rd edition), p.singleton and d.sainsbury (eds.), Wiley-inter (2007); the Chambers Dictionary of Science and Technology (2 nd edition), P.Walker (eds.), Chambers (2007); the vocabulary of Genetics (Glossary of Genetics) (5 th edition), R.Rieger et al (eds.), Springer-Verlag (1991); and The Harper collins Dictionary of Biology (The Harper collins Dictionary of Biology), W.G.Hale and J.P. Margham, (eds.), Harper collins (1991).
Although any methods and compositions similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and compositions are described herein. For purposes of the present invention, the following terms are defined below for clarity and ease of reference: in accordance with established patent statutory convention, when reference is made to the use of items in this application, including the claims, without numerical designations, it is intended to mean "one or more". The terms "about" and "approximately" are used interchangeably herein and are generally understood to refer to a range of numbers around a given number, as well as all numbers within the recited range of numbers (e.g., "about 5 to 15" means "about 5 to about 15" unless otherwise specified). Moreover, all numerical ranges herein should be understood to include each integer within the range.
As used herein, an "antigenic polypeptide" or "immunogenic polypeptide" is a polypeptide that, when introduced into a vertebrate, reacts with, i.e., is antigenic, and/or induces an immune response in, i.e., is immunogenic, the vertebrate's immune system molecules.
"biocompatible" refers to a substance that, when exposed to living cells, will support the appropriate cellular activity of the cells without causing unwanted effects in the cells such as changes in the cell life cycle, changes in the rate of cell proliferation, or cytotoxic effects.
The term "biofunctionally equivalent" is well known in the art and is defined herein in further detail. Thus, sequences having from about 85% to about 90%, or more preferably from about 91% to about 95%, or even more preferably from about 96% to about 99% nucleotides that are identical or functionally equivalent to one or more of the nucleotide sequences provided herein are specifically contemplated for use in the practice of the methods and compositions set forth herein.
As used herein, the term "buffer" includes one or more compositions or aqueous solutions thereof that resist fluctuations in pH when an acid or base is added to a solution or composition containing the buffer. This resistance to pH changes is due to the buffering properties of such solutions and may be a function of the particular compound or compounds contained in the composition. Thus, a solution or other composition exhibiting buffering activity is referred to as a buffer or buffer solution. Buffers generally do not have the unlimited ability to maintain the pH of a solution or composition; rather, they are generally capable of maintaining a pH within a range, for example, a pH of about 5 to 7.
As used herein, the term "carrier" is intended to include any solvent, dispersion medium, coating, diluent, buffer, isotonic agent, solution, suspension, colloid, inert entity, and the like, or combinations thereof, that is pharmaceutically acceptable for administration to the relevant animal or, if applicable, for therapeutic or diagnostic purposes.
As used herein, the term "DNA segment" refers to a DNA molecule that has been isolated from the total genomic DNA of a particular species. Thus, a DNA segment obtained from a biological sample using one of the compositions disclosed herein refers to one or more DNA segments that have been isolated or purified from the total genomic DNA of the particular species from which they were obtained. Included within the term "DNA segment" are DNA segments and smaller fragments of such segments, as well as recombinant vectors, including, for example, plasmids, cosmids, phages, viruses, and the like.
The term "effective amount," as used herein, refers to an amount capable of treating or ameliorating a disease or condition or capable of producing a desired therapeutic effect.
As used herein, the term "epitope" refers to a portion of a given immunogenic agent that is the target of, i.e., bound by, an antibody or cell surface receptor of the host immune system that has mounted an immune response to the given immunogenic agent, as determined by any method known in the art. Further, an epitope can be defined as a portion of an immunogenic substance that elicits an antibody response or induces a T cell response in an animal, as determined by any method available in the art (see, e.g., Geysen et al, 1984). The epitope may be part of any immunogenic substance, such as a protein, polynucleotide, polysaccharide, organic or inorganic chemical, or any combination thereof. The term "epitope" may also be used interchangeably with "antigenic determinant" or "antigenic determinant site".
The term "for example" as used herein is intended to be exemplary only and not intended to be limiting, and should not be construed as referring only to those items explicitly recited in the specification.
As used herein, "heterologous" is defined with respect to a predetermined reference nucleic acid sequence. For example, for a structural gene sequence, a heterologous promoter is defined as a promoter that does not naturally occur adjacent to the reference structural gene, but is placed by laboratory manipulation. Likewise, a heterologous gene or nucleic acid segment is defined as a gene or segment that does not naturally occur adjacent to a reference promoter and/or enhancer element.
As used herein, "homologous," when referring to a polynucleotide, refers to a sequence that, although from a different source, has the same or substantially the same nucleotide sequence. Typically, homologous nucleic acid sequences are derived from closely related genes or organisms having one or more substantially similar genomic sequences. In contrast, an "homologous" polynucleotide is a polynucleotide that shares the same function as a polynucleotide from a different species or organism, but may have a significantly different primary nucleotide sequence, encoding one or more proteins or polypeptides that perform similar functions or have similar biological activities. An isoactive polynucleotide can often be derived from two or more (e.g., genetically or phylogenetically) not closely related organisms.
As used herein, the term "homology" refers to the degree of complementarity between two or more polynucleotide or polypeptide sequences. The word "identity" may replace the word "homology" when a first nucleic acid or amino acid sequence has a primary sequence that is identical to a second nucleic acid or amino acid sequence. Sequence homology and sequence identity can be determined by analyzing two or more sequences using algorithms and computer programs known in the art. Such methods can be used to assess whether a given sequence has identity or homology with another selected sequence.
The term "identical" or percent "identity," in the context of two or more nucleic acid or polypeptide sequences, refers to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same, when compared and aligned for maximum correspondence, using one of the sequence comparison algorithms described below (or other algorithms available to the skilled artisan), or as measured by visual inspection.
As used herein, the phrase "in need of treatment" refers to the judgment made by a caregiver, such as a doctor or veterinarian, that a patient is in need of (or will benefit from in one or more ways) treatment. Such a determination may be made based on various factors in the area of expertise of the caregiver, and may include the realization that the patient is ill with a disease state that may be treated by one or more compounds or pharmaceutical compositions, such as those set forth herein.
The phrases "isolated" or "biologically pure" refer to a substance that is substantially or essentially free of components that normally accompany the substance in its natural state. Thus, isolated polynucleotides or polypeptides according to the present disclosure preferably do not contain materials normally associated with those polynucleotides or polypeptides in their native or in situ environment.
As used herein, the term "kit" may be used to describe a variation of a portable self-contained housing that includes at least one set of reagents, components or pharmaceutically formulated compositions of the invention. Optionally, such kits may include one or more sets of instructions for using the encapsulated compositions, for example, in a laboratory or clinical application.
"linkage" or "joining" refers to any method known in the art for functionally linking one or more proteins, peptides, nucleic acids, or polynucleotides, including, but not limited to, recombinant fusion, covalent bonding, disulfide bonding, ionic bonding, hydrogen bonding, electrostatic bonding, and the like.
The term "naturally occurring" as used herein when applied to an object refers to the fact that the object may exist in nature. For example, a polypeptide or polynucleotide sequence that is present in an organism (including viruses), that can be isolated from a source in nature, and that has not been intentionally modified by man in the laboratory, is naturally occurring. As used herein, laboratory varieties of rodents that have been selectively propagated according to classical genetics are considered to be naturally occurring animals.
As used herein, the term "nucleic acid" includes one or more of the following types: polydeoxyribonucleotides (containing 2-deoxy-D-ribose), polyribonucleotides (containing D-ribose), and any other type of polynucleotide that is an N-glycoside of a purine or pyrimidine base or a modified purine or pyrimidine base (including abasic sites). The term "nucleic acid", as used herein, also includes covalently bonded polymers of ribonucleosides or deoxyribonucleosides, typically through phosphodiester linkages between subunits, but in some cases through phosphorothioate, methylphosphonate, and the like. "nucleic acid" includes single-and double-stranded DNA and single-and double-stranded RNA. Exemplary nucleic acids include, but are not limited to, gDNA; hnRNA; mRNA; rRNA, tRNA, microrna (mirna), small interfering rna (sirna), small nucleolar rna (snorna), small nuclear rna (snrna), and small sequential rna (strna), and the like, and any combination thereof.
The term "operably linked", as used herein, means that the nucleic acid sequences being linked are generally contiguous or substantially contiguous, and, where necessary to join two protein coding regions, contiguous and in reading frame. However, because enhancers generally function when separated from a promoter by thousands of bases, and intronic sequences may be of variable length, some polynucleotide elements may be operably linked but not contiguous.
As used herein, the term "patient" (also interchangeably referred to as "recipient", "subject", "host" or "subject") refers to any host that can be the recipient of one or more vascular access devices discussed herein. In certain aspects, the recipient will be a vertebrate, which is intended to mean any animal species (and preferably, mammalian species, e.g., humans). In certain embodiments, a "patient" refers to any animal host, including, but not limited to, human and non-human primates, avians, reptiles, amphibians, cattle, dogs, goats (caprines), cavines, crows, epines, equines, felines, goats (hircines), rabbits, hares (leporines), wolfs (lupines), murines, sheep, pigs, racines, foxes, and the like, including, but not limited to, domestic livestock, grazing or migrating animals or birds, exotic or zoo specimens, as well as companion animals, pets, and any animal subject to veterinary care.
The phrase "pharmaceutically acceptable" refers to molecular entities and compositions that do not produce allergic or similar untoward reactions when administered to humans, particularly when administered to the human eye. The preparation of aqueous compositions containing proteins as active ingredients is well known in the art. Typically, such compositions are prepared as injectables, either as liquid solutions or as suspensions. Alternatively, they may be prepared in solid form suitable for dissolution or suspension in a liquid prior to injection.
As used herein, "pharmaceutically acceptable salt" refers to a salt that retains the desired biological activity of the parent compound and does not produce any undesired toxicological effects. Examples of such salts include, but are not limited to, acid addition salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, and the like; and salts with organic acids such as acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, tannic acid, pamoic acid (methylenepamoic acid), alginic acid, naphthoic acid, polyglutamic acid, naphthalenesulfonic acid, naphthalenedisulfonic acid, polygalacturonic acid; salts with polyvalent metal cations such as zinc, calcium, bismuth, barium, magnesium, aluminum, copper, cobalt, nickel, cadmium, and the like; salts with organic cations formed from N, N' -dibenzylethylenediamine or ethylenediamine; and combinations thereof.
As used herein, the term "plasmid" or "vector" refers to a genetic construct composed of genetic material (i.e., a nucleic acid). Typically, the plasmid or vector contains an origin of replication functional in a bacterial host cell, such as E.coli, and a selectable marker for detecting a bacterial host cell containing the plasmid. Plasmids and vectors of the invention may comprise one or more genetic elements as described herein arranged such that the inserted coding sequence can be transcribed and translated in a suitable expression cell. In addition, the plasmid or vector may include one or more nucleic acid segments, genes, promoters, enhancers, activators, multiple cloning regions, or any combination thereof, including segments obtained or derived from one or more natural and/or artificial sources.
As used herein, the term "polypeptide" is intended to encompass both singular "polypeptides" and plural "polypeptides" and includes any chain of two or more amino acids. Thus, as used herein, terms including, but not limited to, "peptide," "dipeptide," "tripeptide," "protein," "enzyme," "amino acid chain," and "contiguous amino acid sequence" are encompassed within the definition of "polypeptide," and the term "polypeptide" may be used in place of or interchangeably with any of these terms. The term also includes polypeptides that have undergone or modified by inclusion of one or more non-naturally occurring amino acids, such as, but not limited to, saccharification, acetylation, phosphorylation, amidation, derivatization, proteolytic cleavage, post-translational processing. Conventional nomenclature for polynucleotide and polypeptide structures exists in the art.
For example, the one-and three-letter abbreviations are widely used to describe amino acids: alanine (A; Ala), arginine (R; Arg), asparagine (N; Asn), aspartic acid (D; Asp), cysteine (C; Cys), glutamine (Q; Gln), glutamic acid (E; Glu), glycine (G; Gly), histidine (H; His), isoleucine (I; Ile), leucine (L; Leu), methionine (M; Met), phenylalanine (F; Phe), proline (P; Pro), serine (S; Ser), threonine (T; Thr), tryptophan (W; Trp), tyrosine (Y; Tyr), valine (V; Val), and lysine (K; Lys). The amino acid residues described herein are preferably in the "1" isomeric form. However, residues in the "d" isomeric form may be substituted for the l amino acid residue, provided that the desired polypeptide properties are retained.
As used herein, the terms "prevent" and "inhibiting" as used herein refer to the administration of a compound, alone or contained in a pharmaceutical composition, prior to the onset of a clinical symptom of a disease state, to prevent any symptom, aspect or feature of the disease state. Such prevention and inhibition need not be absolutely considered medically useful.
"protein" is used interchangeably herein with "peptide" and "polypeptide" and includes both synthetically, recombinantly or in vitro produced peptides and polypeptides, as well as peptides and polypeptides that are expressed in vivo following administration of a nucleic acid sequence to a host animal or human subject. The term "polypeptide" preferably means any amino acid chain length, including short peptides from about 2 to about 20 amino acid residues in length, oligopeptides from about 10 to about 100 amino acid residues in length, and longer polypeptides including about 100 amino acid residues in length or more. Furthermore, the term is also intended to include enzymes, i.e. functional biomolecules comprising at least one amino acid polymer. The polypeptides and proteins of the invention also include polypeptides and proteins that are or have been post-translationally modified, and include any saccharide or other derivative or conjugate added to the backbone amino acid chain.
"purified", as used herein, means separated from many other compounds or entities. The compound or entity may be partially purified, substantially purified, or pure. A compound or entity is considered pure when it is removed from substantially all other compounds or entities, i.e., preferably at least about 90%, more preferably at least about 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or greater than 99% pure. A partially or substantially purified compound or entity may remove at least 50%, at least 60%, at least 70%, or at least 80% of the material that is naturally present with it, e.g., cellular material such as cellular proteins and/or nucleic acids.
The term "recombinant" denotes a substance (e.g., a polynucleotide or polypeptide) that has been altered by human intervention, either artificially or by (non-natural) synthesis. The alteration may be made to the substance in its natural environment or state, or to the substance removed from its natural environment or state. Specifically, for example, a promoter sequence is "recombinant" when it is produced by expression of an artificially engineered nucleic acid segment. For example, "recombinant nucleic acids" are made by nucleic acid recombination during, e.g., cloning, DNA shuffling or other procedures, or by chemical or other mutagenesis; a "recombinant polypeptide" or "recombinant protein" is a polypeptide or protein produced by expression of a recombinant nucleic acid; and "recombinant viruses," such as recombinant AAV viruses, are produced by expression of recombinant nucleic acids.
The term "regulatory element", as used herein, refers to a region of a nucleic acid sequence that regulates transcription. Exemplary regulatory elements include, but are not limited to, enhancers, post-transcriptional elements, transcriptional control sequences, and the like.
The term "RNA segment" refers to an RNA molecule that has been isolated from the total cellular RNA of a particular species. Thus, an RNA segment can refer to one or more RNA segments (of natural or synthetic origin) that have been isolated or purified from other RNAs. The term "RNA segment" includes RNA segments and smaller fragments of such segments.
When referring to amino acids, the term "sequence" refers to all or a portion of a linear N-terminal to C-terminal order of amino acids within a given amino acid chain, e.g., a polypeptide or protein; "subsequence" means any contiguous stretch of amino acids within a sequence, e.g., at least 3 contiguous amino acids within a given protein or polypeptide sequence. With respect to nucleotide chains, "sequences" and "subsequences" have similar meanings as related to the 5 'to 3' nucleotide sequence.
The term "substantially as set forth in SEQ ID NO: by "the sequence shown by X is meant that the sequence substantially corresponds to SEQ ID NO: x and has relatively few nucleotides (or amino acids in the case of a polypeptide sequence) that are complementary to SEQ ID NO: x is not identical in nucleotide (or amino acid) or is SEQ ID NO: a biological functional equivalent of a nucleotide (or amino acid) of X. The term "biologically functional equivalent" is well known in the art and is defined herein in further detail. Thus, sequences having from about 65% to about 90%, or more preferably from about 85% to about 95%, or even more preferably from about 96% to about 99% nucleotides that are identical or functionally equivalent to one or more of the nucleotide sequences provided herein are specifically contemplated for use in the practice of the present invention. When referring to a sequence as indicated by a certain numbered sequence, the sequence complementary to that sequence is also included. For example as shown in SEQ ID NO: the sequence represented by X includes not only the sequence characteristics of the sequence itself but also naturally the sequence characteristics complementary to the sequence, and "complementary" herein means that substantially all the sequences are in one-to-one correspondence, as is the complementary sequence under the basic common sense of biology. For example as shown in SEQ ID NO: x represents a DNA sequence and naturally also includes another DNA sequence complementary to the sequence unless the other sequence is specifically excluded.
Suitable standard nucleic acid hybridization conditions for use in the present invention include, for example, hybridization in 50% formamide, 5 XDenTable (Denhardt's) solution, 5 XSSC, 25mM sodium phosphate, 0.1% SDS, and 100. mu.g/mL denatured salmon sperm DNA for 16 hours at 42 ℃ followed by successive washes with 0.1 XSSC, 0.1% SDS solution for 1 hour at 60 ℃ to remove the desired amount of background signal. The hybridization conditions of the present invention, which are less stringent, include, for example, hybridization in 35% formamide, 5 XScost solution, 5 XSSC, 25mM sodium phosphate, 0.1% SDS, and 100. mu.g/mL denatured salmon sperm DNA or E.coli DNA at 42 ℃ for 16 hours, followed by successive washes with 0.8 XSSC, 0.1% SDS at 55 ℃. One of ordinary skill in the art will recognize that such hybridization conditions can be readily adjusted to achieve the desired level of stringency for a particular application.
As used herein, the term "structural gene" is intended to generally describe a polynucleotide, e.g., a gene, that is expressed to produce an encoded peptide, polypeptide, protein, ribozyme, catalytic RNA molecule, or antisense molecule.
The term "subject", as used herein, describes an organism, including mammals such as primates, to which treatment using the compositions of the present invention can be provided. Mammalian species that may benefit from the disclosed treatment methods include, but are not limited to, apes; a chimpanzee; an orangutan; a human being; a monkey; domestic animals such as dogs and cats; livestock such as horses, cattle, pigs, sheep, goats, and chickens; and other animals such as mice, rats, guinea pigs, and hamsters.
The term "substantially complementary", when used to define an amino acid or nucleic acid sequence, means that a particular target sequence, such as an oligonucleotide sequence, is substantially complementary to all or a portion of a selected sequence and, thus, will specifically bind to a portion of the mRNA encoding the selected sequence. Thus, typically the sequence will be highly complementary to an mRNA "target" sequence, and will have no more than about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, or about 10, etc., base mismatches in the complementary portion of the sequence. In many cases, it may be desirable for the sequences to be exact matches, i.e., completely complementary to the sequence to which the oligonucleotide specifically binds, and thus have zero mismatches along the complementary segment. Thus, a highly complementary sequence will typically bind rather specifically to a target sequence region of an mRNA and will therefore efficiently reduce and/or even inhibit translation of the target mRNA sequence into a polypeptide product.
A substantially complementary nucleic acid sequence will be greater than about 80% complementary (or "exact match") to a corresponding nucleic acid target sequence that specifically binds to the nucleic acid, and will more preferably be greater than about 85% complementary to a corresponding target sequence that specifically binds to the nucleic acid. In certain aspects, as described above, it would be desirable to have an even more substantially complementary nucleic acid sequence for use in the practice of the present invention, and in such cases, the nucleic acid sequence would be greater than about 90% complementary to a corresponding target sequence that specifically binds to the nucleic acid, and in certain embodiments may be greater than about 95% complementary to a corresponding target sequence that specifically binds to the nucleic acid, and even up to and including about 96%, about 97%, about 98%, about 99%, and even about 100% exact match complementary to all or part of the target sequence that specifically binds to the designed nucleic acid.
The percent similarity or percent complementarity of any of the disclosed nucleic acid sequences can be determined, for example, by comparing sequence information using the GAP Computer program available from the University of Wisconsin Genetics Computer Group (University of Wisconsin Genetics Computer Group, UWGCG), version 6.0. The GAP program utilizes the alignment method of Needleman and Wunsch (1970). Briefly, the GAP program defines similarity as the number of aligned symbols (i.e., nucleotides or amino acids) that are similar divided by the total number of symbols in the shorter of the two sequences. Preferred default parameters for the GAP program include: (1) unary comparison matrices of nucleotides (containing a value of 1 for identity and a value of 0 for non-identity), and weighted comparison matrices of Gribskov and Burgess (1986), 2) a penalty of 3.0 per gap and an additional 0.10 penalty per symbol in each gap; and (3) no penalty for end gap.
Naturally, the invention also encompasses nucleic acid segments that are complementary, essentially complementary, and/or substantially complementary to at least one or more of the specific nucleotide sequences specifically set forth herein. A "complementary" nucleic acid sequence is one that is capable of base pairing according to standard Watson-Crick complementarity rules. As used herein, the term "complementary sequence" refers to a substantially complementary nucleic acid sequence, which can be assessed by the same nucleotide comparison set forth above, or defined as capable of hybridizing to one or more of the specific nucleic acid segments disclosed herein under relatively stringent conditions, such as those described immediately above.
As used herein, the term "substantially free" or "essentially free" in relation to the amount of a component preferably means that the composition contains less than about 10% by weight, preferably less than about 5% by weight, more preferably less than about 1% by weight of the compound. In preferred embodiments, these terms refer to less than about 0.5 wt%, less than about 0.1 wt%, or less than about 0.01 wt%.
Probes and primers for use in the present invention may be of any suitable length. By assigning values to sequences, e.g., a first residue is 1, a second residue is 2, etc., an algorithm can be proposed that defines all probes or primers contained within a given sequence: n to n + y, wherein n is an integer from 1 to the last number of sequences and y is the length of the probe or primer minus 1, wherein n + y does not exceed the last number of sequences. Thus, for a 25 base pair probe or primer (i.e., a "25 mer"), the collection of probes or primers corresponds to bases 1 to 25, bases 2 to 26, bases 3 to 27, bases 4 to 28, etc., over the entire length of the sequence. Similarly, for a 35 base pair probe or primer (i.e., "35 mer"), exemplary primer or probe sequences include, but are not limited to, sequences corresponding to bases 1 to 35, bases 2 to 36, bases 3 to 37, bases 4 to 38, and the like, over the entire length of the sequence. Likewise, for a 40 mer, such probes or primers may correspond to nucleotides from the first base pair to bp 40, from the second bp to bp 41, from the third bp to bp 42 of the sequence, and so on, while for a 50 mer, such probes or primers may correspond to nucleotide sequences extending from bp 1 to bp 50, from bp 2 to bp 51, from bp 3 to bp 52, from bp 4 to bp 53, and so on.
The terms "substantially corresponds to", "substantially homologous", or "substantial identity", as used herein, refer to a characteristic of a nucleic acid or amino acid sequence in which the selected nucleic acid or amino acid sequence has at least about 70 or about 75% sequence identity as compared to a selected reference nucleic acid or amino acid sequence. More typically, the selected sequence and the reference sequence will have at least about 76, 77, 78, 79, 80, 81, 82, 83, 84, or even 85% sequence identity, more preferably at least about 86, 87, 88, 89, 90, 91, 92, 93, 94, or 95% sequence identity. Still more preferably, highly homologous sequences often share greater than at least about 96, 97, 98, or 99% sequence identity between the selected sequence and the reference sequence to which it is compared.
As used herein, "synthetic" shall mean that the material is not of human or animal origin.
The term "treatment-practical period" refers to the period of time necessary for one or more active agents to be effective for treatment. The term "therapeutically effective" refers to reducing the severity and/or frequency of one or more symptoms, eliminating one or more symptoms and/or underlying causes, preventing the occurrence of symptoms and/or underlying causes thereof, and improving or repairing damage.
A "therapeutic agent" can be any physiologically or pharmacologically active substance that can produce a desired biological effect at a targeted site in a subject. The therapeutic agent may be a chemotherapeutic agent, an immunosuppressive agent, a cytokine, a cytotoxic agent, a nucleolytic compound, a radioisotope, a receptor, and a prodrug-activating enzyme, which may be naturally occurring or produced by synthetic or recombinant methods, or any combination thereof. Drugs that are affected by classical multidrug resistance, such as vinca alkaloids (e.g., vinblastine and vincristine), anthracyclines (e.g., doxorubicin and daunorubicin), RNA transcription inhibitors (e.g., actinomycin-D), and microtubule stabilizing drugs (e.g., paclitaxel), may have particular utility as therapeutic agents. Cytokines may also be used as therapeutic agents. Examples of such cytokines are lymphokines, monokines, and traditional polypeptide hormones. Cancer chemotherapeutic agents may be preferred therapeutic agents. For a more detailed description of anticancer and other therapeutic agents, those skilled in the art may refer to a number of instructional manuals, including, but not limited to, Physician's Desk Reference and Goodman and Gilman's "Pharmacological Basis of Therapeutics", tenth edition, Hardman et al (eds.) (2001).
As used herein, "transcription factor recognition site" and "transcription factor binding site" refer to a polynucleotide sequence or sequence motif that is identified as a site of sequence-specific interaction of one or more transcription factors, often in the form of direct protein-DNA binding. In general, transcription factor binding sites can be identified by DNA footprinting, gel mobility shift analysis, and the like, and/or can be predicted based on known consensus sequence motifs or by other methods known to one of ordinary skill in the art.
A transcriptional regulatory element "refers to a polynucleotide sequence that activates transcription, either alone or in combination with one or more other nucleic acid sequences. The transcriptional regulatory element may, for example, comprise one or more promoters, one or more response elements, one or more negative regulatory elements, and/or one or more enhancers.
"transcriptional unit" refers to a polynucleotide sequence comprising at least a first structural gene operably linked to at least a first cis-acting promoter sequence and optionally to one or more other cis-acting nucleic acid sequences necessary for efficient transcription of the structural gene sequence, as well as at least a first distal regulatory element as may be necessary to operably place proper tissue-specific and developmental transcription of the structural gene sequence under the control of a promoter and/or enhancer element, as well as any additional cis-sequences necessary for efficient transcription and translation (e.g., polyadenylation sites, mRNA stability control sequences, etc.).
As used herein, the term "transformation" is intended to generally describe a method of introducing an exogenous polynucleotide sequence (e.g., a viral vector, plasmid, or recombinant DNA or RNA molecule) into a host cell or protoplast in which the exogenous polynucleotide is incorporated into at least a first chromosome or is capable of autonomous replication within the transformed host cell. Transfection, electroporation, and "naked" nucleic acid uptake all represent examples of techniques for transforming a host cell with one or more polynucleotides.
As used herein, the term "transformed cell" means a host cell whose nucleic acid complementarity has been altered by the introduction into the cell of one or more exogenous polynucleotides.
"treating" as used herein refers to providing any type of medical or surgical management to a subject. Treatment may include, but is not limited to, administering to a subject a composition comprising a therapeutic agent. "treating" includes administering or applying a compound or composition of the invention to a subject for a purpose such as curing, reversing, alleviating, lessening the severity of, inhibiting the progression of, or reducing the likelihood of, a disease, disorder, or condition, or one or more symptoms or manifestations of a disease, disorder, or condition. In certain aspects, the compositions of the invention may also be administered prophylactically, i.e., prior to the development of any symptoms or manifestations of the condition, where such prevention is warranted. Typically, in such cases, the subject will be one who has been diagnosed as "at risk" for developing such a disease or disorder as a result of a family history, medical history, or the performance of one or more diagnostic or prognostic tests indicative of a predisposition to subsequently develop such a disease or disorder.
The term "vector" as used herein refers to a nucleic acid molecule (usually consisting of DNA) that is capable of replication in a host cell and/or is operably linked to another nucleic acid segment so as to cause replication of the linked segment. Plasmids, cosmids, or viruses are exemplary vectors.
The expression "zero order" or "near zero order" as applied to the release kinetics of an active agent from the disclosed vaccine delivery compositions is intended to include the rate at which the active agent is released in a controlled manner over a period of therapeutic practice after administration of the composition, thereby to achieve a therapeutically effective plasma concentration of the active agent.
In certain embodiments, it will be advantageous to use one or more nucleic acid segments of the invention in combination with a suitable detectable marker (i.e., a "label"), for example where a labeled polynucleotide probe is used in a hybridization assay to determine the presence of a given target sequence. A variety of suitable indicator compounds and compositions are known in the art for labeling oligonucleotide probes, including but not limited to fluorescent ligands, radioligands, enzymatic ligands or other ligands, e.g., avidin/biotin, etc., which can be detected in a suitable assay. In particular embodiments, one or more fluorescent labels or enzyme tags, such as urease, alkaline phosphatase, or peroxidase, may also be used in place of radioactive or other environmentally less desirable reagents. In the case of enzyme tags, colorimetric, chromogenic or fluorescent indicator substrates are known to be useful in providing a means for detecting a sample visible to the human eye or by analytical methods such as scintigraphy, fluorimetry, spectrophotometry, and the like, to identify specific hybridization with a sample containing one or more complementary or substantially complementary nucleic acid sequences. In the case of so-called "multiplexed" assays, in which two or more labeled probes are detected simultaneously or sequentially, it may be desirable to label a first oligonucleotide probe with a first label having a first detection property or parameter (e.g., emission and/or excitation spectrum maximum) that also labels a second oligonucleotide with a second label having a different (i.e., unrelated to or distinguishable from the first label) second detection property or parameter. The use of multiplex assays, particularly in the context of genetic amplification/detection schemes, is well known to those of ordinary skill in the art of molecular genetics.
Nucleic acids
The term "nucleic acid" includes any compound and/or substance that can be incorporated into an oligonucleotide chain. Exemplary nucleic acids for use according to the present application include, but are not limited to, DNA, RNA including messenger mrna (mrna), hybrids thereof, RNAi-inducing agents, RNAi agents, siRNA, shRNA, miRNA, antisense RNA, ribozymes, catalytic DNA, RNA that induces triple helix formation, aptamers, vectors, and the like, described in detail herein.
The term "deoxyribonucleic acid", "DNA" or "DNA molecule" refers to a molecule consisting of two strands (polynucleotides), each strand comprising a single unit of nucleotides. Nucleotides are linked to each other in the chain by covalent bonds between the sugar of one nucleotide and the phosphate group of the next nucleotide, creating an alternating sugar-phosphate backbone. The nitrogen-containing bases of the two separate polynucleotide strands are bonded together with hydrogen bonds to prepare double-stranded DNA.
The term "ribonucleic acid", "RNA" or "RNA molecule" refers to a strand composed of at least 2 base-glycosyl-phosphate groups in combination. In one embodiment, the term includes compounds consisting of nucleotides, wherein the sugar moiety is ribose. In another embodiment, the terminus includes RNA and RNA derivatives in which the backbone is modified. In one example, RNA may be in the form of tRNA (transfer RNA), snRNA (small nuclear RNA), rRNA (ribosomal RNA), mRNA (messenger RNA), antisense RNA, small inhibitory RNA (sirna), micro RNA (mirna), and ribozymes. The use of siRNA and miRNA has been described (Caudy A et al, Genes & Dedevel 16: 2491-96and drefferencecitytherein). In addition, these forms of RNA may be single-stranded, double-stranded, triple-stranded, or quadruple stranded. In another embodiment, the term also includes other types of backbones but with the same base of the artificial nucleic acid. In another embodiment, the artificial nucleic acid is PNA (peptide nucleic acid). PNAs contain a peptide backbone and nucleotide bases and are capable of binding to DNA and RNA molecules in another embodiment. In another embodiment, the nucleotide is a modified oxetane. In another embodiment, the nucleotides are modified by replacing one or more phosphodiester linkages with phosphorothioate linkages. In another embodiment, the modified nucleic acid comprises any other variant of the phosphate backbone of a native nucleic acid known in the art. One of ordinary skill in the art is familiar with the use of phosphorothioate-based nucleic acids and PNA, which are described, for example, in Neilsen P E, CurrOpin Struct Biol 9: 353-57; [0280] and Raz N Ket al biochem Biophys Res Commun.297: 1075-84. The production and use of nucleic acids is well known to those skilled in the art and the description, molecular cloning, (2001), Sambrookon and Russell, eds. and methods in enzymology: methods f or molecular cloning of eukaryotic cells (2003) purification and G.C.Fared each represents a separate embodiment of the invention.
Modified nucleic acids
Disclosed herein are modified nucleic acids, such as mRNA, and methods for synthesizing the same. Nucleic acids for use according to the present application may be according to any prior art including, but not limited to, chemical synthesis, enzymatic synthesis, terminal in vitro transcription of typically longer precursors, enzymatic or chemical cleavage, and the like. Methods for synthesizing RNA are well known in the art (see, e.g., Goett, M.J. (Gait, M.J.)) (eds.) Oligonucleotide Synthesis A practical method (Oligonucleotide synthesis: a practical application), Oxford [ Oxford county ], Washington, Columbia, IRL Press, 1984; and Herdwijn, P.) (eds.) Oligonucleotide Synthesis and applications (Oligonucleotide synthesis: Methods and applications), Molecular Biology Methods (Methods in Molecular Biology), v.288 (Cleveland, N.J.), Totoro, N.J.: Humana Press, 2005; both of which are incorporated herein by reference in their entirety). mRNA can be produced using a reaction mixture that includes an RNA polymerase, a linear DNA template, and an RNA polymerase reaction buffer (e.g., nucleotides such as ribonucleotides). US patent publication US20120195936 and international publication WO2011012316, the entire contents of which are incorporated by reference into the present application, disclose the use of RNA. RNA polymerase reaction buffers typically include salts/buffers such as Tris, HEPES, ammonium sulfate, sodium bicarbonate, sodium citrate, sodium acetate, potassium phosphate, sodium chloride, and magnesium chloride. The pH of the reaction mixture may be about 6 to 8.5, 6.5 to 8.0, 7.0 to 7.5, and in some embodiments, the pH is 7.5. In one example, the reaction mixture includes NTP at a concentration ranging from 1-10mM, DNA template at a concentration ranging from 0.01-0.5mg/ml, and RNA polymerase at a concentration ranging from 0.01-0.1mg/ml, e.g., the reaction mixture includes NTP at a concentration of 5mM, DNA template at a concentration of 0.1mg/ml, and RNA polymerase at a concentration of 0.05 mg/ml. In some embodiments, the DNA template is optimized or modified to differ from native DNA by differences in homology analysis. This modified DNA is inverted in vitro to yield the optimized sequence. In some embodiments, the optimized DNA sequence is double-stranded, or may be a single-stranded sequence synthesized in vitro. Such optimized or improved DNA sequences have less than 40%, or less than 45%, less than 50%, less than 55%, less than 58%, less than 60%, less than 65%, less than 70%, less than 69%, less than 75%, less than 77%, less than 78%, less than 80%, less than 90% or less than 95% homology to the native sequence. Even though the optimized DNA sequence is only 95-99.9% homologous to the native sequence, and varies by 1-2 nucleotides, it is considered that the optimized DNA sequence is functionally different, and is an embodiment of the present invention.
Similarly, the RNA sequence translated or transcribed from the optimized or modified DNA has less than 40%, or less than 45%, less than 50%, less than 55%, less than 58%, less than 60%, less than 65%, less than 70%, less than 69%, less than 75%, less than 77%, less than 78%, less than 80%, less than 90% or less than 95% homology to the native RNA sequence. Even though the optimized RNA sequence is only less than 95-99.9% homologous and varies by 1-2 nucleotides from the natural sequence, it is considered that the optimized RNA sequence has a difference in function, and is also an embodiment of the present invention.
Naturally occurring or modified nucleosides and/or nucleotides, or optimized nucleotides, can be used to prepare modified nucleic acids, such as modified mrnas, according to the invention. For example, the modified mRNA can include one or more natural nucleosides (e.g., adenosine, guanosine, cytidine, uridine); modified nucleosides (e.g., 2-aminoadenosine, 2-thiothymidine, inosine, pyrrolopyrimidine, 3-methyladenosine, 5-methylcytidine, C-5 propynyl-cytidine, C-5 propynyl-uridine, 2-aminoadenosine, C5-bromouridine, C5-fluorouridine, C5-iodouridine, C5-propynyl-uridine, C5-propynyl-cytidine, C5-methylcytidine, 2-aminoadenosine, 7-deazaadenosine, 7-deazaguanosine, 8-oxoadenosine, 8-oxoguanosine, O (6) -methylguanine, pseudouridine, (e.g., N-1-methyl-pseudouridine), 2-thiouridine, and 2-thiocytidine); chemically modifying the base; biologically modified bases (e.g., methylated bases); an insertion base; modified sugars (e.g., 2 '-fluororibose, ribose, 2' -deoxyribose, arabinose, and hexose); modified phosphate groups (e.g., phosphorothioate and 5' -N-phosphoramidite linkages), or any combination thereof. These modified nucleotides may be natural nucleotides, or may be artificially optimized or modified nucleotides.
An RNA molecule (e.g., mRNA) can include at least two nucleotides. The nucleotide may be a naturally occurring nucleotide or a modified nucleotide. In some embodiments, the RNA molecule comprises from about 5 nucleotides to about 5,000 nucleotides. In some embodiments, the RNA molecule comprises at least about 5 nucleotides. In some embodiments, the RNA molecule comprises up to about 5,000 nucleotides. In some embodiments, the RNA molecule comprises from about 5 nucleotides to about 20 nucleotides, from about 5 nucleotides to about 40 nucleotides, from about 5 nucleotides to about 60 nucleotides, from about 5 nucleotides to about 80 nucleotides, from about 5 nucleotides to about 100 nucleotides, from about 5 nucleotides to about 200 nucleotides, from about 5 nucleotides to about 500 nucleotides, from about 5 nucleotides to about 1,000 nucleotide nucleotides, from about 5 nucleotides to about 2,000 nucleotides, from about 5 nucleotides to about 5,000 nucleotides, from about 20 nucleotides to about 40 nucleotides, from about 20 nucleotides to about 60 nucleotides, from about 20 nucleotides to about 80 nucleotides, from about 20 nucleotides to about 100 nucleotides, from about 20 nucleotides to about 200 nucleotides, from about 20 nucleotides to about 500 nucleotides, from about 20 nucleotides to about 1,000 nucleotides, or a combination thereof, About 20 nucleotides to about 2,000 nucleotides, about 20 nucleotides to about 5,000 nucleotides, about 40 nucleotides to about 60 nucleotides, about 40 nucleotides to about 80 nucleotides, about 40 nucleotides to about 100 nucleotides, about 40 nucleotides to about 200 nucleotides, about 40 nucleotides to about 500 nucleotides, about 40 nucleotides to about 1,000 nucleotides, about 40 nucleotides to about 2000 nucleotides, about 40 nucleotides to about 5,000 nucleotides, about 60 nucleotides to about 80 nucleotides, about 60 nucleotides to about 100 nucleotides, about 60 nucleotides to about 200 nucleotides, about 60 nucleotides to about 500 nucleotides, about 60 nucleotides to about 1,000 nucleotides, about 60 nucleotides to about 2,000 nucleotides, about 60 nucleotides to about 5,000 nucleotides, about 80 nucleotides to about 100 nucleotides, about 60 nucleotides to about 100 nucleotides, From about 80 nucleotides to about 200 nucleotides, from about 80 nucleotides to about 500 nucleotides, from about 80 nucleotides to about 1,000 nucleotides, from about 80 nucleotides to about 2,000 nucleotides, from about 80 nucleotides to about 5,000 nucleotides, from about 100 nucleotides to about 200 nucleotides, from about 100 nucleotides to about 500 nucleotides, from about 100 nucleotides to about 1,000 nucleotides, from about 100 nucleotides to about 2000 nucleotides, from about 100 nucleotides to about 5,000 nucleotides, from about 200 nucleotides to about 500 nucleotides, from about 200 nucleotides to about 1,000 nucleotides, from about 200 nucleotides to about 2000 nucleotides, from about 200 nucleotides to about 5000 nucleotides, from about 500 nucleotides to about 1,000 nucleotides, from about 500 nucleotides to about 2000 nucleotides, from about 500 nucleotides to about 5,000 nucleotides, from about 1,000 nucleotides to about 2000 nucleotides, From about 1,000 nucleotides to about 5,000 nucleotides or from about 2000 nucleotides to about 5,000 nucleotides. In some embodiments, the RNA molecule comprises about 5 nucleotides, about 20 nucleotides, about 40 nucleotides, about 60 nucleotides, about 80 nucleotides, about 100 nucleotides, about 200 nucleotides, about 500 nucleotides, about 1,000 nucleotides, about 2000 nucleotides, or about 5000 nucleotides.
An RNA molecule (e.g., mRNA) can include at least one modified nucleotide as described herein. In some embodiments, the RNA molecule comprises from about 1 modified nucleotide to about 100 modified nucleotides. In some embodiments, the RNA molecule comprises at least about 1 modified nucleotide. In some embodiments, the RNA molecule comprises up to about 100 modified nucleotides. In some embodiments, the RNA molecule comprises from about 1 modified nucleotide to about 2 modified nucleotides, from about 1 modified nucleotide to about 3 modified nucleotides, from about 1 modified nucleotide to about 4 modified nucleotides, from about 1 modified nucleotide to about 5 modified nucleotides, from about 1 modified nucleotide to about 10 modified nucleotides, from about 1 modified nucleotide to about 20 modified nucleotides, from about 1 modified nucleotide to about 100 modified nucleotides, from about 2 modified nucleotides to about 3 modified nucleotides, from about 2 modified nucleotides to about 4 modified nucleotides, from about 2 modified nucleotides to about 5 modified nucleotides, from about 2 modified nucleotides to about 10 modified nucleotides, from about 2 modified nucleotides to about 20 modified nucleotides, from about 2 modified nucleotides to about 100 modified nucleotides, from about 3 modified nucleotides to about 4 modified nucleotides, From about 3 modified nucleotides to about 5 modified nucleotides, from about 3 modified nucleotides to about 10 modified nucleotides, from about 3 modified nucleotides to about 20 modified nucleotides, from about 3 modified nucleotides to about 100 modified nucleotides, from about 4 modified nucleotides to about 5 modified nucleotides, from about 4 modified nucleotides to about 10 modified nucleotides, from about 4 modified nucleotides to about 20 modified nucleotides, from about 4 modified nucleotides to about 100 modified nucleotides, from about 5 modified nucleotides to about 10 modified nucleotides, from about 5 modified nucleotides to about 20 modified nucleotides, from about 5 modified nucleotides to about 100 modified nucleotides, from about 10 modified nucleotides to about 20 modified nucleotides, from about 10 modified nucleotides to about 100 modified nucleotides, or from about 20 modified nucleotides to about 100 modified nucleotides. In some embodiments, the RNA molecule comprises about 1 modified nucleotide, about 2 modified nucleotides, about 3 modified nucleotides, about 4 modified nucleotides, about 5 modified nucleotides, about 10 modified nucleotides, about 20 modified nucleotides, or about 100 modified nucleotides.
An RNA molecule (e.g., mRNA) can include at least 0.1% modified nucleotides. The fraction of modified nucleotides can be calculated as: number of modified nucleotides/total number of nucleotides 100%. In some embodiments, the RNA molecule comprises from about 0.1% modified nucleotides to about 100% modified nucleotides. In some embodiments, the RNA molecule comprises at least about 0.1% modified nucleotides. In some embodiments, the RNA molecule comprises up to about 100% modified nucleotides. In some embodiments, the RNA molecule comprises from about 0.1% modified nucleotides to about 0.2% modified nucleotides, from about 0.1% modified nucleotides to about 0.5% modified nucleotides, from about 0.1% modified nucleotides to about 1% modified nucleotides, from about 0.1% modified nucleotides to about 2% modified nucleotides, from about 0.1% modified nucleotides to about 5% modified nucleotides, from about 0.1% modified nucleotides to about 10% modified nucleotides, from about 0.1% modified nucleotides to about 20% modified nucleotides, from about 0.1% modified nucleotides to about 50% modified nucleotides, from about 0.1% modified nucleotides to about 100% modified nucleotides, from about 0.2% modified nucleotides to about 0.5% modified nucleotides, from about 0.2% modified nucleotides to about 1% modified nucleotides, from about 0.2% modified nucleotides to about 2% modified nucleotides, from about 0.2% modified nucleotides to about 5% modified nucleotides, from about 0.2% modified nucleotides to about 10% modified nucleotides, From about 0.2% modified nucleotides to about 20% modified nucleotides, from about 0.2% modified nucleotides to about 50% modified nucleotides, from about 0.2% modified nucleotides to about 100% modified nucleotides, from about 0.5% modified nucleotides to about 1% modified nucleotides, from about 0.5% modified nucleotides to about 2% modified nucleotides, from about 0.5% modified nucleotides to about 5% modified nucleotides, from about 0.5% modified nucleotides to about 10% modified nucleotides, from about 0.5% modified nucleotides to about 20% modified nucleotides, from about 0.5% modified nucleotides to about 50% modified nucleotides, from about 0.5% modified nucleotides to about 100% modified nucleotides, from about 1% modified nucleotides to about 2% modified nucleotides, from about 1% modified nucleotides to about 5% modified nucleotides, from about 1% modified nucleotides to about 10% modified nucleotides, from about 1% modified nucleotides to about 20% modified nucleotides, from about 0.2% modified nucleotides to about 2% modified nucleotides, from about 1% modified nucleotides to about 5% modified nucleotides, from about 1% modified nucleotides to about 10% modified nucleotides, from about 1% modified nucleotides to about 20% modified nucleotides, or a combination thereof, About 1% modified nucleotide to about 50% modified nucleotide, about 1% modified nucleotide to about 100% modified nucleotide, about 2% modified nucleotide to about 5% modified nucleotide, about 2% modified nucleotide to about 10% modified nucleotide, about 2% modified nucleotide to about 20% modified nucleotide, about 2% modified nucleotide to about 50% modified nucleotide, about 2% modified nucleotide to about 100% modified nucleotide, about 5% modified nucleotide to about 10% modified nucleotide, about 5% modified nucleotide to about 20% modified nucleotide, about 5% modified nucleotide to about 50% modified nucleotide, about 5% modified nucleotide to about 100% modified nucleotide, about 10% modified nucleotide to about 20% modified nucleotide, about 10% modified nucleotide to about 50% modified nucleotide, about 10% modified nucleotide to about 100% modified nucleotide, about 1% modified nucleotide to about 100% modified nucleotide, or a combination thereof, From about 20% modified nucleotides to about 50% modified nucleotides, from about 20% modified nucleotides to about 100% modified nucleotides, or from about 50% modified nucleotides to about 100% modified nucleotides. In some embodiments, the RNA molecule comprises about 0.1% modified nucleotides, about 0.2% modified nucleotides, about 0.5% modified nucleotides, about 1% modified nucleotides, about 2% modified nucleotides, about 5% modified nucleotides, about 10% modified nucleotides, about 20% modified nucleotides, about 50% modified nucleotides, or about 100% modified nucleotides.
The total concentration of nucleotides, e.g., ribonucleotides (e.g., combined ATP, GTP, CTP, and UTP) used in the reaction is between 0.5mM to about 500 mM. In some embodiments, the total concentration of nucleotides is from about 0.5mM to about 500 mM. In some embodiments, the total concentration of nucleotides is at least about 0.5 mM. In some embodiments, the total concentration of nucleotides is at most about 500 mM. In some embodiments, the total concentration of nucleotides is about 0.5mM to about 1mM, about 0.5mM to about 5mM, about 0.5mM to about 10mM, about 0.5mM to about 50mM, about 0.5mM to about 100mM, about 0.5mM to about 200mM, about 0.5mM to about 300mM, about 0.5mM to about 500mM, about 1mM to about 5mM, about 1mM to about 10mM, about 1mM to about 50mM, about 1mM to about 100mM, about 1mM to about 200mM, about 1mM to about 300mM, about 1mM to about 500mM, about 5mM to about 10mM, about 5mM to about 50mM, about 5mM to about 100mM, about 5mM to about 200mM, about 5mM to about 300mM, about 5mM to about 500mM, about 10mM to about 50mM, about 10mM to about 100mM, about 10mM to about 10mM, about 10mM to about 200mM, about 10mM to about 50mM, about 10mM, about 50mM to about 50mM, about 10mM, about 50mM, about 10mM, about 50mM, about 5mM, about 300mM, about 0mM, about 5mM, about 300mM, about 0mM, about 300mM, about 0mM, about 5mM, about 0mM, about 300mM, about 0mM, about 5mM, about 300mM, about 5mM, about 0mM, about 300mM, about 0mM, about 5mM, about 300mM, about 0mM, about 5mM, about 300mM, about 0mM, about 300mM, about 0mM, about 5mM, about 300mM, about 0mM, about 100mM to about 200mM, about 100mM to about 300mM, about 100mM to about 500mM, about 200mM to about 300mM, about 200mM to about 500mM, or about 300mM to about 500 mM. In some embodiments, the total concentration of nucleotides is about 0.5mM, about 1mM, about 5mM, about 10mM, about 50mM, about 100mM, about 200mM, about 300mM, or about 500 mM.
Post-synthetic treatment
The 5 'cap and/or 3' tail may be added after synthesis. The presence of the cap may provide resistance to nucleases found in most eukaryotic cells. The presence of a "tail" may be used to protect mRNA from exonuclease degradation and/or to modulate protein expression levels.
The 5' cap can be added as follows: first, RNA end phosphatases remove one terminal phosphate group from the 5' nucleotide, leaving two terminal phosphate groups; guanosine Triphosphate (GTP) is then added to the terminal phosphate groups by guanylyl transferase, resulting in 5,5,5 triphosphate linkages; the 7-nitrogen of guanine is then methylated with methyltransferase. Examples of cap structures include, but are not limited to, m7G (5') ppp (5' (A, G (5') ppp (5') A and G (5') ppp (5') G.) more cap structures are described in published U.S. application No. US 2016/0032356, Ashi Querck (Ashiqul Haque) et al, "chemically modified hCFR mRNA restores lung function in the cystic fibrosis mouse model" (chemical modification of CFTR mRNAs recovering function in a mouse model of cystic fibrosis), Scientific report (Scientific Reports) (2018: 16776, and Kore et al, "recent developments in 5' -end cap analogs: synthetic and biological branches "(Recent Developments in 5' -Terminal Cap antibodies: synthetic Biological diagnostics) Organic chemical Mini-readers (Mini-Reviews in Organic Chemistry)2008, 5, 179-192, which is incorporated herein by reference.
The tail structure may include a poly (a) and/or a poly (C) tail. The poly-a tail on the 3 'end of an mRNA (e.g., 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 nucleotides of the 3' end) can include at least 50%, 55%, 65%, 70%, 75%, 80%, 85%, 90%, 92%, 94%, 95%, 96%, 97%, 98%, or 99% adenosine nucleotides. The poly-a tail on the 3 'end of an mRNA (e.g., 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 nucleotides of the 3' end) can include at least 50%, 55%, 65%, 70%, 75%, 80%, 85%, 90%, 92%, 94%, 95%, 96%, 97%, 98%, or 99% cytosine nucleotides.
As described herein, the addition of a5 'cap and/or 3' tail can help detect invalid transcripts generated during in vitro synthesis, since without capping and/or tailing those prematurely aborted mRNA transcripts may be too small to be detected. Thus, in some embodiments, a5 'cap and/or 3' tail is added to the synthesized mRNA prior to testing for mRNA purity (e.g., the level of null transcripts present in the mRNA). In some embodiments, a5 'cap and/or 3' tail is added to the synthesized mRNA prior to purification of the mRNA as described herein. In other embodiments, a5 'cap and/or 3' tail is added to the synthesized mRNA after purification of the mRNA as described herein.
In addition to the above methods, the capping or tailing step is always performed during the transcription process from DNA to RNA in vitro, and these methods are freely selectable by one of ordinary skill in the art.
The mRNA synthesized according to the present invention can be used without further purification. In particular, the mRNA synthesized according to the present invention can be used without the step of removing the short polymer. In some embodiments, mRNA synthesized according to the present invention may be further purified. Various methods can be used to purify the synthesized mRNA according to the present invention. For example, purification of mRNA can be performed using centrifugation, filtration, and/or chromatographic methods. In some embodiments, the synthesized mRNA is purified by ethanol precipitation or filtration or chromatography, or gel purification or any other suitable method. In some embodiments, the mRNA is purified by HPLC. In some embodiments, the ratio of standard phenol: chloroform: extraction of mRNA from an isoamyl alcohol solution is well known to those skilled in the art. In some embodiments, the mRNA is purified using tangential flow filtration. Suitable purification methods include the methods described in US 2016/0040154, US 2015/0376220, PCT application PCT/US18/19954 filed on day 27, 2.2018, entitled "method for purifying messenger RNA" and PCT application PCT/US18/19978 filed on day 27, 2.2018, entitled "method for purifying messenger RNA", all of which are incorporated herein by reference and can be used to practice the present invention.
In some embodiments, mRNA is purified prior to capping and tailing. In some embodiments, mRNA is purified after capping and tailing. In some embodiments, mRNA is purified both before and after capping and tailing. In some embodiments, mRNA is purified by centrifugation either before or after capping and tailing or both. In some embodiments, the mRNA is purified by filtration either before or after capping and tailing or both. In some embodiments, mRNA is purified by Tangential Flow Filtration (TFF) either before or after capping and tailing, or both. In some embodiments, mRNA is purified by chromatography either before or after capping and tailing or both.
In some embodiments, the tailing is accomplished simultaneously with transcription, and thus, the nucleic acid may also be purified after the tailing and capping steps are completed, as described above. Therefore, in some embodiments, the purification steps should all be after the tail-capping. Of course, mRNA can also be purified prior to capping. Purification can of course also be carried out after transcription.
Any method available in the art can be used to detect and quantify full-length or null transcripts of mRNA. In some embodiments, the synthesized mRNA molecules are detected using blotting, capillary electrophoresis, chromatography, fluorescence, gel electrophoresis, HPLC, silver staining, spectroscopy, Ultraviolet (UV) or UPLC, or a combination thereof. Other detection methods known in the art are included in the present invention. In some embodiments, the synthesized mRNA molecules are detected by capillary electrophoresis separation using UV absorption spectroscopy. In some embodiments, the mRNA is denatured with glyoxal dye prior to gel electrophoresis ("glyoxal gel electrophoresis"). In some embodiments, the synthesized mRNA is characterized prior to capping or tailing. In some embodiments, the synthesized mRNA is characterized after capping and tailing.
In some embodiments, mRNA produced by the methods disclosed herein includes less than 10%, less than 9%, less than 8%, less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, less than 1%, less than 0.5%, less than 0.1% of impurities other than full-length mRNA. Impurities include IVT contaminants such as proteins, enzymes, free nucleotides and/or short polymers.
In some embodiments, the mRNA prepared according to the invention is substantially free of short polymers or null transcripts. In particular, mRNA prepared according to the invention includes undetectable levels of short polymers or null transcripts by capillary electrophoresis or glyoxal gel electrophoresis. As used herein, the term "short polymer" or "null transcript" refers to any less than full-length transcript. In some embodiments, a "short polymer" or "null transcript" is less than 100 nucleotides in length, less than 90, less than 80, less than 70, less than 60, less than 50, less than 40, less than 30, less than 20, or less than 10 nucleotides in length. In some embodiments, the short polymer is detected or quantified after the addition of the 5 '-cap and/or the 3' -poly a tail.
UTR sequences
3 '-untranslated region (3' -UTR): generally, the term "3 '-UTR" refers to a portion of an artificial nucleic acid molecule that is located 3' (i.e., "downstream") of an open reading frame and which is not translated into a protein. Typically, the 3' -UTR is a portion of the mRNA between the protein coding region (open reading frame (ORF) or coding sequence (CDS)) and the polyadenylation sequence of the mRNA. In the context of the present invention, the term 3' -UTR may also comprise elements which are not encoded in the template from which the RNA is transcribed, but which are added post-transcriptionally during maturation, for example a polyadenylation sequence. The 3' -UTR of the mRNA is not translated into an amino acid sequence. The 3' UTR sequence is typically encoded by a gene that is transcribed into a respective mRNA during gene expression. The genomic sequence is first transcribed into mature pre-mRNA containing optional introns. The pre-mature mRNA is then further processed during maturation to mature mRNA. The maturation process comprises the following steps: 5' capping, splicing to the pre-mature mRNA to excise optional introns and 3' end modifications (e.g., polyadenylation of the 3' end of the pre-mature mRNA and optional endonuclease/exonuclease cleavage, etc.). In the context of the present invention, the 3 '-UTR corresponds to a position between the termination codon of the protein coding region, preferably immediately 3' of the termination codon of the protein coding region, and the polyadenylation sequence of the mRNA. The term "corresponding to" means that the 3 '-UTR sequence can be an RNA sequence as in the mRNA sequence used to define the 3' -UTR sequence, or a DNA sequence corresponding to this RNA sequence. In the context of the present invention, the term "3 '-UTR of a gene" is a sequence corresponding to the 3' -UTR of a mature mRNA derived from the gene, i.e.an mRNA obtained by transcription of the gene and maturation of a pre-mature mRNA. The term "3 '-UTR of a gene" includes DNA sequences and RNA sequences (both sense and antisense strands as well as both mature and immature) of the 3' -UTR. Preferably the 3' UTR has a length of more than 20, 30, 40 or 50 nucleotides. 3 '-untranslated region (3' UTR): the 3' UTR is typically a portion of an mRNA that is located between the protein coding region (i.e., open reading frame) and the polyadenylation sequence of the mRNA. The 3' UTR of the mRNA is not translated into an amino acid sequence. Within the scope of the present invention, the 3' UTR corresponds to a mature mRNA sequence located 3' of, preferably immediately 3' of, the stop codon of the protein coding region and extending to the 5' side of, preferably to the nucleotide immediately 5' of, the polyadenylation sequence. The term "corresponding to" means that the 3 'UTR sequence may be an RNA sequence as in the mRNA sequence used to define the 3' UTR sequence, or in a DNA sequence corresponding to this RNA sequence. In the context of the present invention, the term "3 ' UTR of a gene", such as "3 ' UTR of an albumin gene", is a sequence corresponding to the 3' UTR of a mature mRNA derived from the gene, i.e. an mRNA obtained by transcription of the gene and maturation of the pre-mature mRNA. The term "3 'UTR of a gene" includes DNA sequences and RNA sequences of the 3' UTR.
5 '-untranslated region (5' -UTR): generally, the term "5 '-UTR" refers to a portion of an artificial nucleic acid molecule that is 5' (i.e., "upstream") of an open reading frame and that is not translated into a protein. A5 '-UTR is generally understood to be a specific segment of messenger RNA (mRNA) that is located 5' to the open reading frame of the mRNA. Typically, the 5' -UTR starts at the transcription start site and terminates one nucleotide before the start codon of the open reading frame. Preferably, the 5' UTR has a length of more than 20, 30, 40 or 50 nucleotides. The 5' -UTR may comprise elements for controlling gene expression, also referred to as regulatory elements. The regulatory element may be, for example, a ribosome binding site. The 5 '-UTR may be post-transcriptionally modified, for example by the addition of a 5' -cap. The 5' -UTR of the mRNA is not translated into an amino acid sequence. The 5' -UTR sequence is usually encoded by a gene which is transcribed into the respective mRNA during gene expression. The genomic sequence is first transcribed as a mature pre-mRNA, which contains optional introns. The pre-mature mRNA is then further processed during maturation to mature mRNA. The maturation process comprises the steps of: 5' capping, splicing of the pre-mature mRNA to excise optional introns and 3' end modifications (e.g., polyadenylation of the 3' end of the pre-mature mRNA and optional endonuclease/exonuclease cleavage, etc.). Within the scope of the present invention, the 5 '-UTR corresponds to the mature mRNA sequence located between the start codon and, for example, the 5' -cap. Preferably, the 5' -UTR corresponds to a sequence extending from a nucleotide located 3' of the 5' cap, more preferably from a nucleotide located 3' of the 5' cap, to a nucleotide located 5' of the initiation codon of the protein coding region, preferably to a nucleotide located 5' of the initiation codon of the protein coding region. The nucleotides immediately 3 'of the 5' cap of the mature mRNA typically correspond to the transcription start site. The term "corresponding to" means that the 5 '-UTR sequence may be an RNA sequence as in the mRNA sequence used to define the 5' -UTR sequence, or a DNA sequence corresponding to this RNA sequence. Within the scope of the present invention, the term "5 '-UTR of a gene" is a sequence corresponding to the 5' -UTR of a mature mRNA derived from the gene, i.e. an mRNA obtained by transcription of the gene and maturation of the pre-mature mRNA. The term "5 '-UTR of a gene" includes DNA sequences and RNA sequences (both sense and antisense strands as well as both mature and immature) of the 5' -UTR.
The invention relates to artificial nucleic acid molecules comprising an open reading frame ORF, a 3 '-untranslated region element (3' -UTR element) and/or a5 '-untranslated region element (5' -UTR element) and optionally a polyadenylation sequence and/or a polyadenylation signal.
The invention further relates to a vector comprising a 3 '-UTR element and/or a 5' -UTR element, to a cell comprising said artificial nucleic acid molecule or said vector, to a pharmaceutical composition comprising said artificial nucleic acid molecule or said vector, and to a kit comprising said artificial nucleic acid molecule, said vector and/or said pharmaceutical composition, preferably for use in the field of gene therapy and/or gene vaccination.
As an alternative to mRNA stabilization, naturally occurring eukaryotic mRNA molecules have been found to contain characteristic stabilizing elements. For example, they may comprise a so-called untranslated region (UTR) at their 5 'end (5' -UTR) and/or at their 3 'end (3' -UTR) as well as other structural features, such as a5 'cap structure or a 3' -poly-A tail. Both the 5 '-UTR and the 3' -UTR are typically transcribed from genomic DNA and are therefore pre-mature mRNA elements. During mRNA processing, the characteristic structural features of mature mRNA, such as the 5 'cap and the 3' -poly A tail (also known as the poly A tail or poly A sequence) are typically added to the transcribed (pre-mature) mRNA.
The 3 '-poly A tail is typically a monotonic sequence of adenosine nucleotides added to the 3' end of the transcribed mRNA. It may comprise up to about 400 adenosine nucleotides. The length of such a 3' -poly A tail was found to be a possible key element for the stability of individual mRNA. Furthermore, it has been shown that the 3' UTR of α -globin mRNA may be an important factor for the well-known stability of α -globin mRNA (Rodgers et al, Regulated α -globin mRNA restriction a cytoplastic acquired through 3' -to-5 ' exosome-dependent restriction, RNA, 8, pages 1526 and 1537, 2002). The 3' UTR of α -globin mRNA is clearly involved in the formation of specific nucleoprotein-complexes (α -complexes), the presence of which is associated with mRNA in vitro stability (Wang et al, An mRNA stability complexes with poly (A) -binding protein to stability mRNA in vitro, Molecular and Cellular biology, Vol.19, No. 7, month 7 1999, p.4552-4560). Interesting regulatory functions have been further demonstrated for UTR in ribosomal protein mRNA: while the 5 '-UTR of ribosomal protein mRNAs controls the translation of growth-related mRNAs, the stringency of this regulation is conferred by the individual 3' -UTRs in ribosomal protein mRNAs (Ledda et al, Effect of the 3 '-UTR length on the translation of 5' -terminal oligopyridinine mRNAs, Gene, Vol. 344, 2005, p.213-220). This mechanism promotes specific Expression of ribosomal proteins, which are usually transcribed in a constant manner so that some ribosomal protein mrnas, such as ribosomal protein S9 or ribosomal protein L32, are called Housekeeping genes (Janovick-gurezky et al, Housekeeping Gene Expression in human Liver is Affected by physiologic state, Feed Intake, and Dietary Treatment, j.dairy sci., vol.90, 2007, p.2246-2252). The growth-related expression pattern of ribosomal proteins is therefore mainly due to the regulation of the translation level.
The term "3 ' -UTR element" refers to a nucleic acid sequence comprising or consisting of a nucleic acid sequence derived from a 3' -UTR or from a variant or fragment of a 3' -UTR.
A "3 '-UTR element" preferably refers to an artificial nucleic acid sequence, such as a nucleic acid sequence comprised by the 3' -UTR of an artificial mRNA.
Thus, in the sense of the present invention, preferably, the 3 '-UTR element can be comprised by the 3' -UTR of an mRNA, preferably an artificial mRNA, or the 3 '-UTR element can be comprised by the 3' -UTR of the respective transcription template. Preferably, the 3' -UTR element is a nucleic acid sequence corresponding to the 3' -UTR of an mRNA, preferably an artificial mRNA, such as a 3' -UTR of an mRNA obtained by transcription of a genetically engineered vector construct. Preferably, a 3' -UTR element in the sense of the present invention functions as a 3' -UTR or encodes a nucleotide sequence which performs the function of a 3' -UTR.
Thus, the term "5 ' -UTR element" refers to a nucleic acid sequence comprising or consisting of a nucleic acid sequence derived from a 5' -UTR or a variant or fragment of a 5' -UTR. A "5 '-UTR element" preferably refers to an artificial nucleic acid sequence, such as a nucleic acid sequence comprised by the 5' -UTR of an artificial mRNA. Thus, in the sense of the present invention, preferably, the 5 '-UTR element may be comprised by the 5' -UTR of an mRNA, preferably an artificial mRNA, or the 5 '-UTR element may be comprised by the 5' -UTR of the respective transcription template. Preferably, the 5' -UTR element is a nucleic acid sequence corresponding to the 5' -UTR of an mRNA, preferably an artificial mRNA, such as the 5' -UTR of an mRNA obtained by transcription of a genetically engineered vector construct. Preferably, a 5' -UTR element in the sense of the present invention functions as a 5' -UTR or encodes a nucleotide sequence which performs the function of a 5' -UTR.
The 3 '-UTR element and/or the 5' -UTR element in the artificial nucleic acid molecule according to the invention extends and/or increases protein production from the artificial nucleic acid molecule. Thus, the artificial nucleic acid molecule according to the invention may comprise, inter alia, one or several of the following functional 3 '-UTR elements and/or 5' -UTR elements: increasing a 3 '-UTR element produced from a protein of the artificial nucleic acid molecule, extending a 3' -UTR element produced from a protein of the artificial nucleic acid molecule, increasing and extending a 3 '-UTR element produced from a protein of the artificial nucleic acid molecule, increasing a 5' -UTR element produced from a protein of the artificial nucleic acid molecule, extending a5 '-UTR element produced from a protein of the artificial nucleic acid molecule, increasing and extending a 5' -UTR element produced from a protein of the artificial nucleic acid molecule, increasing a 3 '-UTR element produced from a protein of the artificial nucleic acid molecule and increasing a 5' -UTR element produced from a protein of the artificial nucleic acid molecule, increasing a 3 '-UTR element produced from a protein of the artificial nucleic acid molecule and extending a 5' -UTR element produced from a protein of the artificial nucleic acid molecule, increasing the 3 '-UTR element produced from the protein of the artificial nucleic acid molecule and increasing and extending the 5' -UTR element produced from the protein of the artificial nucleic acid molecule, extending the 3 '-UTR element produced from the protein of the artificial nucleic acid molecule and increasing the 5' -UTR element produced from the protein of the artificial nucleic acid molecule, extending the 3 '-UTR element produced from the protein of the artificial nucleic acid molecule and extending the 5' -UTR element produced from the protein of the artificial nucleic acid molecule, extending the 3 '-UTR element produced from the protein of the artificial nucleic acid molecule and increasing and extending the 5' -UTR element produced from the protein of the artificial nucleic acid molecule, increasing and extending the 3 '-UTR element produced from the protein of the artificial nucleic acid molecule and increasing the 5' -UTR element produced from the protein of the artificial nucleic acid molecule, increasing and extending the 3 '-UTR element produced from the protein of the artificial nucleic acid molecule and extending the 5' -UTR element produced from the protein of the artificial nucleic acid molecule, or increasing and extending the 3 '-UTR element produced from the protein of the artificial nucleic acid molecule and increasing and extending the 5' -UTR element produced from the protein of the artificial nucleic acid molecule. Preferably, the artificial nucleic acid molecule according to the invention comprises a 3 '-UTR element that prolongs the production of the protein from the artificial nucleic acid molecule and/or a 5' -UTR element that increases the production of the protein from the artificial nucleic acid molecule. Preferably, the artificial nucleic acid molecule according to the invention comprises at least one 3 '-UTR element and at least one 5' -UTR element, i.e. at least one 3 '-UTR element that extends and/or increases the production of protein from the artificial nucleic acid molecule and is derived from a stable mRNA and at least one 5' -UTR element that extends and/or increases the production of protein from the artificial nucleic acid molecule and is derived from a stable mRNA. "extending and/or increasing the production of proteins from said artificial nucleic acid molecule" generally refers to the amount of proteins produced from an artificial nucleic acid molecule according to the invention having individual 3 '-UTR elements and/or 5' -UTR elements compared to the amount of proteins produced from an individual reference nucleic acid lacking the 3 '-UTR and/or 5' -UTR or comprising the reference 3 '-UTR and/or reference 5' -UTR (such as the 3 '-UTR and/or 5' -UTR naturally present in combination with an ORF). In particular, at least one 3 '-UTR element and/or 5' -UTR element of the artificial nucleic acid molecule according to the invention prolongs protein production from the artificial nucleic acid molecule according to the invention, e.g. from an mRNA according to the invention, compared to individual nucleic acids lacking a 3 '-UTR and/or 5' -UTR or comprising a reference 3 '-UTR and/or 5' -UTR, such as a 3 '-and/or 5' -UTR naturally present in combination with an ORF. In particular, the at least one 3 '-UTR element and/or 5' -UTR element of the artificial nucleic acid molecule according to the invention increases protein production, in particular protein expression and/or total protein production, from the artificial nucleic acid molecule according to the invention, for example from an mRNA according to the invention, compared to the respective nucleic acid lacking a 3 '-and/or 5' -UTR or comprising a reference 3 '-and/or 5' -UTR, such as a 3 '-and/or 5' -UTR naturally present in combination with an ORF. Preferably, said at least one 3 '-UTR element and/or said at least one 5' -UTR element of the artificial nucleic acid molecule according to the invention does not negatively influence the translation efficiency of the nucleic acid compared to the translation efficiency of the respective nucleic acid lacking the 3 '-UTR and/or the 5' -UTR or comprising a reference 3 '-UTR and/or a reference 5' -UTR, such as a 3 '-UTR and/or a 5' -UTR, which is naturally present in combination with an ORF. Even more preferably, the translational efficiency is enhanced by the 3 '-UTR and/or the 5' -UTR compared to the translational efficiency of the protein encoded by the respective ORF in its natural case. The term "individual nucleic acid molecule" or "reference nucleic acid molecule" as used herein means-apart from a different 3 '-UTR and/or 5' -UTR-that the reference nucleic acid molecule is comparable, preferably identical, to the artificial nucleic acid molecule of the invention comprising a 3 '-UTR element and/or a 5' -UTR element.
In some embodiments, the 5 'and 3' ends of the ORFs of the invention comprise a UTR sequence comprising a sequence as set forth in SEQ NO: 36-1 to 36-12, or' SEQ NO: 37-1 to 37-12 in sequence. In some embodiments, the 5' sequence is SEQ NO: 36-11, 3 is SEQ NO: 37-11; or the 5' sequence is SEQ NO: 36-12, 3 is SEQ NO: 37-12. Alternatively, in some forms, the 3' end of the ORF sequence of the invention comprises SEQ NO: 37-11 or SEQ NO: 37-12.
Pharmaceutical composition
Also disclosed are pharmaceutical compositions comprising the compounds, modified nucleosides, modified nucleotides, or modified nucleic acids provided herein.
In some embodiments, the pharmaceutical compositions of the invention may be administered to a subject by any method known to those of skill in the art, e.g., parenterally, orally, transmucosally, transdermally, intramuscularly, intravenously, intradermally, subcutaneously, intraperitoneally, intraventricularly, intracranially, intravaginally, or intratumorally.
The pharmaceutical composition may be administered by intravenous, intraarterial or intramuscular injection of a liquid formulation. Suitable liquid formulations include solutions, suspensions, dispersions, emulsions, oils, and the like. In some embodiments, the pharmaceutical composition is administered intravenously, and is therefore formulated in a form suitable for intravenous administration. In some embodiments, the pharmaceutical composition is administered intraarterially, and is therefore formulated in a form suitable for intraarterial administration. In some embodiments, the pharmaceutical composition is administered intramuscularly, and is therefore formulated in a form suitable for intramuscular administration.
Pharmaceutical compositions may be administered using vesicles, for example, liposomes (see Langer, Science 249: 1527-.
The pharmaceutical compositions may be administered orally and may therefore be formulated in a form suitable for oral administration, i.e. solid or liquid preparations. Suitable solid oral formulations may include tablets, capsules, granules, pills, and the like. Suitable liquid oral formulations may include solutions, suspensions, dispersions, emulsions, oils.
The pharmaceutical composition may be administered topically to a body surface and may therefore be formulated in a form suitable for topical administration. Suitable topical formulations may include gels, ointments, creams, lotions, drops and the like. For topical administration, the compositions or physiologically tolerable derivatives thereof may be prepared and administered as a solution, suspension or emulsion in a physiologically acceptable diluent, with or without a pharmaceutical carrier. The pharmaceutical compositions may be administered as suppositories, for example rectal suppositories or urethral suppositories. In some embodiments, the pharmaceutical composition is administered by subcutaneous implantation of particles. In some embodiments, the particles provide controlled release of the pharmaceutical agent over a period of time. The pharmaceutical compositions may additionally include pharmaceutically acceptable excipients, as used herein, including any and all solvents, dispersion media, diluents or other liquid carriers, dispersion or suspension aids, surfactants, isotonicity agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as appropriate for the particular dosage form desired. The pharmaceutical science and practice of Remington, 21 st edition, A.R. Gennaro (Lippincott, Williams & Wilkins, Baltimore, Md., 2006; incorperated herein byyreference) discloses various excipients used in the formulation of pharmaceutical compositions and known techniques for their preparation.
In some embodiments, the pharmaceutically acceptable excipient has a purity of at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%. In some embodiments, the excipient is approved for human and veterinary use. In some embodiments, the excipient is approved by the U.S. food and drug administration. In some embodiments, the excipient is pharmaceutical grade. In some embodiments, the excipient conforms to the standards of the United States Pharmacopeia (USP), European Pharmacopeia (EP), british pharmacopeia, and/or international pharmacopeia.
Pharmaceutically acceptable carriers for liquid formulations may be aqueous or non-aqueous solutions, suspensions, emulsions or oils. Examples of non-aqueous solvents may be propylene glycol, polyethylene glycol and injectable organic esters, such as ethyl oleate. Aqueous carriers can include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Examples of oils may be those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, olive oil, sunflower oil and cod liver oil.
Parenteral carriers (for subcutaneous, intravenous, intraarterial, or intramuscular injection) may include sodium chloride solution, ringer's dextrose, dextrose and sodium chloride, lactated ringer's solution, and fixed oils. Intravenous vehicles include liquid and nutritional supplements, electrolyte supplements such as ringer's dextrose based electrolyte supplements, and the like. Examples may be sterile liquids, such as water and oil, with or without the addition of surfactants and other pharmaceutically acceptable adjuvants. In general, water, saline, aqueous dextrose and related sugar solutions, and glycols such as propylene glycol or polyethylene glycol are preferred liquid carriers, particularly for injectable solutions. Examples of oils may be those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, olive oil, sunflower oil and cod liver oil.
The pharmaceutical composition may further include binders (e.g., acacia, corn starch, gelatin, carbomer, ethylcellulose, guar gum, hydroxypropylcellulose, hydroxypropylmethyl cellulose, povidone), disintegrants (e.g., corn starch, potato starch, alginic acid, silicon dioxide, croscarmellose sodium, crospovidone, guar gum, sodium starch glycolate), buffering agents of various pH and ionic strength (e.g., Tris-HCl, acetate, phosphate), additives such as albumin or gelatin to prevent absorption to the surface, detergents (e.g., tween 20, tween 80, pluronic F68, bile acid salts), protease inhibitors, surfactants (e.g., sodium lauryl sulfate), permeation enhancers, solubilizing agents (e.g., glycerol, macrogol glycerol), antioxidants (e.g., ascorbic acid, sodium lauryl sulfate, etc, Sodium metabisulfite, butylated hydroxyanisole), stabilizers (e.g. hydroxypropylcellulose, hydroxypropylmethylcellulose), viscosity increasing agents (e.g. carbomer, colloidal silica, ethylcellulose, guar gum), sweeteners (e.g. aspartame, citric acid), preservatives (e.g. thimerosal, benzyl alcohol, parabens), lubricants (e.g., stearic acid, magnesium stearate, polyethylene glycol, sodium lauryl sulfate), flow aids (e.g., colloidal silicon dioxide), plasticizers (e.g., diethyl phthalate, triethyl citrate), emulsifiers (e.g., carbomer, hydroxypropyl cellulose, sodium lauryl sulfate), polymeric coatings (e.g., poloxamer or poloxamine), coatings and film formers (e.g., ethyl cellulose, acrylates, polymethacrylates), and/or adjuvants.
The pharmaceutical compositions provided herein can be controlled release compositions, i.e., compositions in which the compound is released over a period of time following administration. Controlled or sustained release compositions may include formulations in lipophilic depots (e.g., fatty acids, waxes, oils). In some embodiments, the pharmaceutical composition may be an immediate release composition, i.e., a composition in which the entire compound is released immediately after administration.
Suitable devices for delivering intradermal pharmaceutical compositions described herein may include short needle devices such as those described in U.S. Pat. Nos. 4,886,499, 5,190,521, 5,328,483, 5,527,288, 4,270,537, 5,015,235, 5,141,496, and 5,417,662. The intradermal composition may be applied by a device that limits the effective penetration length of the needle into the skin, such as those described in PCT publication WO 99/34850 and functional equivalents thereof. A jet injection device that delivers the liquid composition to the dermis by means of a liquid jet injector and/or by means of a needle that pierces the stratum corneum and produces a jet that reaches the dermis may be suitable. Jet injection devices are described, for example, in U.S. patents 5,480,381, 5,599,302, 5,334,144, 5,993,412, 5,649,912, 5,569,189, 5,704,911, 5,383,851, 5,893,397, 5,466,220, 5,339,163, 5,312,335, 5,503,627, 5,064,413, 5,520,639, 4,596,556, 4,790,824, 4,941,880, 4,940,460, and PCT publications WO 97/37705 and WO 97/13537. Ballistic powder/particle delivery devices that use compressed gas to accelerate vaccine in powder form through the outer layers of the skin to the dermis may be suitable. Alternatively or additionally, conventional syringes may be used in the classical tuberculin intradermal method of intradermal administration.
Delivery vehicle
Any method may be used to formulate and deliver mRNA synthesized according to the invention for in vivo protein production. In some embodiments, the mRNA is encapsulated into a transfer vector, such as a nanoparticle. In addition, one purpose of such encapsulation is generally to protect the nucleic acids from the environment of enzymes or chemicals that may contain systems or receptors that degrade the nucleic acids and/or cause rapid excretion of the nucleic acids. Thus, in some embodiments, suitable delivery vehicles are capable of enhancing the stability of the mRNA included therein and/or facilitating the delivery of the mRNA to a target cell or tissue. In some embodiments, the nanoparticle may be a lipid-based nanoparticle, for example including a liposome or a polymer-based nanoparticle. In some embodiments, the nanoparticles may have a diameter of less than about 40-100 nm. The nanoparticle can include at least 1 μ g, 10 μ g, 100 μ g, 1mg, 10mg, 100mg, 1g, or more mRNA.
Of course, the nanoparticle can also be a core-shell type particle, and if the nucleic acid is mixed with the polymer to form a core, and then the liposome is wrapped outside the core structure, the mixing can also be completed by the mixer of the present invention. The nucleic acid and the polymer may be formed into a microparticle structure by a mixer, and then the microparticle and the lipid component may be formed into a microparticle structure by a mixer. All core materials and shell materials of this so-called core-shell structure, such as that of patent application No. 201880001680.5, can be formed using the mixer of the present invention, and all of the core materials and shell-forming materials of this patent are embodiments of the present invention.
In some embodiments, the delivery vehicle is a liposome vesicle, or other means of facilitating transfer of nucleic acids to target cells and tissues. Suitable delivery vehicles may include, but are not limited to, liposomes, nanoliposomes containing ceramides, proteoliposomes, nanoparticles, calcium phosphate-silicate nanoparticles, calcium phosphate nanoparticles, silicon dioxide nanoparticles, nanocrystalline particles, semiconductor nanoparticles, poly (D-arginine), nanotreeds, starch-based delivery systems, micelles, emulsions, vesicles, plasmids, viruses, calcium phosphate-based nucleotides, aptamers, peptides, and other carrier tags. The use of bio-ionic capsules and other viral capsid protein assemblies as suitable transfer vehicles is also contemplated. (hum. Gene Ther.2008September; 19(9): 887-95).
Liposomes can include one or more cationic lipids, one or more non-cationic lipids, one or more sterol-based lipids, and/or one or more PEG-modified lipids. The liposomes can include three or more different lipid components, one different component of the lipid being a sterol-based cationic lipid. In some embodiments, the sterol-based cationic lipid is an imidazole cholesterol ester or "ICE" lipid (see WO2011/068810, which is incorporated herein by reference). In some embodiments, the sterol-based cationic lipid can constitute no more than 70% (e.g., no more than 65% and 60%) of the total lipid in the lipid nanoparticle (e.g., liposome). Examples of suitable lipids can include, for example, phosphatidyl compounds (e.g., phosphatidylglycerols, phosphatidylcholines, phosphatidylserines, phosphatidylethanolamines, sphingolipids, cerebrosides, and gangliosides.
Non-limiting examples OF cationic lipids can include C12-200, MC3, DLinDMA, DLinkC2DMA, cKK-E12, ICE (imidazolyl), HGT5000, HGT5001, OF-02, DODAC, DDAB, DMRIE, DOSPA, DOGS, DODAP, DODMA and DMDMA, DODAC, DLenDMA, DMRIE, CLinDMA, CpLinDMA, DMOBA, DOcarDAP, DLinDLDAP, DLincarDAP, DLinCDAP, KLin-K-DMA, DLin-K-XTC2-DMA and HGT4003, or combinations thereof.
Non-limiting examples of non-cationic lipids can include ceramides, cephalins, cerebrosides, diacylglycerols, 1, 2-dipalmitoyl-sn-glycero-3-phosphorylglycero-sodium salt (DPPG), 1, 2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE), 1, 2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1, 2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1, 2-dioleyl-sn-glycero-3-phosphoethanolamine (DOPE), 1, 2-dioleyl-sn-glycero-3-phosphocholine (DOPC), 1, 2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (DPPE), 1, 2-dimyristoyl-sn-glycero-3-phosphoethanolamine (DMPE), and 1, 2-dioleoyl-sn-glycero-3-phosphate- (1' -rac-glycerol) (DOPG), 1-palmitoyl-2-oleoyl-phosphatidylethanolamine (POPE), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1-stearoyl-2-oleoyl-phosphatidylethanolamine (SOPE), sphingomyelin, or a combination thereof.
In some embodiments, the PEG-modified lipid may be a poly (ethylene) glycol chain up to 5kDa in length, covalently attached to a lipid having an alkyl chain of C6-C20 length. Non-limiting examples of PEG-modified lipids can include DMG-PEG, DMG-PEG2K, C8-PEG, DOGPEG, ceramide PEG, and DSPE-PEG, or combinations thereof.
It is also contemplated to use the polymer as a transfer vehicle, either alone or in combination with other transfer vehicles. Suitable polymers may include, for example, polyacrylates, polyalkylcyanoacrylates, polylactides, polylactide-polyglycolide copolymers, polycaprolactones, dextrans, albumins, gelatins, alginates, collagen, chitosan, cyclodextrins, and polyethyleneimines. The polymer-based nanoparticles may include Polyethylenimine (PEI), such as branched PEI.
The core-shell structure of the support is another specific embodiment. In some embodiments, the vaccine agent comprises a nucleic acid as described above that is capable of translating, expressing an antigen or antigen fragment of a coronavirus, such nucleic acid being contained within a plurality of multimeric complexes or protein core particles, and wherein the plurality of multimeric complexes or protein core particles are themselves encapsulated within a first biocompatible lipid bilayer shell. In some embodiments, the multimeric complex or protein core particle comprises at least a first positively charged polymer or protein. Wherein the first biocompatible lipid bilayer shell promotes megakaryocytic uptake of the plurality of multimeric complexes or protein core particles by one or more mammalian antigen presenting cells. In some embodiments, the vaccine agent further comprises an adjuvant selected from the group consisting of CpG, poly (I: C), alum, and any combination thereof encapsulated within the biocompatible lipid bilayer. In some embodiments, the vaccine agent further comprises an immunomodulatory compound, such as an IL-12p70 protein, FLT3 ligand, or indoleamine 2, 3-dioxygenase (IDO-1) inhibitor, encapsulated within the space between the biocompatible lipid bilayer. In some embodiments, wherein the indoleamine 2, 3-dioxygenase (IDO-1) inhibitor is GDC-0919, INCB24360, or a combination thereof. In some forms, wherein the positively charged polymer or protein comprises protamine, polyethyleneimine, poly (β -amino ester), or any combination thereof. In some embodiments, the biocompatible lipid bilayer comprises one or more of: 1, 2-dioleoyl-sn-glycero-3-Ethylphosphocholine (EDOPC); 1, 2-dioleoyl-sn-glycero-3-phosphatidylethanolamine (DOPE); 1, 2-distearoyl-sn-glycerol-3-phosphoethanolamine-N- [ amino (polyethylene glycol) -2000] (DSPE-PEG); and combinations thereof. In some embodiments, the biocompatible lipid bilayer comprises: (a)
from about 30% to about 70% 1, 2-dioleoyl-sn-glycero-3-Ethylphosphocholine (EDOPC); (b) from about 70% to about 30% of 1, 2-dioleoyl-sn-glycero-3-phosphatidylethanolamine (DOPE); or (c) from about 0.5% to about 5% 1, 2-distearoyl-sn-glycerol-3-phosphoethanolamine-N- [ amino (polyethylene glycol) -2000] (DSPE-PEG). In some forms, the biocompatible lipid bilayer comprises: (a) from about 45% to about 55% 1, 2-dioleoyl-sn-glycero-3-Ethylphosphocholine (EDOPC); (b) from about 55% to about 45% of 1, 2-dioleoyl-sn-glycero-3-phosphatidylethanolamine (DOPE); and (c) from about 1% to about 2% 1, 2-distearoyl-sn-glycerol-3-phosphoethanolamine-N- [ amino (polyethylene glycol) -2000] (DSPE-PEG).
Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. References cited herein are not admitted to be prior art to the claimed invention. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.
Detailed Description
The specific embodiments of the invention are merely a limited list of examples of how the invention may be carried out, and should not be construed as limiting the invention in any way.
Example 1: mRNA candidate sequence design and preparation: mRNA sequence prepared by using SEQ ID NO 1NDA sequence as template
Experimental reagent: (1) SpeI DNA endonuclease, (2) high-fidelity DNA polymerase, (3) DNA purification column, (4) thermofisher T7 RNA polymerase, (5) thermofisher 75mM rNTP, (6)100mM N1-methylpseuduridine-5' -triphosphate, (7) yeasen vaccinia virus capping enzyme, (8)32mM SAM (9) thermofisher dynalabesystem, etc.
1.1 Total Gene Synthesis of template plasmids: DNA sequences of different antigens of interest ORF (open reading frame) sequenceSEQ ID NO:1ToSEQ ID NO:9) The template plasmid was obtained by whole-gene synthesis using Puc57 (supplied by Nanjing Kingsler Biotech Co., Ltd.) as a vector after being connected in series with a T7 promoter sequence (SEQ ID NO:11), a5 'UTR sequence, a 3' UTR sequence and a polyA sequence in the following manner (see FIG. 1 below). Some of the DNA sequences are artificially modified sequences, the modified sequences are artificially synthesized and cloned on the vector, and some are not artificially optimized and modified.
1.2PCR to obtain transcription template DNA sequence: the transcription template DNA can be obtained by using the linearized template plasmid as a template and using raw materials such as poly T long primer, high-fidelity DNA polymerase, dNTP and the like and using a proper program on a PCR instrument. (as shown in figure 2 below).
An upstream primer: 5 'TTGGACCCTCGTACAGAAGCTAATACG 3' (SEQ ID NO: 10);
a downstream long primer:
5’TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT TTTAGTTCTAGACCCTCACTTCCTACTCAGG3’(SEQ ID NO:11)
table 1: for example, a PCR reaction system configuration to obtain SEQ ID NO: 1.
Table 2: PCR procedure of SEQ ID NO 1.
1.3 in vitro transcription reaction to prepare mRNA (in the case of the 60uL reaction system) (SEQ ID NO: 1)): the prepared IVT template was mixed with T7 RNA polymerase, rNTPs mononucleotide and other materials in the following ratio as shown in Table 3, and transcription reaction was performed at 37 ℃ for 8 hours. After the transcription reaction is completed, the IVT template is digested with DNase to reduce the risk of residual DNA template. Wherein, the modification ratio of the methyl pseudouracil nucleotide is 50%.
Table 3: and (3) proportioning an in vitro transcription system.
Reaction system | Dosage (mu L) |
10 |
6 |
|
4 |
ATP(75mM) | 4 |
CTP(75mM) | 4 |
GTP(75mM) | 4 |
UTP(75mM) | 2 |
Methylpseudouracil nucleotide (100mM) | 1.5 |
DNA template | 1μg |
H2O | Supplement to 60 |
And (3) capping reaction: the mRNA transcribed as described above was subjected to 5' -end capping modification using vaccinia virus capping enzyme to produce an mRNA with cap0 structure. The reaction system is shown in the following table 4:
table 4: capped reaction system
Components | Volume of | |
| 15μL | |
10×Capping Buffer | 2.0μL | |
GTP(10mM) | 1.0μL | |
SAM(2mM) | 1.0μL | |
Vaccinia Capping Enzyme(10U/μL) | 1.0μL |
1.5, purification: the mRNA after the end of the capping reaction was purified using thermo fisher dynabenasyn. The volume ratio of the mRNA to the magnetic bead purification buffer is 1:2, and the mass ratio of the magnetic bead to the mRNA is 1: 1. The purified mRNA is dissolved in sodium citrate solution, and can be used for coating of subsequent preparations.
The above is only the process for preparing the final mRNA from the DNA shown in SEQ ID No. 1(SEQ NO:1), and the other 8 DNAs are similar to the above, except that the sequences in the open reading frame are different. It will be appreciated by those skilled in the art that the methods disclosed herein can be performed. The specific information of the present invention using 9 DNA new crown sequences is shown in the following table 5:
table 5: DNA sequence description (including optimized and non-optimized native sequences)
Serial number | Sequence name | Sequence optimization |
(SEQ NO:1) | S | Is that |
(SEQ NO:2) | S RBD | No (Natural sequence) |
(SEQ NO:3) | M | Is that |
(SEQ NO:4) | N | Whether or not |
(SEQ NO:5) | S-RBD | Is that |
(SEQ NO:6) | S-RBD | Is that |
(SEQ NO:7) | E | Is that |
(SEQ NO:8) | S partial | Is that |
(SEQ NO:9) | S1 | Is that |
The wild-type native sequences corresponding to the above optimized sequences are shown in Table 6 below. The sequence numbers 1,8, and 9 in Table 5 were optimized based on the natural sequences shown in the sequence numbers 1-1 in Table 6; sequence numbers 5,6 in Table 5 were optimized based on the native sequences shown in sequence numbers 3-3 in Table 6; sequence number 3 in Table 5 was optimized based on the native sequences shown in sequence numbers 5-5 in Table 6; sequence number 7 in Table 5 was optimized based on the native sequences of sequence numbers 9-9 in Table 6. In fact, only sequences 4 and 2 are native sequences and are not optimized; thus, the native sequence has only 2 strands. The optimization may be a complete optimization of the full-length sequence or a partial sequence optimization, for example, a full-length optimization or a partial optimization of the S gene for each of numbers 1,8, and 9 in table 5, and only shows the length of the sequence or the partial sequence at a different position in the full-length sequence. The optimization process is to modify or design the nucleic acid DNA so that the transformed RNA sequence can express more target antigen in cells, or be more stable, or be functionally required in other aspects.
TABLE 6 list of native (wild type, WT) DNA sequences corresponding to the optimized sequences in Table 5.
Serial number | Sequence name |
(SEQ NO:1-1) | S |
(SEQ NO:3-3) | S-RBD |
(SEQ NO:5-5) | M |
(SEQ NO:6-6) | N |
(SEQ NO:7-7) | S-RBD |
(SEQ NO:8-8) | S-RBD |
(SEQ NO:9-9) | E |
The above DNA sequences, the DNA template sequences numbered 1 to 9, differ only in the sequence of the ORF region, and the remaining functional regions such as the T7 promoter sequence, UTR sequences at the 5 'and 3' ends and polyA sequences are completely identical.
And (3) carrying out homology comparison on the optimized sequence and a corresponding natural wild type DNA sequence, wherein the comparison method is carried out as the method described by the website address: the results obtained by Clustal Omega (https:// www.ebi.ac.uk/Tools/msa/clustalo /) alignment are shown in Table 7 below. However, both sequences numbers 2 and 4 were not optimized, so the sequence homology was 100%.
Table 7: results of homology comparisons of native and optimized DNA sequences.
The sequences of the 9 mRNAs obtained by in vitro transcription according to the above method are shown in Table 8 below:
table 8: list of mRNA sequences obtained as described above.
Serial number | Sequence name | Sequence optimization |
(SEQ NO:1.1) | S | Is that |
(SEQ NO:1.2) | S-RBD | No (natural)Sequence) |
(SEQ NO:1.3) | M | Is that |
(SEQ NO:1.4) | N | No (Natural sequence) |
(SEQ NO:1.5) | S-RBD | Is that |
(SEQ NO:1.6) | S-RBD | Is that |
(SEQ NO:1.7) | E | Is that |
(SEQ NO:1.8) | S partial | Is that |
(SEQ NO:1.9) | S1 | Is that |
The above obtained mRNA sequences of 9 as listed in table 8 differ only in the ORF region, and other functional regions such as UTR sequence and polyA sequence are completely identical: furthermore, the ORF regions are sequences transcribed with optimized or non-optimized DNA sequences. By non-optimized sequence is meant a sequence that is identical or has greater than or equal to 95% homology to a native wild-type nucleic acid sequence, e.g., SEQ NO: 2 or SEQ NO: 1.2; or SEQ NO: 1.4 or SEQ NO: 4, or a sequence shown in the figure.
The T7 promoter: TAATACGACTCACTATA (SEQ ID NO:12)
5' UTR sequence:
ACATTTGCTTCTGACACAACTGTGTTCACTAGCAACCTCAAACAGACACC(SEQ ID NO:13);
3' UTR sequence:
GCTCGCTTTCTTGCTGTCCAATTTCTATTAAAGGTTCCTTTGTTCCCTAAGTCCAA CTACTAAACTGGGGGATATTATGAAGGGCCTTGAGCATCTGGATTCTGCCTAATA AAAAACATTTATTTTCATTGC(SEQ ID NO:14);
polyA tail sequence:
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAA(SEQ ID NO:15)。
the DNA optimized sequences in table 7 correspond to the mRNA sequences of table 9. This is because the optimized DNA sequence is aligned with the analysis of the native sequence, and thus, following this logic, the optimized mRNA sequence obtained also exists in a similar relationship to the native sequence (wild type). See table 9 for a specific list. 1.1 indicated by the sequence number in table 8; 1.8; 1.9 sequences were optimized based on the 1-1-1 native sequences in Table 9; 1.5 indicated by the sequence number in Table 8; 1.6 optimized based on native sequences numbered 5-5-5 in Table 9; sequence 1.3 shown by the sequence numbers in Table 8 was optimized based on the natural sequences numbered 3-3-3 in Table 9; the sequence shown in sequence number 1.7 in Table 8 was optimized based on the native sequence numbers 7-7-7 in Table 9; sequences 2 and 4 are native sequences and are not optimized; thus, the native sequence has only 2: the amino acid sequence of SEQ NO: 2-2-2; the amino acid sequence of SEQ NO: 4-4-4.
Table 9: native mRNA sequence.
Serial number | Sequence name |
(SEQ NO:1-1-1) | S |
(SEQ NO:2-2-2) | S-RBD |
(SEQ NO:3-3-3) | M |
(SEQ NO:4-4-4) | N |
(SEQ NO:5-5-5) | S-RBD |
(SEQ NO:6-6-6) | S-RBD |
(SEQ NO:7-7-7) | E |
(SEQ NO:8-8-8) | S partial (part) |
(SEQ NO:9-9-9) | S1 |
Table 10: the homology of the native mRNA sequence with the sequence optimized is compared.
It is understood here that the optimized RNA sequence can be obtained by means of an optimized DNA sequence, but it is of course also possible to generate the RNA sequence directly by means of sequence synthesis. The promoter can be prepared by adopting a conventional promoter sequence, and an untranslated region, such as a UTR sequence, can be added at the head and tail of the sequence to ensure that the RNA sequence is more stable. For the screening of sequences, particularly UTR sequences, detailed descriptions will be given in the detailed description of the invention. General UTR sequences are possible, and the specific sequences of these so-called promoters, suitable UTR sequences, poly sequences, and also for nucleic acid modifications and sequence optimization, are all intended to ensure stable transport of nucleic acid sequences in vivo and, at the same time, high expression levels. It will be understood by those skilled in the art that any other sequence is contemplated as being within the scope of the invention and is some preferred examples of the invention, but that without these elements, only the optimized new corona sequence is contemplated and the mere potential effect is not very desirable. It can also be seen from the experiments that, even if the sequences of these elements are identical, the key to good and bad functioning, or decisive, is also the nature of the ORF sequence itself. However, it is undeniable that these additional sequences, together with the ORF sequence, can have a better effect.
In some alternative embodiments, additional sequences may be inserted in front of the ORF sequence, which may also help to achieve functional improvements in RNA expression, such as reducing some enzyme cleavage sites, thereby making the protein more active, such sequences may be as follows: for example, a sequence is inserted at the fourth nucleotide at the 5-terminus of the ORF sequence. For example, the 5' ends are all nucleotides that begin with AUG, and the inserted sequence is then looked up from the 4 th nucleotide into one or more of the following sequences.
5’-AUGUUCCUGCUGACUACAAAACGGACU-3’(SEQ NO:38)
5’-GACGCUAUGAAGAGGGGCCUGUGCUGUGUGCUGCUGCUGUGCGGAGCUG UGUUCGUGUCCAACAGC-3’(SEQ NO:39)。
The site of insertion may be inserted after the first few nucleotides at the 5-terminus, or may be inserted after the first few nucleotides at the 3-terminus, or may be directly linked to ORF (open reading frame) sequences, which are diversified in their functions and have sequences that comprehensively improve the properties of RNA. These additional sequences may be inserted into the ORF sequence and become part of the ORF sequence. It is understood that sequences other than ORF sequences are a preferred embodiment of the present invention, but these preferred embodiments do not indicate that these sequences are necessary to achieve the object and intent of the present invention.
Table 11: the amino acid sequences expressed in translation in table 8.
The amino acid sequences of the mRNA translation expression in Table 8 are all 100% homologous to the amino acid sequences of the native mRNA translation expression in Table 9. This indicates that the amino acid sequence of the finally expressed protein, i.e.the amino acid sequence of the protein, is the same, whether it is the optimized sequence or the native sequence. The sequence identity merely indicates that the material is the same in nature, but the content and activity are not equivalent concepts.
Example 2 of implementation: in vitro cell expression level validation of candidate mRNA sequences
1.1 test article:
9 new coronary mRNA vaccines: in order to detect protein products, 6 consecutive histidine codons (CAU, see table 12 in particular) are fused to the 3' end of each mRNA sequence, and a histidine tag (His-tag) formed by 6 consecutive histidines can be generated at the C-end of the protein product, so that the expression of the antigen of interest can be indirectly detected using an anti-histidine tag antibody.
Table 12: specific sequence characteristics of 9 new crown mRNA vaccines.
In the above table, ". indicates" complete sequences "containing 9 different RNAs in Table 8, including other functional regions such as promoter sequence, UTR sequence and polyA sequence which are completely identical (containing no additional sequences)," total 9 "are designated nCoV-N, where N is a natural number from 1 to 9, as shown in the table.
2.2 test reagents: HEK-293 cells (purchased from manufacturer:); DMEM complete medium (Gibco): 1% double antibody (Gibco), 10% fbs (hyclone); PBS (solibao); transfection diluent: Opti-MEM (Gibco); lipofectamine MessengerMAX (Invitrogen); RIPA lysate (strong) (protease inhibitor cocktail Pierce)TMProtein Concentrator PES,3K MWCO (Pierce); BCA protein concentration assay kit (enhanced) (cloudy day); tris-glycine running buffer (solibao); electro-transformation of liquid (solibao); TBST: 1 × TBS (Solebao) +1 ‰ Tween-20 (Solebao); skimmed milk powder (anjia); methanol (alatin); beyogelTMPlus PAGE precast gel (4-20%, 15 wells) (Biyun day); his Tag Antibody (HRP) (solibao); high-sig ECL Western Blotting Substrate (Tanon); development fixing kit (Biyun day).
2.3 test consumables: t75 cell culture flasks (Thermo); 15/50ml centrifuge tubes (Corning); pipettes (Corning); 1.5/0.5ml centrifuge tube (Axygen); PVDF membranes (cloudy days); transfer filter paper (bi yun day); X-OMAT BT film (5X 7 inches) (cloudy day); tablet cassette (cloudy day); 3.3 testing the instrument; CO22Incubators (Panasonic); inverted microscopes (Leica); electrophoresis apparatus (Bio-Rad); electrophoresis tank (Bio-Rad); a transfer tank (Bio-Rad); centrifuge (Kubota); gel imaging Universal Hood II (Bio-Rad).
Test method
1.) HEK293 cells plated in six-well plates, one for each well1×106The cells were incubated in an incubator at 37 ℃ for 16 hours.
2.) the 9 mRNA vaccine sequences in Table 1 were transfected individually at 2. mu.g each (prepared in example 1) using Lipofectamine MessengerMAX transfection reagent, as follows: the solution A was incubated for 10 minutes, mixed with the solution B, and incubated at room temperature for 5 minutes for cell infection.
Table 13: reagent composition and content of solution A and solution B
3) 24 hours after transfection, the culture supernatant was collected, 1/100 volumes of protease inhibitor were added immediately and placed on ice; mu.L of RIPA lysate (1/100 volumes of protease inhibitor had been added) was added to each well of cells, lysed on ice for 30 minutes, the lysate was transferred to a 1.5ml centrifuge tube, centrifuged at 18000rpm for 20 minutes at 4 ℃ and the supernatant transferred to a fresh centrifuge tube.
4) Concentrate the culture supernatant using Protein Concentrator PES: the collected medium supernatant was pipetted 500. mu.l into an adsorption column, centrifuged at 12000rpm for 30 minutes, and the concentrated medium supernatant was transferred to a new centrifuge tube.
5) Using the BCA kit to detect the protein concentration of the cell lysate.
Preparation of BSA standard: 0.8ml of the protein standard preparation solution was added to a tube of protein standard (20mg BSA), and after sufficient dissolution, 25mg/ml BSA standard solution was prepared. Mu.l of 25mg/ml BSA standard solution was taken and added to 920. mu.l PBS to prepare 2mg/ml BSA standard.
Preparing a BCA working solution: according to the number of samples, a proper amount of BCA working solution is prepared by adding 50 volumes of BCA reagent A and 1 volume of BCA reagent B (50:1), and the mixture is fully mixed.
The BSA standards were diluted to make a standard curve as follows (table 14):
each 100. mu.l of 8 standards was added to a 96-well plate, and two wells were set. Sample well: add 100. mu. l H per well in 96-well plates2O, adding 1 μ l of sample and setting two multiple holes. Mu.l of BCA working solution was added to each well, and the mixture was left at 37 ℃ for 30 minutes. Assay A562 with microplate reader. And calculating the protein concentration of the sample according to the standard curve.
6) Protein sample preparation: according to the protein concentration of the sample, the cell lysates containing 45. mu.g of protein were pipetted into 0.5ml centrifuge tubes, 3. mu.l of 5 XSDS loading buffer was added, and H was used2O adjusting each protein sample to a final volume of 15 μ l; the albumin sample in the culture medium is prepared according to the volume of the corresponding cell lysate, and the protein is denatured by boiling water for 5 minutes before loading (the protein containing the coded antigen is obtained).
7) Taking out the prefabricated gel, assembling the electrophoresis device, adding electrophoresis buffer solution, and loading. The wells to which no protein sample was added were loaded with 15. mu.l of 1 XSDS loading buffer.
8) Electrophoresis: electrophoresis was carried out at a constant voltage of 80V for 30 minutes, followed by adjustment of voltage to 100V for 40 minutes. After electrophoresis was completed, the gel plate was washed with H2O, and the gel was carefully removed.
9) Turning the film: activating the PVDF membrane in methanol, and immersing the membrane, sponge and filter paper in the precooled membrane transferring liquid. And (3) putting the rotating membrane into the membrane transferring solution downwards in a black state, and sequentially putting sponge, two layers of filter paper, glue, a PVDF membrane, two layers of filter paper and sponge on the rotating membrane, wherein bubbles cannot exist in each step. Closing the transfer printing clamp, placing the transfer printing clamp into the transfer printing groove, making the black surface of the clamp face the black surface of the groove, making the white surface of the clamp face the red surface of the groove, placing the ice box into the transfer printing groove, pouring electric transfer liquid, and inserting the electrode. For nCoV-1/4/8/9 with larger molecular weight, constant pressure is 100V, and the membrane is rotated for 90 minutes; for nCoV-2/3/5/6/7 with smaller molecular weight, constant pressure 100V, and film transfer for 60 minutes. After the completion, the PVDF membrane is taken out, the direction of the membrane is marked, and the membrane is placed in a Western blot antibody incubation box.
10) Sealing: 10% skimmed milk powder was prepared using 1 × TBST, and the membrane was placed in a confining liquid and sealed on a shaker at room temperature for 1 hour.
11) Primary anti-incubation: 1% skimmed milk powder was prepared using 1 XTSST, the His-tag (HRP) primary antibody was diluted 1:10000, and incubated for 2 hours at room temperature with shaking.
12) Washing the membrane: primary antibody was recovered and the membrane was washed 4 times with 1 XTSST for 5 minutes each.
13) Chemiluminescence, development, fixing: and (3) carrying out detection by a chemiluminescence method, incubating the membrane with a chemiluminescence substrate, developing by X-ray film exposure, and scanning the film.
2.5 the results of the experiment are shown in FIG. 3. And (4) analyzing results: after 9 mRNA vaccine sequences are transfected by Lipofectamine MessengerMAX, the cell state is good; after the Western blot exposure result is scanned by gel imaging Universal Hood II, Image J and Adobe Illustrator are used for mapping and analyzing, and the result shows that the exposure background is low, and the protein band is clear and specific (shown in figure 3). After HEK-293 cells are transfected by the 9 mRNA vaccine sequences, a target band is detected in a culture medium supernatant or a cell lysate, wherein the nCoV-5/6/8/9 protein secreted to the outside of the cells can be detected in the culture medium supernatant due to the signal peptide sequence in nCoV-5/6/8/9.
The molecular weight of each protein is compared with the expected molecular weight of the protein: the molecular weight of nCoV-2/4/5/7 protein is basically consistent with the expectation. The nCoV-1/6/8/9 protein was slightly larger in molecular weight than expected, probably due to the fact that the S protein was highly glycosylated in vivo. In the culture supernatant, nCoV-8 has a band with smaller molecular weight under the expected band, and is probably S2 subunit formed by S protein shearing in vivo. nCoV-3 has a band with a smaller molecular weight below the expected band, and may have shear in vivo, and in addition, has a diffuse band at a higher molecular weight, suggesting that multimeric forms may exist in vivo.
In conclusion, the results show that 9 mRNA vaccines have correct sequence design and can be correctly expressed in vitro. RNA is a major role in gene expression, and the maintenance and expression of the entire genetic information is performed in the "RNA world", in which messenger RNA (mRNA) provides an information transfer intermediate representing the DNA sequence of a protein. Gene expression can be divided into two phases-transcription and translation. Transcription is carried out by taking DNA in cells as a template, generating a single-chain mRNA as a direct template for protein biosynthesis according to the base complementary pairing principle, wherein the sequence of the single-chain mRNA is complementary with a non-coding chain of the DNA and is the same as the coding chain; translation is a process of interpreting genetic information accumulated in a nucleotide sequence of mRNA and generating an amino acid sequence of protein, and a peptide chain of protein having a specific amino acid sequence is synthesized in the 5' → 3' direction from the start codon at the 5' end of mRNA according to the triplet coding rule that determines one amino acid for every three nucleotides. The mRNA vaccine is based on the characteristic that mRNA can be quickly translated into target protein, mRNA transcribed in vitro is conveyed to an antigen presenting cell (dendritic cell) through a delivery system, so that the dendritic cell directly and efficiently expresses antigen, and an antigen-specific T cell is stimulated and activated through MHC I or MHC II molecules, so that a B cell and the T cell are activated, and an organism generates antigen-specific immune response. Therefore, correct expression of the target protein by mRNA is a prerequisite for the mRNA vaccine to function.
This also indicates that some other sequences, either before or after the ORF region, are possible and functionally capable of effecting expression of the antigen. Meanwhile, the successful expression of the antigen in vitro cells can also be realized by increasing the additional sequence (the specific experimental data are omitted). As mentioned above, the RNA itself that plays a determining role is the information of the core coding protein.
In eukaryotic cells, the mature mRNA directly used as a translation template needs to have one or several of the following structural features: (1) a protein coding sequence comprising an initiation codon and a stop codon, with continuity between codons and no nucleotide separation; (2) the coding sequence has an untranslated region (UTR) at both ends, the 5 'UTR located from the methylated guanine nucleotide cap at the beginning of the mRNA to the start codon AUG, and the 3' UTR extending from the stop codon at the end of the coding region to the front of Poly A tail (Poly-A), which are important for translation efficiency and mRNA stability; (3) the 5 'end cap structure, namely a methylated guanine nucleotide (m7GpppNp) combined with the 5' end of mRNA in a distinctive 5 '-5' combination mode, is helpful for the recognition of the mRNA by ribosome during the translation process, stabilizes the combination of the ribosome and the mRNA, promotes the initiation reaction and ensures that the translation is carried out along the correct direction; (4) the 3 'end poly A tail structure can collect key translation initiation factors to enable the key translation initiation factors to be tightly combined with the 3' end of mRNA, so that the mRNA maintains a circular conformation, the translation initiation efficiency is improved, and the poly A tail structure has a promotion effect on reinitiating the translation process. In addition, the Poly a tail and the proteins bound thereto help protect the mRNA from exonuclease degradation, thereby enhancing the stability of the mRNA.
By the present invention, more effective UTR sequences, which have different effects on the expression of the same ORF region, were also screened, and the present invention also improved UTR sequences, thereby improving stable lines of mRNA. It will be appreciated by those of ordinary skill in the art that UTR sequences may have effects not only on new crown mRNA but also on other non-mRNA sequences.
Therefore, to ensure that the in vitro transcribed mRNA can be expressed in cells with high efficiency and stability like the mature mRNA molecules, the test is optimized in a series of processes of vaccine design and synthesis, including: 1) modifying nucleotide to reduce the inherent immune response of human body to mRNA; 2) optimizing codons, and changing rare codons in mRNA into more common synonymous codons to improve the protein expression amount; 3) optimizing 5 'UTR and 3' UTR sequences, improving translation efficiency of mRNA, enhancing mRNA stability and prolonging half-life period of mRNA; 4) 5' capping to enhance the stability of mRNA and increase the protein expression; 5) 3' poly-A tail is added to enhance the stability and translation efficiency of mRNA; 6) the prepared mRNA is purified, double-chain by-products are reduced, and unnecessary immune stimulation is prevented. Any of these optimizations may be an improvement over conventional techniques.
In view of the present invention, the sequences of the 5 'UTR and 3' UTR used in the embodiments are the same for all of the novel corona 1-9 mRNs, and therefore, the nucleic acids are all expressed in cells, indicating that all of these selected genes are likely to produce antigens in vivo and thus cause antibodies in the subject.
In order to detect whether the designed 9 new crown mRNA vaccines can be correctly expressed, the experiment utilizes Lipofectamine MessengerMAX transfection to enable mRNA to enter HEK293 cells for expression, after 24 hours of transfection, the expression level of exogenous proteins reaches a peak value, meanwhile, culture medium supernatant and cell lysate are collected, and the Western blot technology is utilized to detect the target antigen expression. The HEK-293 cell rarely expresses endogenous receptors required by an extracellular ligand, is easy to transfect, and is a very common tool cell strain for expressing and researching exogenous genes, so that the HEK-293 cell is selected as a host cell, and mRNA can be ensured to smoothly enter the cell. Since some mRNA sequences have signal peptides, the protein products are secreted to the outside of the cell, so the test detects the protein expression in the cell lysate and the protein expression in the culture medium supernatant. The Western blot technique is to stain the protein sample treated by gel electrophoresis through specific antibody, and obtain the information of the expression of specific protein in the analyzed cell or tissue through analyzing the stained position and stained depth. In the absence of specific antibodies, 6 consecutive histidine Codons (CAU) were fused to the 3' end of each mRNA sequence in this assay, and a histidine tag consisting of 6 consecutive histidines could be generated at the C-terminus of the protein product, thereby allowing indirect detection of the expression of the antigen of interest using an anti-histidine-tag antibody. In fact, histidine tags formed by amino acids are used to indirectly detect whether an antigenic substance is produced in the cell (the antigen is actually the protein information encoded by the mRNA).
Experiment 3: comparison of immunogenicity of 9 mRNA vaccines in mice
3.1 purpose of the experiment
After 9 different new coronavirus mRNA vaccines are used for immunizing mice, the ELISA method is used for detecting the antigen-specific antibody titer in the mice, and the optimal vaccine reagent is screened by comparing the antibody titer level.
3.2 information on the test article
The drug was supplied directly from Shimi (Shanghai) Biotechnology Co., Ltd., the department of preparation, and adjusted to a predetermined concentration. Carried to the model biology research center of the Shanghai south at 2-8 ℃ and is specially delivered to the intrabarrier administration.
Table 15: various concentrations and dosages of administration and modes of injection.
Note that the sequences numbered 1-9 correspond to the sequence of mRNA1-9 in Table 8 above, where 2019-nCoV-1-9 corresponds to SEQ NO: 1.1-1.9.
3.3 preparation of LPP for delivery vehicles.
Materials: PbAE (protamine sulfate, sigma), DOPE (Avanti), M5 (Megmon Kard), DSPE-mPEG2000(lipoid), mRNA (shown in Table 8 as containing complete sequences of different mRNAOVR, with the code number of 2019-nCoV-1.1-1.9;
the structural formula of M5 is as follows:
the preparation process comprises the following steps:
3.3.1 preparation of solution:
preparation of PbAE solution: dissolving a proper amount of PbAE in a proper amount of aqueous solution to prepare 1mg/ml of PbAE solution;
preparing a lipid solution: preparing a lipid solution with the concentration of 40mg/ml according to the mass ratio of M5 to DOPE to DSPE-mPEG2000 to 49 to 2;
mRNA solution: diluting the appropriate solution to 1 mg/ml;
3.3.2 preparation of core nanoparticles:
preparation of a PbAE phase: taking a proper amount of PbAE solution, and diluting with purified water to 0.60 mg/ml;
preparation of mRNA phase: taking a proper amount of mRNA solution, and diluting the mRNA solution to 0.20mg/ml by using purified water;
adding the PbAE solution into the mRNA solution while stirring, wherein the mixing volume ratio is that the PbAE solution: mRNA solution 5: 1.
3.3.3 preparation of LPP lipid nanoparticles:
according to the parameter Volume being 12.0 mL; mixing Start water 0.35mL, End water 0.10mL, flow rate 3 (core nanoparticle solution): 1 (lipid solution), flow rate 20mL/min, and temperature 37 deg.C; the operation is carried out on a microflow chip device, and the device is used for preparing lipid nanoparticles by a fishbone chip of a commercial manufacturer PNI.
4. Purification of LPP lipid nanoparticles:
and (3) diluting the LPP lipid nanoparticles with a PBS solution, and performing centrifugal purification by using an ultrafiltration centrifugal tube to obtain a purified lipid nanoparticle solution.
3.3 Experimental reagents
0.01M PBS buffer (PH 7.4) (solibao); cleaning solution: 0.05% Tween-20 (solibao) + PBS blocking solution: 10% adult bovine serum (ilex purpurea) plus PBS; sample diluent: 10% adult bovine serum + 0.05% Tween-20 + PBS; color development liquid: 3,3',5,5' -tetramethylbenzidine tmb (thermo); stopping liquid: 2N H2SO 4; secondary antibody: anti-mouse IgG-HRP (Abcam); envelope antigen (antigen to antibody):
table 16: list of different antigens
3.4 administration of drugs
The administration route is intramuscular injection, and the administration mode similar to the route planned in the clinical test is selected. The volume of administration was 100. mu.l/mouse, and 50. mu.l of each of the left and right hind leg thigh muscles was injected with the drug. Blood was collected on day 10 after immunization for antibody titer detection.
3.5 Observation and inspection
During the test period, the animal room manager collaborates the state of the mice and observes the state of the mice according to the test specification every day. The experimenter makes regular observations of the mouse status including, but not limited to: behavioral activity, intake of water, weight change (3 weight measurements per week), appearance signs or other abnormal conditions. The number of deaths and side effects of animals in the groups were recorded based on the number of animals in each group. Mouse abnormalities include, but are not limited to: obviously emaciation, weight loss greater than 20%; the food and the water can not be taken by oneself; and the following clinical manifestations and sustained deterioration of the animals appeared: erecting wool; the back of the bow; the color of ears, nose, eyes or feet is whitish; short breath; twitching; continuous diarrhea; dehydrating; bradykinesia; and (6) sounding.
3.5.3 antibody titer detection
1) Antigen coating: antigen coating was performed according to table 15 for the antigens corresponding to the different vaccines, and the antigen list is shown in table 16. The antigen was diluted with PBS and coated at a concentration of 5. mu.g/ml, 50. mu.l was added to each well of a 96-well plate, and incubated for 12 hours at 4 ℃ in an air bath.
2) Washing: each well was washed three times with 200. mu.l of washing solution.
3) Sealing: blocking of 96-well plates was performed using blocking solution, 200. mu.l per well, and incubation for 2 hours at 27 ℃ in an air bath. The plate after sealing is washed three times by adding 200 mul of washing liquid into each hole.
4) Sample dilution: the samples were diluted with the same volume of serum dilution gradient (200/600/1800/5400/16200/48600/145800/437400) using sample dilutions, and duplicate wells were performed for each sample, 50 μ l of sample was added to each well, and incubated for 2 hours at 27 degrees in air bath.
5) Washing: the plate was washed 3 times with 200. mu.l each time using a washing solution.
6) Secondary antibody incubation (HRP-labeled goat anti-mouse IgG secondary antibody): using the sample dilution, the secondary antibody was diluted at a dilution of 1:100000, 50. mu.l was added to each well, and incubated for 1 hour at 27 degrees in an air bath.
7) Washing: the ELISA plates were washed 4 times, 200. mu.l per well each time, and the final wash removed the liquid from the plates to dryness.
8) Color development: 50 mul of TMB color developing solution is added into each hole of the cleaned plate for color development, and the color development state is observed in real time.
9) Terminating: the wells were stopped by adding 50. mu.l of stop buffer, followed by detection on the machine.
10) The dual-wavelength detection index of the microplate reader: OD values were read using a wavelength of 450nm and a wavelength of 610 nm.
11) Data analysis: 1) the sample dilution was curve-fitted to the detected OD values. 2) R2 was confirmed by substituting the value of Y into the value of negative control OD, resulting in the logarithmic curve equation Y ═ M × ln (x) + Z. 3) The negative control (Cut off) 2.1-fold OD value was substituted into the equation X ═ EXP ((Y-Z)/M), and the antibody titer was calculated.
The results are shown in fig. 4, which shows: the detection of antigen-specific IgG antibodies in mouse sera at day 10 after vaccine administration revealed that the serum titer was highest in mice administered with vaccine No. 1, almost no antibodies were produced in vaccine No. 2/5/9, and lower levels of antibodies were produced in vaccine No. 4/8. The titer level of the No. 1 vaccine antibody reaches 104Can effectively stimulate the immune response of the body fluid. Vaccine No. 1 ((SEQ NO:1), SEQ NO: 1-1) (named COVID-19-LPP-mRNA) is able to stimulate the body to produce higher levels of antigen-specific antibodies in a short time compared to other vaccines. Thus, the vaccine No. 1 (named as COVID-19-LPP-mRNA) is determined to be subjected to subsequent process development and clinical research.
The new crown mRNA vaccine is used for immunizing mice in a muscle administration mode, and during the experiment, except for one experiment group of 2019-nCoV-2, no animal is dying/dead. The mice do not show obvious physical and behavioral abnormalities through daily observation. The body weight of the mice in the test group slightly decreased 1 to 2 days after the administration, but all were within the acceptable range, and the body weight was recovered 1 to 2 days later.
And on the 10 th day after immunization, the immunogenicity of different mRNA vaccines is evaluated by detecting the antibody titer in the mouse serum, so that the mRNA vaccines which have stronger immunogenicity and effectively activate the in-vivo antigen specific immune response are screened out. According to the results, it was found that the antibody titer was highest in mice of the nCoV-1 vaccine administration group, almost no antigen-specific antibody was produced in mice of the nCoV-2/5/9 vaccine administration group, and the nCoV-4/8 vaccine was able to activate the body to produce antigen-specific antibody, but the antibody titer was low. It can be known that nCoV-1 new crown mRNA vaccine can effectively activate humoral immune response in the body, including the formation of germinal center B cells, antibody type conversion, high affinity antibody maturation and the like.
Promotion ofB cells differentiate into memory B cells and plasma cells, producing higher levels of antigen-specific antibodies. The rest vaccines No. 2 and No. 4,No. 5, No. 8 and No. 9 vaccines can not well activate humoral immune response in organisms, and the antigen-specific antibody titer is low and can not reach the ideal standard. The vaccines No. 3, No. 6and No. 7 fail to carry out vaccine immunogenicity detection due to antigen synthesis reasons, and data thereof are not shown in antibody titer detection tests, but after detection, the three vaccines also have antibody production, and the antibody titer is not high but is higher than that of a control, which indicates that all the vaccines have antibody production and can cause organism immunity.
From the above experimental results, it was shown that the reagent No. 1 has a good effect, but the reagent No. 4 or 8 has the production of antibodies. These differences may be due to the different antibody production resulting from the differences in the design and optimization of the nucleic acid sequences, thereby collectively representing the differences in titer.
1 purpose of the test: injecting COVID-19-LPP-mRNA with different concentrations twice into C57BL/6 mice intramuscularly, observing the weight change of the mice on each of day 0 and day 7, collecting blood on day 10 after the second immunization, and centrifuging to obtain serum; spleen tissue was harvested at day 14 after the second immunization and spleen cells were processed.
2. Test drug information
Table 17: name: concentration dilution table of COVID-19-LPP-mRNA
3. Test animals and management
3.1 test animals: species/strain: c57BL/6 mice; grade: an SPF level; female: 30 pieces of the feed are added; weight: about 18-20 g; the week age is as follows: 8-9 weeks. On the day of animal grouping, the ears of the mice are marked by using a perforator, wherein the upper, middle and lower parts of the left ear represent 1/2/3, and the upper, middle and lower parts of the right ear represent 4/5/6.
3.2 animal feeding: the quarantine period is three days, and animals in the animal house and veterinarians perform quarantine on the batch of animals according to specified sampling in the quarantine period. Mice adopt IVC cageThe breeding is carried out, and each cage does not exceed five. Environmental parameters of the animal house (411) are recorded during the rearing period. All the feed and drinking water are purchased and provided with the assistance of Shanghai's Square model biological research center. Warp beam60The SPF-level mouse feed sterilized by Co irradiation is provided by cooperative medical biological responsibility limited company in Jiangsu province, and each batch of feed provides a quality detection report containing detection indexes such as nutrition, pesticides and microorganisms. Deionized water, feeding containers and bedding were autoclaved into the barrier and replaced twice a week.
4 test method
Administration: the administration was performed on day 0 and day 7, respectively (day 0 was recorded on the day of the first administration). The dose was 100. mu.l/mouse, and 50. mu.l of each drug was injected into the thigh muscle of the left and right hind limbs.
4.1 Observation and inspection: mice status was co-checked and observed daily by south model animal house animal care personnel as specified during the trial. The experimenter regularly observes mouse status as prescribed, including but not limited to: behavioral activity, intake of water, weight change (3 weight measurements per week), appearance signs or other abnormal conditions. The number of deaths and side effects of animals in the groups were recorded based on the number of animals in each group. Mouse abnormalities include, but are not limited to: obviously emaciation, the weight reduction is more than 20%; the food and the water can not be taken freely; and the following clinical manifestations and sustained deterioration of the animals appeared: erecting wool; the back of the bow; the color of ears, nose, eyes or feet is whitish; short breath; twitching; continuous diarrhea; dehydrating; bradykinesia; and (6) sounding.
4.2 blood collection preparation and blood sample treatment: after day 10 of the second immunization, we will bleed all mice within the trial. The orbital plexus vein will be used to collect blood, approximately 500uL per mouse. The collected whole blood was allowed to stand at room temperature for 2 hours, centrifuged at 8000rpm for 10 minutes, and serum was collected and stored at-20 ℃.
4.3 spleen harvesting and cell processing: on day 14 of the second immunization, the mice were euthanized and spleens were dissected and spleen single cell suspensions were prepared.
Test results
5.1 death and clinical observations
During the test, no death/moribund condition of the animals was observed. During the test period, no obvious abnormal phenomenon was observed in all the test mice.
5.2 body weight
No significant weight fluctuations occurred during the test period. Because of random grouping, the mean values of basal body weight of each group of mice are not at the same baseline, so the percent change in body weight is compared to measure the change in body weight of animals. The specific weight percentage trend is shown in figure 5 below. During the test period, the mice were observed daily, and no obvious abnormality in posture and behavior was found. The test mice all had slight weight loss 1-2 days after immunization, but no weight loss of more than 10% was observed, and the body weight was recovered after 1-2 days. The weight loss degree and the concentration of the test article basically correspond, but the difference is not obvious. Preliminary presumption, weight loss is caused by immune system stress.
Discussion and conclusions
In summary, under the conditions of this experiment, the C57BL/6 mice were administered COVID-19-LPP-mRNA twice by intramuscular injection, once on day 0 and once on day 7, at dosages of 30/15/7.5/2.5/1. mu.g/mouse, respectively, and the results showed that there was no moribundity/death associated with the drug tested. The behavior and activity of the mice, the amount of water intake for food intake, the weight change (3 weight measurements per week), the physical signs of the appearance and the like are not abnormal. The above data initially indicate that COVID-19-LPP-mRNA is not significantly toxic.
Experiment 6: evaluation of the Effect of mouse antibody response after immunization with COVID-19-LPP-mRNA
6.1 purpose of experiment: the level of specific binding and neutralizing antibodies induced in mice by the novel corona mRNA vaccine COVID-19-LPP-mRNA was evaluated using indirect ELISA, SARS-CoV-2 pseudovirus neutralization, live virus plaque assay.
6.2, test article information: name: mRNA vaccine COVID-19-LPP-mRNA (vaccine No. 1 screened in example 3) size: 0.5 mg/ml; the characteristics are as follows: a milky white liquid; the validity period is as follows: can be stored at 2-8 deg.C for 28 days
6.3 Experimental animals: name: SPF grade inbred mice; quantity: BALB/C mice 18; 30C 57BL/6 mice (white-variant laboratory mice, like numerous common subfamilies, originated in mice (Mus musculus) since 1920 their birth in new york, BALB/C mice have been bred over 200 generations in global research institutes, widely used in immunological, physiological animal experiments); sex: a female; age: 6-8 weeks old.
4.4 Experimental reagents and consumables: SARS-CoV-2(2019-nCoV) Spike Protein (S1+ S2 ECD, His tag) (S1+ S2 ECD is called S1+ S2 extra-cellular domain, i.e. the extracellular domain of S Protein, the full length molecular weight of S Protein is 141.20kDa, and the molecular weight of S1+ S2 ECD Protein is 134.36 kDa); purchased from Beijing Yi Qiao Shenzhou science and technology, Inc.
EIA/RIA 96 pore plates; 0.05M carbonate buffer (coating solution) pH 9.6; 0.5% Tween-20 PBS (PBST lotion); 10% goat serum PBS (blocking solution); 2% goat serum PBST (antibody dilution); HRP-labeled goat anti-mouse IgG secondary antibody; single-component TMB color developing solution; 2M H2SO4 solution (stop solution); a cell culture flask; 96-well cell culture plates; 12-well cell culture plates (Corning); DMEM medium (Hyclone); fetal bovine serum (Gibco; GEMINI); streptomycin qing mixed solution (Gibco); avicel RC-581(FMC Biopolymer); crystal violet (solibao); Bright-Glo luciferase assay reagent (Promega) SARS-CoV-2 virus: SARS-CoV-2(C-Tan-nCoV-HB-01strain, GISAID access No. EPI _ ISL _402119)
SARS-CoV-2 pseudovirus: the laboratory prepared the SARS-CoV-2 pseudovirus of HIV-1 core (i.e., a virus that contains HIV-1 antigens rather than a neocorona).
4.5 Experimental methods
4.5.1. Animal immunization: in this experiment, we used BALB/C and C57BL/6 mice for vaccine immunogenicity testing, using 2 immunization doses: 30 μ g (high dose)/3 μ g (low dose); 2 immune cycles: single-needle immunization (day 0 immunization) and double-needle immunization ( day 0, 21 immunization), for 8 groups. After the vaccine was diluted to a prescribed concentration with PBS, intramuscular injection was performed through the thigh site in a volume of 30. mu.l per side, and bilateral injection was performed. BALB/C and C57BL/6 strain mice were 6 mice each, 18 BALB/C mice, 30C 57BL/6 mice (see Table 18 for details).
4.5.2. Obtaining a serum sample: at 5 weeks after immunization, 500. mu.L of blood was collected from the orbit, centrifuged 2 times at 10000 Xg, and the serum was separated and stored at-30 ℃.
4.5.3. Indirect ELISA:
antigen coating SARS-CoV-2Spike antigen protein was diluted to 0.5. mu.g/mL using coating solution, added to 100. mu.L to EIA/RIA 96 well plate, and antigen was coated overnight at 4 ℃.
Sealing the detection plate: the coated EIA plate was washed 3 times with wash solution, 250. mu.L of 10% goat serum PBS blocking solution was added to each well, and the plate was blocked at 37 ℃ for 2 hours.
Serum sample dilution: the serum was diluted with antibody dilutions and the samples were diluted 2 or 3 fold from 1:100 or 1:300 for a total of 9 dilutions, with specific dilutions being the X-axis values in figure 7, figure 9, figure 10, and figure 12.
Serum antibody adsorption: washing the sealed detection plate with washing solution for 3 times, adding 100 μ L diluted serum sample into each well, incubating at 37 deg.C for 1h, setting blank control, and adding antibody diluent only
And (3) binding of a secondary antibody: the assay plate was washed 5 times with wash solution, 100 μ L of HRP-labeled goat anti-mouse IgG secondary antibody diluted 1:10000 was added to each well, and incubated at room temperature for 1 h.
Color development and termination: the test plate is washed 5 times with lotion, 100 μ L of monocomponent TMB developing solution is added into each well, the color is developed for about 5min at room temperature, and 50 μ L of stop solution is added.
And (3) absorbance detection and titer determination: the 450-wavelength absorption peak was measured using a microplate reader (the measurement at 630 was used as a reference value, and only stability determination was performed), and 2.1 times of blank wells were determined to be positive on the basis of OD450 in the blank wells of the detection plate. The highest dilution rate at which a sample is judged to be positive is the titer of the bound antibody of the sample.
Neutralization assay for SARS-CoV-2 pseudovirus
Cell preparation: huh7.5 cells were passaged one day before infection at 1X 105The cells/mL are inoculated into a 96-well plate and cultured in a CO2 incubator until the cells are 60% -80% confluent.
Serum dilution and virus pre-mixing: serum samples were diluted to 50 μ L using DMEM medium at 2 fold ratio of 9 dilutions from 1:25, mixed with the same volume of pseudovirus, and incubated at 37 ℃ for 1h (specific dilution times are values on the X-axis in fig. 7, 9, 10, 12).
Viral infection: and (3) sucking the cell supernatant prepared on the previous day, adding serum virus mixed solution, culturing in an incubator overnight, and continuously culturing for 48h by replacing the next day with 2% FBS DMEM.
And (3) neutralization detection: the expression of Fluc in cells was measured using the Bright-Glo Luciferase Assay System and reported as Relative Light Units (RLU), and the neutralization was calculated as follows, percent neutralization being equal to (blank RLU-serum neutralization RLU)/blank RLU 100%.
Calculating the half effective concentration: EC50 logarithm (maximum dilution log of percentage of positive > 50% + distance ratio x logarithm of dilution factor (distance ratio (percentage of positive > 50% — 50)/(percentage of positive > 50% — percentage of positive < 50%))
Neutralization assay for reduction of plaques in SARS-CoV-2 live virus
Cell preparation: vero cells were passaged one day before infection at 1X 104Cells/100. mu.L, in an amount of 1mL to 12 well plates, placing CO2Culturing in incubator until 80-90% of cells are in pieces.
Serum dilution: inactivating the serum to be detected at 56 ℃ for 30 minutes, diluting the serum by serum-free DMEM under aseptic conditions, and diluting by 4 times to obtain 3 dilutions.
And (3) washing the cells: the next day before entering the P3 laboratory, the cell culture medium was discarded, and 500. mu.L/well of 2% FBS-DMEM was added and the operator carried into the P3 laboratory.
Preparation of the virus: the virus was removed from the refrigerator at-70 ℃, dissolved in a P3 biosafety cabinet and diluted with serum-free DMEM medium.
Serum/antibody and virus neutralization: the serum/antibody dilutions were mixed with an equal volume of virus at 37 ℃ with 5% CO2Incubate in incubator for 1 h.
Virus-serum/antibody infected cells: the medium was aspirated off, diluted virus-antibody mixture was added, 5% CO at 37 ℃2Incubate for 1 h.
Applying a coverLiquid: the infection solution was aspirated, 1mL of Avicel-2% FBS-DMEM medium was added to each well, 37 ℃ C., 5% CO2And (5) carrying out incubator culture for 72 h.
Fixing: after 72h, 12 well plates were removed from the CO2The incubator is taken out, 1mL of precooled 4% paraformaldehyde is added into each hole, and the mixture is fixed for 30min at room temperature.
Dyeing: paraformaldehyde was removed by blotting and 500. mu.L of 0.1% crystal violet was added to each well and stained for 5 min.
Washing: and absorbing and discarding the staining solution, washing 1-2 times by using 1mL of double distilled water, airing and counting.
And (4) observation and counting: the number of plaques was counted from the staining results and the neutralization rate was calculated from the number of plaques in the virus control wells and the experimental wells.
Neutralization rate ═ 100% (number of virus well plaques-number of experimental well plaques)/number of virus well plaques%
Calculating the half effective concentration: the log of EC 50-the highest dilution log of percentage of positivity greater than 50% + the distance ratio x the log of the dilution factor (distance ratio-the (percentage of positivity greater than 50% -50)/(percentage of positivity greater than 50% — percentage of positivity less than 50%).
4.6 results of the experiment
4.6.1 animal immunization, grouping and time points
Table 18: dosage and different breed mouse inoculation tables
4.6.2. Bound antibody titer detection
Serum samples from vaccine immunized mice were diluted from 1:300 to 3 fold to 1:656100 for 8 dilutions. Serum samples from control mice were diluted from 1:100 to 3-fold to 1:2700 for 4 dilutions (fig. 6-7).
The results of the BALB/C mouse serum test are shown in Table 4-1 and FIG. 6, and the results of the C57BL/6 mouse are shown in Table 4-2 and FIG. 7. High-level antigen-specific IgG can be detected by the high-dose two-needle group of two strains of mice, so that the vaccine is proved to have good immunogenicity, the low-dose two-needle group can also detect the generation of antibodies, the titer is relatively low, the C57BL/6 single-injection group is different, the high-dose single-injection group can generate certain specific antibodies, and the low-dose single-injection group cannot effectively induce the generation of the specific antibodies.
TABLE 4-1 BALB/c mouse antibody assay titers
TABLE 4-2.C57BL/6 mouse antibody assay titers
BALB/c&The serum antibody titers of C57BL/6 mice are shown in FIG. 8: after vaccine immunization, 2 strains of mice all can generate antibodies aiming at the novel coronavirus S protein. After high dose secondary boost, both strains of mice produced over 1:105Titers of specific IgG, where BALB/c mice produced antibody titers averaging 1:310,000; the titer of antibodies produced by C57BL/6 mice averaged 1:180,000. Low dose 2 immunizations also induced approximately 10 in BALB/c mice4Specific antibodies in titer; the antibody levels of the C57BL/6 mice produced by the high dose single immunization and the low dose 2 immunization are similar and both exceed 103. After the vaccine is immunized, the specific humoral immune response can be activated, and the vaccine has good immunogenicity.
4.6.3. Serum neutralizing antibody titer detection based on SARS-CoV-2 pseudovirus
The serum sample of the high-dose double-needle vaccine immunized mouse is diluted from 1:100 and 2 times to 1:25600, and the dilution is total 9; serum samples from mice immunized with the high-dose single-needle and low-dose double-needle vaccines were diluted from 1:50 to 2-fold ratio to 1:12800 for 9 dilutions. Serum samples of low-dose single-needle vaccine immunized mice were diluted from 1:25 to 2-fold ratio to 1:6400 for 9 dilutions; serum samples from control mice were diluted 1:25, 2 fold to 1:800 for 4 dilutions.
The results of detection of BALB/C mouse neutralizing antibody are shown in Table 4-3 and FIG. 9, and the results of C57BL/6 mouse are shown in Table 4-4 and FIG. 10. Except for low-dose single-needle immunization, other immunization groups all induce a certain level of neutralizing antibodies, and high-dose double-needle immunization of two mice induces higher-titer neutralizing antibodies.
TABLE 4-3 BALB/c mouse neutralizing antibody titers
TABLE 4-4.C57BL/6 mouse neutralizing antibody Titers
Serum-free food
BALB/c&The neutralizing antibody titers of the C57BL/6 mouse serum pseudovirus assay are shown in FIG. 11: both strains of mice, following vaccine immunization, can produce neutralizing antibodies against the novel coronavirus. After high dose booster, both strains of mice developed over 1:104Titres of neutralizing antibodies, wherein BALB/c mice produce neutralizing antibody titres averaging 1:13,000; the C57BL/6 mice produced antibody titers averaging 1:25,000. In BALB/c mice, 2 times of low-dose immunization can also induce the generation of neutralizing antibodies, and the neutralizing antibodies can be stably detected; in C57BL/6 mice, high dose single needles induced neutralizing antibody titers that were superior to low dose two-needle immunizations. After the vaccine is immunized, neutralizing antibodies aiming at SARS-CoV-2 can be generated, the dosage and the immunization strategy are proper, and the generation of the neutralizing antibodies with high level can be induced.
4.6.5. detection results of neutralizing antibodies against SARS-CoV-2 plaque reduction
Samples were used for virus serum mixing at 1:50, 1:200, 1:800, 3 dilutions, respectively. The results of BALB/C mouse neutralizing antibody detection are shown in tables 4-5 and FIG. 12, and the results of C57BL/6 mouse are shown in tables 4-6 and FIG. 13. The high-dose double-needle group of two strains of mice induces high-titer neutralizing antibodies to inhibit infection of SARS-CoV-2 live virus.
TABLE 4-5 BALB/c mouse live virus neutralizing antibody titers
TABLE 4-6.C57BL/6 mouse neutralizing antibody Titers
Serum-free food
The neutralizing antibody titer of the BALB/C & C57BL/6 mouse serum live virus assay is shown in FIG. 14.
The results of the live virus plaque reduction test show that high doses of both mice strains produced nearly or more than 1:104Titres of neutralizing antibodies, wherein BALB/c mice produce neutralizing antibody titres averaging 1:9,800; the antibody titers generated by C57BL/6 mice averaged 1:12,000. The neutralizing antibody titer of most serum samples of the low-dose and high-dose single-needle immunization groups is not enough to reach half effective concentration under test dilution, but the test results show that virus infection can be partially inhibited under the low dilution, and the virus infection is obviously different from that of the control group.
4.7. Conclusion of the experiment
After mice are immunized by the novel coronavirus mRNA vaccine SW0123, specific IgG can be induced to generate, and the induced antibody has good neutralizing activity. The two immunization schemes with 30 mu g dose and 3 weeks interval can effectively induce the generation of high-titer specific antibodies, wherein the detectable antibody titer of BALB/c mice is 1:310,000 on average; the titer of antibodies detected in C57BL/6 mice averaged 1:180,000. Bound antibody titers in excess of 1:105The humoral immunity inducing ability is excellent. Two strains of mice are inAfter the vaccine is immunized, neutralizing antibodies aiming at the novel coronavirus can be generated. High dose two-needle immunization of 30. mu.g, both strains of mice produced approximately 1:104The neutralizing antibody with titer can effectively inhibit the infection of virus cell level.
Experiments prove that the SW0123 vaccine can effectively induce BALB/C and C57BL/6 mice to generate specific humoral immune response, and antigen-specific IgG has good neutralizing activity; high-dose double-needle immunization can induce strong neutralizing active antibodies in animals.
Experiment 7: evaluation of the level of antigen-specific T cell responses in mice following immunization with different doses of COVID-LPP-mRNA
7.1. Purpose of the experiment: after the mice are immunized by the COVID-LPP-mRNA, the level of cellular immune response in the mice is detected by using an ELISPOT method.
7.2, test article information: name: mRNA vaccine COVID-19-LPP-mRNA; specification: 0.5 mg/ml; the characteristics are as follows: a milky white liquid; the validity period is as follows: can be stored at 2-8 deg.C for 28 days
7.3 Experimental animals: species, strain, grade, quantity and weight, week age;
species/strain: c57BL/6 mouse, female
Grade: SPF stage
Weight: about 18-20g
The week age is as follows: 8-9 weeks.
The quarantine period is three days, and animals in the batch are quarantined by sampling in the quarantine period by animal house veterinarians. Mice were fed in IVC cages, with no more than five per cage. Environmental parameters of the animal house (411) are recorded during the rearing period. All feed and drinking water were purchased and provided with assistance from the Shanghai Square model Bioresearch center. SPF mouse feed sterilized by 60Co irradiation is provided by cooperative medical biological responsibility company Limited in Jiangsu province, and each batch of feed provides a quality detection report containing detection indexes such as nutrition, pesticides and microorganisms. Deionized water, feeding containers and bedding were autoclaved into the barrier and replaced twice a week.
7.4 Experimental reagent and consumable
0.01M PBS buffer (PH 7.4) (solibao); erythrocyte lysate (diligent kanbiol); RPMI-1640 medium (Gibco); fetal bovine serum; ELISPOT detection: elispot assay kit (Mabtech), OVA antigen (Kinsry), PMA (David); coating antigen: the extracellular domain of the S protein (Yi Qiao Shen state); a centrifuge; carbon dioxide cell culture incubator (Panasonic); ELISPOT plate reader (Germany ai Di)
7.5 Experimental methods
5.5.1 mice immunization
C57BL/6 mice were injected intramuscularly with the novel coronavirus pneumonia vaccine at different concentrations of mRNA twice, once on day 0 and day 7, and spleen cell preparation was performed 14 days after the second immunization.
5.5.2 preparation of spleen cells
Grinding spleens to prepare a single spleen cell suspension, and adding 5ml of erythrocyte lysate into each sample of spleen cells to perform erythrocyte lysis.
Then 25ml 1640 medium was added for termination, the cell suspension was filtered using a cell screen and the contaminating tissue pieces were filtered off.
The cells were centrifuged at 1500rpm for 5min, the supernatant was discarded, and 5ml of medium was added to resuspend the cells for counting.
5.5.3 antigen-specific T cell immune response detection
The counted cells were adjusted to 3 × 10E6 cells/ml.
The cell suspension was added to the assay plate and 100. mu.l of cell suspension (30 ten thousand cells) was added per well.
The cells were resuspended in a solution of the corresponding antigenic polypeptide (20. mu.g/ml) in culture medium, PMA-Ionomycin as a positive control, OVA (20. mu.g/ml) as a negative control and the cell suspension without any additional stimulus as a blank control. Mu.l of antigen dilution (concentration: 10. mu.g/ml) was added to each well, and the cells were stimulated for 24 hours.
The next day after the end of stimulation, the procedure was performed according to the kit instructions:
(1) the cell culture medium in the detection plate was discarded, washed with PBS at 200. mu.l/well for 5 times.
(2) The anti-mouse IFN-. gamma.antibody was diluted to 1. mu.g/ml, and 100. mu.l was added to each well for incubation, and incubated for 2 hours at 27 degrees in an air bath.
(3) After the incubation, the sample was washed with PBS at 200. mu.l/well for 5 times.
(4) The secondary antibody was added, diluted at a dilution of 1:1000, and 100. mu.l of the secondary antibody was added to each well for incubation, followed by incubation for 1 hour at 27 ℃ in an air bath.
(5) After the incubation, the sample was washed with PBS at 200. mu.l/well for 5 times.
(6) Color development: 100. mu.l of a developer was added to each well to develop color.
(7) And (4) terminating: and after the color development is finished, discarding the color development liquid, cleaning by using double distilled water, airing and scanning.
5.6 results of the experiment
According to the results (fig. 15A-15C), after two vaccine immunizations, the mice were blood-taken and tested, and the IgM, IgG, and IgG1 type antibodies were found to have high antibody titers, among which the IgG antibody titer was the highest. According to the results of different vaccine doses, IgM antibody titer is reduced along with the reduction of the administration dose, and IgG1 antibody titer is gradually reduced along with the reduction of the vaccine dose, but the reduction range is not significant. In addition, IgG1 compared to IgG antibody titers found IgG1 titers were lower than IgG antibody titers.
The results show (fig. 16A-16B) that COVID-LPP-mRNA was able to significantly activate antigen-specific T cell response and was dose-dependent. The results show that after the vaccine immunization, the spleen of the mice in the high dose group and the low dose group has obviously increased antigen-specific T cells. According to different dosage results, the antigen-specific T cell response intensity is gradually reduced along with the reduction of the vaccine dosage, wherein the antigen response of the 30 mu g immunization dosage group is the strongest. The COVID-19-LPP-mRNA vaccine is used for immunizing a mouse by adopting a muscle administration mode, and after entering an organism, the mRNA vaccine can activate antigen presenting cells including macrophages, dendritic cells, B lymphocytes and the like. Meanwhile, the vaccine is phagocytized by antigen presenting cells, and mRNA is released to cytoplasm through lysosome escape and is combined with ribosome to be translated into antigen protein in the cells. Subsequently, most of the antigenic proteins are degraded into antigenic polypeptides by proteasome and lysosomal degradation pathways, and a small portion of the undegraded proteins are expressed on the cell surface. The degraded antigen polypeptide is combined with MHC-I molecules and MHC-II molecules in cells and presented to the surface of the cells, and different T cells are stimulated to be activated by combining with TCR molecules on the surfaces of different subgroups of T cells. The activated antigen presenting cell stimulates an organism to generate antigen-specific CTL immune response through the interaction of MHC-I molecules and TCR on the surface of a CD 8T cell, and activates different CD 4T cell immune responses through the interaction of MHC-II molecules and TCR on the surface of a CD 4T cell. Different CD 4T cells exhibit different functions, on the one hand, capable of interacting with CD 8T cells to maintain a CTL immune response, and on the other hand, follicular helper T cells capable of interacting with germinal center B cells to promote secretion of antigen-specific high affinity antibodies by B cells.
Partial expression of antigen on the surface of antigen presenting cells (macrophages, dendritic cells) by reaction withB cell surface BCR binding activates B cells. The activated B cells are gradually differentiated and developed to form germinal center B cells, and under the interaction with follicular helper T cells activated by the same antigen, the germinal center B cells are finally differentiated to form memory B cells and plasma cells through the processes of somatic cell high-frequency mutation, antibody type conversion, high-affinity antibody maturation and the like.
According to IgM and IgG detection results, the antigen-specific IgG type antibodies in the serum of the mice are at a higher level and the antigen-specific IgM antibodies are at a lower level at the tenth day after the second immunization. Mainly, the IgM antibodies are mainly secreted by the body at the initial stage of vaccine immunization, and along with the time, the IgM antibodies are gradually converted to different types of antibodies under the interaction of the B cells and the T cells and the action of different cytokines on the B cells at the germinal center. In the later stage of immunity, the IgM antibody titer in the organism is at a lower level, mainly taking IgG type antibodies as main components.
According to the detection results of the IgG and the IgG1 antibodies, the IgG1 type antibody in the serum of the mouse is at a higher level, which is slightly lower than the total IgG antibody. The results of this experiment indicate that the IgG type antibodies in mice are mainly IgG1 antibodies. After the vaccine is immunized, the interaction between germinal center B cells and follicular helper T cells is promoted, and a large amount of interleukin-4 (IL-4) is secreted. IL-4 binds to the IL-4 receptor on the surface of B cells, and activates a downstream signal path related to the switching of the IgG1 type antibody in the B cells, thereby promoting the switching of the IgM type antibody to the IgG1 type antibody in an organism. Therefore, it can be known that the antigen-specific antibodies generated by the new crown mRNA vaccine activating body are mainly of IgG1 type, while IgG1 type antibodies have a strong effect on resisting virus infection.
According to different dosage results, the IgM type antibody secretion presents a remarkable dose-effect relationship, and the antibody titer is gradually reduced along with the gradual reduction of the vaccine dosage. The total IgG and IgG1 antibodies did not show a significant dose-effect relationship, but differences in antibody titers between the high dose and low dose groups were also seen. Among them, 30. mu.g of the administered group showed the highest antibody titer, 1. mu.g of the administered group showed the lowest antibody titer, and 7.5. mu.g was not significantly different from 15. mu.g. The difference is not obvious mainly because the test adopts the tenth day after two times of administration to detect the antibody titer, the detection time point is in the later stage of immunity, the secretion level of the IgG type antibody is in the highest stage, and the obvious difference before the strength of the immune response caused by the difference of the micro-dose is difficult to observe. Therefore, it was found that the antibody titer produced in the body tends to increase with increasing dose, and the highest antibody titer was exhibited at the highest dose.
According to the result of the antigen-specific T cell immune response, the antigen-specific T cell immune response in the mice after the vaccine immunization is obviously improved, and the dose-effect relationship is shown. This result indicates that the vaccine is phagocytized by antigen-presenting cells after entering the body, and activates the body through a series of immune responsesCD4 and CD 8T cells activate and differentiate to form effector and memory T cells. Phase of in vitro utilizationThe spleen cells were re-stimulated with the same antigen, and antigen-specific effector T cells and memory T cells were rapidly activated in a short time, and secreted corresponding cytokines (e.g., IFN-. gamma.) (FIG. 16A). According to the results of different administration doses, the T cell immune response intensity is gradually reduced along with the reduction of the dose, and the dose-effect relationship is shown. Among them, there was no significant difference between the 15. mu.g-administered group and the 7.5. mu.g-administered group, and there was no significant difference between the 1. mu.g-administered group and the 2.5. mu.g-administered group. No significant change in T cell immune response was elicited, probably due to smaller dose differences. Taken together, the vaccines are capable of activating antigen-specific T cell immune responses in vivo.
In conclusion, the COVID-19-LPP-mRNA vaccine can activate body fluid and cell immune response in an organism, stimulate the organism to generate high-titer antigen-specific IgM, IgG and IgG1 type antibodies and strong antigen-specific T cell immune response. Therefore, the COVID-19-LPP-mRNA vaccine can be considered to have better immunogenicity and immune reactivity.
And (3) test article information:
c57BL/6 mice were injected intramuscularly with COVID-19-LPP-mRNA at different concentrations twice, once on day 0 and day 7, and blood was collected 10 days after the second immunization and centrifuged to obtain serum, the specific procedures are reported in "COVID-19-LPP-mRNA immunized C57BL/6 mice". In the test, the serum of mice in three dose groups of 30 mug, 7.5 mug and 1 mug is selected for detecting the neutralizing antibody.
Test reagents: huh-7cell (from Michem institute); pseudovirus (from the middle school) DMEM complete medium (Gibco): 1% double antibody (Gibco), 10% fbs (hyclone) Luciferase detection kit (PerkinElmer) PBS (solibao); 0.25% pancreatin (Gibco)
Test consumables: t75 cell culture flasks (Thermo); 96-well white cell culture plates (Corning); 15/50ml centrifuge tubes (Corning); 3.3 testing the instrument; inverted microscopes (Leica); CO22Incubator (Panasonic) microplate reader (BioTek)
Test procedure
1. Serum sample dilution: serum samples were diluted with complete medium at 20X, 60X, 180X, 540X,1620X, 4860X.
2. Virus was diluted to 2 x 10 using complete medium4TCID50/ml。
3. 100ul of diluted serum and 50ul of virus diluent were added to each well of the test group; blank control 150ul complete medium; the virus control group was added with 100ul complete medium, 50ul virus dilution.
4. 37℃,5%CO2And incubated for 1 hour.
Adding pancreatin to Huh-7 cells for 1 minute, adding complete medium for neutralization, centrifuging at 210g for 5 minutes, suspending the cells using the complete medium, counting, adjusting the cell concentration to 2 x 105One per ml.
6. After 1 hour incubation of serum and pseudovirus, cells were added to 96-well plates at 100 ul/well, 37 ℃, 5% CO2Culturing for 20-28 hr.
7. Cell supernatants were aspirated and washed once with PBS. After washing, 100ul PBS per well was added.
8. Then 100ul of luciferase assay reagent was added. The reaction was carried out at room temperature for 2min in the dark.
9. After the reaction was completed, the fluorescence value was detected by a microplate reader.
10. Calculation of inhibition and median inhibition dilution ID50. Inhibition rate [ 1- (sample group mean-blank control group mean)/(virus group mean-blank control group mean) ]. 100%. half inhibition dilution ID was calculated using Reed-Muench from inhibition rate data50The specific calculation formula is as follows:
ID50=10lg(X)+lg(1/K)×(0.5-B)/(A-B)
a: inhibition of wells above 50% fluorescence value ratio; b: inhibition of wells at a fluorescence value ratio of less than 50%; x: dilution factor lower than 50% fluorescence value ratio; k: serial dilution factor.
4 results of the test
5.1 inhibition of pseudovirus-infected cells by sera from mice in different dose groups (FIG. 17)
5.2 different dose groupsDilution of suppression of half of mouse serum (ID)50)
By intramuscular administration, mice were bled 10 days after secondary immunization with the COVID-19-LPP-mRNA vaccine and the serum neutralizing antibody levels were measured using pseudoviruses. The result shows that the mouse serum generates a high-level neutralizing antibody after secondary immunization, can effectively neutralize the pseudovirus constructed by SARS-CoV-2S protein, has stronger inhibition effect on pseudovirus infected cells, and presents an obvious dose-effect relationship. Low dose group (1. mu.g/mouse) mouse serum neutralizing antibody half inhibitory dilution ID50Less than 20; medium dose group (7.5. mu.g/mouse) divided by one mouse serum ID50Less than 20, remaining mouse serum ID50An average value of 990; high dose group (30. mu.g/mouse) serum ID50The average value was 2918. The results show that COVID-19-LPP-mRNA can induce high-level neutralizing antibody after being immunized twice, and infection of pseudoviruses can be effectively inhibited.
The neutralizing antibody is an important index for measuring the immune protection effect of the vaccine and is also an important basis for the evaluation and quality control of the vaccine. The in vitro neutralizing antibody detection by using the live virus has high requirements on laboratory grade, needs to be carried out in a biosafety three-grade laboratory, and brings great difficulty to research. Therefore, researchers can also perform the detection of the neutralizing antibody by using a pseudovirus system, wherein the pseudovirus infected cells are constructed by using a pseudovirus containing the spinous process protein (S protein) of the target virus to infect susceptible cells so as to simulate the infection and replication process of the virus, and a reporter gene such as Luciferase (Luciferase) with high sensitivity and easy detection is usually introduced to optimize the detection system. The test uses a pseudovirus containing Spike protein (S) of SARS-CoV-2 virus and a Luciferase reporter gene to detect the serum neutralizing antibody titer of the immunized mice.
The basic principle of the Luciferase reporter gene pseudovirus detection system is as follows: after the pseudovirus infects susceptible cell Huh-7cell, the luciferase can be translated, and the luciferase is in Mg2+、ATP、O2Under the participation of (2), the oxidation decarboxylation of the fluorescein (D-luciferin) is catalyzed, the activated oxyfluorescein is generated, photons are emitted, fluorescence of 550-580 nm is generated, the fluorescence intensity is detected by using an enzyme-labeling instrument, and the obtained detection value can reflect the infection efficiency of the pseudovirus to cells.
In the experiment, a COVID-19-LPP-mRNA vaccine which codes SARS-CoV-2 virus S protein antigen is used for immunizing a mouse, and a neutralizing antibody aiming at SARS-CoV-2 virus S protein is generated in the mouse. After the immune mouse serum is incubated with the pseudovirus, the neutralizing antibody in the serum can be combined with the S protein on the pseudovirus particles to prevent the combination of the S protein and the receptor ACE2, so that the pseudovirus is prevented from entering a host cell, and the expression of luciferase is reduced. The method comprises the steps of setting a series of concentration gradients to dilute mouse serum, incubating the diluted mouse serum with pseudoviruses, adding the pseudoviruses into susceptible cells Huh-7, culturing for 20-28 hours, and detecting the infection efficiency of the viruses on the cells by using a luciferase detection kit. Calculating the inhibition rate of neutralizing antibody to pseudovirus infection, and calculating ID by using Reed-Muench according to the inhibition rate data50。
The COVID-19-LPP-mRNA vaccine can stimulate the organism to generate high-level neutralizing antibodies and prevent pseudovirus from infecting cells, and the COVID-19-LPP-mRNA vaccine has better prevention effect on SARS-CoV-2 virus infection. And through analyzing the neutralizing antibody levels of mice of three different dose groups, the COVID-19-LPP-mRNA is found to have a remarkable dose-effect relationship, which provides a reference for subsequent challenge tests and clinical application.
Experiment 9: evaluation of protective Effect of COVID-19-LPP-mRNA immunized on mice against SARS-CoV-2 infection
Purpose of the experiment: a mouse model transduced by Ad-hACE2 was infected with SARS-CoV-2 to evaluate the protective effect of the novel coronavirus mRNA vaccine.
Information of test article
Name: mRNA vaccine COVID-19-LPP-mRNA
A provider: sciao (Shanghai) Biotech Co., Ltd
Specification: 0.5mg/ml
The characteristics are as follows: milky white liquid
The validity period is as follows: can be stored at 2-8 deg.C for 28 days
Laboratory animal
Name: Ad-hACE2 transduced mice
Quantity: BALB/C mice 12; c57BL/6 mice 19
Sex: female
Age: 18-20 weeks old
Animal sources: witonglihua Co Ltd
Animal production license number: SCXK (Jing) 2016-
Experimental reagent and consumable
Screw port 1.5(SCT-150-C-S) and 2.0ml (SCT-200-C-S) EP tube; pentobarbital sodium anesthetic; 4% paraformaldehyde; DMEM medium; 75% ethanol; sterile PBS; 1ml pipette, 200ul pipette;
one metal bath can be put into the spiral pipe; foam boxes for 50ml tubes, foam boxes for 15ml tubes, 2 each. Body weight record form, lung weight record form. 200ul of gun heads with filter elements and 2 boxes; 1ml filter-element-contained gun head 1 box. A grinder; a high speed centrifuge in the core region; 1ml syringe; anatomical plate-foam; 3 sets of sterile scissors and tweezers;
experimental methods
Mouse grouping condition and immunization method
In this experiment, we used BALB/C and C57BL/6 two mice to jointly complete the immunogenicity testing test, using 2 immunization doses: (high dose) 30 μ g/3 μ g (low dose); 2 immune cycles: single needle immunization (day 0 dosing) and double needle immunization ( day 0, 21 dosing), for a total of 8 groups.
The vaccine was diluted to a defined concentration in PBS and injected intramuscularly at the thigh site in a volume of 30 μ l per side, bilaterally.
The specific groupings and experimental dates are shown in the following table:
note: c: c57 BL/6; b: Balb/C; DD is double-needle immunization; SD: single-needle immunization; LD: low dose; HD: high dose
Transduction of Ad5-hACE2
5 days before challenge, 45. mu.l of the solution containing 2.5X 10 cells was subjected to mild anesthesia8The mouse respiratory system was transfected with the DMEM medium of pfu Ad5-hACE2 by nasal drip. The mice were then transferred to the biosafety laboratory ABSL3 and were kept for 5 days for SARS-CoV-2 infection experiments.
Virus challenge experiment
Day 0: SARS-CoV-2 infection
(1) Weighing: after confirming that Ad5-hACE2 transfected mice were in good condition, body weights were measured.
(2) Anesthesia: anesthesia was performed with sodium pentobarbital at a dose of 60 mg/Kg.
(3) Nasal drop infection: after deep anesthesia, the mice will contain 5X 105TCID50The mice were infected with 50. mu.l nasal drops of virus.
Day 1-3: observing, weighing and preparing articles
(1) Observing and weighing: observing mice every day, recording body weight condition, and continuously observing for 3 days
(2) The following experimental supplies were prepared according to the number of mice and experimental groups:
1XPBS buffer: 1000ml, high pressure ready for use: 500ml was separated and double-resistant PS (10000U) (5ml +500ml) was added at a ratio of 1: 100.
A dissecting instrument: 2 sets of instruments, each set of instruments comprising: 2 pairs of elbow tweezers, tooth tweezers, small scissors, flat-end tweezers, elbow scissors and surgical tweezers are used after high pressure.
Mouse blood, dissection and tissue extraction organ
(1) Blood sampling and sacrifice: 3 mice were collected from each group, blood was collected from the orbit in a biosafety cabinet, and the mice were euthanized by dislocation of the cervical vertebrae.
(2) Dissection and lung harvest: the mice were sprayed with 75% ethanol, fixed with the abdomen facing up, and dissected in a biosafety cabinet. The left hand takes the elbow forceps to clamp the skin of the abdomen, the right hand shears off subcutaneous tissues with scissors to strip the muscles, and the skin is sheared forwards to the neck; turning over the skin to expose the chest, cutting the two ribs with a pair of sterilized scissors, turning the sternum and the ribs upwards, and putting the cut sternum and ribs into the joint of the lung and trachea with curved ophthalmic forceps to hold out the whole lung.
(4) And (3) lung tissue treatment:
(A) left lung: the cells were placed in 2ml PBS (PS +), washed 2 times and then directly soaked in 10ml 4% paraformaldehyde for pathological sectioning and histochemistry. The specimen is subjected to conventional tissue treatment, paraffin embedding, sectioning, H.E. staining, sectioning and digital image acquisition.
(B) Right lung: the weight record, placed in 2ml PBS (PS +), after 2 washes, according to 1:10 ~ 1:20 volumes PBS (heavy suspension volume is not less than 300ul, if too small, scale up 1:30 heavy suspension), transferred to the presence of zirconium beads in 1.5ml spiral tube. 70 frozen overnight, the next day lung homogenate was prepared (K4 laboratory).
(5) Sample transfer: all samples were placed in sealed cryovials and containers, and the container surfaces were thoroughly sterilized before transfer to the K4 laboratory.
Homogenization treatment of lung tissue and measurement of virus titer
(1) Lung tissue homogenization: the lung tissue was removed from the-70 freezer and homogenized after digestion.
(2) Centrifuging: the homogenate was centrifuged at 4000rpm for 5 minutes at 4 ℃ and the supernatant was transferred to a new 1.5ml screw-top EP tube.
(3) Lung tissue homogenate nucleic acid copy number assay (2020.5.12): nucleic acid was extracted from 100. mu.l of the supernatant, and the number of copies of the virus in lung tissue was determined by RT-PCR.
(4) Lung tissue homogenate TCID50Titer determination (2020.5.12-5.15): 100. mu.l of the supernatant was collected and diluted 10-fold from 10-1 to give 4 dilutions (10 dilutions)-1,10-2,10-3,10-4)100 ul of Vero cells prepared in advance are infected, 8 multiple holes are made for each dilution, and TCID is observed and judged after 72-96 h50。
Viral nucleic acid extraction and real-time qpcr detection
200 mul of mouse lung suspension is taken from a biosafety cabinet and added into lysis solution of an Ex-DNA/RNA virus (CDC) nucleic acid extraction kit (T104, Xian Tianlong science and technology limited company) for lysis, after complete inactivation, nucleic acid is extracted according to the instructions of a full-automatic rotary nucleic acid extractor (GeneRotex 96, Xian Tianlong science and technology limited company), and finally 80 mul of eluent is used for elution. A nucleic acid preparation system with 5 mul is taken to perform real-time fluorescence RT-PCR reaction on an ABI Q5 fluorescence quantitative PCR instrument. Forward primer (F): CCCTGTGGGTTTTACACTTAA, respectively; reverse primer (R): ACGATTGTGCATCAGCTGA, respectively; fluorescent probe (P):
5'-FAM-CCGTCTGCGGTATGTGGAAAGGTTATGG-BHQ1-3', the reaction system is as follows: mu.L of 2 Xone Step SYBR RT-PCR Buffer III, 0.5. mu.L Takara Ex Taq HS, 0.5. mu.L of L PrimeScript RT Enzyme Mix II, 1. mu.L of the upstream primer, 1. mu.L of the downstream primer, 1. mu.L of the probe, 5. mu.L of the RNA template, and made up to 25. mu.L with sterile double distilled water. The reaction parameters are as follows: circulating at 42 deg.C for 5min and 95 deg.C for 10 s; circulating for 40 times at 95 ℃ for 10s and 60 ℃ for 30s, and collecting fluorescence signals after extension.
6.6 results of the experiment
6.6.1 mouse body weight: the raw data of the daily mouse body weight are shown in Table 6-1. The body weight of the mice on the first day was used as an initial body weight, and the body weight change tendency of the mice per day was analyzed. The results for Balb/C mice are shown in Table 6-1 and FIG. 18. The Balb/C mice are infected with the novel coronavirus on the 5 th day after being transduced with Ad-hACE2, the condition is good after 4 days of continuous observation, and the weight is not obviously reduced. The results of the C57 mice are shown in Table 6-2 and FIG. 19. The C57 mouse was infected with the novel coronavirus on day 5 after transducing Ad-hACE2, and the condition was good and the body weight was not significantly reduced after 4 days of continuous observation.
TABLE 6-1 Balb/C mice body weight raw data
TABLE 6-2 initial data of body weight of C57 mice
6.6.2 mouse lung tissue viral load titration: lung tissues taken out of the dissections were subjected to weighing, grinding, RNA extraction and quantitative PCR analysis, and the original data of Ct values obtained by the weight of the lung tissues used for grinding and quantitative PCR and the results of the measurement of TCID50 are shown in tables 6-3, tables 6-4 and FIG. 20, FIG. 21. Balb/C mice are infected with a novel coronavirus after being transduced with Ad-hACE2, and the replication and proliferation of the virus in the lung can be detected (average Copies/g is 10 ═ 10)9.12; logTCID504.75 parts per ml). The high-dose mRNA vaccine immunization group can effectively protect Balb/C against the attack of new coronavirus, and the average Copies/g of the double-needle immunization is 107.84;logTCID502.54/ml, statistically different from the control group (tables 6-3, fig. 20).
C57 mice were infected with the novel coronavirus after transduction of Ad-hACE2, and replication and proliferation of the virus in the lung were detected (mean Copies/g 10 ═ 10)9.03;logTCID504.06/ml). The high-dose mRNA vaccine immunization group can effectively protect C57 mice from being attacked by new coronavirus, and the single-needle immunization can ensure that the average Copies/g is 106.67;logTCID502.79 parts per ml; mean Copies/g of double-needle immunization is 104.56;logTCID501.96/ml, statistically different from the control group (tables 6-4, fig. 21).
TABLE 6-3 Balb/C mice Lung tissue viral load titration related raw data
TABLE 6-4C 57 mouse Lung tissue viral load titration related raw data
6.6.3 pathological mechanism of lung tissue
Lungs of 3 mice were taken from each of the immunized group and the control group, and embedded in paraffin for tissue section. Then staining was performed with hematoxin and eosin (H & E). FIGS. 22 to 23 show the results of Balb/C groups of mice, and FIGS. 6 to 6 show the results of C57 groups of mice. Control group: pulmonary venulitis and interstitial pneumonia. Large-area alveolar rupture of lung, infiltration of a large amount of inflammatory cells, serious lung pathology and inflammatory exudation in alveolar cavity. Vaccine groups: pulmonary venulitis and interstitial pneumonia. The alveoli were partially ruptured and partially infiltrated with inflammatory cells. Only partial alveolar fusion, small thickening of alveolar walls, and small infiltration of inflammatory cells.
6.7 conclusion of the experiment
The body weight of the Balb/C mouse control group did not drop significantly after challenge. The lung tissue virus titer RNA copy number reaches 10 per gram Copies/g9.12Viral TCID50Up to logTCID per gram504.75 parts per ml. The lung lesions are obvious and severe interstitial pneumonia exists.
After the Balb/C mice immunization group is attacked, the weight of the mice in the high-dose mRNA vaccine 2-needle immunization group is not obviously reduced. Lung tissue virus titer RNA copy number of 10 per gram Copies/g7.84Average decrease by a factor of 1.28Log (19.1 times); virus TCID50Titre of logTCID per gram50On average, 2.54/ml decreased by a factor of 2.21Log (161 times). The lung lesions are mild with mild interstitial pneumonia. The mRNA vaccine high-dose two-needle vaccine immunization is prompted to have an obvious protective effect.
There was no significant weight loss after challenge in the control group of C57 mice. The lung tissue virus titer RNA copy number reaches 10 per gram Copies/g9.03Virus TCID50Up to logTCID per gram504.06/ml. The lung has obvious pathological changes and severe interstitial pneumonia.
After the C57 mice immunization group is attacked, the weight of the mice in the high-dose mRNA vaccine 2-needle immunization group is not obviously reduced. Lung tissue virus titer RNA copy number of 10 per gram Copies/g4.56Average 4.47Log times (29211 times) lower; virus TCID50Titre of logTCID per gram501.96 on averageReduced by 2.1Log times (120 times). The lung lesions are mild with mild interstitial pneumonia.
The mRNA vaccine high-dose two-needle vaccine immunization is prompted to have an obvious protective effect.
Experiment 10: verification of anti-novel coronavirus infection effect of rhesus monkey after COVID-19-LPP-mRNA immunization
Purpose of the experiment: the immunogenicity in rhesus monkeys after immunization of novel coronavirus mRNA vaccines (COVID-19-LPP-mRNA) and the protective effect after challenge of the novel coronavirus are evaluated by using a P3/P4 laboratory of Kunming high-grade biosafety primate animal experiment center of national institute of medical biology of Chinese medical academy of sciences.
And (3) test article information: name: mRNA vaccine COVID-19-LPP-mRNA; a provider: smi (shanghai) biotechnology limited; specification: 0.2 mg/ml; the characteristics are as follows: a milky white liquid; the validity period is as follows: can be stored at 2-8 deg.C for 28 days.
Experimental animals: 7 Male Experimental rhesus monkeys were provided by the institute of medical biology of Chinese academy of medicine (laboratory animal production license: SCXK (Dian) K2015-0004), aged 4 years, and divided into 2 groups, PBS group (3), and vaccine group (4). Transferring the strain to a P4 large animal laboratory for adaptive breeding 3 days before the challenge. All animal experiments are carried out according to biological safety operation regulations and animal ethics, and the animals are given humanistic care to ensure animal welfare. The experimental operation is carried out under the anesthesia state, and the biological safety and animal ethics criteria can be considered. The animal experiment passes the examination and approval of the ethical committee of experimental animals of the institute of medical and biology of the Chinese medical science institute, and the approval number is as follows: DWSP 202004042.
Experimental strains: the novel coronavirus (SARS-CoV-2) is originated from the Guangdong province disease prevention and control center, and one strain is named as GD108# strain. The introduction and transportation of the virus by the national Kunming high-grade biosafety experiment center obtain the approval of the national Weijian Commission, and the virus is amplified and stored in the center.
Reagent for experiment
Laboratory apparatus
Experimental methods
0.7.1 vaccine immunization
Monkeys are taken under the same feeding condition, grouped according to grouping requirements, and are immunized.
Experimental groups | Required amount of | |
Vaccine groups: COVID-19-LPP- | Male sex | 4 |
PBS injection group (model control group) | |
Primary immunization: day 0; and (3) secondary immunization: day 14; three times of immunization: day 33;
10.7.2 immunization mode and dosage
The immunization mode comprises the following steps: intramuscular injection is carried out, and two-point injection is carried out on the left arm and the right arm;
dosage: adjuvant-free vaccine group: 200 μ g of COVID-19-LPP-mRNA;
volume: 1.0 mL;
concentration: 200 mu g/mL;
10.7.3 culture, concentration and titration of SARS-CoV-2 virus
SARS-CoV-2 virus has better adaptability in VERO-E6 cell, after 20T 225 cell culture bottles are inoculated with virus, obvious CPE is observed by microscope, virus is collected for about 72h and frozen at-80 ℃. Slowly thawing at 4 ℃ the next day, centrifuging, taking supernatant, performing ultrafiltration concentration, filtering for 3 times by PBS, and eluting virus with a total volume of 200mL to obtain 200mL virus concentrate. The virus titer was then determined using plaque assay.
10.7.4 monkey toxin counteracting and detecting method
1) And (3) performing toxicity counteracting in a nasal drop and tracheal injection mode 15 days after the third immunization. GD108# strain (titer 1X 10) was used6Pfu/mL), and the virus is attacked by nasal drip and tracheal injection inoculation of 500 μ L each, and the toxic attacking amount of each monkey is 1 × 106 Pfu.
2) And (3) weight detection: and (3) starting 3 days before the toxin is attacked, carrying out weight detection every day, and carrying out weight detection every day after the toxin is attacked.
3) And (3) detecting body temperature change: the body temperature is tested by using the electronic body temperature measuring instrument, and the test part is an anus. Before attacking, each monkey is subjected to body temperature detection, and data are recorded. After the challenge, the body temperature of the monkeys was monitored every day, and the body temperature change data was recorded.
4) Sample treatment: before and after challenge, animals are anesthetized on days 1, 3, 5 and 7 after challenge, and nasal swabs, pharyngeal swabs and anal swabs are collected. The swab was lysed with 800. mu.L Trizol, 400. mu.L of the extracted RNA template was washed with 50. mu.L of water to prepare an RNA template, which was stored at-80 ℃ for use in the one-step method of qRT-PCR. At the time of dissection, about 50mg of lung tissue per leaf of the animal was taken, homogenized with 500. mu.L of Trizol, and 300. mu.L of the extracted RNA template was taken, washed with 50. mu.L of water to prepare an RNA template, and stored at-80 ℃ for use. For subsequent real-time qRT-PCR analysis of viral load.
5) On day 7 post challenge, lung samples were collected using bronchoalveolar lavage.
6) The lungs of the monkeys were analyzed imagewise using X-rays.
7) And 7 days after the toxic materials are attacked, dissecting and observing the general pathological changes of the lung, and performing virus load detection and tissue section HE staining diagnosis on the lung (left-upper middle lower part, right-upper middle lower part), trachea and bronchus respectively, and performing pathological detection on lung tissues.
10.7.5 viral load detection
Viral genomic rna (grna) was determined using quantitative real-time reverse transcription PCR (qRT-PCR). Viral load amounts of lung tissue, throat swab, anal swab, nasal swab, etc. were determined using qRT-PCR. Primer and probe sequences were derived from the N gene, referenced to sequences recommended by WHO and CDC in china. Forward direction: 5'-GGGGAACTTCTCCTGCTAGAAT-3' the flow of the air in the air conditioner,
and (3) reversing: 5'-CAGACATTTTGCTCTCAAGCTG-3' the flow of the air in the air conditioner,
and (3) probe: 5'-FAMTTGCTGCTGCTTGACAGATT-TAMRA-3'
10.7.6 determination of virus neutralization potency of rhesus monkey immune serum
Serum 0dpi before challenge (45 days after immunization) was subjected to SARS-CoV-2 live virus neutralization test with VeroE6 cells, and antibody neutralizing antibody titer of the mRNA vaccine of the novel coronary pneumonia was preliminarily evaluated by CPE method. The virus titer of the neutralizing antibody in the serum is detected, the corresponding SARS-CoV-2 virus infection is carried out on VEROE6 cells according to different serum dilution ratios and with 0.05MOI as a standard, and the titer of the neutralizing antibody in the serum is judged by cell CPE after 72 h. Detection of neutralizing antibody: the neutralizing antibodies of the immune serum are determined by an in vitro euvirus neutralization method.
10.7.7 pathological analysis
Collecting the organs of the whole body tissue to perform the tissue tropism and pathological analysis of the novel coronavirus. After the animals were euthanized, lung tissues of each lobe (6 lobes in total for the left and right lungs, frontal lobe of right lung was too small and was not analyzed for material drawing) were collected and formalin-fixed for histological observation. Histopathological changes of the lung were observed under a microscope, double blind by two pathologists. And (5) evaluating the vaccine effect.
10.8 results of the experiment
10.8.1 neutralizing titer of rhesus monkey immune serum virus
The neutralizing titer of the rhesus monkey immune serum virus is shown in Table 7-1, and as can be seen from Table 7-1, the neutralizing titer is not detected in the PBS group during the challenge, and the neutralizing titers of the monkeys in the vaccine group are 16249(1:16), 16175(1:8), 16145(1:64) and 16045(1:8), respectively.
TABLE 7-1 rhesus monkey immune serum Virus neutralizing antibody titers
7.8.2 Experimental monkey Change in viral load after infection with SARS-CoV-2
7.8.2.1 viral load in Lung tissue
The results of the viral load detection in lung tissue after experimental monkey infection with SARS-CoV-2 are shown in FIG. 24(gRNA detection). As can be seen in figure 24, the mean viral load vaccine group in trachea decreased by 3 log values compared to the PBS group after euthanasia of animals on day 7 post challenge; none of the 4 animals immunized in the bronchi detected viral load; gRNA was not detected in all 6 lung tissues of 4 animals in the vaccine group. High levels of gRNA were detected in the multilobal lung tissue of all animals in the PBS group.
After infection, alveolar lavage fluid from the left and right lungs was used separately for each animal to determine viral gRNA content, as shown in fig. 25. None of the left alveolar lavage samples from 4 animals in the vaccine group detected virus; whereas high levels of viral load were detected in all the left alveolar lavage samples of 3 animals in the model group.
10.8.2.2 nasal swab viral load
In the nasal swab viral load assay, all experimental monkeys detected a higher viral load on day 1 post-virus inoculation, and the viral load in the initial vaccine group was significantly reduced by at least 3 log values compared to the PBS group on day 3 (see figure 26). The viral load of the PBS group was kept at a high level all the time. At day 3, the viral load of one animal in the vaccine group was 0, although a small rebound was small at day 5, but again 0 in the day 7 test. On day 7, the mean viral load was reduced by 3.3 log values for the vaccine group compared to the model group.
7.8.2.3 pharyngeal swab viral load
The results of the viral load detection in pharyngeal swabs after experimental monkey infection with SARS-CoV-2 are shown in FIG. 27(gRNA detection). As can be seen from fig. 27, grnas were detected in each experimental group starting on day 1 after challenge. From day 3 post challenge, vaccine immunization groups were all lower than PBS. The viral load was 0 in 3 of the 4 animals in the vaccine group on day 7, and the PBS group still had a higher level of viral load.
7.8.3 pathological changes
7.8.3.1 pathological analysis seven days after challenge, lung (left and right lung are upper, middle and lower leaves and total 6 leaves) tissues were collected after euthanasia of each group of rhesus monkeys and used for histological observation after formalin fixation. After a strict procedure for preparation of pathological tissue sections, the histopathological changes of the lung were observed under a microscope, double-blind by two pathologists.
7.8.3.2 assessment of lung tissue lesions
Lung tissues of different parts are fixed by paraformaldehyde, embedded by paraffin and stained by HE, and histopathological changes of the lung are observed under a microscope.
The results of the comprehensive evaluation of monkey 6-lobe lung in PBS group were: local thickening and bleeding of lung septum, lymphocyte nodules, local thickening of blood vessel wall, thrombus formation in cavity, hematocytic exudate in tracheal lumen, local carbon terminal deposition and other pathological changes.
The results of the comprehensive evaluation of monkey 6 leaf lung in the vaccine group were: the alveolar structure is relatively intact, the pulmonary septum is slightly thickened and slightly bleeds, the focal dust cells are distributed, and a small amount of inflammatory cells infiltrate.
7.8.3.2 Lung tissue pathology score
All lung tissue sections were stained with hematoxylin-eosin (H & E) (Bar value represents 100 μm) rhesus lung inflammation, lung structural changes and bleeding were graded according to the method reported in the literature (Liu L, et al. anti-spike IgG mice lung cancer lung not in therapy by y skin with a large porous stress reduction, SARS-CoV infection. JCI insight.2019; 4(4): E123158), and the scoring criteria for each index are given in the table below. The lung histopathology evaluation of this batch of experiments was scored against the scoring criteria table.
Rhesus monkey lung pathological change scoring table
(see: Liu L, et al. JCI insight.2019; 4(4): e123158)
Grading pathological slices of each lobe lung of each monkey lung tissue pathology according to a grading table, firstly randomly selecting at least 5 visual fields for grading each rhesus monkey lung tissue (6 lobe lungs in total, namely, upper left, middle left, lower left, upper right, middle right and lower right), wherein the average number of pathological scores of all the lobe lungs is the comprehensive pathological score result of the whole lung of the monkey, and the comprehensive pathological score result of the lung of each monkey in each group is shown in the statistical table. The results indicated that the lung tissue composite pathology scores for the vaccine group were all significantly lower than those for the PBS group (see table below and figures 28-34). The mean value of the lung pathological damage scores of the animals in the PBS model control group is 6.28 points, and the mean value of the lung pathological damage scores of the animals in the vaccine group is 2.04 points. The result shows that the vaccine has obvious protective effect on the lung tissue damage of rhesus monkeys after immunization.
Statistic of pathological scoring of lung tissue of each lung lobe of rhesus monkey
7.8 conclusion of the experiment
No viral load was detected in the experimental monkey pharyngeal swabs of the vaccine group (3/3) on day 7 post challenge, but the PBS group (3/3) still had viral loads above 5 log values; nasal swabs of the vaccine group significantly reduced the viral load by 3.3 log values compared to the PBS group. Thus, the vaccine can effectively eliminate SARS-CoV-2. On day 7 after challenge, no viral load was detected in both bronchial and left lower lung lavage of vaccinated animals; 3/4 Experimental monkeys showed no detectable viral load in their lungs. The vaccine has the function of eliminating SARS-CoV-2 in lung.
Example 11: screening experiments for UTR sequences
In order to obtain better UTR sequences on the basis of optimizing the sequences, the UTR sequences are screened, and a plurality of UTR sequence pairs used in the invention are obtained through screening of the UTR sequences. The screening was carried out by selecting the ORF sequences of NDA Nos. 1 and 9, and then, by transcription, the sequences were ligated to the 5-terminal UTR sequence, the 3-terminal 3-UTR sequence, and the 3-terminal PloyA sequence, respectively, which were not modified with nucleic acids.
The RNA of the sequences is used for liposome encapsulation, and the specific steps are as follows: an appropriate amount of lipid solution (ionized lipid MC3, DSPC, cholesterol, mPEG2000-DMG prepared as 10mg/ml lipid solution at a molar ratio of 50: 10: 38.5: 1.5) was mixed with eGFP-mRNA (dissolved in 1mM citric acid-sodium citrate buffer pH 6.4) at a mixing flow rate of 12, and the fixed mixing ratio was 3(mRNA solution): 1 (lipid solution), fixed at 37 ℃, to give lipid nanoparticles with a particle size of 90.6 ± 5.4 nanometers (nm) as measured.
Then, in vitro cell experiments were performed in the same manner as in example 2, and the control of blank experiments using UTR-free sequences and PBS was found to improve the expression level of RNA with UTR sequences having the following sequences. UTR pairs are paired one by one according to the number, and a UTR-1 at the 5 'end and a UTR sequence at the 3' end are used as a pair.
5' UTR sequence
>5’UTR-1(SEQ NO:36-1)
GTCTCAGTCGCCGCTGCCAGCTCTCGCACTCTGTTCTTCCGCCGCTCCGCCGTCG CGTTTCTCTGCCGGTCGCA
>5’UTR-2(SEQ NO:36-2)
ACCCGGCGCTCCATTAAATAGCCGTAGACGGAACTTCGCCTTTCTCTCGGCCTTA GCGCCATTTTTTTGGAAACCTCTGCGCC
>5’UTR-3(SEQ NO:36-3)
CTCTCTTCCACAGGAGGCCTACACGCCGCCGCTTGTGCTGCAGCC
>5’UTR-4(SEQ NO:36-4)
GGGACATTTGCTTCTGACACAACTGTGTTCACTAGCAACCTCAAACAGACACC
>5’UTR-5(SEQ NO:36-5)
GGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAATATAAGAGCCACC
>5’UTR-6(SEQ NO:36-6)
CCCCCCGAGCGCCGCTCCGGCTGCACCGCGCTCGCTCCGAGTTTCAGGCTCGTG CTAAGCTAGCGCCGTCGTCGTCTCCCTTCAGTCGCCATC
>5’UTR-7(SEQ NO:36-7)
CTTTCCGGCGGTGACGACCTACGCACACGAGAAC
>5’UTR-8(SEQ NO:36-8)
CGCCTGGCCGGCGGGCTGAGGCGTACGGGTCGCACGCAGCGCC
>5’UTR-9(SEQ NO:36-9)
CGCTCTTATTGGCCAGGGGACGGTAGCTGCAGGACTCTGCTCTCCTGCGGCC
>5’UTR-10(SEQ NO:36-10)
TTCCATTTGGCTGCAGCTTCTGGAGGGAGCCGACAGGAGACGTGGGGAGACG
>5’UTR-11(SEQ NO:36-11)
GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACC
>5’UTR-12(SEQ NO:36-12)
ACATTTGCTTCTGACACAACTGTGTTCACTAGCAACCTCAAACAGACACC
The sequence of the 3' UTR sequence is as follows:
>3’UTR-1(SEQ NO:37-1)
GCTCGCTTTCTTGCTGTCCAATTTCTATTAAAGGTTCCTTTGTTCCCTAAGTCCAA CTACTAAACTGGGGGATATTATGAAGGGCCTTGAGCATCTGGATTCTGCCTAATA AAAAACATTTATTTTCATTGC
>3’UTR-2(SEQ NO:37-2)
ATGGAAGCATTAATTGTTTTGAACATGTAAATATAAATCTGTCAGCCACTACAGC CATCAAAAGAGAGCATCTGGAAGAACAGCCAGCTTGGAAGTTTTACAGCAATAA TGTTGCAGTGGAATATTATTTGTAGTTAAGGTCATCCTCCTCCCCTTTCTGTTTTTT TAAATCAAGAACTACGTTCTGCCCCTCTCTTGGGCTTCAGAAGCATCTAAGAAA AGCAGTCATCAATTATAATTAACTTTCAAAGGGCAAGTCAGAAGTTGTTTATAAA TTACAAAATAAAGGCATATTATGAACTCTTA
>3’UTR-3(SEQ NO:37-3)
GAAAAGACTTCTTCCATCAAGCTTAATTGTTTTGTTATTCATTTAATGACTTTCCC TGCTGTTACCTAATTACAAATTGGATGGAACTGTGTTTTTTTCTGCTTTGTTTTTT CAGTTTGCTGTTTCTGTAGCCATATTGTATTCTGTGTCAAATAAAGTCCAGTTGGA TTCTGGAA
>3’UTR-4(SEQ NO:37-4)
CAAATGTGGCAATTATTTTGGATCTATCACCTGTCATCATAACTGGCTTCTGCTTG TCATCCACACAACACCAGGACTTAAGACAAATGGGACTGATGTCATCTTGAGCT CTTCATTTATTTTGACTGTGATTTATTTGGAGTGGAGGCATTGTTTTTAAGAAAAA CATGTCATGTAGGTTGTCTAAAAATAAAATGCATTTAAACTCATTTGAGAG
>3’UTR-5(SEQ NO:37-5)
AAGCACTCTGAGTCAAGATGAGTGGGAAACCATCTCAATAAACACATTTTGGAT AAATCCTG
>3’UTR-6(SEQ NO:37-6)
GCGCTGGGCTGTTTTAGTGCCAGGCTGCGGTGGGCAGCCATGAGAACAAAACC TCTTCTGTATTTTTTTTTTCCATTAGTAAAACACAAGACTTCAGATTCAGCCGAAT TGTGGTGTCTTACAAGGCAGGCCTTTCCTACAGGGGGTGGAGAGACCAGCCTTT CTTCCTTTGGTAGGAATGGCCTGAGTTGGCGTTGTGGGCAGGCTACTGGTTTGTA TGATGTATTAGTAGAGCAACCCATTAATCTTTTGTAGTTTGTATTAAACTTGAACT GAGACCTTGATGAGTCTTTA
>3’UTR-7(SEQ NO:37-7)
GAAAAATGAAAGGAAGTTCTGCTGTCAGAGGCAAAACATCTGTTTATCATAGAC ATCAACATGACCTATAAGTAAAGTGCGTGTCTAGTGTCTTCTATTGAGAGTACTA CTATTAATTAAGCTTATTTCCAATGTGCCTTTTTAATGCTTGAAGTTTTATCTACAT ACACAGGTAACAGAGGACAGTAGTCTGTAAACATATAAATCGGTCATAACTATCG TGGTCTTTATTTCTGTGAGGATCTAGGGAAATTTCATGTCACTTCCCTCCTTCACT GCATCACAATCATATTCCCTTTTTTTTTTCTTGGATTTGTGTCAGTTGGATGATATC CCCTCCAGATAGTATCAATAAAATGTTAAAATT
>3’UTR-8(SEQ NO:37-8)
ACTCCCTCCTCCTGCCACTGGTGCCTCGAGTAGCCATGGCAACGGGCCCAGTGT CCAGTCACTTAGAAGTTCCCCCCTTGGCCAAAAACCCAATTCACATTGAGAGCT GGTGTTGTCTGAAGTTTTCGTATCACAGTGTTAACCTGTACTCTCTCCTGCAAAC CTACACACCAAAGCTTTATTTATATCATTCCAGTATCAATGCTACACAGTGTTGTC CCGAGCGCCGGGAGGCGTTGGGCAGAAACCCTCGGGAATGCTTCCGAGCACGC TGTAGGGTATGGGAAGAACCCAGCACCACTAATAAAGCTGCTGCTTGGCTGGA
>3’UTR-9(SEQ NO:37-9)
GGTGACCCGGCTGGGTCGGCCCTGCCCAAGGGCCTCCCACCAGAGACTGGGAT GGGAACACTGGTGGGCAGCTGAGGACACACCCCACACCCCAGCCCACCCTGCT CCTCCTGCCCTGTCCCTGTCCCCCTCCCCTCCCAGTCCTCCAGACCACCAGCCGC CCCAGCCCCTTCTCCCAGCACACGGCTGCCTGACACTGAGCCCCACCTCTCCAA GTCTCTCTGTGAATACAATTAAAGGTCCTGCCCTCCC
>3’UTR-10(SEQ NO:37-10)
ACCGCTAGCTTGTTGCACCGTGGAGGCCACAGGAGCAGAAACATGGAATGCCA GACGCTGGGGATGCTGGTACAAGTTGTGGGACTGCATGCTACTGTCTAGAGCTT GTCTCAATGGATCTAGAACTTCATCGCCCTCTGATCGCCGATCACCTCTGAGACC CACCTTGCTCATAAACAAAATGCCCATGTTGGTCCTCTGCCCTGGACCTGTGACA TTCTGGACTATTTCTGTGTTTATTTGTGGCCGAGTGTAACAACCATATAATAAATC ACCTCTTCCGCTGTTTTAGCTGAAGAATTAAATCA
>3’UTR-11(SEQ NO:37-11)
GCUGCCUUCUGCGGGGCUUGCCUUCUGGCCAUGCCCUUCUUCUCUCCCUUGC ACCUGUACCUCUUGGUCUUUGAAUAAAGCCUGAGUAGGAAGUGAGGGUCUA GAACU
>3’UTR-12(SEQ NO:37-12)
GCTCGCTTTCTTGCTGTCCAATTTCTATTAAAGGTTCCTTTGTTCCCTAAGTCCAA CTACTAAACTGGGGGATATTATGAAGGGCCTTGAGCATCTGGATTCTGCCTAATA AAAAACATTTATTTTCATTGC
the mRNA sequence used was the GFP sequence ((SEQ NO: 40):
the specific process is to connect the sequence of UTR-5 'before the 5 sequence of GFP, then to select the sequence of UTR-3' to connect to the 3 end of GFP, the specific connection method is to connect in the process of reversal rate by implementing the connection method in example 1, then to obtain better experimental pairing by the cell experiment as in example 2.
The specific results are that the above correspond to the sequence numbers, i.e. 5' UTRSEQ NO: 36-1) obtaining 12 pairs of sequences corresponding to the 3' UTR code number, and simultaneously carrying out expression of fluorescent protein, wherein the expression results show that the expression quantity of each pair is not obviously different, which indicates that the sequences can be used for carrying out the use of the non-coding region of messenger RNA (the specific data is omitted).
In order to clearly illustrate the correspondence between the accounting sequence cited in the present invention and the accounting sequence number automatically generated by software, the table is specially made for clear illustration, and the following table is specifically shown.
The invention shown and described herein may be practiced in the absence of any element or elements, limitation or limitations, which is specifically disclosed herein. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, and it is recognized that various modifications are possible within the scope of the invention. It should therefore be understood that although the present invention has been specifically disclosed by various embodiments and optional features, modification and variation of the concepts herein described may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention as defined by the appended claims. The contents of the articles, patents, patent applications, and all other documents and electronically available information described or cited herein are hereby incorporated by reference in their entirety to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference. Applicants reserve the right to incorporate into this application any and all materials and information from any such articles, patents, patent applications, or other documents.
Sequence listing
<110> Si micro (Shanghai) Biotech Co., Ltd
<120> vaccine agent for treating or preventing coronavirus disease
<160> 78
<170> SIPOSequenceListing 1.0
<210> 1
<211> 3822
<212> DNA
<213> coronavirus (coronavirus)
<400> 1
atgtttgttt ttcttgtttt attgccacta gtctctagtc agtgtgttaa tcttacaacc 60
agaactcaat taccccctgc atacactaat tctttcacac gtggtgttta ttaccctgac 120
aaagttttca gatcctcagt tttacattca actcaggact tgttcttacc tttcttttcc 180
aatgttactt ggttccatgc tatacatgtc tctgggacca atggtactaa gaggtttgat 240
aaccctgtcc taccatttaa tgatggtgtt tattttgctt ccactgagaa gtctaacata 300
ataagaggct ggatttttgg tactacttta gattcgaaga cccagtccct acttattgtt 360
aataacgcta ctaatgttgt tattaaagtc tgtgaatttc aattttgtaa tgatccattt 420
ttgggtgttt attaccacaa aaacaacaaa agttggatgg aaagtgagtt cagagtttat 480
tctagtgcga ataattgcac ttttgaatat gtctctcagc cttttcttat ggaccttgaa 540
ggaaaacagg gtaatttcaa aaatcttagg gaatttgtgt ttaagaatat tgatggttat 600
tttaaaatat attctaagca cacgcctatt aatttagtgc gtgatctccc tcagggtttt 660
tcggctttag aaccattggt agatttgcca ataggtatta acatcactag gtttcaaact 720
ttacttgctt tacatagaag ttatttgact cctggtgatt cttcttcagg ttggacagct 780
ggtgctgcag cttattatgt gggttatctt caacctagga cttttctatt aaaatataat 840
gaaaatggaa ccattacaga tgctgtagac tgtgcacttg accctctctc agaaacaaag 900
tgtacgttga aatccttcac tgtagaaaaa ggaatctatc aaacttctaa ctttagagtc 960
caaccaacag aatctattgt tagatttcct aatattacaa acttgtgccc ttttggtgaa 1020
gtttttaacg ccaccagatt tgcatctgtt tatgcttgga acaggaagag aatcagcaac 1080
tgtgttgctg attattctgt cctatataat tccgcatcat tttccacttt taagtgttat 1140
ggagtgtctc ctactaaatt aaatgatctc tgctttacta atgtctatgc agattcattt 1200
gtaattagag gtgatgaagt cagacaaatc gctccagggc aaactggaaa gattgctgat 1260
tataattata aattaccaga tgattttaca ggctgcgtta tagcttggaa ttctaacaat 1320
cttgattcta aggttggtgg taattataat tacctgtata gattgtttag gaagtctaat 1380
ctcaaacctt ttgagagaga tatttcaact gaaatctatc aggccggtag cacaccttgt 1440
aatggtgttg aaggttttaa ttgttacttt cctttacaat catatggttt ccaacccact 1500
aatggtgttg gttaccaacc atacagagta gtagtacttt cttttgaact tctacatgca 1560
ccagcaactg tttgtggacc taaaaagtct actaatttgg ttaaaaacaa atgtgtcaat 1620
ttcaacttca atggtttaac aggcacaggt gttcttactg agtctaacaa aaagtttctg 1680
cctttccaac aatttggcag agacattgct gacactactg atgctgtccg tgatccacag 1740
acacttgaga ttcttgacat tacaccatgt tcttttggtg gtgtcagtgt tataacacca 1800
ggaacaaata cttctaacca ggttgctgtt ctttatcagg atgttaactg cacagaagtc 1860
cctgttgcta ttcatgcaga tcaacttact cctacttggc gtgtttattc tacaggttct 1920
aatgtttttc aaacacgtgc aggctgttta ataggggctg aacatgtcaa caactcatat 1980
gagtgtgaca tacccattgg tgcaggtata tgcgctagtt atcagactca gactaattct 2040
cctcggcggg cacgtagtgt agctagtcaa tccatcattg cctacactat gtcacttggt 2100
gcagaaaatt cagttgctta ctctaataac tctattgcca tacccacaaa ttttactatt 2160
agtgttacca cagaaattct accagtgtct atgaccaaga catcagtaga ttgtacaatg 2220
tacatttgtg gtgattcaac tgaatgcagc aatcttttgt tgcaatatgg cagtttttgt 2280
acacaattaa accgtgcttt aactggaata gctgttgaac aagacaaaaa cacccaagaa 2340
gtttttgcac aagtcaaaca aatttacaaa acaccaccaa ttaaagattt tggtggtttt 2400
aatttttcac aaatattacc agatccatca aaaccaagca agaggtcatt tattgaagat 2460
ctacttttca acaaagtgac acttgcagat gctggcttca tcaaacaata tggtgattgc 2520
cttggtgata ttgctgctag agacctcatt tgtgcacaaa agtttaacgg ccttactgtt 2580
ttgccacctt tgctcacaga tgaaatgatt gctcaataca cttctgcact gttagcgggt 2640
acaatcactt ctggttggac ctttggtgca ggtgctgcat tacaaatacc atttgctatg 2700
caaatggctt ataggtttaa tggtattgga gttacacaga atgttctcta tgagaaccaa 2760
aaattgattg ccaaccaatt taatagtgct attggcaaaa ttcaagactc actttcttcc 2820
acagcaagtg cacttggaaa acttcaagat gtggtcaacc aaaatgcaca agctttaaac 2880
acgcttgtta aacaacttag ctccaatttt ggtgcaattt caagtgtttt aaatgatatc 2940
ctttcacgtc ttgacaaagt tgaggctgaa gtgcaaattg ataggttgat cacaggcaga 3000
cttcaaagtt tgcagacata tgtgactcaa caattaatta gagctgcaga aatcagagct 3060
tctgctaatc ttgctgctac taaaatgtca gagtgtgtac ttggacaatc aaaaagagtt 3120
gatttttgtg gaaagggcta tcatcttatg tccttccctc agtcagcacc tcatggtgta 3180
gtcttcttgc atgtgactta tgtccctgca caagaaaaga acttcacaac tgctcctgcc 3240
atttgtcatg atggaaaagc acactttcct cgtgaaggtg tctttgtttc aaatggcaca 3300
cactggtttg taacacaaag gaatttttat gaaccacaaa tcattactac agacaacaca 3360
tttgtgtctg gtaactgtga tgttgtaata ggaattgtca acaacacagt ttatgatcct 3420
ttgcaacctg aattagactc attcaaggag gagttagata aatattttaa gaatcataca 3480
tcaccagatg ttgatttagg tgacatctct ggcattaatg cttcagttgt aaacattcaa 3540
aaagaaattg accgcctcaa tgaggttgcc aagaatttaa atgaatctct catcgatctc 3600
caagaacttg gaaagtatga gcagtatata aaatggccat ggtacatttg gctaggtttt 3660
atagctggct tgattgccat agtaatggtg acaattatgc tttgctgtat gaccagttgc 3720
tgtagttgtc tcaagggctg ttgttcttgt ggatcctgct gcaaatttga tgaagacgac 3780
tctgagccag tgctcaaagg agtcaaatta cattacacat aa 3822
<210> 2
<211> 3825
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 2
atgttcgtct tcctggtgct gctgcctctg gtgtcttccc agtgcgtgaa tctgactacc 60
aggacccagc tgccccctgc ctataccaat tccttcacac ggggcgtgta ctatcccgac 120
aaggtgttta gaagctccgt gctgcactct acacaggatc tgtttctgcc tttctttagc 180
aacgtgacct ggttccacgc catccacgtg agcggcacca atggcacaaa gcggttcgac 240
aatccagtgc tgccctttaa cgatggcgtg tacttcgcct ctaccgagaa gagcaacatc 300
atcagaggct ggatctttgg caccacactg gactccaaga cacagtctct gctgatcgtg 360
aacaatgcca ccaacgtggt catcaaggtg tgcgagttcc agttttgtaa tgatccattc 420
ctgggcgtgt actatcacaa gaacaataag agctggatgg agtccgagtt tcgcgtgtat 480
tctagcgcca acaattgcac atttgagtac gtgtcccagc ccttcctgat ggacctggag 540
ggcaagcagg gcaatttcaa gaacctgagg gagttcgtgt ttaagaatat cgatggctac 600
ttcaagatct actctaagca caccccaatc aacctggtgc gcgacctgcc acagggcttc 660
agcgccctgg agccactggt ggatctgccc atcggcatca acatcacccg gtttcagaca 720
ctgctggccc tgcacagaag ctacctgaca ccaggcgact cctctagcgg atggaccgca 780
ggagcagcag cctactatgt gggctatctg cagcccagga ccttcctgct gaagtacaac 840
gagaatggca ccatcacaga cgccgtggat tgcgccctgg atcccctgag cgagacaaag 900
tgtacactga agtcctttac cgtggagaag ggcatctatc agacatccaa tttcagggtg 960
cagcctaccg agtctatcgt gcgctttccc aatatcacaa acctgtgccc ttttggcgag 1020
gtgttcaacg caaccaggtt cgcaagcgtg tacgcatgga ataggaagcg catctctaac 1080
tgcgtggccg actatagcgt gctgtacaac tccgcctctt tcagcacctt taagtgctat 1140
ggcgtgtccc ccacaaagct gaatgacctg tgctttacca acgtgtacgc cgattctttc 1200
gtgatcaggg gcgacgaggt gcgccagatc gcaccaggac agacaggcaa gatcgcagac 1260
tacaattata agctgcctga cgatttcacc ggctgcgtga tcgcctggaa cagcaacaat 1320
ctggattcca aagtgggcgg caactacaat tatctgtacc ggctgtttag aaagagcaat 1380
ctgaagccat tcgagaggga catctctaca gagatctacc aggcaggaag caccccatgc 1440
aatggagtgg agggctttaa ctgttatttc cctctgcagt cctacggctt ccagccaacc 1500
aacggcgtgg gctatcagcc ctaccgcgtg gtggtgctga gctttgagct gctgcacgca 1560
cctgcaacag tgtgcggacc aaagaagtcc accaatctgg tgaagaacaa gtgcgtgaac 1620
ttcaacttca acggcctgac cggaacaggc gtgctgaccg agtccaacaa gaagttcctg 1680
ccttttcagc agttcggcag ggacatcgca gataccacag acgccgtgcg cgaccctcag 1740
accctggaga tcctggatat cacaccatgc tctttcggcg gcgtgagcgt gatcacacca 1800
ggcaccaata caagcaacca ggtggccgtg ctgtatcagg acgtgaattg taccgaggtg 1860
ccagtggcaa tccacgcaga tcagctgacc cctacatggc gggtgtacag caccggctcc 1920
aacgtgttcc agacaagagc aggatgtctg atcggagcag agcacgtgaa caattcctat 1980
gagtgcgaca tccctatcgg cgccggcatc tgtgcctctt accagaccca gacaaactct 2040
ccaaggagag cacggagcgt ggcatcccag tctatcatcg cctataccat gtccctgggc 2100
gccgagaatt ctgtggccta ctctaacaat agcatcgcca tccctaccaa cttcacaatc 2160
tctgtgacca cagagatcct gccagtgtcc atgaccaaga catctgtgga ctgcacaatg 2220
tatatctgtg gcgattctac cgagtgcagc aacctgctgc tgcagtacgg cagcttttgt 2280
acccagctga atagagccct gacaggcatc gccgtggagc aggataagaa cacacaggag 2340
gtgttcgccc aggtgaagca gatctacaag accccaccca tcaaggactt tggcggcttc 2400
aatttttccc agatcctgcc cgatccttcc aagccctcta agcggagctt tatcgaggac 2460
ctgctgttca acaaggtgac cctggccgat gccggcttca tcaagcagta tggcgattgc 2520
ctgggcgaca tcgcagcacg ggacctgatc tgtgcccaga agtttaatgg cctgaccgtg 2580
ctgcctccac tgctgacaga tgagatgatc gcacagtaca caagcgccct gctggcagga 2640
accatcacat ccggatggac cttcggcgca ggagccgccc tgcagatccc ctttgccatg 2700
cagatggcct atcggttcaa cggcatcggc gtgacccaga atgtgctgta cgagaaccag 2760
aagctgatcg ccaatcagtt taactccgcc atcggcaaga tccaggacag cctgtcctct 2820
acagcctccg ccctgggcaa gctgcaggat gtggtgaatc agaacgccca ggccctgaat 2880
accctggtga agcagctgag ctccaacttc ggcgccatct ctagcgtgct gaatgatatc 2940
ctgagccggc tggacaaggt ggaggcagag gtgcagatcg accggctgat cacaggcaga 3000
ctgcagtctc tgcagaccta tgtgacacag cagctgatca gggcagcaga gatcagggca 3060
agcgccaatc tggcagcaac caagatgtcc gagtgcgtgc tgggccagtc taagagagtg 3120
gacttttgtg gcaagggcta tcacctgatg tccttcccac agtctgcccc tcacggagtg 3180
gtgtttctgc acgtgaccta cgtgccagcc caggagaaga acttcaccac agcaccagca 3240
atctgccacg atggcaaggc acactttcct agggagggcg tgttcgtgtc caacggcacc 3300
cactggtttg tgacacagcg caatttctac gagccacaga tcatcaccac agacaatacc 3360
ttcgtgagcg gcaactgtga cgtggtcatc ggcatcgtga acaataccgt gtatgatcct 3420
ctgcagccag agctggacag ctttaaggag gagctggata agtacttcaa gaatcacacc 3480
tcccccgacg tggatctggg cgacatcagc ggcatcaatg cctccgtggt gaacatccag 3540
aaggagatcg acaggctgaa cgaggtggcc aagaatctga acgagagcct gatcgatctg 3600
caggagctgg gcaagtatga gcagtacatc aagtggcctt ggtacatctg gctgggcttc 3660
atcgccggcc tgatcgccat cgtgatggtg accatcatgc tgtgctgtat gacatcctgc 3720
tgttcttgcc tgaagggctg ctgtagctgc ggctcctgtt gtaaattcga tgaggatgat 3780
tccgagcctg tgctgaaggg cgtgaaactg cattatacct aatag 3825
<210> 3
<211> 768
<212> DNA
<213> coronavirus (coronavirus)
<400> 3
atgcctaata ttacaaactt gtgccctttt ggtgaagttt ttaacgccac cagatttgca 60
tctgtttatg cttggaacag gaagagaatc agcaactgtg ttgctgatta ttctgtccta 120
tataattccg catcattttc cacttttaag tgttatggag tgtctcctac taaattaaat 180
gatctctgct ttactaatgt ctatgcagat tcatttgtaa ttagaggtga tgaagtcaga 240
caaatcgctc cagggcaaac tggaaagatt gctgattata attataaatt accagatgat 300
tttacaggct gcgttatagc ttggaattct aacaatcttg attctaaggt tggtggtaat 360
tataattacc tgtatagatt gtttaggaag tctaatctca aaccttttga gagagatatt 420
tcaactgaaa tctatcaggc cggtagcaca ccttgtaatg gtgttgaagg ttttaattgt 480
tactttcctt tacaatcata tggtttccaa cccactaatg gtgttggtta ccaaccatac 540
agagtagtag tactttcttt tgaacttcta catgcaccag caactgtttg tggacctaaa 600
aagtctacta atttggttaa aaacaaatgt gtcaatttca acttcaatgg tttaacaggc 660
acaggtgttc ttactgagtc taacaaaaag tttctgcctt tccaacaatt tggcagagac 720
attgctgaca ctactgatgc tgtccgtgat ccacagacac ttgagtaa 768
<210> 4
<211> 771
<212> DNA
<213> coronavirus (coronavirus)
<400> 4
atgcctaata ttacaaactt gtgccctttt ggtgaagttt ttaacgccac cagatttgca 60
tctgtttatg cttggaacag gaagagaatc agcaactgtg ttgctgatta ttctgtccta 120
tataattccg catcattttc cacttttaag tgttatggag tgtctcctac taaattaaat 180
gatctctgct ttactaatgt ctatgcagat tcatttgtaa ttagaggtga tgaagtcaga 240
caaatcgctc cagggcaaac tggaaagatt gctgattata attataaatt accagatgat 300
tttacaggct gcgttatagc ttggaattct aacaatcttg attctaaggt tggtggtaat 360
tataattacc tgtatagatt gtttaggaag tctaatctca aaccttttga gagagatatt 420
tcaactgaaa tctatcaggc cggtagcaca ccttgtaatg gtgttgaagg ttttaattgt 480
tactttcctt tacaatcata tggtttccaa cccactaatg gtgttggtta ccaaccatac 540
agagtagtag tactttcttt tgaacttcta catgcaccag caactgtttg tggacctaaa 600
aagtctacta atttggttaa aaacaaatgt gtcaatttca acttcaatgg tttaacaggc 660
acaggtgttc ttactgagtc taacaaaaag tttctgcctt tccaacaatt tggcagagac 720
attgctgaca ctactgatgc tgtccgtgat ccacagacac ttgagtaata g 771
<210> 5
<211> 669
<212> DNA
<213> coronavirus (coronavirus)
<400> 5
atggcagatt ccaacggtac tattaccgtt gaagagctta aaaagctcct tgaacaatgg 60
aacctagtaa taggtttcct attccttaca tggatttgtc ttctacaatt tgcctatgcc 120
aacaggaata ggtttttgta tataattaag ttaattttcc tctggctgtt atggccagta 180
actttagctt gttttgtgct tgctgctgtt tacagaataa attggatcac cggtggaatt 240
gctatcgcaa tggcttgtct tgtaggcttg atgtggctca gctacttcat tgcttctttc 300
agactgtttg cgcgtacgcg ttccatgtgg tcattcaatc cagaaactaa cattcttctc 360
aacgtgccac tccatggcac tattctgacc agaccgcttc tagaaagtga actcgtaatc 420
ggagctgtga tccttcgtgg acatcttcgt attgctggac accatctagg acgctgtgac 480
atcaaggacc tgcctaaaga aatcactgtt gctacatcac gaacgctttc ttattacaaa 540
ttgggagctt cgcagcgtgt agcaggtgac tcaggttttg ctgcatacag tcgctacagg 600
attggcaact ataaattaaa cacagaccat tccagtagca gtgacaatat tgctttgctt 660
<210> 6
<211> 672
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 6
atggccgata gcaacggcac catcaccgtg gaagaactga agaaactgct ggaacagtgg 60
aacctcgtga tcggcttcct gttcctgacc tggatctgcc tgctgcagtt cgcctacgcc 120
aaccggaaca gattcctgta tattatcaag ctgatcttcc tgtggctgct gtggcccgtg 180
acactggcct gttttgtgct ggccgccgtg taccggatca actggatcac aggcggaatc 240
gccattgcca tggcctgtct cgttggcctg atgtggctga gctactttat cgccagcttc 300
cggctgttcg cccggaccag atccatgtgg tccttcaatc ccgagacaaa catcctgctg 360
aacgtgcccc tgcacggcac aatcctgaca agacctctgc tggaaagcga gctggttatc 420
ggcgccgtga tcctgagagg ccacctgaga attgccggac accacctggg cagatgcgac 480
atcaaggacc tgcctaaaga aatcacagtg gccaccagca gaaccctgtc ctactataag 540
ctgggcgcca gccagagagt ggccggcgat tctggatttg ccgcctacag cagataccgg 600
atcggcaact acaagctgaa caccgaccac agctccagca gcgacaatat cgcactgctg 660
<210> 7
<211> 1260
<212> DNA
<213> coronavirus (coronavirus)
<400> 7
atgtctgata atggacccca aaatcagcga aatgcacccc gcattacgtt tggtggaccc 60
tcagattcaa ctggcagtaa ccagaatgga gaacgcagtg gggcgcgatc aaaacaacgt 120
cggccccaag gtttacccaa taatactgcg tcttggttca ccgctctcac tcaacatggc 180
aaggaagacc ttaaattccc tcgaggacaa ggcgttccaa ttaacaccaa tagcagtcca 240
gatgaccaaa ttggctacta ccgaagagct accagacgaa ttcgtggtgg tgacggtaaa 300
atgaaagatc tcagtccaag atggtatttc tactacctag gaactgggcc agaagctgga 360
cttccctatg gtgctaacaa agacggcatc atatgggttg caactgaggg agccttgaat 420
acaccaaaag atcacattgg cacccgcaat cctgctaaca atgctgcaat cgtgctacaa 480
cttcctcaag gaacaacatt gccaaaaggc ttctacgcag aagggagcag aggcggcagt 540
caagcctctt ctcgttcctc atcacgtagt cgcaacagtt caagaaattc aactccaggc 600
agcagtaggg gaacttctcc tgctagaatg gctggcaatg gcggtgatgc tgctcttgct 660
ttgctgctgc ttgacagatt gaaccagctt gagagcaaaa tgtctggtaa aggccaacaa 720
caacaaggcc aaactgtcac taagaaatct gctgctgagg cttctaagaa gcctcggcaa 780
aaacgtactg ccactaaagc atacaatgta acacaagctt tcggcagacg tggtccagaa 840
caaacccaag gaaattttgg ggaccaggaa ctaatcagac aaggaactga ttacaaacat 900
tggccgcaaa ttgcacaatt tgcccccagc gcttcagcgt tcttcggaat gtcgcgcatt 960
ggcatggaag tcacaccttc gggaacgtgg ttgacctaca caggtgccat caaattggat 1020
gacaaagatc caaatttcaa agatcaagtc attttgctga ataagcatat tgacgcatac 1080
aaaacattcc caccaacaga gcctaaaaag gacaaaaaga agaaggctga tgaaactcaa 1140
gccttaccgc agagacagaa gaaacagcaa actgtgactc ttcttcctgc tgcagatttg 1200
gatgatttct ccaaacaatt gcaacaatcc atgagcagtg ctgactcaac tcaggcctaa 1260
<210> 8
<211> 1263
<212> DNA
<213> coronavirus (coronavirus)
<400> 8
atgtctgata atggacccca aaatcagcga aatgcacccc gcattacgtt tggtggaccc 60
tcagattcaa ctggcagtaa ccagaatgga gaacgcagtg gggcgcgatc aaaacaacgt 120
cggccccaag gtttacccaa taatactgcg tcttggttca ccgctctcac tcaacatggc 180
aaggaagacc ttaaattccc tcgaggacaa ggcgttccaa ttaacaccaa tagcagtcca 240
gatgaccaaa ttggctacta ccgaagagct accagacgaa ttcgtggtgg tgacggtaaa 300
atgaaagatc tcagtccaag atggtatttc tactacctag gaactgggcc agaagctgga 360
cttccctatg gtgctaacaa agacggcatc atatgggttg caactgaggg agccttgaat 420
acaccaaaag atcacattgg cacccgcaat cctgctaaca atgctgcaat cgtgctacaa 480
cttcctcaag gaacaacatt gccaaaaggc ttctacgcag aagggagcag aggcggcagt 540
caagcctctt ctcgttcctc atcacgtagt cgcaacagtt caagaaattc aactccaggc 600
agcagtaggg gaacttctcc tgctagaatg gctggcaatg gcggtgatgc tgctcttgct 660
ttgctgctgc ttgacagatt gaaccagctt gagagcaaaa tgtctggtaa aggccaacaa 720
caacaaggcc aaactgtcac taagaaatct gctgctgagg cttctaagaa gcctcggcaa 780
aaacgtactg ccactaaagc atacaatgta acacaagctt tcggcagacg tggtccagaa 840
caaacccaag gaaattttgg ggaccaggaa ctaatcagac aaggaactga ttacaaacat 900
tggccgcaaa ttgcacaatt tgcccccagc gcttcagcgt tcttcggaat gtcgcgcatt 960
ggcatggaag tcacaccttc gggaacgtgg ttgacctaca caggtgccat caaattggat 1020
gacaaagatc caaatttcaa agatcaagtc attttgctga ataagcatat tgacgcatac 1080
aaaacattcc caccaacaga gcctaaaaag gacaaaaaga agaaggctga tgaaactcaa 1140
gccttaccgc agagacagaa gaaacagcaa actgtgactc ttcttcctgc tgcagatttg 1200
gatgatttct ccaaacaatt gcaacaatcc atgagcagtg ctgactcaac tcaggcctaa 1260
<210> 9
<211> 600
<212> DNA
<213> coronavirus (coronavirus)
<400> 9
atgattacaa acttgtgccc ttttggtgaa gtttttaacg ccaccagatt tgcatctgtt 60
tatgcttgga acaggaagag aatcagcaac tgtgttgctg attattctgt cctatataat 120
tccgcatcat tttccacttt taagtgttat ggagtgtctc ctactaaatt aaatgatctc 180
tgctttacta atgtctatgc agattcattt gtaattagag gtgatgaagt cagacaaatc 240
gctccagggc aaactggaaa gattgctgat tataattata aattaccaga tgattttaca 300
ggctgcgtta tagcttggaa ttctaacaat cttgattcta aggttggtgg taattataat 360
tacctgtata gattgtttag gaagtctaat ctcaaacctt ttgagagaga tatttcaact 420
gaaatctatc aggccggtag cacaccttgt aatggtgttg aaggttttaa ttgttacttt 480
cctttacaat catatggttt ccaacccact aatggtgttg gttaccaacc atacagagta 540
gtagtacttt cttttgaact tctacatgca ccagcaactg tttgtggacc taaaaagtaa 600
<210> 10
<211> 603
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 10
atgatcacca atctgtgccc cttcggcgag gtgttcaacg ccacaagatt cgcctctgtg 60
tacgcctgga accggaagcg gatcagcaat tgcgtggccg actacagcgt gctgtacaac 120
agcgccagct tcagcacctt caagtgctac ggcgtgtccc ctaccaagct gaacgacctg 180
tgcttcacca acgtgtacgc cgacagcttc gtgatcagag gcgacgaagt gcggcagatt 240
gcccctggac agacaggcaa gatcgccgat tacaactaca agctgcccga cgacttcacc 300
ggctgtgtga ttgcctggaa cagcaacaac ctggacagca aagtcggcgg caactacaac 360
tacctgtacc ggctgttccg gaagtccaac ctgaagcctt tcgagcggga catcagcacc 420
gagatctatc aggccggcag caccccttgc aatggcgtgg aaggcttcaa ctgctacttc 480
ccactgcagt cctacggctt ccagcctaca aacggcgtgg gctaccagcc ttacagagtg 540
gtggtgctga gcttcgagct gctgcatgct cctgccacag tgtgcggacc taagaagtaa 600
<210> 11
<211> 600
<212> DNA
<213> coronavirus (coronavirus)
<400> 11
atgattacaa acttgtgccc ttttggtgaa gtttttaacg ccaccagatt tgcatctgtt 60
tatgcttgga acaggaagag aatcagcaac tgtgttgctg attattctgt cctatataat 120
tccgcatcat tttccacttt taagtgttat ggagtgtctc ctactaaatt aaatgatctc 180
tgctttacta atgtctatgc agattcattt gtaattagag gtgatgaagt cagacaaatc 240
gctccagggc aaactggaaa gattgctgat tataattata aattaccaga tgattttaca 300
ggctgcgtta tagcttggaa ttctaacaat cttgattcta aggttggtgg taattataat 360
tacctgtata gattgtttag gaagtctaat ctcaaacctt ttgagagaga tatttcaact 420
gaaatctatc aggccggtag cacaccttgt aatggtgttg aaggttttaa ttgttacttt 480
cctttacaat catatggttt ccaacccact aatggtgttg gttaccaacc atacagagta 540
gtagtacttt cttttgaact tctacatgca ccagcaactg tttgtggacc taaaaagtaa 600
<210> 12
<211> 603
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 12
atgatcacca atctgtgccc cttcggcgag gtgttcaacg ccacaagatt cgcctctgtg 60
tacgcctgga accggaagcg gatcagcaat tgcgtggccg actacagcgt gctgtacaac 120
agcgccagct tcagcacctt caagtgctac ggcgtgtccc ctaccaagct gaacgacctg 180
tgcttcacca acgtgtacgc cgacagcttc gtgatcagag gcgacgaagt gcggcagatt 240
gcccctggac agacaggcaa gatcgccgat tacaactaca agctgcccga cgacttcacc 300
ggctgtgtga ttgcctggaa cagcaacaac ctggacagca aagtcggcgg caactacaac 360
tacctgtacc ggctgttccg gaagtccaac ctgaagcctt tcgagcggga catcagcacc 420
gagatctatc aggccggcag caccccttgc aatggcgtgg aaggcttcaa ctgctacttc 480
ccactgcagt cctacggctt ccagcctaca aacggcgtgg gctaccagcc ttacagagtg 540
gtggtgctga gcttcgaact gctgcacgcc aatgccacag tgtgcggccc taagaaataa 600
<210> 13
<211> 228
<212> DNA
<213> coronavirus (coronavirus)
<400> 13
atgtactcat tcgtttcgga agagacaggt acgttaatag ttaatagcgt acttcttttt 60
cttgctttcg tggtattctt gctagttaca ctagccatcc ttactgcgct tcgattgtgt 120
gcgtactgct gcaatattgt taacgtgagt cttgtaaaac cttcttttta cgtttactct 180
cgtgttaaaa atctgaattc ttctagagtt cctgatcttc tggtctaa 228
<210> 14
<211> 231
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 14
atgtacagct tcgtgtccga ggaaaccggc acactgatcg tgaacagcgt gctgctgttc 60
ctggccttcg tggtgtttct gctggtcacc ctggccatcc tgacagccct gagactgtgc 120
gcctactgct gcaacatcgt gaacgtgtcc ctggtcaagc ccagcttcta cgtgtacagc 180
agagtgaaga acctgaacag ctccagagtg cccgacctgc tggtgtaata g 231
<210> 15
<211> 3612
<212> DNA
<213> coronavirus (coronavirus)
<400> 15
atgtctagtc agtgtgttaa tcttacaacc agaactcaat taccccctgc atacactaat 60
tctttcacac gtggtgttta ttaccctgac aaagttttca gatcctcagt tttacattca 120
actcaggact tgttcttacc tttcttttcc aatgttactt ggttccatgc tatacatgtc 180
tctgggacca atggtactaa gaggtttgat aaccctgtcc taccatttaa tgatggtgtt 240
tattttgctt ccactgagaa gtctaacata ataagaggct ggatttttgg tactacttta 300
gattcgaaga cccagtccct acttattgtt aataacgcta ctaatgttgt tattaaagtc 360
tgtgaatttc aattttgtaa tgatccattt ttgggtgttt attaccacaa aaacaacaaa 420
agttggatgg aaagtgagtt cagagtttat tctagtgcga ataattgcac ttttgaatat 480
gtctctcagc cttttcttat ggaccttgaa ggaaaacagg gtaatttcaa aaatcttagg 540
gaatttgtgt ttaagaatat tgatggttat tttaaaatat attctaagca cacgcctatt 600
aatttagtgc gtgatctccc tcagggtttt tcggctttag aaccattggt agatttgcca 660
ataggtatta acatcactag gtttcaaact ttacttgctt tacatagaag ttatttgact 720
cctggtgatt cttcttcagg ttggacagct ggtgctgcag cttattatgt gggttatctt 780
caacctagga cttttctatt aaaatataat gaaaatggaa ccattacaga tgctgtagac 840
tgtgcacttg accctctctc agaaacaaag tgtacgttga aatccttcac tgtagaaaaa 900
ggaatctatc aaacttctaa ctttagagtc caaccaacag aatctattgt tagatttcct 960
aatattacaa acttgtgccc ttttggtgaa gtttttaacg ccaccagatt tgcatctgtt 1020
tatgcttgga acaggaagag aatcagcaac tgtgttgctg attattctgt cctatataat 1080
tccgcatcat tttccacttt taagtgttat ggagtgtctc ctactaaatt aaatgatctc 1140
tgctttacta atgtctatgc agattcattt gtaattagag gtgatgaagt cagacaaatc 1200
gctccagggc aaactggaaa gattgctgat tataattata aattaccaga tgattttaca 1260
ggctgcgtta tagcttggaa ttctaacaat cttgattcta aggttggtgg taattataat 1320
tacctgtata gattgtttag gaagtctaat ctcaaacctt ttgagagaga tatttcaact 1380
gaaatctatc aggccggtag cacaccttgt aatggtgttg aaggttttaa ttgttacttt 1440
cctttacaat catatggttt ccaacccact aatggtgttg gttaccaacc atacagagta 1500
gtagtacttt cttttgaact tctacatgca ccagcaactg tttgtggacc taaaaagtct 1560
actaatttgg ttaaaaacaa atgtgtcaat ttcaacttca atggtttaac aggcacaggt 1620
gttcttactg agtctaacaa aaagtttctg cctttccaac aatttggcag agacattgct 1680
gacactactg atgctgtccg tgatccacag acacttgaga ttcttgacat tacaccatgt 1740
tcttttggtg gtgtcagtgt tataacacca ggaacaaata cttctaacca ggttgctgtt 1800
ctttatcagg atgttaactg cacagaagtc cctgttgcta ttcatgcaga tcaacttact 1860
cctacttggc gtgtttattc tacaggttct aatgtttttc aaacacgtgc aggctgttta 1920
ataggggctg aacatgtcaa caactcatat gagtgtgaca tacccattgg tgcaggtata 1980
tgcgctagtt atcagactca gactaattct cctcggcggg cacgtagtgt agctagtcaa 2040
tccatcattg cctacactat gtcacttggt gcagaaaatt cagttgctta ctctaataac 2100
tctattgcca tacccacaaa ttttactatt agtgttacca cagaaattct accagtgtct 2160
atgaccaaga catcagtaga ttgtacaatg tacatttgtg gtgattcaac tgaatgcagc 2220
aatcttttgt tgcaatatgg cagtttttgt acacaattaa accgtgcttt aactggaata 2280
gctgttgaac aagacaaaaa cacccaagaa gtttttgcac aagtcaaaca aatttacaaa 2340
acaccaccaa ttaaagattt tggtggtttt aatttttcac aaatattacc agatccatca 2400
aaaccaagca agaggtcatt tattgaagat ctacttttca acaaagtgac acttgcagat 2460
gctggcttca tcaaacaata tggtgattgc cttggtgata ttgctgctag agacctcatt 2520
tgtgcacaaa agtttaacgg ccttactgtt ttgccacctt tgctcacaga tgaaatgatt 2580
gctcaataca cttctgcact gttagcgggt acaatcactt ctggttggac ctttggtgca 2640
ggtgctgcat tacaaatacc atttgctatg caaatggctt ataggtttaa tggtattgga 2700
gttacacaga atgttctcta tgagaaccaa aaattgattg ccaaccaatt taatagtgct 2760
attggcaaaa ttcaagactc actttcttcc acagcaagtg cacttggaaa acttcaagat 2820
gtggtcaacc aaaatgcaca agctttaaac acgcttgtta aacaacttag ctccaatttt 2880
ggtgcaattt caagtgtttt aaatgatatc ctttcacgtc ttgacaaagt tgaggctgaa 2940
gtgcaaattg ataggttgat cacaggcaga cttcaaagtt tgcagacata tgtgactcaa 3000
caattaatta gagctgcaga aatcagagct tctgctaatc ttgctgctac taaaatgtca 3060
gagtgtgtac ttggacaatc aaaaagagtt gatttttgtg gaaagggcta tcatcttatg 3120
tccttccctc agtcagcacc tcatggtgta gtcttcttgc atgtgactta tgtccctgca 3180
caagaaaaga acttcacaac tgctcctgcc atttgtcatg atggaaaagc acactttcct 3240
cgtgaaggtg tctttgtttc aaatggcaca cactggtttg taacacaaag gaatttttat 3300
gaaccacaaa tcattactac agacaacaca tttgtgtctg gtaactgtga tgttgtaata 3360
ggaattgtca acaacacagt ttatgatcct ttgcaacctg aattagactc attcaaggag 3420
gagttagata aatattttaa gaatcataca tcaccagatg ttgatttagg tgacatctct 3480
ggcattaatg cttcagttgt aaacattcaa aaagaaattg accgcctcaa tgaggttgcc 3540
aagaatttaa atgaatctct catcgatctc caagaacttg gaaagtatga gcagtatata 3600
<210> 16
<211> 3615
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 16
atgagcagcc agtgcgtgaa cctgaccacc agaactcagc tgcctccagc ctacaccaac 60
agcttcacca gaggcgtgta ctaccccgac aaggtgttca gatccagcgt gctgcactct 120
acccaggacc tgttcctgcc tttcttcagc aacgtgacct ggttccacgc catccacgtg 180
tccggcacca atggcaccaa gagattcgac aaccccgtgc tgcccttcaa cgacggggtg 240
tactttgcca gcaccgagaa gtccaacatc atcagaggct ggatcttcgg caccacactg 300
gacagcaaga cccagagcct gctgatcgtg aacaacgcca ccaacgtggt catcaaagtg 360
tgcgagttcc agttctgcaa cgaccccttc ctgggcgtct actaccacaa gaacaacaag 420
agctggatgg aaagcgagtt ccgggtgtac agcagcgcca acaactgcac cttcgagtac 480
gtgtcccagc ctttcctgat ggacctggaa ggcaagcagg gcaacttcaa gaacctgcgc 540
gagttcgtgt tcaagaacat cgacggctac ttcaagatct acagcaagca cacccctatc 600
aacctcgtgc gggatctgcc tcagggcttc tctgctctgg aacccctggt ggatctgccc 660
atcggcatca acatcacccg gtttcagaca ctgctggccc tgcacagaag ctacctgaca 720
cctggcgata gcagctctgg atggacagct ggcgccgctg cctactatgt gggatacctg 780
cagcctcgga ccttcctgct gaagtacaac gagaacggca ccatcaccga cgccgtggat 840
tgtgctctgg atcctctgag cgagacaaag tgcaccctga agtccttcac cgtggaaaag 900
ggcatctacc agaccagcaa cttccgggtg cagcccaccg aatccatcgt gcggttcccc 960
aatatcacca atctgtgccc cttcggcgag gtgttcaatg ccaccagatt cgcctctgtg 1020
tacgcctgga accggaagcg gatcagcaat tgcgtggccg actactccgt gctgtacaac 1080
tccgccagct tcagcacctt caagtgctac ggcgtgtccc ctaccaagct gaacgacctg 1140
tgcttcacaa acgtgtacgc cgacagcttc gtgatccggg gagatgaagt gcggcagatt 1200
gcccctggac agacaggcaa gatcgccgac tacaactaca agctgcccga cgacttcacc 1260
ggctgtgtga ttgcctggaa cagcaacaac ctggactcca aagtcggcgg caactacaat 1320
tacctgtacc ggctgttccg gaagtccaat ctgaagccct tcgagcggga catctccacc 1380
gagatctatc aggccggcag caccccttgt aacggcgtgg aaggcttcaa ctgctacttc 1440
ccactgcagt cctacggctt tcagcccaca aatggcgtgg gctaccagcc ttacagagtg 1500
gtggtgctga gcttcgagct gctgcatgct cctgccacag tgtgcggccc taagaaaagc 1560
accaatctcg tgaagaacaa atgcgtgaac ttcaacttca acggcctgac cggcaccggc 1620
gtgctgacag agagcaacaa gaagttcctg ccattccagc agttcggccg ggatatcgcc 1680
gataccacag acgccgttag agatccccag acactggaaa tcctggacat caccccttgc 1740
agcttcggcg gagtgtctgt gatcacccct ggcaccaaca ccagcaatca ggtggcagtg 1800
ctgtaccagg acgtgaactg taccgaagtg cccgtggcca ttcacgccga tcagctgaca 1860
cctacatggc gggtgtactc caccggcagc aatgtgtttc agaccagagc cggctgtctg 1920
atcggagccg agcacgtgaa caatagctac gagtgcgaca tccccatcgg cgctggcatc 1980
tgtgccagct accagacaca gacaaacagc cccagacggg ccagatctgt ggccagccag 2040
agcatcattg cctacacaat gtctctgggc gccgagaaca gcgtggccta ctccaacaac 2100
tctatcgcta tccccaccaa cttcaccatc agcgtgacca cagagatcct gcctgtgtcc 2160
atgaccaaga ccagcgtgga ctgcaccatg tacatctgcg gcgattccac cgagtgctcc 2220
aacctgctgc tgcagtacgg cagcttctgc acccagctga atagagccct gacagggatc 2280
gccgtggaac aggacaagaa cacccaagag gtgttcgccc aagtgaagca gatctacaag 2340
acccctccta tcaaggactt cggcggcttc aatttcagcc agattctgcc cgatcctagc 2400
aagcccagca agcggagctt catcgaggac ctgctgttca acaaagtgac actggccgac 2460
gccggcttca tcaagcagta tggcgattgt ctgggcgaca ttgccgccag ggatctgatt 2520
tgcgcccaga agtttaacgg actgacagtg ctgcctcctc tgctgaccga tgagatgatc 2580
gcccagtaca catctgccct gctggccggc acaatcacaa gcggctggac atttggagct 2640
ggcgctgccc tgcagatccc ctttgctatg cagatggcct accggttcaa cggcatcgga 2700
gtgacccaga atgtgctgta cgagaaccag aagctgatcg ccaaccagtt caacagcgcc 2760
atcggcaaga tccaggacag cctgagcagc acagcaagcg ccctgggaaa gctgcaggac 2820
gtggtcaacc agaatgccca ggcactgaac accctggtca agcagctgtc tagcaacttc 2880
ggcgccatca gctctgtgct gaacgatatc ctgagcagac tggacaaggt ggaagccgag 2940
gtgcagatcg acagactgat caccggaagg ctgcagtccc tgcagaccta cgttacccag 3000
cagctgatca gagccgccga gattagagcc tctgccaatc tggccgccac caagatgtct 3060
gagtgtgtgc tgggccagag caagagagtg gacttttgcg gcaagggcta ccacctgatg 3120
agcttccctc agtctgcccc tcacggcgtg gtgtttctgc acgtgacata cgtgcccgct 3180
caagagaaga atttcaccac cgctccagcc atctgccacg acggcaaagc ccactttcct 3240
agagaaggcg tgttcgtcag caacggcacc cattggttcg tgacccagcg gaacttctac 3300
gagccccaga tcatcaccac cgacaacacc ttcgtgtctg gcaactgcga cgtcgtgatc 3360
ggcattgtga acaataccgt gtacgaccct ctgcagcccg agctggacag cttcaaagag 3420
gaactggata agtactttaa gaaccacaca agccccgacg tggacctggg cgatatcagc 3480
ggaatcaatg ccagcgtcgt gaacatccag aaagagatcg accggctgaa cgaggtggcc 3540
aagaatctga acgagagcct gatcgacctg caagaactgg ggaagtacga gcagtacatc 3600
<210> 17
<211> 2028
<212> DNA
<213> coronavirus (coronavirus)
<400> 17
atgtctagtc agtgtgttaa tcttacaacc agaactcaat taccccctgc atacactaat 60
tctttcacac gtggtgttta ttaccctgac aaagttttca gatcctcagt tttacattca 120
actcaggact tgttcttacc tttcttttcc aatgttactt ggttccatgc tatacatgtc 180
tctgggacca atggtactaa gaggtttgat aaccctgtcc taccatttaa tgatggtgtt 240
tattttgctt ccactgagaa gtctaacata ataagaggct ggatttttgg tactacttta 300
gattcgaaga cccagtccct acttattgtt aataacgcta ctaatgttgt tattaaagtc 360
tgtgaatttc aattttgtaa tgatccattt ttgggtgttt attaccacaa aaacaacaaa 420
agttggatgg aaagtgagtt cagagtttat tctagtgcga ataattgcac ttttgaatat 480
gtctctcagc cttttcttat ggaccttgaa ggaaaacagg gtaatttcaa aaatcttagg 540
gaatttgtgt ttaagaatat tgatggttat tttaaaatat attctaagca cacgcctatt 600
aatttagtgc gtgatctccc tcagggtttt tcggctttag aaccattggt agatttgcca 660
ataggtatta acatcactag gtttcaaact ttacttgctt tacatagaag ttatttgact 720
cctggtgatt cttcttcagg ttggacagct ggtgctgcag cttattatgt gggttatctt 780
caacctagga cttttctatt aaaatataat gaaaatggaa ccattacaga tgctgtagac 840
tgtgcacttg accctctctc agaaacaaag tgtacgttga aatccttcac tgtagaaaaa 900
ggaatctatc aaacttctaa ctttagagtc caaccaacag aatctattgt tagatttcct 960
aatattacaa acttgtgccc ttttggtgaa gtttttaacg ccaccagatt tgcatctgtt 1020
tatgcttgga acaggaagag aatcagcaac tgtgttgctg attattctgt cctatataat 1080
tccgcatcat tttccacttt taagtgttat ggagtgtctc ctactaaatt aaatgatctc 1140
tgctttacta atgtctatgc agattcattt gtaattagag gtgatgaagt cagacaaatc 1200
gctccagggc aaactggaaa gattgctgat tataattata aattaccaga tgattttaca 1260
ggctgcgtta tagcttggaa ttctaacaat cttgattcta aggttggtgg taattataat 1320
tacctgtata gattgtttag gaagtctaat ctcaaacctt ttgagagaga tatttcaact 1380
gaaatctatc aggccggtag cacaccttgt aatggtgttg aaggttttaa ttgttacttt 1440
cctttacaat catatggttt ccaacccact aatggtgttg gttaccaacc atacagagta 1500
gtagtacttt cttttgaact tctacatgca ccagcaactg tttgtggacc taaaaagtct 1560
actaatttgg ttaaaaacaa atgtgtcaat ttcaacttca atggtttaac aggcacaggt 1620
gttcttactg agtctaacaa aaagtttctg cctttccaac aatttggcag agacattgct 1680
gacactactg atgctgtccg tgatccacag acacttgaga ttcttgacat tacaccatgt 1740
tcttttggtg gtgtcagtgt tataacacca ggaacaaata cttctaacca ggttgctgtt 1800
ctttatcagg atgttaactg cacagaagtc cctgttgcta ttcatgcaga tcaacttact 1860
cctacttggc gtgtttattc tacaggttct aatgtttttc aaacacgtgc aggctgttta 1920
ataggggctg aacatgtcaa caactcatat gagtgtgaca tacccattgg tgcaggtata 1980
tgcgctagtt atcagactca gactaattct cctcggcggg cacgttaa 2028
<210> 18
<211> 2031
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 18
atgagcagcc agtgcgtgaa cctgaccacc agaactcagc tgcctccagc ctacaccaac 60
agcttcacca gaggcgtgta ctaccccgac aaggtgttca gatccagcgt gctgcactct 120
acccaggacc tgttcctgcc tttcttcagc aacgtgacct ggttccacgc catccacgtg 180
tccggcacca atggcaccaa gagattcgac aaccccgtgc tgcccttcaa cgacggggtg 240
tactttgcca gcaccgagaa gtccaacatc atcagaggct ggatcttcgg caccacactg 300
gacagcaaga cccagagcct gctgatcgtg aacaacgcca ccaacgtggt catcaaagtg 360
tgcgagttcc agttctgcaa cgaccccttc ctgggcgtct actaccacaa gaacaacaag 420
agctggatgg aaagcgagtt ccgggtgtac agcagcgcca acaactgcac cttcgagtac 480
gtgtcccagc ctttcctgat ggacctggaa ggcaagcagg gcaacttcaa gaacctgcgc 540
gagttcgtgt tcaagaacat cgacggctac ttcaagatct acagcaagca cacccctatc 600
aacctcgtgc gggatctgcc tcagggcttc tctgctctgg aacccctggt ggatctgccc 660
atcggcatca acatcacccg gtttcagaca ctgctggccc tgcacagaag ctacctgaca 720
cctggcgata gcagctctgg atggacagct ggcgccgctg cctactatgt gggatacctg 780
cagcctcgga ccttcctgct gaagtacaac gagaacggca ccatcaccga cgccgtggat 840
tgtgctctgg atcctctgag cgagacaaag tgcaccctga agtccttcac cgtggaaaag 900
ggcatctacc agaccagcaa cttccgggtg cagcccaccg aatccatcgt gcggttcccc 960
aatatcacca atctgtgccc cttcggcgag gtgttcaatg ccaccagatt cgcctctgtg 1020
tacgcctgga accggaagcg gatcagcaat tgcgtggccg actactccgt gctgtacaac 1080
tccgccagct tcagcacctt caagtgctac ggcgtgtccc ctaccaagct gaacgacctg 1140
tgcttcacaa acgtgtacgc cgacagcttc gtgatccggg gagatgaagt gcggcagatt 1200
gcccctggac agacaggcaa gatcgccgac tacaactaca agctgcccga cgacttcacc 1260
ggctgtgtga ttgcctggaa cagcaacaac ctggactcca aagtcggcgg caactacaat 1320
tacctgtacc ggctgttccg gaagtccaat ctgaagccct tcgagcggga catctccacc 1380
gagatctatc aggccggcag caccccttgt aacggcgtgg aaggcttcaa ctgctacttc 1440
ccactgcagt cctacggctt tcagcccaca aatggcgtgg gctaccagcc ttacagagtg 1500
gtggtgctga gcttcgagct gctgcatgct cctgccacag tgtgcggccc taagaaaagc 1560
accaatctcg tgaagaacaa atgcgtgaac ttcaacttca acggcctgac cggcaccggc 1620
gtgctgacag agagcaacaa gaagttcctg ccattccagc agttcggccg ggatatcgcc 1680
gataccacag acgccgttag agatccccag acactggaaa tcctggacat caccccttgc 1740
agcttcggcg gagtgtctgt gatcacccct ggcaccaaca ccagcaatca ggtggcagtg 1800
ctgtaccagg acgtgaactg taccgaagtg cccgtggcca ttcacgccga tcagctgaca 1860
cctacatggc gggtgtactc caccggcagc aatgtgtttc agaccagagc cggctgtctg 1920
atcggagccg agcacgtgaa caatagctac gagtgcgaca tccccatcgg cgctggcatc 1980
tgtgccagct accagacaca gacaaacagc cccagacggg ccagataata g 2031
<210> 19
<211> 3822
<212> RNA
<213> coronavirus (coronavirus)
<400> 19
auguuuguuu uucuuguuuu auugccacua gucucuaguc aguguguuaa ucuuacaacc 60
agaacucaau uacccccugc auacacuaau ucuuucacac gugguguuua uuacccugac 120
aaaguuuuca gauccucagu uuuacauuca acucaggacu uguucuuacc uuucuuuucc 180
aauguuacuu gguuccaugc uauacauguc ucugggacca augguacuaa gagguuugau 240
aacccugucc uaccauuuaa ugaugguguu uauuuugcuu ccacugagaa gucuaacaua 300
auaagaggcu ggauuuuugg uacuacuuua gauucgaaga cccagucccu acuuauuguu 360
aauaacgcua cuaauguugu uauuaaaguc ugugaauuuc aauuuuguaa ugauccauuu 420
uuggguguuu auuaccacaa aaacaacaaa aguuggaugg aaagugaguu cagaguuuau 480
ucuagugcga auaauugcac uuuugaauau gucucucagc cuuuucuuau ggaccuugaa 540
ggaaaacagg guaauuucaa aaaucuuagg gaauuugugu uuaagaauau ugaugguuau 600
uuuaaaauau auucuaagca cacgccuauu aauuuagugc gugaucuccc ucaggguuuu 660
ucggcuuuag aaccauuggu agauuugcca auagguauua acaucacuag guuucaaacu 720
uuacuugcuu uacauagaag uuauuugacu ccuggugauu cuucuucagg uuggacagcu 780
ggugcugcag cuuauuaugu ggguuaucuu caaccuagga cuuuucuauu aaaauauaau 840
gaaaauggaa ccauuacaga ugcuguagac ugugcacuug acccucucuc agaaacaaag 900
uguacguuga aauccuucac uguagaaaaa ggaaucuauc aaacuucuaa cuuuagaguc 960
caaccaacag aaucuauugu uagauuuccu aauauuacaa acuugugccc uuuuggugaa 1020
guuuuuaacg ccaccagauu ugcaucuguu uaugcuugga acaggaagag aaucagcaac 1080
uguguugcug auuauucugu ccuauauaau uccgcaucau uuuccacuuu uaaguguuau 1140
ggagugucuc cuacuaaauu aaaugaucuc ugcuuuacua augucuaugc agauucauuu 1200
guaauuagag gugaugaagu cagacaaauc gcuccagggc aaacuggaaa gauugcugau 1260
uauaauuaua aauuaccaga ugauuuuaca ggcugcguua uagcuuggaa uucuaacaau 1320
cuugauucua agguuggugg uaauuauaau uaccuguaua gauuguuuag gaagucuaau 1380
cucaaaccuu uugagagaga uauuucaacu gaaaucuauc aggccgguag cacaccuugu 1440
aaugguguug aagguuuuaa uuguuacuuu ccuuuacaau cauaugguuu ccaacccacu 1500
aaugguguug guuaccaacc auacagagua guaguacuuu cuuuugaacu ucuacaugca 1560
ccagcaacug uuuguggacc uaaaaagucu acuaauuugg uuaaaaacaa augugucaau 1620
uucaacuuca augguuuaac aggcacaggu guucuuacug agucuaacaa aaaguuucug 1680
ccuuuccaac aauuuggcag agacauugcu gacacuacug augcuguccg ugauccacag 1740
acacuugaga uucuugacau uacaccaugu ucuuuuggug gugucagugu uauaacacca 1800
ggaacaaaua cuucuaacca gguugcuguu cuuuaucagg auguuaacug cacagaaguc 1860
ccuguugcua uucaugcaga ucaacuuacu ccuacuuggc guguuuauuc uacagguucu 1920
aauguuuuuc aaacacgugc aggcuguuua auaggggcug aacaugucaa caacucauau 1980
gagugugaca uacccauugg ugcagguaua ugcgcuaguu aucagacuca gacuaauucu 2040
ccucggcggg cacguagugu agcuagucaa uccaucauug ccuacacuau gucacuuggu 2100
gcagaaaauu caguugcuua cucuaauaac ucuauugcca uacccacaaa uuuuacuauu 2160
aguguuacca cagaaauucu accagugucu augaccaaga caucaguaga uuguacaaug 2220
uacauuugug gugauucaac ugaaugcagc aaucuuuugu ugcaauaugg caguuuuugu 2280
acacaauuaa accgugcuuu aacuggaaua gcuguugaac aagacaaaaa cacccaagaa 2340
guuuuugcac aagucaaaca aauuuacaaa acaccaccaa uuaaagauuu uggugguuuu 2400
aauuuuucac aaauauuacc agauccauca aaaccaagca agaggucauu uauugaagau 2460
cuacuuuuca acaaagugac acuugcagau gcuggcuuca ucaaacaaua uggugauugc 2520
cuuggugaua uugcugcuag agaccucauu ugugcacaaa aguuuaacgg ccuuacuguu 2580
uugccaccuu ugcucacaga ugaaaugauu gcucaauaca cuucugcacu guuagcgggu 2640
acaaucacuu cugguuggac cuuuggugca ggugcugcau uacaaauacc auuugcuaug 2700
caaauggcuu auagguuuaa ugguauugga guuacacaga auguucucua ugagaaccaa 2760
aaauugauug ccaaccaauu uaauagugcu auuggcaaaa uucaagacuc acuuucuucc 2820
acagcaagug cacuuggaaa acuucaagau guggucaacc aaaaugcaca agcuuuaaac 2880
acgcuuguua aacaacuuag cuccaauuuu ggugcaauuu caaguguuuu aaaugauauc 2940
cuuucacguc uugacaaagu ugaggcugaa gugcaaauug auagguugau cacaggcaga 3000
cuucaaaguu ugcagacaua ugugacucaa caauuaauua gagcugcaga aaucagagcu 3060
ucugcuaauc uugcugcuac uaaaauguca gaguguguac uuggacaauc aaaaagaguu 3120
gauuuuugug gaaagggcua ucaucuuaug uccuucccuc agucagcacc ucauggugua 3180
gucuucuugc augugacuua ugucccugca caagaaaaga acuucacaac ugcuccugcc 3240
auuugucaug auggaaaagc acacuuuccu cgugaaggug ucuuuguuuc aaauggcaca 3300
cacugguuug uaacacaaag gaauuuuuau gaaccacaaa ucauuacuac agacaacaca 3360
uuugugucug guaacuguga uguuguaaua ggaauuguca acaacacagu uuaugauccu 3420
uugcaaccug aauuagacuc auucaaggag gaguuagaua aauauuuuaa gaaucauaca 3480
ucaccagaug uugauuuagg ugacaucucu ggcauuaaug cuucaguugu aaacauucaa 3540
aaagaaauug accgccucaa ugagguugcc aagaauuuaa augaaucucu caucgaucuc 3600
caagaacuug gaaaguauga gcaguauaua aaauggccau gguacauuug gcuagguuuu 3660
auagcuggcu ugauugccau aguaauggug acaauuaugc uuugcuguau gaccaguugc 3720
uguaguuguc ucaagggcug uuguucuugu ggauccugcu gcaaauuuga ugaagacgac 3780
ucugagccag ugcucaaagg agucaaauua cauuacacau aa 3822
<210> 20
<211> 3825
<212> RNA
<213> Artificial Sequence (Artificial Sequence)
<400> 20
auguucgucu uccuggugcu gcugccucug gugucuuccc agugcgugaa ucugacuacc 60
aggacccagc ugcccccugc cuauaccaau uccuucacac ggggcgugua cuaucccgac 120
aagguguuua gaagcuccgu gcugcacucu acacaggauc uguuucugcc uuucuuuagc 180
aacgugaccu gguuccacgc cauccacgug agcggcacca auggcacaaa gcgguucgac 240
aauccagugc ugcccuuuaa cgauggcgug uacuucgccu cuaccgagaa gagcaacauc 300
aucagaggcu ggaucuuugg caccacacug gacuccaaga cacagucucu gcugaucgug 360
aacaaugcca ccaacguggu caucaaggug ugcgaguucc aguuuuguaa ugauccauuc 420
cugggcgugu acuaucacaa gaacaauaag agcuggaugg aguccgaguu ucgcguguau 480
ucuagcgcca acaauugcac auuugaguac gugucccagc ccuuccugau ggaccuggag 540
ggcaagcagg gcaauuucaa gaaccugagg gaguucgugu uuaagaauau cgauggcuac 600
uucaagaucu acucuaagca caccccaauc aaccuggugc gcgaccugcc acagggcuuc 660
agcgcccugg agccacuggu ggaucugccc aucggcauca acaucacccg guuucagaca 720
cugcuggccc ugcacagaag cuaccugaca ccaggcgacu ccucuagcgg auggaccgca 780
ggagcagcag ccuacuaugu gggcuaucug cagcccagga ccuuccugcu gaaguacaac 840
gagaauggca ccaucacaga cgccguggau ugcgcccugg auccccugag cgagacaaag 900
uguacacuga aguccuuuac cguggagaag ggcaucuauc agacauccaa uuucagggug 960
cagccuaccg agucuaucgu gcgcuuuccc aauaucacaa accugugccc uuuuggcgag 1020
guguucaacg caaccagguu cgcaagcgug uacgcaugga auaggaagcg caucucuaac 1080
ugcguggccg acuauagcgu gcuguacaac uccgccucuu ucagcaccuu uaagugcuau 1140
ggcguguccc ccacaaagcu gaaugaccug ugcuuuacca acguguacgc cgauucuuuc 1200
gugaucaggg gcgacgaggu gcgccagauc gcaccaggac agacaggcaa gaucgcagac 1260
uacaauuaua agcugccuga cgauuucacc ggcugcguga ucgccuggaa cagcaacaau 1320
cuggauucca aagugggcgg caacuacaau uaucuguacc ggcuguuuag aaagagcaau 1380
cugaagccau ucgagaggga caucucuaca gagaucuacc aggcaggaag caccccaugc 1440
aauggagugg agggcuuuaa cuguuauuuc ccucugcagu ccuacggcuu ccagccaacc 1500
aacggcgugg gcuaucagcc cuaccgcgug guggugcuga gcuuugagcu gcugcacgca 1560
ccugcaacag ugugcggacc aaagaagucc accaaucugg ugaagaacaa gugcgugaac 1620
uucaacuuca acggccugac cggaacaggc gugcugaccg aguccaacaa gaaguuccug 1680
ccuuuucagc aguucggcag ggacaucgca gauaccacag acgccgugcg cgacccucag 1740
acccuggaga uccuggauau cacaccaugc ucuuucggcg gcgugagcgu gaucacacca 1800
ggcaccaaua caagcaacca gguggccgug cuguaucagg acgugaauug uaccgaggug 1860
ccaguggcaa uccacgcaga ucagcugacc ccuacauggc ggguguacag caccggcucc 1920
aacguguucc agacaagagc aggaugucug aucggagcag agcacgugaa caauuccuau 1980
gagugcgaca ucccuaucgg cgccggcauc ugugccucuu accagaccca gacaaacucu 2040
ccaaggagag cacggagcgu ggcaucccag ucuaucaucg ccuauaccau gucccugggc 2100
gccgagaauu cuguggccua cucuaacaau agcaucgcca ucccuaccaa cuucacaauc 2160
ucugugacca cagagauccu gccagugucc augaccaaga caucugugga cugcacaaug 2220
uauaucugug gcgauucuac cgagugcagc aaccugcugc ugcaguacgg cagcuuuugu 2280
acccagcuga auagagcccu gacaggcauc gccguggagc aggauaagaa cacacaggag 2340
guguucgccc aggugaagca gaucuacaag accccaccca ucaaggacuu uggcggcuuc 2400
aauuuuuccc agauccugcc cgauccuucc aagcccucua agcggagcuu uaucgaggac 2460
cugcuguuca acaaggugac ccuggccgau gccggcuuca ucaagcagua uggcgauugc 2520
cugggcgaca ucgcagcacg ggaccugauc ugugcccaga aguuuaaugg ccugaccgug 2580
cugccuccac ugcugacaga ugagaugauc gcacaguaca caagcgcccu gcuggcagga 2640
accaucacau ccggauggac cuucggcgca ggagccgccc ugcagauccc cuuugccaug 2700
cagauggccu aucgguucaa cggcaucggc gugacccaga augugcugua cgagaaccag 2760
aagcugaucg ccaaucaguu uaacuccgcc aucggcaaga uccaggacag ccuguccucu 2820
acagccuccg cccugggcaa gcugcaggau guggugaauc agaacgccca ggcccugaau 2880
acccugguga agcagcugag cuccaacuuc ggcgccaucu cuagcgugcu gaaugauauc 2940
cugagccggc uggacaaggu ggaggcagag gugcagaucg accggcugau cacaggcaga 3000
cugcagucuc ugcagaccua ugugacacag cagcugauca gggcagcaga gaucagggca 3060
agcgccaauc uggcagcaac caagaugucc gagugcgugc ugggccaguc uaagagagug 3120
gacuuuugug gcaagggcua ucaccugaug uccuucccac agucugcccc ucacggagug 3180
guguuucugc acgugaccua cgugccagcc caggagaaga acuucaccac agcaccagca 3240
aucugccacg auggcaaggc acacuuuccu agggagggcg uguucguguc caacggcacc 3300
cacugguuug ugacacagcg caauuucuac gagccacaga ucaucaccac agacaauacc 3360
uucgugagcg gcaacuguga cguggucauc ggcaucguga acaauaccgu guaugauccu 3420
cugcagccag agcuggacag cuuuaaggag gagcuggaua aguacuucaa gaaucacacc 3480
ucccccgacg uggaucuggg cgacaucagc ggcaucaaug ccuccguggu gaacauccag 3540
aaggagaucg acaggcugaa cgagguggcc aagaaucuga acgagagccu gaucgaucug 3600
caggagcugg gcaaguauga gcaguacauc aaguggccuu gguacaucug gcugggcuuc 3660
aucgccggcc ugaucgccau cgugauggug accaucaugc ugugcuguau gacauccugc 3720
uguucuugcc ugaagggcug cuguagcugc ggcuccuguu guaaauucga ugaggaugau 3780
uccgagccug ugcugaaggg cgugaaacug cauuauaccu aauag 3825
<210> 21
<211> 768
<212> RNA
<213> coronavirus (coronavirus)
<400> 21
augccuaaua uuacaaacuu gugcccuuuu ggugaaguuu uuaacgccac cagauuugca 60
ucuguuuaug cuuggaacag gaagagaauc agcaacugug uugcugauua uucuguccua 120
uauaauuccg caucauuuuc cacuuuuaag uguuauggag ugucuccuac uaaauuaaau 180
gaucucugcu uuacuaaugu cuaugcagau ucauuuguaa uuagagguga ugaagucaga 240
caaaucgcuc cagggcaaac uggaaagauu gcugauuaua auuauaaauu accagaugau 300
uuuacaggcu gcguuauagc uuggaauucu aacaaucuug auucuaaggu uggugguaau 360
uauaauuacc uguauagauu guuuaggaag ucuaaucuca aaccuuuuga gagagauauu 420
ucaacugaaa ucuaucaggc cgguagcaca ccuuguaaug guguugaagg uuuuaauugu 480
uacuuuccuu uacaaucaua ugguuuccaa cccacuaaug guguugguua ccaaccauac 540
agaguaguag uacuuucuuu ugaacuucua caugcaccag caacuguuug uggaccuaaa 600
aagucuacua auuugguuaa aaacaaaugu gucaauuuca acuucaaugg uuuaacaggc 660
acagguguuc uuacugaguc uaacaaaaag uuucugccuu uccaacaauu uggcagagac 720
auugcugaca cuacugaugc uguccgugau ccacagacac uugaguaa 768
<210> 22
<211> 771
<212> RNA
<213> Artificial Sequence (Artificial Sequence)
<400> 22
augccuaaua uuacaaacuu gugcccuuuu ggugaaguuu uuaacgccac cagauuugca 60
ucuguuuaug cuuggaacag gaagagaauc agcaacugug uugcugauua uucuguccua 120
uauaauuccg caucauuuuc cacuuuuaag uguuauggag ugucuccuac uaaauuaaau 180
gaucucugcu uuacuaaugu cuaugcagau ucauuuguaa uuagagguga ugaagucaga 240
caaaucgcuc cagggcaaac uggaaagauu gcugauuaua auuauaaauu accagaugau 300
uuuacaggcu gcguuauagc uuggaauucu aacaaucuug auucuaaggu uggugguaau 360
uauaauuacc uguauagauu guuuaggaag ucuaaucuca aaccuuuuga gagagauauu 420
ucaacugaaa ucuaucaggc cgguagcaca ccuuguaaug guguugaagg uuuuaauugu 480
uacuuuccuu uacaaucaua ugguuuccaa cccacuaaug guguugguua ccaaccauac 540
agaguaguag uacuuucuuu ugaacuucua caugcaccag caacuguuug uggaccuaaa 600
aagucuacua auuugguuaa aaacaaaugu gucaauuuca acuucaaugg uuuaacaggc 660
acagguguuc uuacugaguc uaacaaaaag uuucugccuu uccaacaauu uggcagagac 720
auugcugaca cuacugaugc uguccgugau ccacagacac uugaguaaua g 771
<210> 23
<211> 669
<212> RNA
<213> coronavirus (coronavirus)
<400> 23
auggcagauu ccaacgguac uauuaccguu gaagagcuua aaaagcuccu ugaacaaugg 60
aaccuaguaa uagguuuccu auuccuuaca uggauuuguc uucuacaauu ugccuaugcc 120
aacaggaaua gguuuuugua uauaauuaag uuaauuuucc ucuggcuguu auggccagua 180
acuuuagcuu guuuugugcu ugcugcuguu uacagaauaa auuggaucac cgguggaauu 240
gcuaucgcaa uggcuugucu uguaggcuug auguggcuca gcuacuucau ugcuucuuuc 300
agacuguuug cgcguacgcg uuccaugugg ucauucaauc cagaaacuaa cauucuucuc 360
aacgugccac uccauggcac uauucugacc agaccgcuuc uagaaaguga acucguaauc 420
ggagcuguga uccuucgugg acaucuucgu auugcuggac accaucuagg acgcugugac 480
aucaaggacc ugccuaaaga aaucacuguu gcuacaucac gaacgcuuuc uuauuacaaa 540
uugggagcuu cgcagcgugu agcaggugac ucagguuuug cugcauacag ucgcuacagg 600
auuggcaacu auaaauuaaa cacagaccau uccaguagca gugacaauau ugcuuugcuu 660
<210> 24
<211> 672
<212> RNA
<213> Artificial Sequence (Artificial Sequence)
<400> 24
auggccgaua gcaacggcac caucaccgug gaagaacuga agaaacugcu ggaacagugg 60
aaccucguga ucggcuuccu guuccugacc uggaucugcc ugcugcaguu cgccuacgcc 120
aaccggaaca gauuccugua uauuaucaag cugaucuucc uguggcugcu guggcccgug 180
acacuggccu guuuugugcu ggccgccgug uaccggauca acuggaucac aggcggaauc 240
gccauugcca uggccugucu cguuggccug auguggcuga gcuacuuuau cgccagcuuc 300
cggcuguucg cccggaccag auccaugugg uccuucaauc ccgagacaaa cauccugcug 360
aacgugcccc ugcacggcac aauccugaca agaccucugc uggaaagcga gcugguuauc 420
ggcgccguga uccugagagg ccaccugaga auugccggac accaccuggg cagaugcgac 480
aucaaggacc ugccuaaaga aaucacagug gccaccagca gaacccuguc cuacuauaag 540
cugggcgcca gccagagagu ggccggcgau ucuggauuug ccgccuacag cagauaccgg 600
aucggcaacu acaagcugaa caccgaccac agcuccagca gcgacaauau cgcacugcug 660
<210> 25
<211> 1260
<212> RNA
<213> coronavirus (coronavirus)
<400> 25
augucugaua auggacccca aaaucagcga aaugcacccc gcauuacguu ugguggaccc 60
ucagauucaa cuggcaguaa ccagaaugga gaacgcagug gggcgcgauc aaaacaacgu 120
cggccccaag guuuacccaa uaauacugcg ucuugguuca ccgcucucac ucaacauggc 180
aaggaagacc uuaaauuccc ucgaggacaa ggcguuccaa uuaacaccaa uagcagucca 240
gaugaccaaa uuggcuacua ccgaagagcu accagacgaa uucguggugg ugacgguaaa 300
augaaagauc ucaguccaag augguauuuc uacuaccuag gaacugggcc agaagcugga 360
cuucccuaug gugcuaacaa agacggcauc auauggguug caacugaggg agccuugaau 420
acaccaaaag aucacauugg cacccgcaau ccugcuaaca augcugcaau cgugcuacaa 480
cuuccucaag gaacaacauu gccaaaaggc uucuacgcag aagggagcag aggcggcagu 540
caagccucuu cucguuccuc aucacguagu cgcaacaguu caagaaauuc aacuccaggc 600
agcaguaggg gaacuucucc ugcuagaaug gcuggcaaug gcggugaugc ugcucuugcu 660
uugcugcugc uugacagauu gaaccagcuu gagagcaaaa ugucugguaa aggccaacaa 720
caacaaggcc aaacugucac uaagaaaucu gcugcugagg cuucuaagaa gccucggcaa 780
aaacguacug ccacuaaagc auacaaugua acacaagcuu ucggcagacg ugguccagaa 840
caaacccaag gaaauuuugg ggaccaggaa cuaaucagac aaggaacuga uuacaaacau 900
uggccgcaaa uugcacaauu ugcccccagc gcuucagcgu ucuucggaau gucgcgcauu 960
ggcauggaag ucacaccuuc gggaacgugg uugaccuaca caggugccau caaauuggau 1020
gacaaagauc caaauuucaa agaucaaguc auuuugcuga auaagcauau ugacgcauac 1080
aaaacauucc caccaacaga gccuaaaaag gacaaaaaga agaaggcuga ugaaacucaa 1140
gccuuaccgc agagacagaa gaaacagcaa acugugacuc uucuuccugc ugcagauuug 1200
gaugauuucu ccaaacaauu gcaacaaucc augagcagug cugacucaac ucaggccuaa 1260
<210> 26
<211> 1263
<212> RNA
<213> Artificial Sequence (Artificial Sequence)
<400> 26
augucugaua auggacccca aaaucagcga aaugcacccc gcauuacguu ugguggaccc 60
ucagauucaa cuggcaguaa ccagaaugga gaacgcagug gggcgcgauc aaaacaacgu 120
cggccccaag guuuacccaa uaauacugcg ucuugguuca ccgcucucac ucaacauggc 180
aaggaagacc uuaaauuccc ucgaggacaa ggcguuccaa uuaacaccaa uagcagucca 240
gaugaccaaa uuggcuacua ccgaagagcu accagacgaa uucguggugg ugacgguaaa 300
augaaagauc ucaguccaag augguauuuc uacuaccuag gaacugggcc agaagcugga 360
cuucccuaug gugcuaacaa agacggcauc auauggguug caacugaggg agccuugaau 420
acaccaaaag aucacauugg cacccgcaau ccugcuaaca augcugcaau cgugcuacaa 480
cuuccucaag gaacaacauu gccaaaaggc uucuacgcag aagggagcag aggcggcagu 540
caagccucuu cucguuccuc aucacguagu cgcaacaguu caagaaauuc aacuccaggc 600
agcaguaggg gaacuucucc ugcuagaaug gcuggcaaug gcggugaugc ugcucuugcu 660
uugcugcugc uugacagauu gaaccagcuu gagagcaaaa ugucugguaa aggccaacaa 720
caacaaggcc aaacugucac uaagaaaucu gcugcugagg cuucuaagaa gccucggcaa 780
aaacguacug ccacuaaagc auacaaugua acacaagcuu ucggcagacg ugguccagaa 840
caaacccaag gaaauuuugg ggaccaggaa cuaaucagac aaggaacuga uuacaaacau 900
uggccgcaaa uugcacaauu ugcccccagc gcuucagcgu ucuucggaau gucgcgcauu 960
ggcauggaag ucacaccuuc gggaacgugg uugaccuaca caggugccau caaauuggau 1020
gacaaagauc caaauuucaa agaucaaguc auuuugcuga auaagcauau ugacgcauac 1080
aaaacauucc caccaacaga gccuaaaaag gacaaaaaga agaaggcuga ugaaacucaa 1140
gccuuaccgc agagacagaa gaaacagcaa acugugacuc uucuuccugc ugcagauuug 1200
gaugauuucu ccaaacaauu gcaacaaucc augagcagug cugacucaac ucaggccuaa 1260
<210> 27
<211> 600
<212> RNA
<213> coronavirus (coronavirus)
<400> 27
augauuacaa acuugugccc uuuuggugaa guuuuuaacg ccaccagauu ugcaucuguu 60
uaugcuugga acaggaagag aaucagcaac uguguugcug auuauucugu ccuauauaau 120
uccgcaucau uuuccacuuu uaaguguuau ggagugucuc cuacuaaauu aaaugaucuc 180
ugcuuuacua augucuaugc agauucauuu guaauuagag gugaugaagu cagacaaauc 240
gcuccagggc aaacuggaaa gauugcugau uauaauuaua aauuaccaga ugauuuuaca 300
ggcugcguua uagcuuggaa uucuaacaau cuugauucua agguuggugg uaauuauaau 360
uaccuguaua gauuguuuag gaagucuaau cucaaaccuu uugagagaga uauuucaacu 420
gaaaucuauc aggccgguag cacaccuugu aaugguguug aagguuuuaa uuguuacuuu 480
ccuuuacaau cauaugguuu ccaacccacu aaugguguug guuaccaacc auacagagua 540
guaguacuuu cuuuugaacu ucuacaugca ccagcaacug uuuguggacc uaaaaaguaa 600
<210> 28
<211> 603
<212> RNA
<213> Artificial Sequence (Artificial Sequence)
<400> 28
augaucacca aucugugccc cuucggcgag guguucaacg ccacaagauu cgccucugug 60
uacgccugga accggaagcg gaucagcaau ugcguggccg acuacagcgu gcuguacaac 120
agcgccagcu ucagcaccuu caagugcuac ggcguguccc cuaccaagcu gaacgaccug 180
ugcuucacca acguguacgc cgacagcuuc gugaucagag gcgacgaagu gcggcagauu 240
gccccuggac agacaggcaa gaucgccgau uacaacuaca agcugcccga cgacuucacc 300
ggcuguguga uugccuggaa cagcaacaac cuggacagca aagucggcgg caacuacaac 360
uaccuguacc ggcuguuccg gaaguccaac cugaagccuu ucgagcggga caucagcacc 420
gagaucuauc aggccggcag caccccuugc aauggcgugg aaggcuucaa cugcuacuuc 480
ccacugcagu ccuacggcuu ccagccuaca aacggcgugg gcuaccagcc uuacagagug 540
guggugcuga gcuucgagcu gcugcaugcu ccugccacag ugugcggacc uaagaaguaa 600
<210> 29
<211> 600
<212> RNA
<213> coronavirus (coronavirus)
<400> 29
augauuacaa acuugugccc uuuuggugaa guuuuuaacg ccaccagauu ugcaucuguu 60
uaugcuugga acaggaagag aaucagcaac uguguugcug auuauucugu ccuauauaau 120
uccgcaucau uuuccacuuu uaaguguuau ggagugucuc cuacuaaauu aaaugaucuc 180
ugcuuuacua augucuaugc agauucauuu guaauuagag gugaugaagu cagacaaauc 240
gcuccagggc aaacuggaaa gauugcugau uauaauuaua aauuaccaga ugauuuuaca 300
ggcugcguua uagcuuggaa uucuaacaau cuugauucua agguuggugg uaauuauaau 360
uaccuguaua gauuguuuag gaagucuaau cucaaaccuu uugagagaga uauuucaacu 420
gaaaucuauc aggccgguag cacaccuugu aaugguguug aagguuuuaa uuguuacuuu 480
ccuuuacaau cauaugguuu ccaacccacu aaugguguug guuaccaacc auacagagua 540
guaguacuuu cuuuugaacu ucuacaugca ccagcaacug uuuguggacc uaaaaaguaa 600
<210> 30
<211> 603
<212> RNA
<213> Artificial Sequence (Artificial Sequence)
<400> 30
augaucacca aucugugccc cuucggcgag guguucaacg ccacaagauu cgccucugug 60
uacgccugga accggaagcg gaucagcaau ugcguggccg acuacagcgu gcuguacaac 120
agcgccagcu ucagcaccuu caagugcuac ggcguguccc cuaccaagcu gaacgaccug 180
ugcuucacca acguguacgc cgacagcuuc gugaucagag gcgacgaagu gcggcagauu 240
gccccuggac agacaggcaa gaucgccgau uacaacuaca agcugcccga cgacuucacc 300
ggcuguguga uugccuggaa cagcaacaac cuggacagca aagucggcgg caacuacaac 360
uaccuguacc ggcuguuccg gaaguccaac cugaagccuu ucgagcggga caucagcacc 420
gagaucuauc aggccggcag caccccuugc aauggcgugg aaggcuucaa cugcuacuuc 480
ccacugcagu ccuacggcuu ccagccuaca aacggcgugg gcuaccagcc uuacagagug 540
guggugcuga gcuucgaacu gcugcacgcc aaugccacag ugugcggccc uaagaaauaa 600
<210> 31
<211> 228
<212> RNA
<213> coronavirus (coronavirus)
<400> 31
auguacucau ucguuucgga agagacaggu acguuaauag uuaauagcgu acuucuuuuu 60
cuugcuuucg ugguauucuu gcuaguuaca cuagccaucc uuacugcgcu ucgauugugu 120
gcguacugcu gcaauauugu uaacgugagu cuuguaaaac cuucuuuuua cguuuacucu 180
cguguuaaaa aucugaauuc uucuagaguu ccugaucuuc uggucuaa 228
<210> 32
<211> 231
<212> RNA
<213> Artificial Sequence (Artificial Sequence)
<400> 32
auguacagcu ucguguccga ggaaaccggc acacugaucg ugaacagcgu gcugcuguuc 60
cuggccuucg ugguguuucu gcuggucacc cuggccaucc ugacagcccu gagacugugc 120
gccuacugcu gcaacaucgu gaacgugucc cuggucaagc ccagcuucua cguguacagc 180
agagugaaga accugaacag cuccagagug cccgaccugc ugguguaaua g 231
<210> 33
<211> 3612
<212> RNA
<213> coronavirus (coronavirus)
<400> 33
augucuaguc aguguguuaa ucuuacaacc agaacucaau uacccccugc auacacuaau 60
ucuuucacac gugguguuua uuacccugac aaaguuuuca gauccucagu uuuacauuca 120
acucaggacu uguucuuacc uuucuuuucc aauguuacuu gguuccaugc uauacauguc 180
ucugggacca augguacuaa gagguuugau aacccugucc uaccauuuaa ugaugguguu 240
uauuuugcuu ccacugagaa gucuaacaua auaagaggcu ggauuuuugg uacuacuuua 300
gauucgaaga cccagucccu acuuauuguu aauaacgcua cuaauguugu uauuaaaguc 360
ugugaauuuc aauuuuguaa ugauccauuu uuggguguuu auuaccacaa aaacaacaaa 420
aguuggaugg aaagugaguu cagaguuuau ucuagugcga auaauugcac uuuugaauau 480
gucucucagc cuuuucuuau ggaccuugaa ggaaaacagg guaauuucaa aaaucuuagg 540
gaauuugugu uuaagaauau ugaugguuau uuuaaaauau auucuaagca cacgccuauu 600
aauuuagugc gugaucuccc ucaggguuuu ucggcuuuag aaccauuggu agauuugcca 660
auagguauua acaucacuag guuucaaacu uuacuugcuu uacauagaag uuauuugacu 720
ccuggugauu cuucuucagg uuggacagcu ggugcugcag cuuauuaugu ggguuaucuu 780
caaccuagga cuuuucuauu aaaauauaau gaaaauggaa ccauuacaga ugcuguagac 840
ugugcacuug acccucucuc agaaacaaag uguacguuga aauccuucac uguagaaaaa 900
ggaaucuauc aaacuucuaa cuuuagaguc caaccaacag aaucuauugu uagauuuccu 960
aauauuacaa acuugugccc uuuuggugaa guuuuuaacg ccaccagauu ugcaucuguu 1020
uaugcuugga acaggaagag aaucagcaac uguguugcug auuauucugu ccuauauaau 1080
uccgcaucau uuuccacuuu uaaguguuau ggagugucuc cuacuaaauu aaaugaucuc 1140
ugcuuuacua augucuaugc agauucauuu guaauuagag gugaugaagu cagacaaauc 1200
gcuccagggc aaacuggaaa gauugcugau uauaauuaua aauuaccaga ugauuuuaca 1260
ggcugcguua uagcuuggaa uucuaacaau cuugauucua agguuggugg uaauuauaau 1320
uaccuguaua gauuguuuag gaagucuaau cucaaaccuu uugagagaga uauuucaacu 1380
gaaaucuauc aggccgguag cacaccuugu aaugguguug aagguuuuaa uuguuacuuu 1440
ccuuuacaau cauaugguuu ccaacccacu aaugguguug guuaccaacc auacagagua 1500
guaguacuuu cuuuugaacu ucuacaugca ccagcaacug uuuguggacc uaaaaagucu 1560
acuaauuugg uuaaaaacaa augugucaau uucaacuuca augguuuaac aggcacaggu 1620
guucuuacug agucuaacaa aaaguuucug ccuuuccaac aauuuggcag agacauugcu 1680
gacacuacug augcuguccg ugauccacag acacuugaga uucuugacau uacaccaugu 1740
ucuuuuggug gugucagugu uauaacacca ggaacaaaua cuucuaacca gguugcuguu 1800
cuuuaucagg auguuaacug cacagaaguc ccuguugcua uucaugcaga ucaacuuacu 1860
ccuacuuggc guguuuauuc uacagguucu aauguuuuuc aaacacgugc aggcuguuua 1920
auaggggcug aacaugucaa caacucauau gagugugaca uacccauugg ugcagguaua 1980
ugcgcuaguu aucagacuca gacuaauucu ccucggcggg cacguagugu agcuagucaa 2040
uccaucauug ccuacacuau gucacuuggu gcagaaaauu caguugcuua cucuaauaac 2100
ucuauugcca uacccacaaa uuuuacuauu aguguuacca cagaaauucu accagugucu 2160
augaccaaga caucaguaga uuguacaaug uacauuugug gugauucaac ugaaugcagc 2220
aaucuuuugu ugcaauaugg caguuuuugu acacaauuaa accgugcuuu aacuggaaua 2280
gcuguugaac aagacaaaaa cacccaagaa guuuuugcac aagucaaaca aauuuacaaa 2340
acaccaccaa uuaaagauuu uggugguuuu aauuuuucac aaauauuacc agauccauca 2400
aaaccaagca agaggucauu uauugaagau cuacuuuuca acaaagugac acuugcagau 2460
gcuggcuuca ucaaacaaua uggugauugc cuuggugaua uugcugcuag agaccucauu 2520
ugugcacaaa aguuuaacgg ccuuacuguu uugccaccuu ugcucacaga ugaaaugauu 2580
gcucaauaca cuucugcacu guuagcgggu acaaucacuu cugguuggac cuuuggugca 2640
ggugcugcau uacaaauacc auuugcuaug caaauggcuu auagguuuaa ugguauugga 2700
guuacacaga auguucucua ugagaaccaa aaauugauug ccaaccaauu uaauagugcu 2760
auuggcaaaa uucaagacuc acuuucuucc acagcaagug cacuuggaaa acuucaagau 2820
guggucaacc aaaaugcaca agcuuuaaac acgcuuguua aacaacuuag cuccaauuuu 2880
ggugcaauuu caaguguuuu aaaugauauc cuuucacguc uugacaaagu ugaggcugaa 2940
gugcaaauug auagguugau cacaggcaga cuucaaaguu ugcagacaua ugugacucaa 3000
caauuaauua gagcugcaga aaucagagcu ucugcuaauc uugcugcuac uaaaauguca 3060
gaguguguac uuggacaauc aaaaagaguu gauuuuugug gaaagggcua ucaucuuaug 3120
uccuucccuc agucagcacc ucauggugua gucuucuugc augugacuua ugucccugca 3180
caagaaaaga acuucacaac ugcuccugcc auuugucaug auggaaaagc acacuuuccu 3240
cgugaaggug ucuuuguuuc aaauggcaca cacugguuug uaacacaaag gaauuuuuau 3300
gaaccacaaa ucauuacuac agacaacaca uuugugucug guaacuguga uguuguaaua 3360
ggaauuguca acaacacagu uuaugauccu uugcaaccug aauuagacuc auucaaggag 3420
gaguuagaua aauauuuuaa gaaucauaca ucaccagaug uugauuuagg ugacaucucu 3480
ggcauuaaug cuucaguugu aaacauucaa aaagaaauug accgccucaa ugagguugcc 3540
aagaauuuaa augaaucucu caucgaucuc caagaacuug gaaaguauga gcaguauaua 3600
<210> 34
<211> 3615
<212> RNA
<213> Artificial Sequence (Artificial Sequence)
<400> 34
augagcagcc agugcgugaa ccugaccacc agaacucagc ugccuccagc cuacaccaac 60
agcuucacca gaggcgugua cuaccccgac aagguguuca gauccagcgu gcugcacucu 120
acccaggacc uguuccugcc uuucuucagc aacgugaccu gguuccacgc cauccacgug 180
uccggcacca auggcaccaa gagauucgac aaccccgugc ugcccuucaa cgacggggug 240
uacuuugcca gcaccgagaa guccaacauc aucagaggcu ggaucuucgg caccacacug 300
gacagcaaga cccagagccu gcugaucgug aacaacgcca ccaacguggu caucaaagug 360
ugcgaguucc aguucugcaa cgaccccuuc cugggcgucu acuaccacaa gaacaacaag 420
agcuggaugg aaagcgaguu ccggguguac agcagcgcca acaacugcac cuucgaguac 480
gugucccagc cuuuccugau ggaccuggaa ggcaagcagg gcaacuucaa gaaccugcgc 540
gaguucgugu ucaagaacau cgacggcuac uucaagaucu acagcaagca caccccuauc 600
aaccucgugc gggaucugcc ucagggcuuc ucugcucugg aaccccuggu ggaucugccc 660
aucggcauca acaucacccg guuucagaca cugcuggccc ugcacagaag cuaccugaca 720
ccuggcgaua gcagcucugg auggacagcu ggcgccgcug ccuacuaugu gggauaccug 780
cagccucgga ccuuccugcu gaaguacaac gagaacggca ccaucaccga cgccguggau 840
ugugcucugg auccucugag cgagacaaag ugcacccuga aguccuucac cguggaaaag 900
ggcaucuacc agaccagcaa cuuccgggug cagcccaccg aauccaucgu gcgguucccc 960
aauaucacca aucugugccc cuucggcgag guguucaaug ccaccagauu cgccucugug 1020
uacgccugga accggaagcg gaucagcaau ugcguggccg acuacuccgu gcuguacaac 1080
uccgccagcu ucagcaccuu caagugcuac ggcguguccc cuaccaagcu gaacgaccug 1140
ugcuucacaa acguguacgc cgacagcuuc gugauccggg gagaugaagu gcggcagauu 1200
gccccuggac agacaggcaa gaucgccgac uacaacuaca agcugcccga cgacuucacc 1260
ggcuguguga uugccuggaa cagcaacaac cuggacucca aagucggcgg caacuacaau 1320
uaccuguacc ggcuguuccg gaaguccaau cugaagcccu ucgagcggga caucuccacc 1380
gagaucuauc aggccggcag caccccuugu aacggcgugg aaggcuucaa cugcuacuuc 1440
ccacugcagu ccuacggcuu ucagcccaca aauggcgugg gcuaccagcc uuacagagug 1500
guggugcuga gcuucgagcu gcugcaugcu ccugccacag ugugcggccc uaagaaaagc 1560
accaaucucg ugaagaacaa augcgugaac uucaacuuca acggccugac cggcaccggc 1620
gugcugacag agagcaacaa gaaguuccug ccauuccagc aguucggccg ggauaucgcc 1680
gauaccacag acgccguuag agauccccag acacuggaaa uccuggacau caccccuugc 1740
agcuucggcg gagugucugu gaucaccccu ggcaccaaca ccagcaauca gguggcagug 1800
cuguaccagg acgugaacug uaccgaagug cccguggcca uucacgccga ucagcugaca 1860
ccuacauggc ggguguacuc caccggcagc aauguguuuc agaccagagc cggcugucug 1920
aucggagccg agcacgugaa caauagcuac gagugcgaca uccccaucgg cgcuggcauc 1980
ugugccagcu accagacaca gacaaacagc cccagacggg ccagaucugu ggccagccag 2040
agcaucauug ccuacacaau gucucugggc gccgagaaca gcguggccua cuccaacaac 2100
ucuaucgcua uccccaccaa cuucaccauc agcgugacca cagagauccu gccugugucc 2160
augaccaaga ccagcgugga cugcaccaug uacaucugcg gcgauuccac cgagugcucc 2220
aaccugcugc ugcaguacgg cagcuucugc acccagcuga auagagcccu gacagggauc 2280
gccguggaac aggacaagaa cacccaagag guguucgccc aagugaagca gaucuacaag 2340
accccuccua ucaaggacuu cggcggcuuc aauuucagcc agauucugcc cgauccuagc 2400
aagcccagca agcggagcuu caucgaggac cugcuguuca acaaagugac acuggccgac 2460
gccggcuuca ucaagcagua uggcgauugu cugggcgaca uugccgccag ggaucugauu 2520
ugcgcccaga aguuuaacgg acugacagug cugccuccuc ugcugaccga ugagaugauc 2580
gcccaguaca caucugcccu gcuggccggc acaaucacaa gcggcuggac auuuggagcu 2640
ggcgcugccc ugcagauccc cuuugcuaug cagauggccu accgguucaa cggcaucgga 2700
gugacccaga augugcugua cgagaaccag aagcugaucg ccaaccaguu caacagcgcc 2760
aucggcaaga uccaggacag ccugagcagc acagcaagcg cccugggaaa gcugcaggac 2820
guggucaacc agaaugccca ggcacugaac acccugguca agcagcuguc uagcaacuuc 2880
ggcgccauca gcucugugcu gaacgauauc cugagcagac uggacaaggu ggaagccgag 2940
gugcagaucg acagacugau caccggaagg cugcaguccc ugcagaccua cguuacccag 3000
cagcugauca gagccgccga gauuagagcc ucugccaauc uggccgccac caagaugucu 3060
gagugugugc ugggccagag caagagagug gacuuuugcg gcaagggcua ccaccugaug 3120
agcuucccuc agucugcccc ucacggcgug guguuucugc acgugacaua cgugcccgcu 3180
caagagaaga auuucaccac cgcuccagcc aucugccacg acggcaaagc ccacuuuccu 3240
agagaaggcg uguucgucag caacggcacc cauugguucg ugacccagcg gaacuucuac 3300
gagccccaga ucaucaccac cgacaacacc uucgugucug gcaacugcga cgucgugauc 3360
ggcauuguga acaauaccgu guacgacccu cugcagcccg agcuggacag cuucaaagag 3420
gaacuggaua aguacuuuaa gaaccacaca agccccgacg uggaccuggg cgauaucagc 3480
ggaaucaaug ccagcgucgu gaacauccag aaagagaucg accggcugaa cgagguggcc 3540
aagaaucuga acgagagccu gaucgaccug caagaacugg ggaaguacga gcaguacauc 3600
<210> 35
<211> 2028
<212> RNA
<213> coronavirus (coronavirus)
<400> 35
augucuaguc aguguguuaa ucuuacaacc agaacucaau uacccccugc auacacuaau 60
ucuuucacac gugguguuua uuacccugac aaaguuuuca gauccucagu uuuacauuca 120
acucaggacu uguucuuacc uuucuuuucc aauguuacuu gguuccaugc uauacauguc 180
ucugggacca augguacuaa gagguuugau aacccugucc uaccauuuaa ugaugguguu 240
uauuuugcuu ccacugagaa gucuaacaua auaagaggcu ggauuuuugg uacuacuuua 300
gauucgaaga cccagucccu acuuauuguu aauaacgcua cuaauguugu uauuaaaguc 360
ugugaauuuc aauuuuguaa ugauccauuu uuggguguuu auuaccacaa aaacaacaaa 420
aguuggaugg aaagugaguu cagaguuuau ucuagugcga auaauugcac uuuugaauau 480
gucucucagc cuuuucuuau ggaccuugaa ggaaaacagg guaauuucaa aaaucuuagg 540
gaauuugugu uuaagaauau ugaugguuau uuuaaaauau auucuaagca cacgccuauu 600
aauuuagugc gugaucuccc ucaggguuuu ucggcuuuag aaccauuggu agauuugcca 660
auagguauua acaucacuag guuucaaacu uuacuugcuu uacauagaag uuauuugacu 720
ccuggugauu cuucuucagg uuggacagcu ggugcugcag cuuauuaugu ggguuaucuu 780
caaccuagga cuuuucuauu aaaauauaau gaaaauggaa ccauuacaga ugcuguagac 840
ugugcacuug acccucucuc agaaacaaag uguacguuga aauccuucac uguagaaaaa 900
ggaaucuauc aaacuucuaa cuuuagaguc caaccaacag aaucuauugu uagauuuccu 960
aauauuacaa acuugugccc uuuuggugaa guuuuuaacg ccaccagauu ugcaucuguu 1020
uaugcuugga acaggaagag aaucagcaac uguguugcug auuauucugu ccuauauaau 1080
uccgcaucau uuuccacuuu uaaguguuau ggagugucuc cuacuaaauu aaaugaucuc 1140
ugcuuuacua augucuaugc agauucauuu guaauuagag gugaugaagu cagacaaauc 1200
gcuccagggc aaacuggaaa gauugcugau uauaauuaua aauuaccaga ugauuuuaca 1260
ggcugcguua uagcuuggaa uucuaacaau cuugauucua agguuggugg uaauuauaau 1320
uaccuguaua gauuguuuag gaagucuaau cucaaaccuu uugagagaga uauuucaacu 1380
gaaaucuauc aggccgguag cacaccuugu aaugguguug aagguuuuaa uuguuacuuu 1440
ccuuuacaau cauaugguuu ccaacccacu aaugguguug guuaccaacc auacagagua 1500
guaguacuuu cuuuugaacu ucuacaugca ccagcaacug uuuguggacc uaaaaagucu 1560
acuaauuugg uuaaaaacaa augugucaau uucaacuuca augguuuaac aggcacaggu 1620
guucuuacug agucuaacaa aaaguuucug ccuuuccaac aauuuggcag agacauugcu 1680
gacacuacug augcuguccg ugauccacag acacuugaga uucuugacau uacaccaugu 1740
ucuuuuggug gugucagugu uauaacacca ggaacaaaua cuucuaacca gguugcuguu 1800
cuuuaucagg auguuaacug cacagaaguc ccuguugcua uucaugcaga ucaacuuacu 1860
ccuacuuggc guguuuauuc uacagguucu aauguuuuuc aaacacgugc aggcuguuua 1920
auaggggcug aacaugucaa caacucauau gagugugaca uacccauugg ugcagguaua 1980
ugcgcuaguu aucagacuca gacuaauucu ccucggcggg cacguuaa 2028
<210> 36
<211> 2031
<212> RNA
<213> Artificial Sequence (Artificial Sequence)
<400> 36
augagcagcc agugcgugaa ccugaccacc agaacucagc ugccuccagc cuacaccaac 60
agcuucacca gaggcgugua cuaccccgac aagguguuca gauccagcgu gcugcacucu 120
acccaggacc uguuccugcc uuucuucagc aacgugaccu gguuccacgc cauccacgug 180
uccggcacca auggcaccaa gagauucgac aaccccgugc ugcccuucaa cgacggggug 240
uacuuugcca gcaccgagaa guccaacauc aucagaggcu ggaucuucgg caccacacug 300
gacagcaaga cccagagccu gcugaucgug aacaacgcca ccaacguggu caucaaagug 360
ugcgaguucc aguucugcaa cgaccccuuc cugggcgucu acuaccacaa gaacaacaag 420
agcuggaugg aaagcgaguu ccggguguac agcagcgcca acaacugcac cuucgaguac 480
gugucccagc cuuuccugau ggaccuggaa ggcaagcagg gcaacuucaa gaaccugcgc 540
gaguucgugu ucaagaacau cgacggcuac uucaagaucu acagcaagca caccccuauc 600
aaccucgugc gggaucugcc ucagggcuuc ucugcucugg aaccccuggu ggaucugccc 660
aucggcauca acaucacccg guuucagaca cugcuggccc ugcacagaag cuaccugaca 720
ccuggcgaua gcagcucugg auggacagcu ggcgccgcug ccuacuaugu gggauaccug 780
cagccucgga ccuuccugcu gaaguacaac gagaacggca ccaucaccga cgccguggau 840
ugugcucugg auccucugag cgagacaaag ugcacccuga aguccuucac cguggaaaag 900
ggcaucuacc agaccagcaa cuuccgggug cagcccaccg aauccaucgu gcgguucccc 960
aauaucacca aucugugccc cuucggcgag guguucaaug ccaccagauu cgccucugug 1020
uacgccugga accggaagcg gaucagcaau ugcguggccg acuacuccgu gcuguacaac 1080
uccgccagcu ucagcaccuu caagugcuac ggcguguccc cuaccaagcu gaacgaccug 1140
ugcuucacaa acguguacgc cgacagcuuc gugauccggg gagaugaagu gcggcagauu 1200
gccccuggac agacaggcaa gaucgccgac uacaacuaca agcugcccga cgacuucacc 1260
ggcuguguga uugccuggaa cagcaacaac cuggacucca aagucggcgg caacuacaau 1320
uaccuguacc ggcuguuccg gaaguccaau cugaagcccu ucgagcggga caucuccacc 1380
gagaucuauc aggccggcag caccccuugu aacggcgugg aaggcuucaa cugcuacuuc 1440
ccacugcagu ccuacggcuu ucagcccaca aauggcgugg gcuaccagcc uuacagagug 1500
guggugcuga gcuucgagcu gcugcaugcu ccugccacag ugugcggccc uaagaaaagc 1560
accaaucucg ugaagaacaa augcgugaac uucaacuuca acggccugac cggcaccggc 1620
gugcugacag agagcaacaa gaaguuccug ccauuccagc aguucggccg ggauaucgcc 1680
gauaccacag acgccguuag agauccccag acacuggaaa uccuggacau caccccuugc 1740
agcuucggcg gagugucugu gaucaccccu ggcaccaaca ccagcaauca gguggcagug 1800
cuguaccagg acgugaacug uaccgaagug cccguggcca uucacgccga ucagcugaca 1860
ccuacauggc ggguguacuc caccggcagc aauguguuuc agaccagagc cggcugucug 1920
aucggagccg agcacgugaa caauagcuac gagugcgaca uccccaucgg cgcuggcauc 1980
ugugccagcu accagacaca gacaaacagc cccagacggg ccagauaaua g 2031
<210> 37
<211> 27
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 37
ttggaccctc gtacagaagc taatacg 27
<210> 38
<211> 149
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 38
tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 60
tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 120
tagttctaga ccctcacttc ctactcagg 149
<210> 39
<211> 17
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 39
taatacgact cactata 17
<210> 40
<211> 50
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 40
acatttgctt ctgacacaac tgtgttcact agcaacctca aacagacacc 50
<210> 41
<211> 132
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 41
gctcgctttc ttgctgtcca atttctatta aaggttcctt tgttccctaa gtccaactac 60
taaactgggg gatattatga agggccttga gcatctggat tctgcctaat aaaaaacatt 120
tattttcatt gc 132
<210> 42
<211> 120
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 42
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 60
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 120
<210> 43
<211> 1273
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 43
Met Pro Val Pro Leu Val Leu Leu Pro Leu Val Ser Ser Gly Cys Val
1 5 10 15
Ala Leu Thr Thr Ala Thr Gly Leu Pro Pro Ala Thr Thr Ala Ser Pro
20 25 30
Thr Ala Gly Val Thr Thr Pro Ala Leu Val Pro Ala Ser Ser Val Leu
35 40 45
His Ser Thr Gly Ala Leu Pro Leu Pro Pro Pro Ser Ala Val Thr Thr
50 55 60
Pro His Ala Ile His Val Ser Gly Thr Ala Gly Thr Leu Ala Pro Ala
65 70 75 80
Ala Pro Val Leu Pro Pro Ala Ala Gly Val Thr Pro Ala Ser Thr Gly
85 90 95
Leu Ser Ala Ile Ile Ala Gly Thr Ile Pro Gly Thr Thr Leu Ala Ser
100 105 110
Leu Thr Gly Ser Leu Leu Ile Val Ala Ala Ala Thr Ala Val Val Ile
115 120 125
Leu Val Cys Gly Pro Gly Pro Cys Ala Ala Pro Pro Leu Gly Val Thr
130 135 140
Thr His Leu Ala Ala Leu Ser Thr Met Gly Ser Gly Pro Ala Val Thr
145 150 155 160
Ser Ser Ala Ala Ala Cys Thr Pro Gly Thr Val Ser Gly Pro Pro Leu
165 170 175
Met Ala Leu Gly Gly Leu Gly Gly Ala Pro Leu Ala Leu Ala Gly Pro
180 185 190
Val Pro Leu Ala Ile Ala Gly Thr Pro Leu Ile Thr Ser Leu His Thr
195 200 205
Pro Ile Ala Leu Val Ala Ala Leu Pro Gly Gly Pro Ser Ala Leu Gly
210 215 220
Pro Leu Val Ala Leu Pro Ile Gly Ile Ala Ile Thr Ala Pro Gly Thr
225 230 235 240
Leu Leu Ala Leu His Ala Ser Thr Leu Thr Pro Gly Ala Ser Ser Ser
245 250 255
Gly Thr Thr Ala Gly Ala Ala Ala Thr Thr Val Gly Thr Leu Gly Pro
260 265 270
Ala Thr Pro Leu Leu Leu Thr Ala Gly Ala Gly Thr Ile Thr Ala Ala
275 280 285
Val Ala Cys Ala Leu Ala Pro Leu Ser Gly Thr Leu Cys Thr Leu Leu
290 295 300
Ser Pro Thr Val Gly Leu Gly Ile Thr Gly Thr Ser Ala Pro Ala Val
305 310 315 320
Gly Pro Thr Gly Ser Ile Val Ala Pro Pro Ala Ile Thr Ala Leu Cys
325 330 335
Pro Pro Gly Gly Val Pro Ala Ala Thr Ala Pro Ala Ser Val Thr Ala
340 345 350
Thr Ala Ala Leu Ala Ile Ser Ala Cys Val Ala Ala Thr Ser Val Leu
355 360 365
Thr Ala Ser Ala Ser Pro Ser Thr Pro Leu Cys Thr Gly Val Ser Pro
370 375 380
Thr Leu Leu Ala Ala Leu Cys Pro Thr Ala Val Thr Ala Ala Ser Pro
385 390 395 400
Val Ile Ala Gly Ala Gly Val Ala Gly Ile Ala Pro Gly Gly Thr Gly
405 410 415
Leu Ile Ala Ala Thr Ala Thr Leu Leu Pro Ala Ala Pro Thr Gly Cys
420 425 430
Val Ile Ala Thr Ala Ser Ala Ala Leu Ala Ser Leu Val Gly Gly Ala
435 440 445
Thr Ala Thr Leu Thr Ala Leu Pro Ala Leu Ser Ala Leu Leu Pro Pro
450 455 460
Gly Ala Ala Ile Ser Thr Gly Ile Thr Gly Ala Gly Ser Thr Pro Cys
465 470 475 480
Ala Gly Val Gly Gly Pro Ala Cys Thr Pro Pro Leu Gly Ser Thr Gly
485 490 495
Pro Gly Pro Thr Ala Gly Val Gly Thr Gly Pro Thr Ala Val Val Val
500 505 510
Leu Ser Pro Gly Leu Leu His Ala Pro Ala Thr Val Cys Gly Pro Leu
515 520 525
Leu Ser Thr Ala Leu Val Leu Ala Leu Cys Val Ala Pro Ala Pro Ala
530 535 540
Gly Leu Thr Gly Thr Gly Val Leu Thr Gly Ser Ala Leu Leu Pro Leu
545 550 555 560
Pro Pro Gly Gly Pro Gly Ala Ala Ile Ala Ala Thr Thr Ala Ala Val
565 570 575
Ala Ala Pro Gly Thr Leu Gly Ile Leu Ala Ile Thr Pro Cys Ser Pro
580 585 590
Gly Gly Val Ser Val Ile Thr Pro Gly Thr Ala Thr Ser Ala Gly Val
595 600 605
Ala Val Leu Thr Gly Ala Val Ala Cys Thr Gly Val Pro Val Ala Ile
610 615 620
His Ala Ala Gly Leu Thr Pro Thr Thr Ala Val Thr Ser Thr Gly Ser
625 630 635 640
Ala Val Pro Gly Thr Ala Ala Gly Cys Leu Ile Gly Ala Gly His Val
645 650 655
Ala Ala Ser Thr Gly Cys Ala Ile Pro Ile Gly Ala Gly Ile Cys Ala
660 665 670
Ser Thr Gly Thr Gly Thr Ala Ser Pro Ala Ala Ala Ala Ser Val Ala
675 680 685
Ser Gly Ser Ile Ile Ala Thr Thr Met Ser Leu Gly Ala Gly Ala Ser
690 695 700
Val Ala Thr Ser Ala Ala Ser Ile Ala Ile Pro Thr Ala Pro Thr Ile
705 710 715 720
Ser Val Thr Thr Gly Ile Leu Pro Val Ser Met Thr Leu Thr Ser Val
725 730 735
Ala Cys Thr Met Thr Ile Cys Gly Ala Ser Thr Gly Cys Ser Ala Leu
740 745 750
Leu Leu Gly Thr Gly Ser Pro Cys Thr Gly Leu Ala Ala Ala Leu Thr
755 760 765
Gly Ile Ala Val Gly Gly Ala Leu Ala Thr Gly Gly Val Pro Ala Gly
770 775 780
Val Leu Gly Ile Thr Leu Thr Pro Pro Ile Leu Ala Pro Gly Gly Pro
785 790 795 800
Ala Pro Ser Gly Ile Leu Pro Ala Pro Ser Leu Pro Ser Leu Ala Ser
805 810 815
Pro Ile Gly Ala Leu Leu Pro Ala Leu Val Thr Leu Ala Ala Ala Gly
820 825 830
Pro Ile Leu Gly Thr Gly Ala Cys Leu Gly Ala Ile Ala Ala Ala Ala
835 840 845
Leu Ile Cys Ala Gly Leu Pro Ala Gly Leu Thr Val Leu Pro Pro Leu
850 855 860
Leu Thr Ala Gly Met Ile Ala Gly Thr Thr Ser Ala Leu Leu Ala Gly
865 870 875 880
Thr Ile Thr Ser Gly Thr Thr Pro Gly Ala Gly Ala Ala Leu Gly Ile
885 890 895
Pro Pro Ala Met Gly Met Ala Thr Ala Pro Ala Gly Ile Gly Val Thr
900 905 910
Gly Ala Val Leu Thr Gly Ala Gly Leu Leu Ile Ala Ala Gly Pro Ala
915 920 925
Ser Ala Ile Gly Leu Ile Gly Ala Ser Leu Ser Ser Thr Ala Ser Ala
930 935 940
Leu Gly Leu Leu Gly Ala Val Val Ala Gly Ala Ala Gly Ala Leu Ala
945 950 955 960
Thr Leu Val Leu Gly Leu Ser Ser Ala Pro Gly Ala Ile Ser Ser Val
965 970 975
Leu Ala Ala Ile Leu Ser Ala Leu Ala Leu Val Gly Ala Gly Val Gly
980 985 990
Ile Ala Ala Leu Ile Thr Gly Ala Leu Gly Ser Leu Gly Thr Thr Val
995 1000 1005
Thr Gly Gly Leu Ile Ala Ala Ala Gly Ile Ala Ala Ser Ala Ala Leu
1010 1015 1020
Ala Ala Thr Leu Met Ser Gly Cys Val Leu Gly Gly Ser Leu Ala Val
1025 1030 1035 1040
Ala Pro Cys Gly Leu Gly Thr His Leu Met Ser Pro Pro Gly Ser Ala
1045 1050 1055
Pro His Gly Val Val Pro Leu His Val Thr Thr Val Pro Ala Gly Gly
1060 1065 1070
Leu Ala Pro Thr Thr Ala Pro Ala Ile Cys His Ala Gly Leu Ala His
1075 1080 1085
Pro Pro Ala Gly Gly Val Pro Val Ser Ala Gly Thr His Thr Pro Val
1090 1095 1100
Thr Gly Ala Ala Pro Thr Gly Pro Gly Ile Ile Thr Thr Ala Ala Thr
1105 1110 1115 1120
Pro Val Ser Gly Ala Cys Ala Val Val Ile Gly Ile Val Ala Ala Thr
1125 1130 1135
Val Thr Ala Pro Leu Gly Pro Gly Leu Ala Ser Pro Leu Gly Gly Leu
1140 1145 1150
Ala Leu Thr Pro Leu Ala His Thr Ser Pro Ala Val Ala Leu Gly Ala
1155 1160 1165
Ile Ser Gly Ile Ala Ala Ser Val Val Ala Ile Gly Leu Gly Ile Ala
1170 1175 1180
Ala Leu Ala Gly Val Ala Leu Ala Leu Ala Gly Ser Leu Ile Ala Leu
1185 1190 1195 1200
Gly Gly Leu Gly Leu Thr Gly Gly Thr Ile Leu Thr Pro Thr Thr Ile
1205 1210 1215
Thr Leu Gly Pro Ile Ala Gly Leu Ile Ala Ile Val Met Val Thr Ile
1220 1225 1230
Met Leu Cys Cys Met Thr Ser Cys Cys Ser Cys Leu Leu Gly Cys Cys
1235 1240 1245
Ser Cys Gly Ser Cys Cys Leu Pro Ala Gly Ala Ala Ser Gly Pro Val
1250 1255 1260
Leu Leu Gly Val Leu Leu His Thr Thr
1265 1270
<210> 44
<211> 255
<212> PRT
<213> coronavirus (coronavirus)
<400> 44
Met Pro Ala Ile Thr Ala Leu Cys Pro Pro Gly Gly Val Pro Ala Ala
1 5 10 15
Thr Ala Pro Ala Ser Val Thr Ala Thr Ala Ala Leu Ala Ile Ser Ala
20 25 30
Cys Val Ala Ala Thr Ser Val Leu Thr Ala Ser Ala Ser Pro Ser Thr
35 40 45
Pro Leu Cys Thr Gly Val Ser Pro Thr Leu Leu Ala Ala Leu Cys Pro
50 55 60
Thr Ala Val Thr Ala Ala Ser Pro Val Ile Ala Gly Ala Gly Val Ala
65 70 75 80
Gly Ile Ala Pro Gly Gly Thr Gly Leu Ile Ala Ala Thr Ala Thr Leu
85 90 95
Leu Pro Ala Ala Pro Thr Gly Cys Val Ile Ala Thr Ala Ser Ala Ala
100 105 110
Leu Ala Ser Leu Val Gly Gly Ala Thr Ala Thr Leu Thr Ala Leu Pro
115 120 125
Ala Leu Ser Ala Leu Leu Pro Pro Gly Ala Ala Ile Ser Thr Gly Ile
130 135 140
Thr Gly Ala Gly Ser Thr Pro Cys Ala Gly Val Gly Gly Pro Ala Cys
145 150 155 160
Thr Pro Pro Leu Gly Ser Thr Gly Pro Gly Pro Thr Ala Gly Val Gly
165 170 175
Thr Gly Pro Thr Ala Val Val Val Leu Ser Pro Gly Leu Leu His Ala
180 185 190
Pro Ala Thr Val Cys Gly Pro Leu Leu Ser Thr Ala Leu Val Leu Ala
195 200 205
Leu Cys Val Ala Pro Ala Pro Ala Gly Leu Thr Gly Thr Gly Val Leu
210 215 220
Thr Gly Ser Ala Leu Leu Pro Leu Pro Pro Gly Gly Pro Gly Ala Ala
225 230 235 240
Ile Ala Ala Thr Thr Ala Ala Val Ala Ala Pro Gly Thr Leu Gly
245 250 255
<210> 45
<211> 222
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 45
Met Ala Ala Ser Ala Gly Thr Ile Thr Val Gly Gly Leu Leu Leu Leu
1 5 10 15
Leu Gly Gly Thr Ala Leu Val Ile Gly Pro Leu Pro Leu Thr Thr Ile
20 25 30
Cys Leu Leu Gly Pro Ala Thr Ala Ala Ala Ala Ala Pro Leu Thr Ile
35 40 45
Ile Leu Leu Ile Pro Leu Thr Leu Leu Thr Pro Val Thr Leu Ala Cys
50 55 60
Pro Val Leu Ala Ala Val Thr Ala Ile Ala Thr Ile Thr Gly Gly Ile
65 70 75 80
Ala Ile Ala Met Ala Cys Leu Val Gly Leu Met Thr Leu Ser Thr Pro
85 90 95
Ile Ala Ser Pro Ala Leu Pro Ala Ala Thr Ala Ser Met Thr Ser Pro
100 105 110
Ala Pro Gly Thr Ala Ile Leu Leu Ala Val Pro Leu His Gly Thr Ile
115 120 125
Leu Thr Ala Pro Leu Leu Gly Ser Gly Leu Val Ile Gly Ala Val Ile
130 135 140
Leu Ala Gly His Leu Ala Ile Ala Gly His His Leu Gly Ala Cys Ala
145 150 155 160
Ile Leu Ala Leu Pro Leu Gly Ile Thr Val Ala Thr Ser Ala Thr Leu
165 170 175
Ser Thr Thr Leu Leu Gly Ala Ser Gly Ala Val Ala Gly Ala Ser Gly
180 185 190
Pro Ala Ala Thr Ser Ala Thr Ala Ile Gly Ala Thr Leu Leu Ala Thr
195 200 205
Ala His Ser Ser Ser Ser Ala Ala Ile Ala Leu Leu Val Gly
210 215 220
<210> 46
<211> 419
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 46
Met Ser Ala Ala Gly Pro Gly Ala Gly Ala Ala Ala Pro Ala Ile Thr
1 5 10 15
Pro Gly Gly Pro Ser Ala Ser Thr Gly Ser Ala Gly Ala Gly Gly Ala
20 25 30
Ser Gly Ala Ala Ser Leu Gly Ala Ala Pro Gly Gly Leu Pro Ala Ala
35 40 45
Thr Ala Ser Thr Pro Thr Ala Leu Thr Gly His Gly Leu Gly Ala Leu
50 55 60
Leu Pro Pro Ala Gly Gly Gly Val Pro Ile Ala Thr Ala Ser Ser Pro
65 70 75 80
Ala Ala Gly Ile Gly Thr Thr Ala Ala Ala Thr Ala Ala Ile Ala Gly
85 90 95
Gly Ala Gly Leu Met Leu Ala Leu Ser Pro Ala Thr Thr Pro Thr Thr
100 105 110
Leu Gly Thr Gly Pro Gly Ala Gly Leu Pro Thr Gly Ala Ala Leu Ala
115 120 125
Gly Ile Ile Thr Val Ala Thr Gly Gly Ala Leu Ala Thr Pro Leu Ala
130 135 140
His Ile Gly Thr Ala Ala Pro Ala Ala Ala Ala Ala Ile Val Leu Gly
145 150 155 160
Leu Pro Gly Gly Thr Thr Leu Pro Leu Gly Pro Thr Ala Gly Gly Ser
165 170 175
Ala Gly Gly Ser Gly Ala Ser Ser Ala Ser Ser Ser Ala Ser Ala Ala
180 185 190
Ser Ser Ala Ala Ser Thr Pro Gly Ser Ser Ala Gly Thr Ser Pro Ala
195 200 205
Ala Met Ala Gly Ala Gly Gly Ala Ala Ala Leu Ala Leu Leu Leu Leu
210 215 220
Ala Ala Leu Ala Gly Leu Gly Ser Leu Met Ser Gly Leu Gly Gly Gly
225 230 235 240
Gly Gly Gly Gly Thr Val Thr Leu Leu Ser Ala Ala Gly Ala Ser Leu
245 250 255
Leu Pro Ala Gly Leu Ala Thr Ala Thr Leu Ala Thr Ala Val Thr Gly
260 265 270
Ala Pro Gly Ala Ala Gly Pro Gly Gly Thr Gly Gly Ala Pro Gly Ala
275 280 285
Gly Gly Leu Ile Ala Gly Gly Thr Ala Thr Leu His Thr Pro Gly Ile
290 295 300
Ala Gly Pro Ala Pro Ser Ala Ser Ala Pro Pro Gly Met Ser Ala Ile
305 310 315 320
Gly Met Gly Val Thr Pro Ser Gly Thr Thr Leu Thr Thr Thr Gly Ala
325 330 335
Ile Leu Leu Ala Ala Leu Ala Pro Ala Pro Leu Ala Gly Val Ile Leu
340 345 350
Leu Ala Leu His Ile Ala Ala Thr Leu Thr Pro Pro Pro Thr Gly Pro
355 360 365
Leu Leu Ala Leu Leu Leu Leu Ala Ala Gly Thr Gly Ala Leu Pro Gly
370 375 380
Ala Gly Leu Leu Gly Gly Thr Val Thr Leu Leu Pro Ala Ala Ala Leu
385 390 395 400
Ala Ala Pro Ser Leu Gly Leu Gly Gly Ser Met Ser Ser Ala Ala Ser
405 410 415
Thr Gly Ala
<210> 47
<211> 221
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 47
Met Ala Ala Met Leu Ala Gly Leu Cys Cys Val Leu Leu Leu Cys Gly
1 5 10 15
Ala Val Pro Val Ser Ala Ser Ile Thr Ala Leu Cys Pro Pro Gly Gly
20 25 30
Val Pro Ala Ala Thr Ala Pro Ala Ser Val Thr Ala Thr Ala Ala Leu
35 40 45
Ala Ile Ser Ala Cys Val Ala Ala Thr Ser Val Leu Thr Ala Ser Ala
50 55 60
Ser Pro Ser Thr Pro Leu Cys Thr Gly Val Ser Pro Thr Leu Leu Ala
65 70 75 80
Ala Leu Cys Pro Thr Ala Val Thr Ala Ala Ser Pro Val Ile Ala Gly
85 90 95
Ala Gly Val Ala Gly Ile Ala Pro Gly Gly Thr Gly Leu Ile Ala Ala
100 105 110
Thr Ala Thr Leu Leu Pro Ala Ala Pro Thr Gly Cys Val Ile Ala Thr
115 120 125
Ala Ser Ala Ala Leu Ala Ser Leu Val Gly Gly Ala Thr Ala Thr Leu
130 135 140
Thr Ala Leu Pro Ala Leu Ser Ala Leu Leu Pro Pro Gly Ala Ala Ile
145 150 155 160
Ser Thr Gly Ile Thr Gly Ala Gly Ser Thr Pro Cys Ala Gly Val Gly
165 170 175
Gly Pro Ala Cys Thr Pro Pro Leu Gly Ser Thr Gly Pro Gly Pro Thr
180 185 190
Ala Gly Val Gly Thr Gly Pro Thr Ala Val Val Val Leu Ser Pro Gly
195 200 205
Leu Leu His Ala Pro Ala Thr Val Cys Gly Pro Leu Leu
210 215 220
<210> 48
<211> 221
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 48
Met Ala Ala Met Leu Ala Gly Leu Cys Cys Val Leu Leu Leu Cys Gly
1 5 10 15
Ala Val Pro Val Ser Ala Ser Ile Thr Ala Leu Cys Pro Pro Gly Gly
20 25 30
Val Pro Ala Ala Thr Ala Pro Ala Ser Val Thr Ala Thr Ala Ala Leu
35 40 45
Ala Ile Ser Ala Cys Val Ala Ala Thr Ser Val Leu Thr Ala Ser Ala
50 55 60
Ser Pro Ser Thr Pro Leu Cys Thr Gly Val Ser Pro Thr Leu Leu Ala
65 70 75 80
Ala Leu Cys Pro Thr Ala Val Thr Ala Ala Ser Pro Val Ile Ala Gly
85 90 95
Ala Gly Val Ala Gly Ile Ala Pro Gly Gly Thr Gly Leu Ile Ala Ala
100 105 110
Thr Ala Thr Leu Leu Pro Ala Ala Pro Thr Gly Cys Val Ile Ala Thr
115 120 125
Ala Ser Ala Ala Leu Ala Ser Leu Val Gly Gly Ala Thr Ala Thr Leu
130 135 140
Thr Ala Leu Pro Ala Leu Ser Ala Leu Leu Pro Pro Gly Ala Ala Ile
145 150 155 160
Ser Thr Gly Ile Thr Gly Ala Gly Ser Thr Pro Cys Ala Gly Val Gly
165 170 175
Gly Pro Ala Cys Thr Pro Pro Leu Gly Ser Thr Gly Pro Gly Pro Thr
180 185 190
Ala Gly Val Gly Thr Gly Pro Thr Ala Val Val Val Leu Ser Pro Gly
195 200 205
Leu Leu His Ala Ala Ala Thr Val Cys Gly Pro Leu Leu
210 215 220
<210> 49
<211> 75
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 49
Met Thr Ser Pro Val Ser Gly Gly Thr Gly Thr Leu Ile Val Ala Ser
1 5 10 15
Val Leu Leu Pro Leu Ala Pro Val Val Pro Leu Leu Val Thr Leu Ala
20 25 30
Ile Leu Thr Ala Leu Ala Leu Cys Ala Thr Cys Cys Ala Ile Val Ala
35 40 45
Val Ser Leu Val Leu Pro Ser Pro Thr Val Thr Ser Ala Val Leu Ala
50 55 60
Leu Ala Ser Ser Ala Val Pro Ala Leu Leu Val
65 70 75
<210> 50
<211> 1225
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 50
Met Ala Ala Met Leu Ala Gly Leu Cys Cys Val Leu Leu Leu Cys Gly
1 5 10 15
Ala Val Pro Val Ser Ala Ser Ser Ser Gly Cys Val Ala Leu Thr Thr
20 25 30
Ala Thr Gly Leu Pro Pro Ala Thr Thr Ala Ser Pro Thr Ala Gly Val
35 40 45
Thr Thr Pro Ala Leu Val Pro Ala Ser Ser Val Leu His Ser Thr Gly
50 55 60
Ala Leu Pro Leu Pro Pro Pro Ser Ala Val Thr Thr Pro His Ala Ile
65 70 75 80
His Val Ser Gly Thr Ala Gly Thr Leu Ala Pro Ala Ala Pro Val Leu
85 90 95
Pro Pro Ala Ala Gly Val Thr Pro Ala Ser Thr Gly Leu Ser Ala Ile
100 105 110
Ile Ala Gly Thr Ile Pro Gly Thr Thr Leu Ala Ser Leu Thr Gly Ser
115 120 125
Leu Leu Ile Val Ala Ala Ala Thr Ala Val Val Ile Leu Val Cys Gly
130 135 140
Pro Gly Pro Cys Ala Ala Pro Pro Leu Gly Val Thr Thr His Leu Ala
145 150 155 160
Ala Leu Ser Thr Met Gly Ser Gly Pro Ala Val Thr Ser Ser Ala Ala
165 170 175
Ala Cys Thr Pro Gly Thr Val Ser Gly Pro Pro Leu Met Ala Leu Gly
180 185 190
Gly Leu Gly Gly Ala Pro Leu Ala Leu Ala Gly Pro Val Pro Leu Ala
195 200 205
Ile Ala Gly Thr Pro Leu Ile Thr Ser Leu His Thr Pro Ile Ala Leu
210 215 220
Val Ala Ala Leu Pro Gly Gly Pro Ser Ala Leu Gly Pro Leu Val Ala
225 230 235 240
Leu Pro Ile Gly Ile Ala Ile Thr Ala Pro Gly Thr Leu Leu Ala Leu
245 250 255
His Ala Ser Thr Leu Thr Pro Gly Ala Ser Ser Ser Gly Thr Thr Ala
260 265 270
Gly Ala Ala Ala Thr Thr Val Gly Thr Leu Gly Pro Ala Thr Pro Leu
275 280 285
Leu Leu Thr Ala Gly Ala Gly Thr Ile Thr Ala Ala Val Ala Cys Ala
290 295 300
Leu Ala Pro Leu Ser Gly Thr Leu Cys Thr Leu Leu Ser Pro Thr Val
305 310 315 320
Gly Leu Gly Ile Thr Gly Thr Ser Ala Pro Ala Val Gly Pro Thr Gly
325 330 335
Ser Ile Val Ala Pro Pro Ala Ile Thr Ala Leu Cys Pro Pro Gly Gly
340 345 350
Val Pro Ala Ala Thr Ala Pro Ala Ser Val Thr Ala Thr Ala Ala Leu
355 360 365
Ala Ile Ser Ala Cys Val Ala Ala Thr Ser Val Leu Thr Ala Ser Ala
370 375 380
Ser Pro Ser Thr Pro Leu Cys Thr Gly Val Ser Pro Thr Leu Leu Ala
385 390 395 400
Ala Leu Cys Pro Thr Ala Val Thr Ala Ala Ser Pro Val Ile Ala Gly
405 410 415
Ala Gly Val Ala Gly Ile Ala Pro Gly Gly Thr Gly Leu Ile Ala Ala
420 425 430
Thr Ala Thr Leu Leu Pro Ala Ala Pro Thr Gly Cys Val Ile Ala Thr
435 440 445
Ala Ser Ala Ala Leu Ala Ser Leu Val Gly Gly Ala Thr Ala Thr Leu
450 455 460
Thr Ala Leu Pro Ala Leu Ser Ala Leu Leu Pro Pro Gly Ala Ala Ile
465 470 475 480
Ser Thr Gly Ile Thr Gly Ala Gly Ser Thr Pro Cys Ala Gly Val Gly
485 490 495
Gly Pro Ala Cys Thr Pro Pro Leu Gly Ser Thr Gly Pro Gly Pro Thr
500 505 510
Ala Gly Val Gly Thr Gly Pro Thr Ala Val Val Val Leu Ser Pro Gly
515 520 525
Leu Leu His Ala Pro Ala Thr Val Cys Gly Pro Leu Leu Ser Thr Ala
530 535 540
Leu Val Leu Ala Leu Cys Val Ala Pro Ala Pro Ala Gly Leu Thr Gly
545 550 555 560
Thr Gly Val Leu Thr Gly Ser Ala Leu Leu Pro Leu Pro Pro Gly Gly
565 570 575
Pro Gly Ala Ala Ile Ala Ala Thr Thr Ala Ala Val Ala Ala Pro Gly
580 585 590
Thr Leu Gly Ile Leu Ala Ile Thr Pro Cys Ser Pro Gly Gly Val Ser
595 600 605
Val Ile Thr Pro Gly Thr Ala Thr Ser Ala Gly Val Ala Val Leu Thr
610 615 620
Gly Ala Val Ala Cys Thr Gly Val Pro Val Ala Ile His Ala Ala Gly
625 630 635 640
Leu Thr Pro Thr Thr Ala Val Thr Ser Thr Gly Ser Ala Val Pro Gly
645 650 655
Thr Ala Ala Gly Cys Leu Ile Gly Ala Gly His Val Ala Ala Ser Thr
660 665 670
Gly Cys Ala Ile Pro Ile Gly Ala Gly Ile Cys Ala Ser Thr Gly Thr
675 680 685
Gly Thr Ala Ser Pro Ala Ala Ala Ala Ser Val Ala Ser Gly Ser Ile
690 695 700
Ile Ala Thr Thr Met Ser Leu Gly Ala Gly Ala Ser Val Ala Thr Ser
705 710 715 720
Ala Ala Ser Ile Ala Ile Pro Thr Ala Pro Thr Ile Ser Val Thr Thr
725 730 735
Gly Ile Leu Pro Val Ser Met Thr Leu Thr Ser Val Ala Cys Thr Met
740 745 750
Thr Ile Cys Gly Ala Ser Thr Gly Cys Ser Ala Leu Leu Leu Gly Thr
755 760 765
Gly Ser Pro Cys Thr Gly Leu Ala Ala Ala Leu Thr Gly Ile Ala Val
770 775 780
Gly Gly Ala Leu Ala Thr Gly Gly Val Pro Ala Gly Val Leu Gly Ile
785 790 795 800
Thr Leu Thr Pro Pro Ile Leu Ala Pro Gly Gly Pro Ala Pro Ser Gly
805 810 815
Ile Leu Pro Ala Pro Ser Leu Pro Ser Leu Ala Ser Pro Ile Gly Ala
820 825 830
Leu Leu Pro Ala Leu Val Thr Leu Ala Ala Ala Gly Pro Ile Leu Gly
835 840 845
Thr Gly Ala Cys Leu Gly Ala Ile Ala Ala Ala Ala Leu Ile Cys Ala
850 855 860
Gly Leu Pro Ala Gly Leu Thr Val Leu Pro Pro Leu Leu Thr Ala Gly
865 870 875 880
Met Ile Ala Gly Thr Thr Ser Ala Leu Leu Ala Gly Thr Ile Thr Ser
885 890 895
Gly Thr Thr Pro Gly Ala Gly Ala Ala Leu Gly Ile Pro Pro Ala Met
900 905 910
Gly Met Ala Thr Ala Pro Ala Gly Ile Gly Val Thr Gly Ala Val Leu
915 920 925
Thr Gly Ala Gly Leu Leu Ile Ala Ala Gly Pro Ala Ser Ala Ile Gly
930 935 940
Leu Ile Gly Ala Ser Leu Ser Ser Thr Ala Ser Ala Leu Gly Leu Leu
945 950 955 960
Gly Ala Val Val Ala Gly Ala Ala Gly Ala Leu Ala Thr Leu Val Leu
965 970 975
Gly Leu Ser Ser Ala Pro Gly Ala Ile Ser Ser Val Leu Ala Ala Ile
980 985 990
Leu Ser Ala Leu Ala Leu Val Gly Ala Gly Val Gly Ile Ala Ala Leu
995 1000 1005
Ile Thr Gly Ala Leu Gly Ser Leu Gly Thr Thr Val Thr Gly Gly Leu
1010 1015 1020
Ile Ala Ala Ala Gly Ile Ala Ala Ser Ala Ala Leu Ala Ala Thr Leu
1025 1030 1035 1040
Met Ser Gly Cys Val Leu Gly Gly Ser Leu Ala Val Ala Pro Cys Gly
1045 1050 1055
Leu Gly Thr His Leu Met Ser Pro Pro Gly Ser Ala Pro His Gly Val
1060 1065 1070
Val Pro Leu His Val Thr Thr Val Pro Ala Gly Gly Leu Ala Pro Thr
1075 1080 1085
Thr Ala Pro Ala Ile Cys His Ala Gly Leu Ala His Pro Pro Ala Gly
1090 1095 1100
Gly Val Pro Val Ser Ala Gly Thr His Thr Pro Val Thr Gly Ala Ala
1105 1110 1115 1120
Pro Thr Gly Pro Gly Ile Ile Thr Thr Ala Ala Thr Pro Val Ser Gly
1125 1130 1135
Ala Cys Ala Val Val Ile Gly Ile Val Ala Ala Thr Val Thr Ala Pro
1140 1145 1150
Leu Gly Pro Gly Leu Ala Ser Pro Leu Gly Gly Leu Ala Leu Thr Pro
1155 1160 1165
Leu Ala His Thr Ser Pro Ala Val Ala Leu Gly Ala Ile Ser Gly Ile
1170 1175 1180
Ala Ala Ser Val Val Ala Ile Gly Leu Gly Ile Ala Ala Leu Ala Gly
1185 1190 1195 1200
Val Ala Leu Ala Leu Ala Gly Ser Leu Ile Ala Leu Gly Gly Leu Gly
1205 1210 1215
Leu Thr Gly Gly Thr Ile Leu Thr Pro
1220 1225
<210> 51
<211> 697
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 51
Met Ala Ala Met Leu Ala Gly Leu Cys Cys Val Leu Leu Leu Cys Gly
1 5 10 15
Ala Val Pro Val Ser Ala Ser Ser Ser Gly Cys Val Ala Leu Thr Thr
20 25 30
Ala Thr Gly Leu Pro Pro Ala Thr Thr Ala Ser Pro Thr Ala Gly Val
35 40 45
Thr Thr Pro Ala Leu Val Pro Ala Ser Ser Val Leu His Ser Thr Gly
50 55 60
Ala Leu Pro Leu Pro Pro Pro Ser Ala Val Thr Thr Pro His Ala Ile
65 70 75 80
His Val Ser Gly Thr Ala Gly Thr Leu Ala Pro Ala Ala Pro Val Leu
85 90 95
Pro Pro Ala Ala Gly Val Thr Pro Ala Ser Thr Gly Leu Ser Ala Ile
100 105 110
Ile Ala Gly Thr Ile Pro Gly Thr Thr Leu Ala Ser Leu Thr Gly Ser
115 120 125
Leu Leu Ile Val Ala Ala Ala Thr Ala Val Val Ile Leu Val Cys Gly
130 135 140
Pro Gly Pro Cys Ala Ala Pro Pro Leu Gly Val Thr Thr His Leu Ala
145 150 155 160
Ala Leu Ser Thr Met Gly Ser Gly Pro Ala Val Thr Ser Ser Ala Ala
165 170 175
Ala Cys Thr Pro Gly Thr Val Ser Gly Pro Pro Leu Met Ala Leu Gly
180 185 190
Gly Leu Gly Gly Ala Pro Leu Ala Leu Ala Gly Pro Val Pro Leu Ala
195 200 205
Ile Ala Gly Thr Pro Leu Ile Thr Ser Leu His Thr Pro Ile Ala Leu
210 215 220
Val Ala Ala Leu Pro Gly Gly Pro Ser Ala Leu Gly Pro Leu Val Ala
225 230 235 240
Leu Pro Ile Gly Ile Ala Ile Thr Ala Pro Gly Thr Leu Leu Ala Leu
245 250 255
His Ala Ser Thr Leu Thr Pro Gly Ala Ser Ser Ser Gly Thr Thr Ala
260 265 270
Gly Ala Ala Ala Thr Thr Val Gly Thr Leu Gly Pro Ala Thr Pro Leu
275 280 285
Leu Leu Thr Ala Gly Ala Gly Thr Ile Thr Ala Ala Val Ala Cys Ala
290 295 300
Leu Ala Pro Leu Ser Gly Thr Leu Cys Thr Leu Leu Ser Pro Thr Val
305 310 315 320
Gly Leu Gly Ile Thr Gly Thr Ser Ala Pro Ala Val Gly Pro Thr Gly
325 330 335
Ser Ile Val Ala Pro Pro Ala Ile Thr Ala Leu Cys Pro Pro Gly Gly
340 345 350
Val Pro Ala Ala Thr Ala Pro Ala Ser Val Thr Ala Thr Ala Ala Leu
355 360 365
Ala Ile Ser Ala Cys Val Ala Ala Thr Ser Val Leu Thr Ala Ser Ala
370 375 380
Ser Pro Ser Thr Pro Leu Cys Thr Gly Val Ser Pro Thr Leu Leu Ala
385 390 395 400
Ala Leu Cys Pro Thr Ala Val Thr Ala Ala Ser Pro Val Ile Ala Gly
405 410 415
Ala Gly Val Ala Gly Ile Ala Pro Gly Gly Thr Gly Leu Ile Ala Ala
420 425 430
Thr Ala Thr Leu Leu Pro Ala Ala Pro Thr Gly Cys Val Ile Ala Thr
435 440 445
Ala Ser Ala Ala Leu Ala Ser Leu Val Gly Gly Ala Thr Ala Thr Leu
450 455 460
Thr Ala Leu Pro Ala Leu Ser Ala Leu Leu Pro Pro Gly Ala Ala Ile
465 470 475 480
Ser Thr Gly Ile Thr Gly Ala Gly Ser Thr Pro Cys Ala Gly Val Gly
485 490 495
Gly Pro Ala Cys Thr Pro Pro Leu Gly Ser Thr Gly Pro Gly Pro Thr
500 505 510
Ala Gly Val Gly Thr Gly Pro Thr Ala Val Val Val Leu Ser Pro Gly
515 520 525
Leu Leu His Ala Pro Ala Thr Val Cys Gly Pro Leu Leu Ser Thr Ala
530 535 540
Leu Val Leu Ala Leu Cys Val Ala Pro Ala Pro Ala Gly Leu Thr Gly
545 550 555 560
Thr Gly Val Leu Thr Gly Ser Ala Leu Leu Pro Leu Pro Pro Gly Gly
565 570 575
Pro Gly Ala Ala Ile Ala Ala Thr Thr Ala Ala Val Ala Ala Pro Gly
580 585 590
Thr Leu Gly Ile Leu Ala Ile Thr Pro Cys Ser Pro Gly Gly Val Ser
595 600 605
Val Ile Thr Pro Gly Thr Ala Thr Ser Ala Gly Val Ala Val Leu Thr
610 615 620
Gly Ala Val Ala Cys Thr Gly Val Pro Val Ala Ile His Ala Ala Gly
625 630 635 640
Leu Thr Pro Thr Thr Ala Val Thr Ser Thr Gly Ser Ala Val Pro Gly
645 650 655
Thr Ala Ala Gly Cys Leu Ile Gly Ala Gly His Val Ala Ala Ser Thr
660 665 670
Gly Cys Ala Ile Pro Ile Gly Ala Gly Ile Cys Ala Ser Thr Gly Thr
675 680 685
Gly Thr Ala Ser Pro Ala Ala Ala Ala
690 695
<210> 52
<211> 74
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 52
gtctcagtcg ccgctgccag ctctcgcact ctgttcttcc gccgctccgc cgtcgcgttt 60
ctctgccggt cgca 74
<210> 53
<211> 83
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 53
acccggcgct ccattaaata gccgtagacg gaacttcgcc tttctctcgg ccttagcgcc 60
atttttttgg aaacctctgc gcc 83
<210> 54
<211> 45
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 54
ctctcttcca caggaggcct acacgccgcc gcttgtgctg cagcc 45
<210> 55
<211> 53
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 55
gggacatttg cttctgacac aactgtgttc actagcaacc tcaaacagac acc 53
<210> 56
<211> 47
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 56
gggaaataag agagaaaaga agagtaagaa gaaatataag agccacc 47
<210> 57
<211> 93
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 57
ccccccgagc gccgctccgg ctgcaccgcg ctcgctccga gtttcaggct cgtgctaagc 60
tagcgccgtc gtcgtctccc ttcagtcgcc atc 93
<210> 58
<211> 34
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 58
ctttccggcg gtgacgacct acgcacacga gaac 34
<210> 59
<211> 43
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 59
cgcctggccg gcgggctgag gcgtacgggt cgcacgcagc gcc 43
<210> 60
<211> 52
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 60
cgctcttatt ggccagggga cggtagctgc aggactctgc tctcctgcgg cc 52
<210> 61
<211> 52
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 61
ttccatttgg ctgcagcttc tggagggagc cgacaggaga cgtggggaga cg 52
<210> 62
<211> 47
<212> RNA
<213> Artificial Sequence (Artificial Sequence)
<400> 62
gggaaauaag agagaaaaga agaguaagaa gaaauauaag agccacc 47
<210> 63
<211> 50
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 63
acatttgctt ctgacacaac tgtgttcact agcaacctca aacagacacc 50
<210> 64
<211> 132
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 64
gctcgctttc ttgctgtcca atttctatta aaggttcctt tgttccctaa gtccaactac 60
taaactgggg gatattatga agggccttga gcatctggat tctgcctaat aaaaaacatt 120
tattttcatt gc 132
<210> 65
<211> 306
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 65
atggaagcat taattgtttt gaacatgtaa atataaatct gtcagccact acagccatca 60
aaagagagca tctggaagaa cagccagctt ggaagtttta cagcaataat gttgcagtgg 120
aatattattt gtagttaagg tcatcctcct cccctttctg tttttttaaa tcaagaacta 180
cgttctgccc ctctcttggg cttcagaagc atctaagaaa agcagtcatc aattataatt 240
aactttcaaa gggcaagtca gaagttgttt ataaattaca aaataaaggc atattatgaa 300
ctctta 306
<210> 66
<211> 176
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 66
gaaaagactt cttccatcaa gcttaattgt tttgttattc atttaatgac tttccctgct 60
gttacctaat tacaaattgg atggaactgt gtttttttct gctttgtttt ttcagtttgc 120
tgtttctgta gccatattgt attctgtgtc aaataaagtc cagttggatt ctggaa 176
<210> 67
<211> 217
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 67
caaatgtggc aattattttg gatctatcac ctgtcatcat aactggcttc tgcttgtcat 60
ccacacaaca ccaggactta agacaaatgg gactgatgtc atcttgagct cttcatttat 120
tttgactgtg atttatttgg agtggaggca ttgtttttaa gaaaaacatg tcatgtaggt 180
tgtctaaaaa taaaatgcat ttaaactcat ttgagag 217
<210> 68
<211> 62
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 68
aagcactctg agtcaagatg agtgggaaac catctcaata aacacatttt ggataaatcc 60
tg 62
<210> 69
<211> 294
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 69
gcgctgggct gttttagtgc caggctgcgg tgggcagcca tgagaacaaa acctcttctg 60
tatttttttt ttccattagt aaaacacaag acttcagatt cagccgaatt gtggtgtctt 120
acaaggcagg cctttcctac agggggtgga gagaccagcc tttcttcctt tggtaggaat 180
ggcctgagtt ggcgttgtgg gcaggctact ggtttgtatg atgtattagt agagcaaccc 240
attaatcttt tgtagtttgt attaaacttg aactgagacc ttgatgagtc ttta 294
<210> 70
<211> 367
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 70
gaaaaatgaa aggaagttct gctgtcagag gcaaaacatc tgtttatcat agacatcaac 60
atgacctata agtaaagtgc gtgtctagtg tcttctattg agagtactac tattaattaa 120
gcttatttcc aatgtgcctt tttaatgctt gaagttttat ctacatacac aggtaacaga 180
ggacagtagt ctgtaaacat ataaatcggt cataactatc gtggtcttta tttctgtgag 240
gatctaggga aatttcatgt cacttccctc cttcactgca tcacaatcat attccctttt 300
ttttttcttg gatttgtgtc agttggatga tatcccctcc agatagtatc aataaaatgt 360
taaaatt 367
<210> 71
<211> 325
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 71
actccctcct cctgccactg gtgcctcgag tagccatggc aacgggccca gtgtccagtc 60
acttagaagt tccccccttg gccaaaaacc caattcacat tgagagctgg tgttgtctga 120
agttttcgta tcacagtgtt aacctgtact ctctcctgca aacctacaca ccaaagcttt 180
atttatatca ttccagtatc aatgctacac agtgttgtcc cgagcgccgg gaggcgttgg 240
gcagaaaccc tcgggaatgc ttccgagcac gctgtagggt atgggaagaa cccagcacca 300
ctaataaagc tgctgcttgg ctgga 325
<210> 72
<211> 252
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 72
ggtgacccgg ctgggtcggc cctgcccaag ggcctcccac cagagactgg gatgggaaca 60
ctggtgggca gctgaggaca caccccacac cccagcccac cctgctcctc ctgccctgtc 120
cctgtccccc tcccctccca gtcctccaga ccaccagccg ccccagcccc ttctcccagc 180
acacggctgc ctgacactga gccccacctc tccaagtctc tctgtgaata caattaaagg 240
tcctgccctc cc 252
<210> 73
<211> 308
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 73
accgctagct tgttgcaccg tggaggccac aggagcagaa acatggaatg ccagacgctg 60
gggatgctgg tacaagttgt gggactgcat gctactgtct agagcttgtc tcaatggatc 120
tagaacttca tcgccctctg atcgccgatc acctctgaga cccaccttgc tcataaacaa 180
aatgcccatg ttggtcctct gccctggacc tgtgacattc tggactattt ctgtgtttat 240
ttgtggccga gtgtaacaac catataataa atcacctctt ccgctgtttt agctgaagaa 300
ttaaatca 308
<210> 74
<211> 108
<212> RNA
<213> Artificial Sequence (Artificial Sequence)
<400> 74
gcugccuucu gcggggcuug ccuucuggcc augcccuucu ucucucccuu gcaccuguac 60
cucuuggucu uugaauaaag ccugaguagg aagugagggu cuagaacu 108
<210> 75
<211> 132
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 75
gctcgctttc ttgctgtcca atttctatta aaggttcctt tgttccctaa gtccaactac 60
taaactgggg gatattatga agggccttga gcatctggat tctgcctaat aaaaaacatt 120
tattttcatt gc 132
<210> 76
<211> 720
<212> RNA
<213> Fluorescent protein (Fluorescent protein)
<400> 76
auggugagca agggcgagga gcuguucacc gggguggugc ccauccuggu cgagcuggac 60
ggcgacguaa acggccacaa guucagcgug uccggcgagg gcgagggcga ugccaccuac 120
ggcaagcuga cccugaaguu caucugcacc accggcaagc ugcccgugcc cuggcccacc 180
cucgugacca cccugaccua cggcgugcag ugcuucagcc gcuaccccga ccacaugaag 240
cagcacgacu ucuucaaguc cgccaugccc gaaggcuacg uccaggagcg caccaucuuc 300
uucaaggacg acggcaacua caagacccgc gccgagguga aguucgaggg cgacacccug 360
gugaaccgca ucgagcugaa gggcaucgac uucaaggagg acggcaacau ccuggggcac 420
aagcuggagu acaacuacaa cagccacaac gucuauauca uggccgacaa gcagaagaac 480
ggcaucaagg ugaacuucaa gauccgccac aacaucgagg acggcagcgu gcagcucgcc 540
gaccacuacc agcagaacac ccccaucggc gacggccccg ugcugcugcc cgacaaccac 600
uaccugagca cccaguccgc ccugagcaaa gaccccaacg agaagcgcga ucacaugguc 660
cugcuggagu ucgugaccgc cgccgggauc acucucggca uggacgagcu guacaaguaa 720
<210> 77
<211> 27
<212> RNA
<213> Artificial Sequence (Artificial Sequence)
<400> 77
auguuccugc ugacuacaaa acggacu 27
<210> 78
<211> 66
<212> RNA
<213> Artificial Sequence (Artificial Sequence)
<400> 78
gacgcuauga agaggggccu gugcugugug cugcugcugu gcggagcugu guucgugucc 60
aacagc 66
Claims (52)
1. A DNA sequence comprising the sequence set forth in SEQ NO: 1. the amino acid sequence of SEQ NO: 2. the amino acid sequence of SEQ NO: 3. the amino acid sequence of SEQ NO: 4. the amino acid sequence of SEQ NO: 5. the amino acid sequence of SEQ NO: 6. the amino acid sequence of SEQ NO: 7. the amino acid sequence of SEQ NO: 8 or SEQ NO: 9, or a sequence having 60% to 100% homology to one of said arbitrary sequences, or a sequence functionally identical thereto, or a complementary sequence.
2. The DNA sequence of claim 1, wherein the sequence is SEQ NO:1, SEQ NO: 2. the amino acid sequence of SEQ NO: 4. the amino acid sequence of SEQ NO: 5. the amino acid sequence of SEQ NO: 8 or SEQ NO: 9; or a sequence functionally identical thereto, or a complementary sequence.
3. The DNA sequence of claim 1, wherein the sequence is SEQ NO:1, or a sequence 60% -100% homologous to said sequence, or a sequence complementary thereto.
4. The DNA sequence of claim 1, further comprising at the 5' end of the sequence set forth in SEQ NO: 11; or a sequence which is 60% -100% homologous to said sequence, or a sequence which is complementary thereto.
5. The DNA sequence of claim 1, further comprising at the 5' end of the sequence set forth in SEQ NO: 12; or a sequence which is 60% -100% homologous to said sequence, or a sequence which is complementary thereto.
6. The DNA sequence of claim 1, further comprising at the 3' end of the sequence as set forth in SEQ NO: 13, and (c) a sequence set forth in (c); or a sequence which is 60% -100% homologous to said sequence, or a sequence which is complementary thereto.
7. The DNA sequence of claim 1, further comprising at the 3' end of the sequence as set forth in SEQ NO: 14, or a sequence shown in fig. 14; or a sequence which is 60% -100% homologous to said sequence, or a sequence which is complementary thereto.
8. The DNA sequence of claim 1, wherein said homology is 65-100%.
9. The DNA sequence of claim 8, wherein said homology is 70-100%.
10. The DNA sequence of claim 9, wherein said homology is 71-100%.
11. The DNA sequence of claim 10, wherein said homology is 73-100%.
12. The DNA sequence of claim 11, wherein said homology is 74-100%.
13. The DNA sequence of claim 11, wherein said homology is 100%.
14. The DNA sequence of claim 11, which is identical to SEQ NO:1, the homology of the sequence shown in 1 is 70-100 percent; and SEQ NO:3, the homology of the sequence shown in the sequence is 74-100 percent; and SEQ NO: 5, sequences with 70-100% homology; and SEQ NO: 6 has 65-100% homology; and SEQ NO: 7, and 65-100% of the sequence shown in the sequence table; and SEQ NO: 8, the sequence with 70-100% of homology; or with SEQ NO: 9 said sequence homology is 70-100% sequence.
15. An mRNA sequence comprising the sequence set forth in SEQ NO: 1.1, SEQ NO: 2.2, SEQ NO: 3.3, SEQ NO: 4.4, SEQ NO: 5.5, SEQ NO: 6.6, SEQ NO: 7.7, SEQ NO: 8.8 or SEQ NO: 9.9 or one or more of the sequences shown in seq id No. or having 60% to 100% homology to one of said sequences; or a sequence functionally identical thereto, or a sequence complementary thereto.
16. The mRNA sequence of claim 15, wherein the sequence is SEQ NO: 1.1, SEQ NO: 2.2, SEQ NO: 4.4, SEQ NO: 5.5, SEQ NO: 8.8 or SEQ NO: 9.9 one or more of the sequences shown; or 60% to 100% homology to one of said sequences.
17. The mRNA sequence according to claim 15 or 16, which is SEQ NO: 1.1 or a sequence having 60% to 100% homology to said sequence or a sequence complementary thereto.
18. The mRNA sequence according to claim 17, wherein the homology is 65-100%.
19. The mRNA sequence according to claim 18, wherein the homology is 75-100%.
20. The mRNA sequence according to claim 19, wherein the homology is 85-100%.
21. The mRNA sequence according to claim 20, wherein the homology is 95-100%.
22. The mRNA sequence according to claim 21, wherein the homology is 98-100%.
23. The RNA sequence of claim 22, wherein the homology is 99-100%.
24. The mRNA sequence according to claim 23, wherein the homology is 100%.
25. The mRNA sequence according to one of claims 15 to 24, further comprising at the 5' end of the sequence as set forth in SEQ NO:11, and (c) the sequence shown in fig. 11.
26. The mRNA sequence according to one of claims 15 to 25, further comprising at the 5' end of the sequence as set forth in SEQ NO: 15, or a sequence shown in figure 15.
27. The mRNA sequence according to one of claims 15 to 26, further comprising at the 3' end of the sequence as set forth in SEQ NO: 16, or a sequence shown in figure 16.
28. The mRNA sequence according to one of claims 15 to 27, further comprising at the 3' end of the sequence as set forth in SEQ NO: 17, and (b) is the sequence shown in 17.
29. A coronavirus mRNA vaccine agent, said vaccine agent comprising an mRNA sequence according to any one of claims 15 to 28, or an mRNA sequence reverse transcribed from a DNA sequence according to any one of claims 1 to 14.
30. The vaccine agent of claim 29, wherein the mRNA comprises modified nucleotides, wherein the modified nucleotides are selected from one or more of the following nucleotides: 2-aminoadenosine, 2-thiothymidine, inosine, pyrrolopyrimidine, 3-methyladenosine, 5-methylcytidine, C-5 propynyl-cytidine, C-5 propynyl-uridine, 2-aminoadenosine, C5-bromouridine, C5-fluorouridine, C5-iodouridine, C5-propynyl-uridine, C5-propynyl-cytidine, C5-methylcytidine, 2-aminoadenosine, 7-deadenosine, 7-deazaguanosine, 8-oxoadenosine, 8-oxoguanosine, O (6) -methylguanine, pseudouridine, N-1-methyl-pseudouridine, 2-thiouridine, and 2-thiocytidine; a methylated base; an insertion base; 2 '-fluororibose, ribose, 2' -deoxyribose, arabinose, and hexose; a phosphorothioate group and a 5' -N-phosphoramidite bond.
31. The vaccine agent of claim 30, wherein said RNA comprises modified nucleotides, said modified nucleotides being N-1-methyl-pseudouridine.
32. The vaccine agent according to claim 30, wherein the modification ratio is 1% to 80%.
33. The vaccine agent according to claim 30, wherein the modification ratio is 2% to 80%.
34. The vaccine agent according to claim 30, wherein the modification ratio is 10% to 80%.
35. The vaccine agent according to claim 30, wherein the modification ratio is 30% to 80%.
36. The vaccine agent according to claim 30, wherein the modification ratio is 40-60%.
37. The vaccine agent of claim 30, wherein the modification is at a rate of 50%.
38. The vaccine agent of claim 29, further comprising a polymer that forms a nanoparticle with the nucleotide, the polymer being selected from one or more of the following polymers: polyacrylate, polyalkylcyanoacrylate, polylactide-polyglycolide copolymer, polycaprolactone, dextran, albumin, gelatin, alginate, collagen, chitosan, cyclodextrin, Polyethyleneimine (PEI), or branched PEI.
39. The vaccine agent of claim 38, further comprising a liposome, wherein the core structure comprising the nucleotide polymer is encapsulated in the liposome to form a nanoparticle.
40. The vaccine agent of claim 29 or 39, further comprising a liposome, wherein the nucleotide is encapsulated by the liposome to form a nanoparticle.
41. The vaccine agent according to any one of claims 39 to 40, wherein the liposomes are selected from one or more of the following liposomes: cationic lipids, non-cationic lipids, sterol-based lipids, and/or PEG-modified lipids.
42. The vaccine agent of claim 41, the cationic lipid comprising: c12-200, MC3, DLinDMA, DLinkC2DMA, cKK-E12, ICE (imidazolyl), HGT5000, HGT5001, OF-02, DODAC, DDAB, DMRIE, DOSPA, DOGS, DODAP, DODMA and DMDMA, DODAC, DLenDMA, DMRIE, CLinDMA, CpLinDMA, DMOBA, DOcarDAP, DLinDAP, DLincarDAP, DLinCDAP, KLin-K-DMA, DLin-K-XTC2-DMA and HGT4003, or a combination thereof.
43. The vaccine agent of claim 41, non-limiting examples of the non-cationic lipid may include ceramide, cephalin, cerebroside, diacylglycerol, 1, 2-dipalmitoyl-sn-glycero-3-phosphorylglycero glycerol sodium salt (DPPG), 1, 2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE), 1, 2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1, 2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1, 2-dioleyl-sn-glycero-3-phosphoethanolamine (DOPE), 1, 2-dioleyl-sn-glycero-3-phosphocholine (DOPC), 1, 2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (DPPE), 1, 2-dimyristoyl-sn-glycero-3-phosphoethanolamine (DMPE), and 1, 2-dioleoyl-sn-glycero-3-phospho- (1' -rac-glycerol) (DOPG), 1-palmitoyl-2-oleoyl-phosphatidylethanolamine (POPE), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1-stearoyl-2-oleoyl-phosphatidylethanolamine (SOPE), sphingomyelin, or a combination thereof.
44. The vaccine agent of claim 41, wherein the sterol-based cationic lipid comprises no more than 70% of the total lipid in the lipid nanoparticle.
45. The vaccine agent of claim 44, wherein the sterol-based cationic lipid comprises a phosphatidyl compound, a phosphatidyl glycerol, a phosphatidyl choline, a phosphatidyl serine, a phosphatidyl ethanolamine, a sphingolipid, a cerebroside, and a ganglioside, or a combination thereof.
46. The vaccine agent of any one of claims 39 to 46, further comprising a PEG modified lipid, such as DMG-PEG, DMG-PEG2K, C8-PEG, DOGPEG, ceramide PEG and DSPE-PEG, or a combination thereof.
48. the vaccine agent according to claim 47, wherein M5: DOPE: DSPE-mPEG 2000: 49:2 (mass ratio).
49. A DNA vaccine agent comprising the NDA sequence of any one of claims 1-14.
50. A UTR sequence comprising a sequence as set forth in SEQ NO: 36-1 to 36-12, or' SEQ NO: 37-1 to 37-12.
51. The UTR sequence of claim 51, wherein the 5' sequence is SEQ NO: 36-11, 3 is SEQ NO: 37-11; or the 5' sequence is SEQ NO: 36-12, 3 is SEQ NO: 37-12.
52. A 3' UTR sequence, said sequence comprising; the amino acid sequence of SEQ NO: 37-11 or SEQ NO: 37-12.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2021/074670 WO2021159985A1 (en) | 2020-02-13 | 2021-02-01 | Vaccine agent for treating or preventing coronavirus disease |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2020100905644 | 2020-02-13 | ||
CN202010090564 | 2020-02-13 | ||
CN2020104182112 | 2020-05-18 | ||
CN202010418211 | 2020-05-18 | ||
CN202010767364 | 2020-08-03 | ||
CN2020107673648 | 2020-08-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113186203A true CN113186203A (en) | 2021-07-30 |
CN113186203B CN113186203B (en) | 2022-12-30 |
Family
ID=76972663
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110109503.2A Active CN113186203B (en) | 2020-02-13 | 2021-01-27 | Vaccine agent for treating or preventing coronavirus diseases |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN113186203B (en) |
WO (1) | WO2021159985A1 (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113322271A (en) * | 2020-06-24 | 2021-08-31 | 西南交通大学 | COVID-19 subunit vaccine based on yeast surface display system |
CN114432435A (en) * | 2022-01-25 | 2022-05-06 | 苏州大学 | SARS-Cov-2 vaccine based on polyhedron nano structure and its preparing method and use |
CN114644686A (en) * | 2022-03-24 | 2022-06-21 | 中国人民解放军陆军军医大学 | DNA vaccine delivery system and application thereof and DNA vaccine |
US11547673B1 (en) | 2020-04-22 | 2023-01-10 | BioNTech SE | Coronavirus vaccine |
CN115869332A (en) * | 2022-10-27 | 2023-03-31 | 北京新合睿恩生物医疗科技有限公司 | mRNA drug with low expression in liver after delivery into body and preparation method thereof |
CN116121277A (en) * | 2020-12-31 | 2023-05-16 | 四川大学华西医院 | Nucleic acid molecules encoding structural proteins of novel coronaviruses and uses thereof |
CN116925195A (en) * | 2022-04-22 | 2023-10-24 | 仁景(苏州)生物科技有限公司 | mRNA vaccine based on novel coronavirus |
WO2023208118A1 (en) * | 2022-04-27 | 2023-11-02 | 瑞可迪(上海)生物医药有限公司 | Nucleic acid construct and use thereof |
WO2023217267A1 (en) * | 2022-05-13 | 2023-11-16 | 上海瑞宏迪医药有限公司 | Nucleic acid construct comprising utr and use thereof |
US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
WO2024017253A1 (en) * | 2022-07-19 | 2024-01-25 | 深圳深信生物科技有限公司 | Mrna for sars-cov-2 s protein and use thereof |
WO2024032611A1 (en) * | 2022-08-09 | 2024-02-15 | 斯微(上海)生物科技股份有限公司 | Lipid composition |
WO2024098361A1 (en) * | 2022-11-11 | 2024-05-16 | 斯微(上海)生物科技股份有限公司 | Artificial nucleic acid molecule |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL3864163T3 (en) | 2018-10-09 | 2024-05-20 | The University Of British Columbia | Compositions and systems comprising transfection-competent vesicles free of organic-solvents and detergents and methods related thereto |
US20240277830A1 (en) | 2020-02-04 | 2024-08-22 | CureVac SE | Coronavirus vaccine |
US11241493B2 (en) | 2020-02-04 | 2022-02-08 | Curevac Ag | Coronavirus vaccine |
KR20230164648A (en) | 2020-12-22 | 2023-12-04 | 큐어백 에스이 | RNA vaccines against SARS-CoV-2 variants |
CN113633764B (en) * | 2021-09-02 | 2024-05-14 | 中国食品药品检定研究院 | New crown DNA vaccine containing adjuvant |
AU2022374004A1 (en) * | 2021-10-22 | 2024-05-02 | BioNTech SE | Compositions for administration of different doses of rna |
WO2023113094A1 (en) * | 2021-12-16 | 2023-06-22 | 주식회사 씨티씨백 | Covid-19 vaccine composition with increased immunogenicity |
WO2024144348A1 (en) * | 2022-12-29 | 2024-07-04 | 주식회사 바이오파마 | Vaccine composition comprising ionic complex of cationic molecular transporter and mrna |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018115527A2 (en) * | 2016-12-23 | 2018-06-28 | Curevac Ag | Mers coronavirus vaccine |
CN110167587A (en) * | 2016-11-11 | 2019-08-23 | 摩登纳特斯有限公司 | Influenza vaccines |
WO2019209914A2 (en) * | 2018-04-27 | 2019-10-31 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Homology-directed repair template design and delivery to edit hemoglobin-related mutations |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2523875A1 (en) * | 2003-04-28 | 2004-11-11 | Public Health Agency Of Canada | Sars virus nucleotide and amino acid sequences and uses thereof |
GB201718660D0 (en) * | 2017-11-10 | 2017-12-27 | Ucl Business Plc | Improved liposome for mRNA delivery to cells |
WO2019232097A1 (en) * | 2018-05-30 | 2019-12-05 | Translate Bio, Inc. | Phosphoester cationic lipids |
-
2021
- 2021-01-27 CN CN202110109503.2A patent/CN113186203B/en active Active
- 2021-02-01 WO PCT/CN2021/074670 patent/WO2021159985A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110167587A (en) * | 2016-11-11 | 2019-08-23 | 摩登纳特斯有限公司 | Influenza vaccines |
WO2018115527A2 (en) * | 2016-12-23 | 2018-06-28 | Curevac Ag | Mers coronavirus vaccine |
WO2019209914A2 (en) * | 2018-04-27 | 2019-10-31 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Homology-directed repair template design and delivery to edit hemoglobin-related mutations |
Non-Patent Citations (1)
Title |
---|
GENBANK: "MN938384.1", 《GENBANK》 * |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11779659B2 (en) | 2020-04-22 | 2023-10-10 | BioNTech SE | RNA constructs and uses thereof |
US11925694B2 (en) | 2020-04-22 | 2024-03-12 | BioNTech SE | Coronavirus vaccine |
US11547673B1 (en) | 2020-04-22 | 2023-01-10 | BioNTech SE | Coronavirus vaccine |
CN113322271A (en) * | 2020-06-24 | 2021-08-31 | 西南交通大学 | COVID-19 subunit vaccine based on yeast surface display system |
CN116121277B (en) * | 2020-12-31 | 2024-04-30 | 四川大学华西医院 | Nucleic acid molecules encoding structural proteins of novel coronaviruses and uses thereof |
CN116121277A (en) * | 2020-12-31 | 2023-05-16 | 四川大学华西医院 | Nucleic acid molecules encoding structural proteins of novel coronaviruses and uses thereof |
CN114432435B (en) * | 2022-01-25 | 2024-05-17 | 苏州大学 | SARS-Cov-2 vaccine based on polyhedra nano structure and its preparation method and application |
CN114432435A (en) * | 2022-01-25 | 2022-05-06 | 苏州大学 | SARS-Cov-2 vaccine based on polyhedron nano structure and its preparing method and use |
CN114644686A (en) * | 2022-03-24 | 2022-06-21 | 中国人民解放军陆军军医大学 | DNA vaccine delivery system and application thereof and DNA vaccine |
CN114644686B (en) * | 2022-03-24 | 2023-09-05 | 中国人民解放军陆军军医大学 | Delivery system for DNA vaccine, application of delivery system and DNA vaccine |
CN116925195A (en) * | 2022-04-22 | 2023-10-24 | 仁景(苏州)生物科技有限公司 | mRNA vaccine based on novel coronavirus |
CN116925195B (en) * | 2022-04-22 | 2024-06-21 | 仁景(苏州)生物科技有限公司 | MRNA vaccine based on novel coronavirus |
WO2023208118A1 (en) * | 2022-04-27 | 2023-11-02 | 瑞可迪(上海)生物医药有限公司 | Nucleic acid construct and use thereof |
WO2023217267A1 (en) * | 2022-05-13 | 2023-11-16 | 上海瑞宏迪医药有限公司 | Nucleic acid construct comprising utr and use thereof |
US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
WO2024017253A1 (en) * | 2022-07-19 | 2024-01-25 | 深圳深信生物科技有限公司 | Mrna for sars-cov-2 s protein and use thereof |
WO2024032611A1 (en) * | 2022-08-09 | 2024-02-15 | 斯微(上海)生物科技股份有限公司 | Lipid composition |
WO2024087423A1 (en) * | 2022-10-27 | 2024-05-02 | 北京新合睿恩生物医疗科技有限公司 | Mrna drug that is less expressed in liver after being delivered to body and preparation method therefor |
CN115869332A (en) * | 2022-10-27 | 2023-03-31 | 北京新合睿恩生物医疗科技有限公司 | mRNA drug with low expression in liver after delivery into body and preparation method thereof |
WO2024098361A1 (en) * | 2022-11-11 | 2024-05-16 | 斯微(上海)生物科技股份有限公司 | Artificial nucleic acid molecule |
Also Published As
Publication number | Publication date |
---|---|
CN113186203B (en) | 2022-12-30 |
WO2021159985A1 (en) | 2021-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113186203B (en) | Vaccine agent for treating or preventing coronavirus diseases | |
KR102469450B1 (en) | Polynucleotides Encoding Interleukin-12 (IL12) and Uses Thereof | |
JP6646773B2 (en) | Lipid formulations for delivery of messenger RNA | |
CA3169664A1 (en) | Respiratory virus immunizing compositions | |
TW202305140A (en) | Methods for identification and ratio determination of rna species in multivalent rna compositions | |
WO2023283651A1 (en) | Pan-human coronavirus vaccines | |
TW202216739A (en) | mRNA and novel coronavirus mRNA vaccine containing the same which is economical and efficient, safer and more efficient, more stable in structure, and more efficient in protein expression | |
US20240026317A1 (en) | PAN-RAS mRNA CANCER VACCINES | |
EP3987027A1 (en) | Endonuclease-resistant messenger rna and uses thereof | |
JP2022536951A (en) | Methods of administering cyclic polyribonucleotides | |
AU2021360796A9 (en) | PAN-RAS mRNA CANCER VACCINES | |
CN116157148A (en) | Immunogenic compositions and uses thereof | |
US11007248B2 (en) | Suppression of allergic lung inflammation and hyperreactivity | |
US20210163928A1 (en) | Messenger rna comprising functional rna elements | |
TW202413424A (en) | Immunomodulatory proteins and related methods | |
WO2022233287A1 (en) | Vaccine reagent and vaccination method | |
WO2023091766A2 (en) | Compositions and methods of ribonucleic acid respiratory syncytial virus (rsv) vaccines | |
TW202328166A (en) | Composition and methods of mrna vaccines against novel coronavirus infection | |
CN115960180A (en) | 2019-nCoV S protein mutant and genetically engineered mRNA and vaccine composition thereof | |
JP2024522215A (en) | Multiplexed TP53 and pan-RAS mRNA cancer vaccine | |
WO2024141784A2 (en) | Broadly protective betacoronavirus vaccines and compositions | |
JP2007099724A (en) | Antiviral agent targeting sulfatide | |
CN117187266A (en) | mRNA rabies vaccine for animals | |
TW202345870A (en) | Messenger ribonucleic acids with extended half-life | |
WO2022187230A2 (en) | Methods and compositions for detecting and producing porcine morbillivirus and immunogenic compositions thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: Room 603 and 604, building 2, No. 1295, chuanqiao Road, China (Shanghai) pilot Free Trade Zone, Pudong New Area, Shanghai, 200120 Applicant after: Siwei (Shanghai) Biotechnology Co.,Ltd. Address before: Room 603 and 604, building 2, No. 1295, chuanqiao Road, China (Shanghai) pilot Free Trade Zone, Pudong New Area, Shanghai, 200120 Applicant before: Siwei (Shanghai) Biotechnology Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PP01 | Preservation of patent right | ||
PP01 | Preservation of patent right |
Effective date of registration: 20231201 Granted publication date: 20221230 |